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Summary of Thesis 
 
Drugs are pharmaceutical compounds administered to treat or diagnose disease. In the human 
body, drugs have specific reactions with molecular structures or drug targets to produce an 
effect. Some major concerns of current drugs include undesired side effects or toxicity and 
poor therapeutic response. Drug discovery is a crucial step to produce new and improved 
drugs with better efficacy and safety profiles to benefit patients. Generally, drug discovery 
can be improved in 3 aspects: better understanding of diseases, search for new target classes 
and the use of new and improved biological and chemical tools.  
 
Using advanced bioinformatics tools, this project aimed to study: a) genotype-phenotype 
relations of Phase II drug metabolising enzyme uridine 5’-diphospho-glucuronosyltransferase 
(UGT); b) disposition pathways and targets of synthetic drugs and herbal medicines; and c) to 
design a comprehensive drug and herb target database.  
 
We used 2 algorithms, Sorting Intolerant From Tolerant (SIFT) and Polymorphism 
Phenotyping (Polyphen) to predict the genotype-phenotype relationship of UGTs. Results 
showed that SIFT and Polyphen are good prediction tools with correct prediction rates of 
57.1% and 66.7 %, respectively. Using this method, we can screen for polymorphisms of 
various genes that may potentially cause diseases and altered  drug response or toxicity.  
 
Further to this, we used Protein ANalysis THrough Evolutionary Relationships (PANTHER) 
to classify human therapeutic targets of rheumatoid arthritis and non-insulin-dependent 
diabetes mellitus (NIDDM), and to identify which classes of molecular targets are most 
targeted by current medications for these common conditions. The results give us a focus on 
chief target classes and can be useful in the future to identify new therapeutic targets.  
 
Then, we explored targets that are associated with herbal compounds. Using berberine as an 
example, we collected available human target data and via PANTHER analysis, identified its 
major target classes. Together with this data and known clinical effects of berberine, we 
discussed the identification of new therapeutic targets and the development of new drugs from 
herbal medicines.  
 
 VI 
Finally, we summarised key databases for drug and herbal targets and propose to construct a 
database containing comprehensive data on drug and herbal targets. Initial stages of the 
database design are discussed.  
 
Findings from these studies suggests that: predicting the phenotypic consequence of nsSNPs 
in human UGTs using computational algorithms may provide further understanding of genetic 
differences in susceptibility to diseases and drug response and would be useful information 
for further genotype-phenotype studies; and b) therapeutic targets of rheumatoid arthritis, 
NIDDM and berberine can be investigated using a computational approach and has important 
implications in potential target discovery.  Furthermore, the study of current therapeutic 
targets of drugs and herbal medicine can lead a new direction of future targets identification. 
Our studies show a promising future for the use of bioinformatics tools in the identification of 
new therapeutic targets and the exploration of novel drugs. This is valuable for the drug 
discovery and development process and ultimately, improving drug efficacy and safety 
profiles to benefit patients.  
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Chapter 1. General Introduction 
 
The cycle of life consists of birth, age, illness and death. Living beings cannot escape this 
cycle of life and illness is common to all. In ancient times, people relied on supernatural 
thinking and different belief systems to explain disease and attempt cures. The oldest 
discovery in medicine occurred when primitive man used plants as medicine. Through 
experimentation, herbal application using plants was found to be useful in curing diseases. In 
the history of Chinese medicine, the first recognised herbalist was Shen Nong or the God of 
Agriculture, who is said to have lived around 2800 BC. He is said to have tasted hundreds of 
herbs and compiled the Shen Nong’s Materia Medica. This compilation recorded 365 herbal 
medicines and is considered to be the oldest book on Chinese medicine [1]. Till the 18th 
century, empirical sciences were used to understand illness. Since then, modern medicine has 
been based on experiments and observations. However, the focus has shifted now, 
concentrating more on understanding the complexity of the human body, of disease and the 
chemicals that affect both the body and disease.  
 
When the word “drug” is mentioned, it can reflect negative connotations, usually in reference 
to the use of illicit street drugs such as cocaine, amphetamines and steroids. This is 
unfortunate as there is a much simpler meaning to the word. The World Health Organisation 
(WHO) defines the term “drug” in pharmacology as any chemical agent that alters the 
biochemical and physiological processes of tissues or organism. In this thesis, when the word 
“drug” is used, it refers to pharmaceutical drugs that are administered to modify the 
pathological states of the body to benefit patients.  
 
Since illness is universal to humans, it is inevitable that everyone crosses path with the use of 
drugs. According to a report on the Australian pharmaceutical industry, the National Health 
Survey undertaken by the Australian Bureau of Statistics in 1995 provides the most 
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comprehensive information on the use of medicines in Australia [2, 3]. This survey found that 
10.7 million people, which represents 59% of the Australians population, used one or more 
medications over a two week period; the most popular of which were pain relievers, skin 
ointments and creams, medicines for coughs and colds, and medications for heart problems or 
high blood pressure [2, 3]. There were also 26% who had used vitamins or minerals, and 9% 
who had used herbal or natural preparations [3]. Clearly, the use of pharmaceutical drugs is 
common among the general public.   
 
As the reports have shown, the general public consumes an enormous amount of medication 
each year. This significant market demand drives the pharmaceutical industry forward and 
generates growth on the global economy. Integrated Medical System, the premier provider of 
integrated medical information systems for the healthcare industry stated an annual U.S 
prescription growth of 1.3 percent in 2008, to $291 billion [4]. Figures show that Australian 
medicinal and pharmaceutical product manufacturing sales and service income totalled 
approximately $6.73 billion Australian dollars in 2006-07 [5]. Overall, the Australian 
pharmaceutical industry represents 1% of the global market [4]. Therefore, the pharmaceutical 
industry contributes to the global economy in a great extent.   
 
Due to the imperative role of pharmaceutical drugs play in today’s society, much effort has 
been put towards the understanding of drug metabolism and dispostition. This is crucial to the 
understanding of drug safety and efficacy, as well as drug discovery and development.  
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1.1 Pharmacokinetics and Pharmacodynamics 
 
Pharmacology is the study of drugs; it comes from the Greek words pharmakon (poison in 
classic Greek; drug in Modern Greek) and logia (Study of). More specifically, it is the study 
of effects of drugs and how they exert these effects. 
 
The establishment of pharmacotherapy is based on the assumption that there is a relationship 
between the drug dosage regimen, exposure and drug effects, either beneficial or adverse [6]. 
Nevertheless, how one person responds to drugs is unpredictable and drug response is highly 
variable between each person. Hence, unexpected drug response is a major concern for both 
practitioners and patients. 
 
There are many factors that may affect how a person responds to a drug, which can be broadly 
divided into drug-associated factors and patient-related factors. Drug-related factors include 
dosage, regimen, and administration route. Patient-related factors include age, sex, ethnic 
group, genetic makeup, body weight, comedication, use of dietary supplements and the 
development of drug tolerance and resistance. Pharmacokinetics and pharmacodynamics are 
the main principles that determine the link between drug dose and response [6]. The 
relationship of pharmacokinetics and pharmacodynamics is demonstrated in  Figure 1-1. 
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    Figure 1-1. Principle of pharmacology. 
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1.1.1 Pharmacokinetics 
 
Pharmacokinetics is the study of “what the body does to the drug” [8]. It is the study of the 
absorption, distribution, metabolism and excretion, collectively ADME of a drug when 
introduced into a biological system such as the human body [9, 10].  A summary of ADME in 
the body is summarised below.  
 
Absorption -  the process of drug molecules from administration site into the systematic  
 circulation. 
Distribution -  Drug molecules travel from the circulation into target organs and tissues.  
  Relates to drug concentrations in target sites and determines drug effects.   
Metabolism -  Inactivate and detoxify drugs that can harm the body.  Responsible for the  
 decline of plasma drug concentration over time. 
Excretion -  Elimination of drugs and their metabolites from the body, primarily in the  
 urine. 
 
ADME affects the concentration of drug that interacts with its targets, determining the  
duration and magnitude of both desired and undesired pharmacodynamic effects of the drug 
[7]. The relationship of drug dose and pharmacokinetics/pharmacodynamics is demonstrated 
in Figure 1-2.
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Figure 1-2. Relationship of pharmacokinetics and pharmacodynamics. 
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Primary pharmacokinetic parameters include clearance, bioavailability, volume of distribution 
and half-life (t1/2). Clearance is the measure of the body’s ability to eliminate the drug from 
the plasma, either by metabolism or excretion; main organs involved are liver and kidney. The 
concept of renal clearance was introduced by Moller et al in 1929 [11]. In 1956, Hoenig and 
Schuck defined clearance as the ratio of dose and area under the curve [12]. Bioavailability is 
“the proportion of the drug that reaches the systemic circulation”. It was first introduced by 
Oser et al in 1945 when they compared the physiological availability of vitamin oral solutions 
with vitamin tablets [13]. Volume of distribution is the ratio of the total amount of the drug to 
the plasma concentration and was first developed by Dominguez in 1934 [14]. Half-life is the 
time taken for the drug plasma concentration to fall by 50%. It is determined by volume of 
distribution and bioavailability and is useful in calculation of dosing regimen [7]. These 
parameters are important factors in the drug metabolism process, as well as the drug 
development process.  
 
Each drug also goes under several reactions in the body. Pathways of drug metabolism are 
classified as either Phase I reactions (i.e., oxidation, reduction, and hydrolysis) or Phase II, 
conjugation reactions (e.g., acetylation, glucuronidation, sulfation, and methylation) [15]. The 
human cytochrome P450 enzymes are a family of membrane-associated heme proteins and 
hepatic microsomal enzymes, they are grouped into 18 families including CYPs 1, 2, 3, 4, 5, 
7, 8, 11, 17, 19, 20, 21, 24, 26, 27, 39, 46 and 51 
(http://drnelson.utmem.edu/CytochromeP450.html, access date: 15 June 2011). Amongst all 
CYP enzymes, members from the CYP1, CYP2 and CYP3 families are the main contributors 
to the oxidative metabolism of more than 90% of clinical drugs. Whilst other CYP families 
(e.g. CYPs 4, 7, 11, 17, 19, and 21) are involve in the metabolism of endogenous compounds 
such as steroids, bile acids, leukotrienes and eicosanoids [519, 520]. On the other hand, 
almost 35% of drugs metabolised by Phase II drug-metabolising enzymes undergo 
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glucuronidation, a process that increase the polarity of xenobiotics and some endogenous 
compounds to facilitate their excretion via the bile or urine [16, 17]. The uridine 5'-
diphospho-glucuronosyltransferase (UGTs) are a superfamily of endoplasmic reticulum-
bound enzymes that catalyse glucuronidation, and they play an important role in the 
detoxification and excretion of drugs and/or their metabolites [17]. Overall, pharmacokinetics 
determines the drug dose at the target site and is crucial knowledge for the understanding of 
drug response.  
 
1.1.2 Pharmacodynamics 
 
Pharmacodynamics is the study of what the drug does to the body; it is the study of the 
interaction between a drug and its molecular target producing pharmacological effects, 
altering the biochemical or biophysical activities of the drug targets [8, 18, 19]. Drug targets 
are molecular structures in our body that will undergo a specific interaction with drugs (e.g. 
receptors, enzymes, ion channels, nuclear receptors and DNA) [20].  
 
Therefore, the course of pharmacological effects begins with the binding of a drug to its 
target, followed by signal transduction pathway with the activation of second messenger 
molecules, and produces the alteration of intracellular process that leads to a functional drug 
response Figure 1-2. 
 
The magnitude and duration of drug response is linked to drug concentration at a target site, 
which is determined by pharmacokinetics and influenced by ADME of the drug. These factors 
have been discussed in the previous section. The relationship between the concentration of the 
drug and the response is commonly portrayed as the dose-response relationship [18].  
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There are different types of dose-response relationships. Graded dose-response relationship 
describes the response produced by each dose of a drug in terms of a percentage of the 
maximal response and is plotted against the log dose of the drug. Graded dose-response 
curves illustrate the relationship between drug dose, receptor occupancy, and the scale of the 
physiologic effect produced [21]. Quantal dose-response relationship is also plotted against 
log dose of the drug, but it illustrate the response of a drug in terms of cumulative percentage 
of subjects exhibiting a defined all-or-none-effect and can be used to calculate the therapeutic 
index of a drug [21]. Therapeutic index provides a general indication of the margin of safety 
of a drug. Drugs with a narrow therapeutic index should be used with great care as side effects 
can be easily caused, e.g. irinotecan (colorectal cancer agent).  
 
Efficacy is the maximal response produced by a drug. Drugs with greater affinity require a 
lower dose to occupy 50% of the functional receptors. The median effective dose (ED50) 
produces 50% of the drug efficacy. In in vitro studies, this value may be expressed as EC50, 
effective concentration for 50% effect. Drugs are often refereed to as ‘potent’; the affinity of a 
drug for its receptor determines the potency of a drug. Potency can also be used to compare 
different pharmacologic agents. Taken together, an in-depth understanding of 
pharmacodynamics is crucial in the understanding of how drugs act on the body to achieve 
therapeutic effects and sometimes cause side effects.  
 
1.1.3 Inheritance and drug response (Pharmacogenetics) 
 
Although the concept of DNA only became popular in the last couple of decades, the entire 
human genome has been mapped owing to the worldwide genome project [22, 23]. The vast 
gained popularity of genetic studies has found to be useful in pharmacology.  
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Pharmacogenetics is the study of genetic variations between individuals and how it affect 
individual responses to medicine [24]. Pharmacogenetics is a comparatively new aspect of 
drug metabolism and was first developed in the 1950s. It came to our attention when a series 
of discoveries—primaquine sensitivity, slow isoniazid acetylation, and butyrylcholinesterase 
deficiency— that demonstrated the influence of genetics on drug response [25-27].  
 
In the human genome, the most frequent type of DNA variation is single nucleotide 
polymorphisms (SNPs), when a single nucleotide (A, T, C or G) vary in the genome sequence 
and occurs in at least 1% of the population [28, 29]. Currently, there are a total of 41,365,915 
SNPs in human genome identified and deposited to the Single Nucleotide Polymorphism 
Database (dbSNP) at National Center for Biotechnology Information (NCBI)  
(http://www.ncbi.nlm.nih.gov/sites/entrez, Build 134). SNPs in a coding region that leads to 
amino acid substitution in the corresponding protein is non-synonymous SNPs (nsSNPs) and 
deleterious nsSNPs cause clinical phenotypic consequences in individuals [28-32]. 
Deleterious nsSNPs can lead to disease or biochemical abnormalities in individuals. 
Therefore, information on SNPs is highly relevant to drug metabolism and adverse drug 
reactions (ADRs). 
  
Genetic variation in drug metabolising enzymes is critical in the understanding of varied 
individual drug responses. Mutations of the human cytochrome P450 (CYP450) enzyme 
family can result in a range of clinical consequences. For instance, CYP2B6*5 (1459C>T 
giving an Arg487Cys substitution) is associated with altered response or survival in patients 
with proliferative lupus nephritis when treated with cyclophosphamide [33]. In the same 
report, patients who were either heterozygous or homozygous for CYP2C19*2 (430C>T 
resulting in an R144C substitution) had a significantly lower risk of developing premature 
ovarian failure, compared to the wild-type CYP2C19*1. Variations in the CYP450 genes can 
 11 
lead to reduced or delayed enzymatic activities and be associated with delayed 
pharmacokinetic clearance of drugs. In a group of Japanese patient after percutaneous 
coronary intervention, CYP2C9*2 and *3 showed reduced antiplatelet effect of pro drug 
clopidogrel [34]. 
 
Human UGTs are an important class of Phase II enzymes involved in the metabolism and 
detoxification of numerous xenobiotics including therapeutic drugs and endogenous 
compounds (e.g. bilirubin). nsSNPs of the human UGT genes may cause absent or reduced 
enzyme activity and polymorphisms of UGT have been found to be closely related to altered 
drug clearance and/or drug response, hyperbilirubinemia, Gilbert’s syndrome and Crigler-
Najjar syndrome.  
 
Genetic variations in the UGT1A1 promoter (*28) is associated with increased drug toxicity 
and hyperbilirubinemia in cancer patients receiving irinotecan-based chemotherapy [35-38] 
and reports also show increased risk of tranilast-induced hyperbilirubinemia [39]. 
Furthermore,  the UGT2B7 promoter variant is associated with significantly reduced 
glucuronidation of morphine in sickle cell disease and contributes to the variability in hepatic 
clearance of morphine in these patients [40]. Therefore, it is important to identify nsSNPs of 
UGT genes to avoid undesirable drug response.  
 
Moreover, genetic variations have been characterised for genes encoding various receptors, 
thereby eliciting variability in pharmacodynamic responses. For example, among heart failure 
patients on <50% of the target dose for β-blocker, the β1-adrenergic receptor (ADBR1) allele 
Ser49Gly carriers were associated with longer survival than Ser49Ser [41]. In healthy 
volunteers, β2-adrenergic receptor (ADBR2) alleles (Arg16 and Gln27) are shown to be 
associated with increased desensitization mediated by isoproterenol infusion [42]. In a clinical 
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report, a 204 cm tall man with a cytosine-to-thymine transition at codon 157 in the estrogen 
receptor gene resulted in a premature stop codon. This man received estrogen for osteoporosis 
but had no response due to estrogen resistant [43]. Thus, we can see from these examples that 
some genetic variations of receptors can lead to significantly altered pharmacodynamic 
responses in the carriers.  
 
In conclusion, genetic variations between individuals can affect individual response to 
medicine; therefore, genetic variations are important in the understanding of individual 
pharmacokinetics and pharmacodynamics. In the future, more advanced knowledge of the 
relationship between polymorphisms and pharmacological response can provide medical 
practitioners the basis to determine the optimal drug or drug dosage for an individual. This is 
the first step for individualised therapy. 
 
1.1.4 Drug toxicity/Adverse drug reaction 
 
Some say that an ideal drug should have these characteristics: be easily administered (orally), 
fully absorbed from the gastrointestinal tract, potent, highly specific and selective, with rapid 
onset and useful duration of action, of high therapeutic index with no adverse drug reactions 
and no interference with body functions, does not interact with other drugs or foods, 
spontaneously eliminated and inexpensive [18]. However, this is not the case in reality. 
Therefore, the goal of therapeutics is to achieve a desired beneficial effect with minimal 
adverse effects.  
 
Whether natural or synthetic products, undesirable patient response does exist. As previously 
mentioned, drug responses differ from patient to patient and factors contributing to 
unpredictable drug response can be drug-related or patient-related. In this section, some drug-
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related undesirable drug response will be discussed, including drug toxicity and drug 
interactions.  
 
Drug safety is closely related to drug dose and this concept was raised by Paracelsus over 500 
years ago, who stated that “Solely the dose determines that a thing is not a poison” [44]. 
WHO defines an ADR as “any response to a drug which is noxious, unintended, and which 
occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease. In 
clinical practice, drug safety is the greatest concern for practitioners and patients. 
 
A summary of mechanistic classification of ADRs can be found in   Table 1-1. The 
classifications of ADRs integrate chemical, pharmacological and clinical concepts. Type A 
reactions are the most common and account for about 80% of ADRs. These reactions can be 
predictable from known pharmacology of the drug [18]. They present a dose-response 
relationship and can be avoided by dose reduction. For instance, the incorrect dose use of 
insulin can lead to excess reduction of blood glucose level and result in hypoglycaemia; this 
can be avoided by correct insulin dosage. Type B reactions are idiosyncratic and cannot be 
predicted during the preclinical or early clinical phases, they are more serious than type A 
reactions and may be life-threatening [18]. Type C reactions occur as a consequence of long 
term use. Type D reactions are defined as long-term toxicities such as carcinogenicity and 
teratogenicity, which are of greatest concern during the development and licensing of a new 
drug [45]. Type E reactions are defined as end-of-treatment ADRs, which usually involves 
some form of receptor adaptation during chronic exposure to a drug [45].  
 
As a safety concern for the consumers, severe ADRs can result in drug withdrawal from the 
market by regulatory authorities. There have been a number of notable incidences of 
withdrawals of drugs causing serious ADRs (Table 1-2). 
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Furthermore, one of the key issues with toxicity is the benefit/risk ratio. This is an important 
consideration in drug development for life threatening diseases such as antibiotic-resistant 
infections, cancer and AIDs, where no good alternatives are available. In drugs that treat life-
threatening conditions there are more tolerance of safety issues [46]. For instance, anticaner 
agents (e.g. topotecan & irinotecan) often cause several adverse effects such as diarrhoea and 
immunosuppression. However due to the seriousness of the disease, anticancer drugs are 
continued to be used. The impact of toxicity on the process of drug development will be 
discussed in Section 1.3.
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  Table 1-1. Mechanistic classification of adverse drug reactions 
[Adapted from Bryant, B. and K. Knights, Pharmacology for Health Professionals (3rd ed) 
& Park, B.K, et.al. Chemical Research in Toxicology, 1998. 11(9): p. 969-88.] 
 
 
Classification of 
ADRs 
Characteristics Examples 
Type A (augmented, 
dose-related) 
• Predictable reactions from known 
pharmacology, often representing 
an exaggeration of the 
pharmacological effect of the drug 
• Dose related 
• Common occurrence and usually 
mild 
• Reproducible in animals 
Bleeding with the used of 
anticoagulants.  
 
Hypoglycaemia from use of 
insulin.  
 
 
Type B (bizarre, 
non-dose-related ) 
• Unpredictable from a knowledge of 
the basic pharmacology of the drug  
• No simple dose–response 
relationship 
• Increase severity  
• Lack of reproducibility in animal 
Interstitial nephritis with the 
use of NSAIDs. 
 
Eosinophilia with the use of 
anticonvulsants. 
Type C (chemical, 
dose and time-
related) 
• Reactions whose biological 
characteristics can either be 
predicted or rationalised in terms of 
chemical structure 
• Occurs after long-term use 
• Rebound phenomena 
Rebound tachycardia after 
abrupt discontinuation of β-
blockers.  
Type D (delayed, 
time-related ) 
• Delayed effects 
• Include carcinogenicity and 
teratogenicity 
Lymphoma associated with 
immunosuppressive drugs. 
Type E (end of 
treatment, 
withdrawal) 
• Occurs on drug withdrawal Opiate withdrawal syndrome.  
Myocardial ischaemia after β-
blocker cessation. 
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Table 1-2. Notable adverse drug reactions leading to drug withdrawal from the market. 
 
Year Drug Use Adverse drug reaction Reference 
1961 Thalidomide Sedative Teratogenecity [48] 
1978 Phenformin  Hypoglycaemic Lactic acidosis [49] 
1983 Zimelidine Antidepressant Guillian-Barré syndrome  
1992 Temafloxacin Antibiotic Hymolytic anemia  [50] 
1998 Terfenadine Antihistamine Ventricular arrhythmia [51] 
2000 Troglitazone Hypoglycaemic Hepatotoxicity  [52] 
2007 Lumiracoxib 
COX-2 selective 
NSAID Hepatotoxicity [53] 
2008 Rimonabant Obesity 
Severe depression and 
suicide  [54] 
2009 Efalizumab 
Immunosuppressant 
humanised 
monoclonal antibody 
Progressive mulitifocal 
leukoencephalopathy [55] 
2010 Sibutramine Obesity  Cardiovascular risk [56] 
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1.2  Drug discovery and development  
 
1.2.1 Introduction 
 
Drug discovery and development is mandatory in the effort to produce new drugs that are 
more effective and have improved safety profiles. The successful market of a new drug 
product requires an initial drug discovery, drug development, animal and human testing and 
approval before it is marketed and reaches the consumer. It has been estimated that 5,000 – 
10,000 compounds must be introduced to the drug discovery pipeline for every successful 
new drug that reaches the market [57].  
 
As a result, the pharmaceutical industry not only spends huge amounts of money in the 
production of drugs, a significant amount of funds has also been put towards research and 
development (R&D). Figures show R&D expenditure by business enterprises on human 
pharmaceutical products was $456.4 million Australian dollars in year 2006 [58]. Medicines 
Australia shows that this R&D expenditure has increased strongly from $210 million in 2001-
02, with an average annual growth rate of 32% [59]. Further, business expenditure on R&D 
on pharmacology and pharmaceutical sciences alone was $257,999,000 in 2008–09 [60]. In 
addition, the cost of bringing one new molecular entity (NMEs) successfully to the market are 
approximately $US1.8 billion [61]. 
  
As can be seen from the figures, drug discovery and development is highly costly, not only 
that, it is a highly complex, time-consuming and multidisciplinary process. It may take more 
than 10 years from the early discovery phase to the launch of the compound on the market and 
because only one in ten drugs entering clinical development reaches the market, drug 
discovery and development is said to be a high-risk enterprise [6].   
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Pharmaceutical drug development has traditionally been performed in sequential phases to 
answer 2 basic questions: 1) which compound should be selected for development?  and 2) 
how should it be dosed? 
 
Drug development begins with a hypothesis or a new idea. The idea may be related to a new 
hypothetical cause of a disease, new therapeutic targets, and research with new technology 
such as genetic engineering techniques.  
 
The drug development process is an information gathering process based on the “learn-and-
confirm” paradigm proposed by Sheiner, and are characterised as two successive learning-
confirming cycles [62, 63]. Sequential phases of drug discovery include preclinical phases 
(target identification, lead optimisation, pre-clinical safety test), Phase I-II clinical trials, 
Phase III clinical trials and finally, approval and registration. The main learning phases of 
drug development are Phase 0 (preclinical) and the early clinical development stages (Phase I 
and II). The main goal of pharmaceutical companies is to produce an effective and safe drug 
to the patient in the shortest time possible.  
 
To begin the drug development process, studies must be carried out to design and synthesis 
new molecules. When a disease is established, researchers look into the pathological changes 
in the body and determine a protein/molecular structure to be the target that if modulated or 
acted upon by chemicals will alter the disease, this is the “hit” compound. Out of tens of 
thousands of chemical compounds, using the high throughput technology, sometimes only 
one “hit” compound is found. Lead optimization is then accomplished through chemical 
modification of the hit structure, with modifications to refine its efficacy and safety.  
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Each phase of the drug development process is designed to increase the level of 
pharmacological knowledge of the NME, thus allowing assessment of the probability of 
success for an NME [6]. The goals and objectives of each stage of drug development are 
shown in the following table (Table 1-3).  
 
 
 
Table 1-3. Phases of drug development  
 
Stage of drug 
development 
Testing 
population  
Goal and objectives 
Phase 0 Animal models Efficacy and safety  
Define dose range to be tested in humans 
Phase I Healthy humans 
(where possible, 
patients may be 
used for some 
drugs) 
Tolerability 
Safety 
Pharmacokinetics 
Pharmacodynamics 
Phase II Small group of 
patients 
Safety and efficacy 
Phase IIa- selection of doses and dosing regimen 
Phase IIb- dosing range  
Phase III Large scale of 
clinical trials 
Validation of pharmacokinetics and pharmacodynamics. 
Further evaluating safety and efficacy in a larger population.   
 
 
 
After the approval of the new drug by the regulatory authorities, the drug is continually 
monitored for safety issues. Capital cost per launch involved in different stages of a new 
successful molecular entity is demonstrated in Figure 1-3 [61].  
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Figure 1-3. Flow chart of the drug discovery and development process. 
[Adapted from Paul, S. M., et al. (2010). Nature Reveiws Drug Discovery 9(3): 203-214. Money unit: $M] 
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1.2.2 Drug metabolism and drug development 
 
In the 1960s and 1970s, the primary reason for failure of drug candidates in clinical 
development was due to inappropriate human pharmacokinetics. This led to progressive 
integration of drug metabolism and pharmacokinetics as a key component of the overall drug 
discovery process [64]. As a result of this paradigm shift, selection of drug candidates for 
entry into development became based on their drug metabolism and pharmacokinetics 
properties in animals, allowing cautious predictions to be made for corresponding properties 
in humans [65].   
 
One of the key roles of preclinical pharmacokinetic studies in the pharmaceutical industry 
presently is to identify potential liabilities in new chemical entities as early as possible, with 
the aim of eliminating molecules that exhibit metabolic or pharmacokinetic properties that are 
likely to preclude their successful development as therapeutic agents [65].  
 
Traditional drug metabolism research focused on ADME, with particular emphasis on in vivo 
and in vitro metabolite identification, enzymology of DMEs, and associated metabolic 
pathways and reaction mechanisms [66]. However, the paradigm has shifted to advanced 
fields such as pharmacogenetics, pharmacogenomics and transporters, which has provided 
exceptional insights into the biochemical processes that can affect the biochemical processes 
that can affect the ADME properties of a drug [66].  
 
Drug metabolism focuses and methods used during the discovery and development stages are 
different. In the early drug discovery phase, the primary goal is to screen large amounts of 
compounds to select ideal candidates for development; drug metabolism input provides a 
basis for choosing chemical structures and desirable lead compounds [66]. Drug metabolism 
plays a key role in the lead optimisation stage of drug discovery, through the identification of 
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undesirable ADME characteristics in candidate molecules that would impede a successful 
development program [65].  
 
Understanding of pharmacokinetics of the drug has helped to design rational dosing 
recommendations. The information of pharmacokinetic parameters of drugs helps us 
understand the physiologic process in drug metabolism, further, it can be used to design drug 
and dosage regime. Volume of distribution is useful in determining the size of the dose 
required to reach the desired target plasma concentration with the “loading dose” (first dose). 
Clearance will determine the maintenance dosing rate to maintain average plasma 
concentration. Half-life (both volume of distribution and clearance) will guide how the 
maintaining dosing rate should be divided in time to keep fluctuations in plasma 
concentration within acceptable limit [7]. However, calculations of clearance and volume of 
distribution can only be calculated for intravenous administrations. 
 
Hence, understanding pharmacokinetics plays a central role in the development of a new drug 
and studies of drug metabolism can effectively assist in the process of drug discovery. 
Pharmacokinetic studies are also an essential component of drug evaluation. It is also 
necessary to design drug metabolism studies that can effectively assist in the process of drug 
discovery. Interpretation of results from drug metabolism studies must be taken into account 
in drug discovery.  
 
1.2.3 Toxicology and drug development  
 
Drug safety is not only a major concern for the consumers but also one of the biggest hurdles 
for drug development. Two decades ago, the major problem that caused drug candidates fail 
to reach the market was unpredictable metabolism and pharmacokinetics in humans. 
However, advances in the knowledge of basic and practical aspects of human 
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metabolism/disposition had significant positive impact on the reduction of failures due to 
metabolic issues. Nowadays, a main reason why drugs fail is toxicity; more vigorous 
regulation and monitoring from the regulatory authorities also make a contribution. [46].  
 
Drug safety issues occur throughout the process of drug discovery and development. These 
issues need to be addressed to make the new drug development more effective and timely. 
Proactive use of toxicity information can predict possible human safety issues with potential 
drug candidates. Success of the prediction must be based on an understanding of mechanisms 
of toxicity. It is logical to address toxicity earlier in the drug discovery and development 
process. Predicting toxicity earlier in the drug development paradigm has three other 
advantages, inclucing saving time, decreased amount of drug to be synthesized and reduced 
cost [46]. On the other hand, due to the complexity of the human body and drug metabolism, 
issues with predictive toxicity also arises, including (i) whether we can predict in vivo 
response from in vitro systems and (ii) whether we can predict long-term effects from short 
ones.  
 
1.2.4 Genetics and drug discovery 
 
The complete mapping of the human genome project is a landmark achievement for 
bioinformatics [22, 23]. Integrating genetic and molecular sciences, the identification of genes 
and pathways involved in disease states enables scientists to define diseases much more 
accurately for targeted therapy. For instance, ERBB2 over-expression is found in some breast 
cancer patients [67]. Using ERBB2 as a target, the monoclonal antibody Herceptin was 
developed and is currently used in the treatment of breast cancer patients expressing high 
levels of ERBB2 [68].  
 
 24 
The advancement in genetic science also encouraged new discoveries of experimental models 
that are helpful in drug discovery. A number of experimental discoveries related to genes have 
received honourable awards. In 2006, the Nobel Prize in Physiology or Medicine was 
awarded for the discovery of RNA interference, known as gene silencing or “knocked down” 
by double-stranded RNA [69]. This method allows modification of gene activities in selected 
tissues. In the following year, the Nobel Prize was awarded for the discoveries of “principles 
for introducing specific gene modifications in mice by the used of embryonic stem cells” [70]. 
The method developed was by inactivation of specific gene in an embryonic stem cell then 
implanting the genetically modified cell into a surrogate mother, giving rise to a strain of mice 
that is homozygous for the inert gene – the “knockout mouse”, to study the effects of the loss 
of a gene [71, 72]. The technique has been used to generate thousands of different kinds of 
knockout mice with features of particular human diseases. The first direct genetic evidence 
that COX-2 plays a key role in tumorgenesis was shown using gene knockout mice [73], and 
indicate that COX-2-selective inhibitors can be a novel class of therapeutic agents for 
colorectal polyps and cancer.  Later, the function of cannabinoid receptor was investigated 
and confirmed in CB1 knockout mice model [74]. The “knock-in” method has also been 
developed  to study the effects of an introduced gene with specific mutation [71].  
 
Genetic studies in spontaneous animal disease models provide direct link of gene targets to 
disease phenotypes [75]. These models have been used extensively in in vivo studies. This 
process allows potential drug compounds to be tested in diseased animal models, thus 
eliminating unsuitable compounds before arriving at the clinical study stage. Evidently, 
genetic studies have contributed greatly to drug development and modern medicine.  Further, 
the incorporation of pharmacogenetics with drug discovery and development will benefit the 
future development of personalised medicine and individualised therapy.  
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1.2.5 Challenges of the pharmaceutical industry 
 
By the 21st century, pharmaceutical drug discovery and development model has evolved to a 
relatively mature model. However, there are still some challenges that lie within current 
pharmaceutical products.  
 
First of all, some common diseases such as rheumatoid arthritis and non-insulin-dependent 
diabetes mellitus (NIDDM) do not have very effective treatments. Rheumatoid arthritis is a 
worldwide disease with an estimated prevalence of 1% of the world population [76]. 
Although there are a number of available therapies for rheumatoid arthritis, such as 
corticosteroid, disease modifying anti-rheumatic drugs, anti-TNFα agents and emerging 
biologics, few anti-rheumatic drugs can completely stop the progression of the disease and 
reverse damage on the joints.  
 
In 2007-2008, 4% of the Australian population were medically diagnosed with diabetes 
mellitus and the International Diabetes Federation forecasts by the year 2030, the total 
number of people with diabetes will rise to 440 million worldwide (www.diabetesatlas.org). 
Current NIDDM therapies can effectively reduce blood glucose to a desirable level, but the 
underlying cause of insulin resistance is not addressed. With the progressive nature of 
NIDDM, patients will eventually depend on external delivery of insulin which does not 
encourage patient adherence. Despite extensive research into treatment and prevention of 
these diseases, there are still shortcomings in the current available therapy and the search for 
more effective therapy is necessary.  
 
Secondly, drug safety is a major concern in the clinical setting and the research setting. 
Clinically, many drugs which still have severe adverse effects are continued to be used due to 
lack of other therapeutic options. For example, anticancer agents (e.g. topotecan & irinotecan) 
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often cause several adverse effects such as diarrhoea and immunosuppression; anti-rheumatic 
agent methotrexate is associated with hepatotoxicity; and some anti-diabetic agents cause 
weight gain and hypoglycaemia. Severe drug adverse effects can lead to death. During the 
drug development process, toxic side effects can cause potential drug candidate fail to reach 
the market. This can result in huge loss in time and money.  
 
Thirdly, R&D productivity is the pharmaceutical industry’s grand challenge and has become 
one of the most hindering obstacles for new drug development. Cost of one successfully 
marketed NME is approximately $US1.8 billion [61]. Further, $US1.8 billion per launch does 
not include the cost of exploratory phase, which includes target identification, validation and 
selection (see Table 1-3 in Section 1.2.1). Although the devlopment of NMEs are expensive, 
patient benefit is relatively small. High cost of production is reasonable if patient benefit is 
high, however, cost/benefit ratio is difficult to predict or calculate. Short term benefit maybe 
good but long term benefits are unknown and unpredictable because people may develop drug 
resistance in the long run.  
 
Lastly, a key part of reduced R&D productivity is reduced number of truly innovative new 
medicines approved by the authorities such as the US FDA. Due to concerns about 
pharmaceutical industry’s integrity and transparency around issues such as drug safety and 
efficacy, increased scrutiny has been put on the industry by regulatory authorities. In the past 
5 years, the number of approved drugs is very small, 19 NMEs were approved in 2007, with a 
slight increase to 21 NMEs in 2008 and 24 new drugs were approved in 2009 [61]. As a 
result, the R&D productivity of pharmaceutical industry nowadays is greatly reduced.  
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Overall, pharmaceutical R&D has difficulties with high cost, time consumption and 
productivity. The ultimate goal of pharmaceutical companies is to deliver safe and efficient 
drugs to consumers in the shortest time possible. 
 
1.3 Drug Targets 
 
1.3.1 Introduction of drug targets 
 
As discussed in Section 1.1.2, pharmacological effects and drug response are produced via 
interactions between drug molecules and their therapeutic targets. At a molecular level, drug 
targets are structures in our body which are chemically definable by at least a molecular mass, 
that will undergo a specific interaction with chemicals that we call drugs [20]. For most drugs, 
several if not many targets are identified. 
 
The majority of drug molecules achieve their effects by binding to and regulating its protein 
targets [77]. In general, drugs act on four main types of regulatory proteins that mediate the 
actions of hormones, neurotransmitters and autocoids. These four types of regulatory proteins 
are carriers, enzymes, ion channels and receptors [18]. 
 
The “rule-of-five” analysis by Lipinski et al [78] shows that poor absorption or permeation of 
a compound are more likely when: there are more than five hydrogen-bond donors; the 
molecular mass is more than 500 Da; the lipophilicity is high (expressed as cLogP >5); and 
the sum of nitrogen and oxygen is more than 10. Specific structural and physiochemical 
properties, such as “rule of five” are required for drug molecules to have sufficient levels of 
efficacy, bioavailability, and safety, which define target sites to which drug-like molecules 
can bind [79].  
 
 28 
Certain characteristics are expected for therapeutic targets [80]. A potential target need not 
only to be druggable but also linked to disease, most preferably playing critical and inimitable 
roles in disease state. Binding sites need to possess certain structural and physiochemical 
properties to accommodate high-affinity site-specific binding and subsequent regulation of 
protein activity by drugs. They are not significantly involved in other important biological 
processes to avoid potential side effects. Useful information about these targets may be 
investigated by analysing their sequence properties, protein families, structural folds, 
biochemical classes, similarity proteins, gene location in the human genome, and associated 
pathways [79]. This information can be potentially useful in derivation of rule and developing 
predictive tools in the search for druggable and potential targets [79].  
 
The number of molecular targets acted on by current drug therapy is still in dispute. In 1996, 
Drews and Reiser identified a total of 483 drug targets addressed by drug therapy [81, 82]. 
Approximately 45% are cell membrane receptors, 28% are enzymes and the remaining classes 
comprise hormones (11%), ion channels (5%), nuclear receptors (2%) and DNA (2%). About 
7% of the targets are not known biochemically. Later, Hopkins and Groom challenged this 
figure and suggested that “rule-of-five”-compliant drugs acted primarily through only 120 
underlying molecular targets [78, 80]. However, the statistical analysis of disease genes and 
related proteins suggested that the total number of the estimated potential targets in the human 
genome ranges from 600-1,500 [80]. In the meantime, another report showed the estimated 
total number of distinct targets is in the range of 1,700-3,000 [83]. Chen et al. reported targets 
collected in the Therapeutic Target Database [84] is 997 distinct proteins, 1,494 distinct 
protein subtypes, and 41 nucleic acids , which are only targeted by at least one marketed drug 
and 1,267 research targets, which are only targeted by investigational agents not approved for 
clinical use at present [79]. Overall, targets for neoplasm diseases, circulatory system 
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diseases, infectious diseases and nervous system and sense organs disorders constitute the 
largest number of targets [77]. 
 
This increase in target numbers is made possible by advances in genomics, proteomics, better 
molecular understanding of diseases, increased effort in the exploration of new therapeutic 
targets as well as increased knowledge of unknown or unreported targets of previous existing 
drugs. An improvement in technology for target identification and validation also contributes 
greatly.  
 
1.3.2 Significance of drug targets in drug response and drug development 
 
Pharmacological effects begin with the binding of a drug to its target. Therefore, molecular 
understanding of the drug target is important in the understanding of drug responses.  
 
The origins and the progression of diseases are multifactorial. Drug responses are also 
affected by many physiological factors. Complex disorders such as cancer, cardiovascular 
disease and depression tend to result from multiple molecular abnormalities, not from a single 
defect [85]. Reports show that targets for neoplasm diseases, circulatory system diseases, 
infectious diseases and nervous system and sense organs disorders constitute the largest 
number of targets [77]. Because drug targets are presented at the molecular level, increased 
knowledge of targets can facilitate a  deeper understanding of complex diseases at its 
fundamental level. This in turn, can determine the optimal molecular targets for drug 
discovery and development [82]. Biochemical and genetic studies can be used to reveal the 
molecular mechanism that underlie common illnesses [85]. 
 
Further in assisting the molecular dissection of  mechanism of action of drugs, knowledge on 
drug targets makes it possible to use disease specific targets to design more desirable drugs 
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with increased specificity and efficacy. Target-oriented synthesis in drug discovery involves 
in pre-selected protein targets [86]. Binding of drugs to pre-selected protein target/s is 
dependent on which biological pathway the drug is aimed to modulate the target or the 
diseased pathway(s) [86]. Target and disease specific drug design aims to produce drugs with  
improved efficacy and reduced side effects, especially in high impact diseases that require 
more effective and more treatment options. However due to the fact that diseases often 
involve in multiple molecular abnormalities, diversity-oriented syntheses are used in efforts to 
identify simultaneously therapeutic protein targets and their small-molecule regulators [86].  
Further, target-oriented drug design allows more focused drug design, which in turn costs less 
time and money for pharmaceutical companies.    
 
Study of various aspects of known targets including molecular mechanism of their binding 
agents and related adverse effects is useful for finding clues to new target identification [84]. 
Protein structure of well-validated old and new targets should be able to guide the chemical 
effort directed at new drugs [87]. Based on the knowledge of molecular targets and molecular 
understanding of disease state and using this knowledge will allow some direction in 
identifying potential targets. Potential targets may come from the same class as confirmed 
therapeutic targets and have similar physiological functions, or maybe a structure along a 
biological pathway. Additionally, with increased number of potential targets from ~500 to 
>5,000, the nature of pharmaceutical research has changed. This increase in numbers has 
given researchers more opportunities to discover and design new and improved drugs.  
 
In terms of R&D productivity for pharmaceutical companies, target selection may be one of 
the most important determinants of attrition. There are few ways to overcome this challenge 
and improve the target selection process, in turn, improving R&D productivity. First of all, 
researchers can discover new target classes. Targets of herbal medicine are becoming a 
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popular resource to find new target classes (discussed further in secion 1.4.3). In addition, 
increased understanding of genetic variations/polymorphisms of drug targets or drug 
metabolising enzymes can assist in target selection and drug metabolism. Further, the use of 
new technology can help speed up the early exploratory discovery phase of drug discovery.   
 
In summary, updated knowledge of drug targets are valuable contribution to complex disease 
understanding and drug responses. Further, drug discovery and development can be supported 
by new target discovery and target-focused drug design. This will speed up the exploratory 
phase of drug R&D and benefit the pharmaceutical industry in terms of cost and time.  
 
 
1.4 Herbal medicine and herbal targets 
 
1.4.1 General Information 
 
Chinese Herbal Medicine (CHM) has always been an integral part of Traditional Chinese 
Medicine (TCM), which has been practiced in the east for thousands of years.  Chinese herbs 
are usually in the forms of dried whole plants or parts of the plants (roots, leaves, body etc.), 
sometimes shells and even minerals are used. Chinese herbs are often used in a complex 
formula, consisting of several different herbs hosting different roles according to the principle 
of Jun-Chen-Zuo-Shi (monarch, minisister, assistant and guide) described by the ancient 
Chinese. Each of  Jun, Chen, Zuo, Shi function together to harmonise the body, with shi 
(courier) herbs are included in many formulae to ensure that all components in the 
prescription are well absorbed, and to help deliver or guide them to the target organs [88]. To 
certain extent, the guiding function of Shi (courier) herbs is similar to modern drug delivery 
techniques, guiding the drug compound to target tissues.   
 
In the modern world, complementary medicine has gained vast popularity in the West. There 
has been increased use of herbal medicine to manage chronic diseases and promote wellbeing, 
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in countries such as Australia, New Zealand, USA and Europe [89]. Reports show that 18.9% 
of the American population used natural products in the precedent year [90]. This increase in 
popularity is closely related to its proven effectiveness in clinical practice over the past 
centuries. To date, more than 11,000 species of plants are used medicinally and about 300 are 
commonly used [91]. Besides clinical efficacy, molecular actions and ADME of herbal 
remedies largely remain a mystery.  
 
1.4.2 Current understanding of disposition of herbal medicines 
 
Despite its widespread use, CHM is associated with high levels of uncertainty. This is mainly 
due to lack of evidence base of efficacy, herb targets and safety data. During the process of 
therapeutic drug development, owing to the pre-selection of targets, researchers have a basic 
if not full understanding of which molecular structures the drug will react with or which 
biological pathway in the body it might alter. Knowledge on molecular interactions and 
modulations of the drug is anticipated and researched on. However, this is not the case for 
CHM. There is no pre-selection of molecular targets in the body but CHM has been used for 
thousands of years and is proven to be effective. The exact mechanism of the herbs actions are 
yet to be elucidated.  
 
Like synthetic drugs, herbal remedies undergo metabolism in the body to attain clinical 
effects. Therefore, pharmacokinetic principles of synthetic drugs can be applicable to herbal 
remedies [92]. In recent years, there has been increased interest in the pharmacokinetic and 
disposition studies of herbal remedies and valuable data has been accumulated. However, the 
pharmacokinetic data of most herbal remedies in humans are not available except for a small 
number of commonly used herbs or herbal compounds, such as baicalin, curcumin, danshen, 
echinacea, ginger, ginkgo, milk thistle, ginseng, and St John’s wort [92, 93]. Considering the 
large amount of herbs that are used clinically, this means that a large portion of commonly 
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used herbs have no reported pharmacokinetic studies. Further, most studies report only 
pharmacokinetic parameters of active components of herbs. Herbs are often used in 
compound formulas and contain a number of bioactive compounds; therefore, 
pharmacokinetic studies of single compounds cannot elucidate mechanisms of herb actions.     
 
Similar to synthetic drugs, active compounds of herbal medicine bind to and undergo 
interactions with molecular structures or herbal targets to produce therapeutic or adverse 
effects. The identification of herbal targets can also help clarify pharmacokinetics of herbal 
medicine.  
 
In general, there is a lack of understanding of CHM at a molecular level, which impedes 
development of CHM and the incorporation of CHM into mainstream medicine in the west. 
Hence, relevant pharmacokinetic studies are warranted for herbal medicines to increase our 
knowledge on herb pharmacology, herb targets and herb safety.  
 
 
1.4.3 Implications of medicinal plants in drug discovery and development  
 
Chinese herbs are among the best investigated plants from a chemical perspective, and a 
considerable amount of information is available on their chemical constitution [94]. 
Interestingly, in recent years, herbal compounds have been source of new drugs [94]. 
Approximately 28% of NMEs between 1981 and 2002 were natural products or natural 
product derived, further to this, 20% of these NMEs were natural product mimics [95]. There 
are a number of successful plant derived drugs, especially in anti-cancer treatment.  
 
Paclitaxel (Taxol®, Figure 1-4) was discovered from the bark of the Pacific Yew (Taxus 
brevifolia). It is significantly active against ovarian cancer, advanced breast cancer, small and 
non-small cell lung cancer [96]. Another compound camptothecin was isolated from the 
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Chinese ornamental tree (Camptotheca acuminate). Two camptothecin semi-synthetic 
derivatives topotecan and irinotecan have been successfully developed and are used in the 
treatment of ovarian and colon cancers, respectively (Figure 1-4). Topotecan and irinotecan 
are both topisomerase I inhibitors. Topotecan is one of the most effective and tolerable 
treatment options for recurrent ovarian cancer [97]. It is a potent topoisomerase 1 inhibitor 
and induces tumor cell death [98]. In addition, topotecan may have an antiangiogenic effect 
by inhibiting endothelial cell proliferation [99]. Another clinically useful compound 
homoharringtonine was also isolated from a tree. It has been used in China for the treatment 
of acute myelogenous leukemia and chronic myelogenous leukemia [100]. Thus, medicinal 
herbal compounds have become an important source for the discovery of new drugs. Further, 
Drugs derived from medicinal plants can also be used as drug leads suitable for optimization 
by medicinal and synthetic chemists [95]. 
 
Some medicinal compounds have also shown to act on novel molecular targets. For example, 
β-lapachone, found in bark of the lapacho tree (Tabebuia avellanedae), selectively kills 
various cancer cells over normal cells by inducing novel caspase- and p53-independent 
apoptotic pathway [101-103]. This compound can be further investigated for its antitumor 
activities. Medicinal compounds with novel targets and mechanisms can potentially become a 
successful drug.  
 
In recent years, there has been a growing interest in the pharmacological activities of 
berberine, one of the main alkaloids found in the Chinese herb Huang lian (Rhizoma 
Coptidis). Many studies have been carried out to elucidate the mechanisms of action of 
berberine, which have shown anti-cancer and anti-diabetic effects in vitro. It is of great 
interest to explore berberine targets to discover novel drugs. 
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Plant compounds exhibit enormous structural diversity but only a small portion of the 
diversity has been explored for its pharmacological potential [94].  With large numbers of 
medicinal compounds available and accessible. Using high screening technology and 
modelling of compounds can accelerate the speed of drug discovery from medicinal herbal 
compounds.   
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Figure 1-4. Chemical structures of Taxol, topotecan and irinotecan. .  
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1.5 Bioinformatics 
 
1.5.1 Introduction of bioinformatics 
 
Bioinformatics is defined as the application of computational tools and analysis to the capture 
and interpretation of biological data [22]. It is a field of information technology concerned 
with the storage, retrieval, visualization, prediction and analysis of molecular data having 
biological or clinical importance [104]. Bioinformatics is currently evolving to a non-
commercial, web-based and open source model [105], which makes it possible for scientific 
researchers and  the general public to have access to useful biological data.    
 
The primary goal of bioinformatics is to increase the understanding of biological processes, 
using computationally intensive techniques (e.g., pattern recognition, data mining, machine 
learning algorithms, and visualization) to achieve this goal. Data and databases are the key to 
bioinformatics.  
 
Bioinformatics has become essential in modern biology and medicine [22]. It is useful in the 
management and analysis of biological data. Further, bioinformatics has opened new avenues 
for molecular aspects of the body and disease and has tremendous impact on the drug 
discovery and development processes.  
 
1.5.2 Bioinformatics tools  
 
As previously mentioned, data and databases are the key for bioinformatics. Databases make 
it possible for large quantities of biological data to be collected and easily accessed; they also 
instigate the development of analytical and predictive softwares. The main tools of 
bioinformatics are computer software programs and the internet [22]. These bioinformatics 
tools allow researchers to have free access to biological data without software and database 
maintenance costs. 
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1.5.2.1 Databases 
 
Important databases in drug metabolism research include sequence or sequence annotation 
databases, SNP or mutation databases, general metabolism databases and drug 
metabolism/interaction databases [105], all of which will be introduced briefly.  
 
Sequence and sequence annotation databases contain gene and sequence data which now 
critical to almost all aspects of pharmaceutical research. Sequence and sequence annotation 
data play a key role not only in identifying possible protein targets, but also in providing a 
basis to our understanding of the mechanism or process by which a drug may work, where it 
may target, or how it might be metabolised [105]. Curated databases are specialised data 
resources maintained by one or more curators who select, input, or invite only the “highest 
quality” data from selected niches. In relation to pharmaceutical research, curated databases 
are important because they offer high quality and specialised data relating especially to 
humans [105]. The two main providers and curators of annotated sequence databases are the 
National Centre for Biotechnology Information (NCBI) in USA and the European 
Bioinformatics Institute (EBI) in the UK. Both providers maintain and operate dozens of 
sequence databases which are freely accessible via their home pages, NCBI at 
http://www.ncbi.nlm.nih.gov/ and EBI at http://www.ebi.ac.uk/. Some useful sequence and 
sequence annotation databases that can be accessed via NCBI and EBI are Ensembl, 
EntrezGene and SwissProt, they all contain rich data of genome sequence and genome 
annotation of organisms such as human, dog, rat and mouse. More human specific database 
for human genome data is GeneCards. 
 
The most frequent type of DNA variation is SNPs in the human genome [28, 29]. Deleterious 
nsSNPs cause clinical phenotypic consequences in individuals [28-32], and can lead to 
disease or biochemical abnormalities in individuals. Hence, this area of genetics is relevant to 
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drug metabolism and ADRs. There are several key public SNP databases, one of them is 
dbSNP database that is maintained at the NCBI, and it currently contains 41,365,915  million 
human SNP records (http://www.ncbi.nlm.nih.gov/sites/entrez, Build 134). Other human 
mutation databases include On-line Mendellian Inheritance of Man (OMIM) and Human 
Gene Mutation Database (HGMD). There are ongoing efforts to relate SNPs and mutation 
data to metabolic responses.  
 
There are also databases used for data analysis. PANTHER (Protein ANalysis THrough 
Evolutionary Relationships, http://www.pantherdb.org/) is a database designed for high-
throughput functional analysis of large sets of protein sequences [106]. PANTHER is a 
resource to classify proteins based on published scientific evidence and evolutionary 
relationships [107]. Gene ontology enables large-scale computational analysis. In biology, 
gene ontology contains >7,000 terms to describe molecular function, and almost 5000 terms 
to describe biological process [106]. PANTHER structured functional specificity to no more 
than three levels for easy navigation and partition of proteins into biologically meaningful 
groups [106]. For the human genome, the updated PANTHER version 7 provides 
functionalities including stored classification for all protein-coding genes (family, subfamily, 
molecular function, biological process and pathway) [107]. 
 
Other databases relevant to pharmacology and pharmaceutical research are metabolic 
databases, drug metabolism and interactions databases. A well-known metabolic pathway 
database is the Kyoto Encyclopedia of Genes and Genomes (KEGG). It provides detailed, 
organism-specific information such as protein, pathways, chemical structures and more about 
metabolism for different organisms and different compounds. Drug metabolism and 
interaction databases focuses more on known drugs, drug compounds and drug metabolites. A 
public available database DrugBank (http://www.drugbank.ca/) contains detailed information 
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about drugs, metabolism and their known protein targets. Data fields also provide hyperlinks 
to external databases or graphical views. Therapeutic Target Database and Potential Drug 
Target Database (http://www.dddc.ac.cn/pdtd/) also contain useful drug target information.  
 
Further, various databases relevant to CHM has been developed. These databases contain 
basic information related to the herb, original plants, bioactive compounds, therapeutic 
indications and clinical applications [108-111]. 3D structure database of components from 
CHM pays special attention to 3D structure of components from TCM herbs; designed to aim 
primarily at drug designers wanting to speed up the process of lead compounds and 
phytomedicine researchers [110]. The CHM Toxicology Database summarised detailed herb 
monographs containing full toxicity profile and grading of reported herbs [111]. Bioactive 
Plant Compound Database (BPCD) contains herbal targets information (a total of 78) [94]. 
 
Nowadays, there are many useful databases available with large quantities of valuable 
biological data. These databases allow users to access, search, visualise and retrieve data that 
is most relevant to them. The creation, continuation and improvement of databases is 
invaluable in modern medicine and research.  
 
1.5.2.2 Software tools 
 
It is commented that in the past century, the chemistry discipline has gone from purely 
“observational” to somewhat “predictive science” [105]. Computers and largely available 
biological data sets allow us to have the opportunity to apply statistics to mine for novel 
patterns, relationships to make pharmaceutical research more predictive.  
 
In particular, two predictive softwares relevant to predictions of phenotypic effects of SNPs 
will be discussed. Sorting Intolerant from Tolerant (SIFT) and Polymorphism Phenotyping 
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(PolyPhen) are two algorithms, they represent powerful bioinformatic tools that enable high-
throughput prediction of the potential impact of nsSNPs and large-scale polymorphism 
analysis. By predicting potential deleterious nsSNPs that may cause clinical significance, this 
process has the prospective to reduce the number of SNPs that may need to be validated in the 
laboratory setting and clinical studies.  
 
The elementary theory of SIFT have been developed and illustrated by Ng and Henikoff [29, 
112, 113]; it is used to predict the effect of an amino acid substitution on protein function 
according to sequence homology and the physical properties of amino acids. SIFT examines 
sequence similarity among related genes and does not require the knowledge of protein 
structural or functional information, therefore can be applied to a much larger number of 
proteins [29]. The PolyPhen algorithm is a structure-sequence based amino acid substitution 
prediction method; it utilizes the data available in Swiss-Prot 
(http://au.expasy.org/sprot/userman.html) and predicts the possible impact of an amino acid 
substitutions on the structure and function of a human protein [28]. Mapping of an amino acid 
replacement to a known 3D structure reveals whether the replacement is likely to destroy the 
hydrophobic core of a protein, electrostatic interactions, interactions with ligands or other 
important features of a protein [28, 114]. Multiple alignment-based profile scores provide the 
major contribution to the prediction therefore reliable prediction can be reasonably achieved 
even if  the proteins has no known 3D structure [28]. Phenotype predictions of nSNPs in 
human ATP-binding cassette transporter genes and human nuclear receptors have been 
studied using SIFT and PolyPhen [115, 116]. Results from these studies showed useful hints 
for further phenotype-genotype studies.  
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1.5.3 Bioinformatics and drug discovery and development 
 
A landmark achievement of bioinformatics is said to be the completed mapping of the entire 
human genome [22, 23]. More and more information is now available owing to advance in 
technology. The completion of the mapping of human genome has also contributed 
significantly to pharmaceutical R&D, especially in the process of drug target identification. 
The mapping of human genome has led to the identification of 3,000-5,000 genes encoding 
proteins that are considered to be useful drug targets. In addition, more potential drug targets 
can be identified using SNP- marked genes. In 2001, it was reported that in the human 
genome, 93% of genes contain an SNP, which means that nearly every human gene is marked 
by a sequence variation and there are ~1.2 million SNPs in the total genome [117]. At that 
time, there were potentially ~1.2 million drug targets which can be identified in the SNP-
marked sequences of the human genome. Currently, there are a total of 41,365,915 SNPs in 
human genome identified and deposited to the NCBI dbSNP 
(http://www.ncbi.nlm.nih.gov/sites/entrez, Build 134). This represents the number of potential 
targets that ay be identified in the SNP marked genes.  
 
Furthermore, researchers can now use computational methods to search for gene sequences of 
paralogues (copies of a gene within an individual that have diverged during evolution) of 
known drug targets in the human genome [118]. This approach identifies proteins that are 
closely related to classic drug targets and these proteins could represent possible drug targets, 
provided that they share similar physiological functions as known drug targets.  
 
Starting from the late 20th century, the fields of information technology and the drug 
discovery process engaged with one another and flourished together ever since. Traditionally, 
drug discovery is mainly a linear process based on the screening and testing of thousands of 
chemicals and natural substances for potential therapeutic activity [118]. Nowadays, with the 
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help of technology and data, bioinformatics and some software tools are designed to support 
the selection, optimization and application of active compounds at different stages of drug 
R&D process.  
 
In the early drug discovery phase, the primary goal is to screen large amounts of compounds 
to select ideal candidates for drug development, however, the screening process of drug 
discovery is time consuming and rather random [118]. Nevertheless, the use of technologies 
with high throughput capabilities can greatly assist in this selection process by accelerated 
speed to identify the most promising compounds. High throughput methods can be used in 
vitro, in silico, in situ and isolated organs and in vivo [66], candidate selection from “many” to 
“potential” can be sped up efficiently by these methods. Reports show that in the 1990s, a 
good research chemist could produce 50-100 new compounds a year. In 2005, the same 
chemist can turn out a couple of thousand compounds a year [119].   
 
One of the major issues that impede the drug development process is ADME and toxicity 
related failure of drug candidates. To reduce or avoid ADME related drug candidate failure, 
prediction of ADME by in silico tools has now become an inevitable paradigm to reduce cost 
and enhance efficiency in pharmaceutical research. Modelling, simulation and high-
performance computing enables the industry to model how drugs act in whole body systems, 
organs and at a sub-cellular level [120]. In 2010, using the protein docking algorithm 
EADock, researchers found potential inhibitors to an enzyme associated with cancer activity 
in silico [121].  Fifty percent of the molecules were later shown to be active inhibitors in 
vitro. In silico ADME prediction tools allow normally expensive and time-consuming bench 
tests to be done in seconds on a computer, at a tiny fraction of the cost. While these 
techniques are not yet as reliable as experimental methods, the utility of in silico methods in 
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combination with high-throughput in vitro methods is allowing drug metabolism/toxicity 
screening to be done much faster and more efficiently [105].  
 
Generally speaking, bioinformatics and the drug discovery process have evolved in a parallel 
manner, and have generated a close integrative relationship. The speedy development of 
technology directly stimulates the rate of successful drug development. For instance, using 
traditional drug development techniques it took nearly 40 years to capitalise on a basic 
understanding of the cholesterol biosynthesis pathway to develop statin drugs- those that 
inhibit the enzyme 3-hydroxy-3-methyglutaryl coenzyme A reductase, the rate limiting step in 
cholesterol biosynthesis [122]. On the other hand, a molecular-level understanding of the role 
of the HER-2 receptor in breast cancer led to the development of the chemotherapeutic agent 
Herceptin® within only 3 years [123]. The comparative rapid development of Herceptin® is 
due to in sillico molecular modelling, high throughput screening and access to databases 
containing genomic and proteomic information.   In silico technologies enables drug 
manufacturers to accelerate the selection process [119], and by producing and screening drug 
candidates more effectively, the cost of expensive bench work and clinical trials can in turn be 
reduced.  
 
The fully integrated model of bioinformatics, pharmacology and drug R&D have the potential 
to greatly reduce the time and cost of making new drugs. Creating a time and cost efficient 
future for drug research.  
 
 
1.6 Aims of this thesis  
 
Drug safety and unexpected drug response are currently a major concern for medical 
practitioners and patients. Drug safety is also a hindrance for new drug development due to 
more vigorous regulations. In addition, productivity has become a major challenge for the 
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pharmaceutical industry. Therefore, only effective and productive drug discovery and 
development can overcome these problems.  
 
Understanding different aspects of drug metabolism not only improves our understanding of 
drug response but also plays an important role in new drug discovery and development. 
Further, drug development is essential for improved clinical outcome and reduced side effects 
and toxicity. Target identification is a more focused perspective of drug discovery, it allows 
researchers to design chemical entities based on pre-selected molecular targets. Generally, 
drug discovery can be approached mainly in 3 aspects: better understanding of diseases, 
search for new target classes and the use of new and improved biological and chemical tools.  
 
Advancement of bioinformatics can assist in these aspects of drug discovery. In this project, 
we hypothesize that the phenotypic effects of human SNPs can be predicted using 
bioinformatic tools and that bioinformatic tools are useful in the study of drug and herb 
disposition.  
 
Using advanced bioinformatic tools, the project was undertaken to  
• investigate the potential effect of known human UGT nsSNPs on protein functions 
using bioinformatics prediction tools;  
• examine current identified targets of rheumatoid arthritis and type 2 diabetes mellitus 
using a bioinformatic approach;  
• examine current identified targets of berberine using a bioinformatic approach; 
•  investigate database construction that includes comprehensive data on synthetic 
drugs, herbal medicine and their known therapeutic targets.  
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Chapter 2. Prediction of Deleterious Non-synonymous Single Nucleotide 
Polymorphisms of Human UGT Genes 
 
2.1  Introduction 
 
As previously discussed in Section 1.1.3, in the human genome, the most frequent type of 
DNA variation is called single nucleotide polymorphisms (SNPs) [28, 29]. The number of 
human SNPs identified and deposited to the NCBI Single Nucleotide Polymorphism Database 
(dbSNP) (http://www.ncbi.nlm.nih.gov/sites/entrez, Build 134) is increasing at a hasty rate, 
the total number of reference SNPs in human genome increased from 14,708,752 in 2009 in 
dbSNP to 41,365,915 in August 2011. A non-synonymous (nsSNPs) or missense variant is a 
single base change in a coding region that leads to amino acid substitution in the 
corresponding protein [28, 30, 31]. Some amino acid substitution does not cause any change 
in the corresponding protein, whilst others cause clinical phenotypic consequences in 
individuals (e.g. disease or biochemical abnormality), these nsSNPs are termed tolerated and 
deleterious nsSNPs, respectively [29, 32]. Compared to tolerated nsSNPs, deleterious nsSNPs 
are more clinically relevant and is crucial in the understanding of some disease occurrence 
and drug metabolism related issues.  
 
Almost 35% of drugs metabolised by Phase II drug-metabolising enzymes undergo 
glucuronidation, a process that increase the polarity of xenobiotics and some endogenous 
compounds to facilitate their excretion via the bile or urine [16, 17]. The UGTs are a 
superfamily of endoplasmic reticulum-bound enzymes that catalyse glucuronidation, and they 
play an important role in the detoxification and excretion of drugs and/or their metabolites 
[17] . Additionally, UGTs play a critical role in the disposition of several important 
endogenous substrates, including bilirubin, bile acids, steroids, thyroxine, biogenic amines, 
and fat-soluble vitamins [124, 125].  
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Currently, there are 21 human UGTs identified (http://www.ugtalleles.ulaval.ca, access date: 
11 June 2009), and based on their sequence identities, human UGTs are classified into UGT1, 
2, 3 and 8 families [124, 126]. The UGT1 locus in humans has been mapped to chromosome 
2q37 [124, 127].  All UGT1 genes contain unique first exons, and they are subsequently 
spliced into common exons 2 through 5, leading to different N-terminal halves but identical 
C-terminal halves of the gene products [124]. Unlike the UGT1 family, the human UGT2 
mRNAs are transcribed from separate genes and are divided into UGT2A and 2B subfamilies 
[125, 128]. In humans, the genes encoding several UGT2 enzymes form a cluster on 
chromosome 4 (UGT2B7-UGT2B4-UGT2B15) [125]. UGT3 has two members, namely 
UGT3A1 and 3A2 and UGT8 family has one member (UGT8).  
 
The identification of deleterious nsSNPs in the human genome is important. This process 
relates human phenotypes to variation at the DNA level and links genetic and phenotypic 
differences in individuals; it is believed that nsSNPs and SNPs in regulatory regions together 
have the highest impact on phenotype [28]. The identification and characterization of SNPs of 
major drug-metabolizing enzymes such as UGTs is crucial for understanding individual 
differences in drug metabolism, therapeutic efficacy, inherited diseases and also for the 
predisposition toward diseases such as cancer [129]. However, humans have vast numbers of 
SNPs and presently it is unlikely to investigate their functional impact of these SNPs by 
experiments. Alternatively, bioinformatics approaches have gained increased use in the 
prediction of the functional effect of SNPs. 
 
Deleterious nsSNPs of UGT have shown to alter bilirubin metabolism, drug disposition and 
predisposition to diseases in individuals carrying the polymorphism [129, 130]. Variation in 
UGT1A coding sequences may lead to deficiency of UGT1A1 activity, often leading to high 
level of unconjugated hyperbilirubinemia which is closely related to diseases such as Crigler-
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Najjar syndrome (CN) [131] and Gilbert’s syndrome [132]. Nonsense mutations in the UGT1 
gene resulting in a premature termination codon and absent UGT1A1 activity have been 
reported in CN patients [133, 134]. Furthermore, some genetic variations in the UGT1A1 
promoter (*28) is associated with increased drug toxicity and hyperbilirubinemia in cancer 
patients receiving irinotecan-based chemotherapy, [35-38] and reports also show increased 
risk of tranilast-induced hyperbilirubinemia [39]. UGT1A7*3 leading to a low enzyme activity 
has been linked to increased risk of the cancer of the colon, mouth, esophagus, stomach and 
the liver  [135-138]. A number of UGT2 genetic variants have been shown to relate to altered 
drug metabolism and disease risk [17, 40, 139]. For example, the UGT2B7 promoter variant is 
associated with significantly reduced glucuronidation of morphine in sickle cell disease and 
contributes to the variability in hepatic clearance of morphine in these patients [40]. A 
UGT2B15 variant has been shown to relate to prostate cancer [140].  
 
2.2 Aim of the study 
 
The present study aimed to use SIFT and PolyPhen to investigate the potential effect of 
known human UGT nsSNPs on protein function. UGTs have been known to be important 
metabolising enzymes for xenobiotics and some endogenous compounds; therefore it is of 
great significance to determine deleterious UGT nsNSPs.  
 
2.3 Methods 
 
2.3.1 Gene nomenclature and dataset 
 
In the present study, the human UGT genes were named according to the UGT Nomenclature 
Committee (http://www.ugtalleles.ulaval.ca/). Only data on human UGT genes were collected 
from Entrez Gene on NCBI Website (http://www.ncbi.nlm.nih.gov/sites/enterz), and expired 
and merged gene names were excluded from the study.  Databases MutDB 
(http://www.mutdb.org) and PolyDoms (http://www.polydoms.cchmc.org/polydoms) were 
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used to identify UGT variants used in this study. MutDB integrates genetic variants from 
Swiss-Prot and dbSNP and links to functional disruption prediction scores. PolyDoms 
incorporate the results of multiple algorithmic procedures and functional criteria applied to 
the entire Entrez dbSNP dataset. Majority of the variants were identified by screening 21 
human UGT genes on MutDB and PolyDoms. Most of the data and information describing 
the genes and variants, including Entrez Gene ID are accessible on their homepages.  For each 
UGT gene, information including gene symbol, gene name, mRNA accession number, protein 
accession number, SNP ID, amino acid residue 1 (wild-type), amino acid position and amino 
acid residue 2 (missense) were collected. Additionally, supplementary variants were identified 
from Entrez Gene on NCBI (http://www.ncbi.nlm.nih.gov/sites/entrez) and added to the 
dataset after cross examination. Finally, through literature research, data on the effect of the 
nsSNPs on enzyme activity and the correlation between the nsSNPs and disease were 
extracted from in vivo and in vitro experiments (e.g. site-directed mutagenesis analysis).  
 
2.3.2 Prediction of the phenotype of nsSNPs in human UGT Genes 
 
Identified UGT nsSNPs and prediction effect of the variant amino acid substitution on protein 
function was performed using SIFT (http://blocks.fhcrc.org/sift/SIFT.html) and Polyphen 
(http://genetics.bwh.harvard.edu/pph/), listed in Supplementary Table 1.  
 
In this study, SIFT version 3 was used. This algorithm uses a query sequence to search for 
similar sequences that may share similar function, generates the alignment of the chosen 
sequences, and predicts the probability score of the impact of an amino acid substitution on 
protein function effects. SIFT scores ranges from 0 to 1, outcome scores from 0.00-0.05 are 
elected as intolerant, 0.051-0.10 as potentially tolerant, 0.101-0.20 as borderline and 0.201-
1.00 as tolerant [112, 141]. Information such as dbSNP ID and GI number of an amino acid 
substitution can be employed to predict the effect on protein functions in SIFT. The 
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algorithms and instructions for analysis of amino acid substitutions are available at 
http://www.blocks.fhcrc.org/sift/SIFT.html. The data employed in the SIFT analysis were the 
UGT gene sequences available in the NCBI non-redundant database 
(http://www.ncbi.nlm.nih.gov), orthologous sequences were used as paralogous sequences 
confounds predictions [113].  
 
PolyPhen uses empirically derived rules based on previous research in protein structure, 
interaction and evolution that automatically predict whether a replacement is likely to be 
deleterious for the protein on the basis of three-dimensional structure and multiple alignments 
of homologous sequences [28, 114]. PolyPhen input is a protein amino acid sequence or the 
SWALL database (http://srs.ebi.ac.uk/srs6bin/cgi-bin/wgetz?-page+LibInfo+-newId+-
lib+SWALL) ID or accession number together with sequence position and two amino acid 
variants characterising the polymorphism [28]. PolyPhen scores range from 0 ≤ 2 ≤ X, 
outcome scores of 0.00-0.99 are classified as benign, 1.00-1.24 as borderline, 1.25-1.19 as 
potentially damaging, 1.50-1.99 as possibly damaging and ≥2 as damaging [141]. Additional 
details of the algorithm and instructions for analysis of amino acid substitutions are available 
at http://www.bork.embl-heidelberg.de/PolyPhen/.  
 
2.3.3 Validation of the prediction results 
 
nsSNPs with experimental evidences of changing enzyme activity or disease association were 
regarded as deleterious. The phenotypic data are from both in vivo and in vitro studies, in 
which analysis of site-directed mutagenesis or enzymatic changes often provide direct 
evidence indicating the functional impact of nsSNPs. Prediction accuracy was analysed 
according to these positive findings from these experiments.  
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As a test for the ability of the SIFT and PolyPhen algorithms to identify substitutions 
impacting enzymatic activity of UGT proteins, scores were obtained and compared for the 
collected nsSNPs of human UGT genes related to loss of enzyme activity and disease based 
on experimental and clinical studies. 
 
2.3.4 Statistical analysis 
 
Given that SIFT and PolyPhen employ different approaches and also different datasets as 
foundations for their analysis, it is important to find the concordance of the two prediction 
tools on functional consequences of each nsSNP prediction. Concordance analysis of each 
nsSNP predicted by SIFT and PolyPhen were assessed using Spearman’s rank correlation 
coefficient ρ using SPSS 15. Prediction scores of each nsSNP were plotted on scatter graphs 
and analysed using linear trend lines.  
 
2.4  Results 
 
2.4.1 Validated nsSNPs of human UGT genes 
 
A total of 248 amino acid substitution variants were identified in the systemic screening of 21 
human UGT genes for the analysis of the potential impact of all nsSNPs in human UGT 
genes. With development and updated data in bioinformatics, some previously reported SNPs 
in dbSNP have been identified as invalid by later studies due to wrong sequencing and 
alignment. These incorrect SNPs have either been terminated or merged into other SNPs. We 
have cross-examined the databases and removed those invalid SNPs. Number of variants from 
4 UGT subfamilies (UGT1, UGT2, UGT3 and UGT8) are shown Table 2-1. Three SNPs were 
identified in the screening of UGT2B17 but none were non-synonymous, therefore are not 
included in this study.   
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Table 2-1.A summary of allelic variants of human UGT genes. 
 
 
 
 
 
 
 
 
Gene 
Symbol No. nsSNPs  
No. of nsSNPs 
scored by SIFT 
No. of nsSNPs 
scored by 
PolyPhen 
No. of nsSNPs 
scored by both 
algorithms 
UGT1A1 51 51 50 50 
UGT1A3 20 20 20 20 
UGT1A4 12 12 12 12 
UGT1A5 25 25 25 25 
UGT1A6 9 9 9 9 
UGT1A7 14 14 14 14 
UGT1A8 29 29 29 29 
UGT1A9 11 11 11 11 
UGT1A10 25 25 25 25 
UGT2A1 5 5 5 5 
UGT2A2 3 3 3 3 
UGT2A3 1 1 1 1 
UGT2B4 9 9 9 9 
UGT2B7 10 10 10 10 
UGT2B10 6 6 6 6 
UGT2B11 6 6 6 6 
UGT2B15 2 2 2 2 
UGT2B17 0 0 0 0 
UGT2B28 5 5 5 5 
UGT3A1 1 1 1 1 
UGT3A2 2 2 2 2 
UGT8 2 2 2 2 
 
TOTAL 248 248 247 247 
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2.4.2 Prediction of functional effect of nsSNPs of human UGT genes 
 
SIFT scores for all 248 nsSNPs identified in this study was found, Polyphen classified UGT1A1 
(L15R) as benign but did not provide a prediction score, therefore 247 nsSNPs in this study were 
scored by both SIFT and PolyPhen, these nsSNPs were used in the statistical concordance test. 
Predictions scores from SIFT and PolyPhen for UGTs are presented in Supplementary Table 1.  
As shown in Table 2-2. 88 of 248 or 35.5% of identified UGT nsSNPs exhibited SIFT scores of 
<0.05 and are classified as “Intolerant” variants by SIFT. 114 of 248 or 46.0% of identified UGT 
nsSNPs had prediction scores of ≥1.5 and are classified as “probably damaging” by PolyPhen.  
 
SIFT predicted a few nsSNPs of UGT genes to have no deleterious nsSNPs causing functional 
effects on protein function of UGT2A3, of 2B15, of 2B28, 3A1 and 8 (Table 2-3), including 
Ala496Thr, Asp84Tyr, Lys522Thr, Leu364His, Asn441Ser, Cys120Gly and Pro225Leu. 
PolyPhen also predicted some nsSNPs of UGT genes to have none of deleterious nsSNPs, these 
included UGT2A3, 2B15 and 8 (Table 2-3). UGT2A3, 2B15 and 8 did not have any deleterious 
nsSNPs predicted by both SIFT and PolyPhen (Table 2-3), which are Ala496Thr, Asp84Tyr, 
Lys522Thr and Ile367Met.  
 
Table 2-2. Prediction results of nsSNPs of human UGT genes.  
 
SIFTa Polyphenb Prediction 
result Number of 
nsSNPs % 
Number of 
nsSNPs % 
Tolerated 160 35.5% 114 46% 
Deleterious 88 64.5% 133 53.6% 
Not scored 0  1 0.4% 
Total 248 100 248 100 
aSee website: SIFT (http://blocks.fhcrc.org/sift/SIFT.html); Positions with normalized probabilities < 0.05 are 
predicted to be deleterious, those ≥ 0.05 are predicted to be tolerated. 
bSee website: Polyphen (http://genetics.bwh.harvard.edu/pph/) Positions with normalized probabilities > 1.5 are 
predicted to be deleterious, those <1.5 are predicted to be tolerated.
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  Table 2-3. Distribution of deleterious nsSNPs in human UGT genes predicted by SIFT and PolyPhen. 
 
UGT gene 
Number of 
deleterious 
nsSNPs 
predicted by 
SIFT 
UGT gene 
Number of 
deleterious 
nsSNPs 
predicted by 
PolyPhen 
UGT gene 
Number of 
deleterious 
nsSNPs 
predicted by 
SIFT or 
PolyPhen 
Number of 
deleterious 
nsSNPs 
predicted 
by SIFT 
and 
PolyPhen 
UGT1A1 32 UGT1A1 38 UGT1A1 38 32 
UGT1A3 8 UGT1A3 10 UGT1A3 11 7 
UGT1A4 3 UGT1A4 7 UGT1A4 7 3 
UGT1A5 5 UGT1A5 6 UGT1A5 7 4 
UGT1A6 3 UGT1A6 4 UGT1A6 5 4 
UGT1A7 2 UGT1A7 3 UGT1A7 3 2 
UGT1A8 8 UGT1A8 10 UGT1A8 10 8 
UGT1A9 6 UGT1A9 7 UGT1A9 7 6 
UGT1A10 7 UGT1A10 8 UGT1A10 9 6 
UGT2A1 1 UGT2A1 1 UGT2A1 1 1 
UGT2A2 1 UGT2A2 1 UGT2A2 1 1 
UGT2A3 0 UGT2A3 0 UGT2A3 0 0 
UGT2B4 4 UGT2B4 3 UGT2B4 4 3 
UGT2B7 2 UGT2B7 3 UGT2B7 3 2 
UGT2B10 2 UGT2B10 4 UGT2B10 4 2 
UGT2B11 3 UGT2B11 3 UGT2B11 3 3 
UGT2B15 0 UGT2B15 0 UGT2B15 0 0 
UGT2B28 0 UGT2B28 2 UGT2B28 2 0 
UGT3A1 0 UGT3A1 1 UGT3A1 1 0 
UGT3A2 1 UGT3A2 2 UGT3A2 2 1 
UGT8 0 UGT8 0 UGT8 0 0 
Total 88  113  118 85 
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2.4.3 Potential effect of nsSNPs of UGTs on amino acid change 
 
Representative deleterious nsSNPs and the corresponding amino acid substitution of various 
UGT genes are listed in Table 2-4. As many as 31 UGT1A1 nsSNPs of 80 UGT nsSNPs were 
predicted as deleterious by both algorithms. For UGT1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9 and 
1A10, deleterious nsSNPs predicted by both SIFT and PolyPhen includes Arg45Trp, 
Ile322Thr, Leu60His, Ser69Tyr, Ile318Thr, Thr202Ala, Val264Glu and Ile 211Thr. 13 UGT 
nsSNPs (Gly307Arg, Gly309Arg, Phe396Leu, Asp457glu, Leu46Pro, Ser299Phe, Ala381thr, 
Leu497Pro, Cys155Arg, Pro288Leu, and Lys367Ile) predicted deleterious by both SIFT and 
PolyPhen algorithms were from the UGT2 family, including UGT2A1, 2A2, 2B4, 2B7, 2B10 
and 2B11. For UGT3A2, Ala343Thr was predicted as deleterious, respectively, by both SIFT 
and PolyPhen algorithms.  
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Table 2-4. Deleterious nsSNPs predicted by both SIFT and PolyPhen. 
 
Gene Symbol SNP ID Amino acid 
change 
Gene 
Symbol SNP ID 
Amino acid 
change 
UGT1A1 VAR_026134 Pro34Gln UGT1A5 rs17851756 Ile322Thr 
UGT1A1 VAR_026135 His39Asp UGT1A5 rs28934877 Asn400Asp 
UGT1A1 
- Gln185Pro UGT1A6 rs1042708 Ser69Tyr 
UGT1A1 VAR_007698 Arg209Trp UGT1A6 rs17851756 Ile320Thr 
UGT1A1 VAR_007699 Gly276Arg UGT1A6 rs28934877 Asn398Asp 
UGT1A1 
 VAR_026138 Glu291Val UGT1A6 rs34993780 Tyr485Asp 
UGT1A1 
 VAR_026139 Ile294Thr UGT1A6 rs1042709 Ala509Pro 
UGT1A1 
 VAR_007701 Gly308Glu UGT1A7 rs17851756 Ile318Thr 
UGT1A1 rs17851756 Ile322Thr UGT1A7 rs28934877 Asn396Asp 
UGT1A1 
 VAR_007702 Gln331Arg UGT1A8 rs45504099 His53Asn 
UGT1A1 
 VAR_026140 Arg336Leu UGT1A8  VAR_015546 Thr202Ala 
UGT1A1 
 VAR_026142 Arg336Trp UGT1A8 rs17863762 Cys276Tyr 
UGT1A1 
 VAR_026143 Trp354Arg UGT1A8 rs17851756 Ile318Thr 
UGT1A1 
 VAR_007703 Gln357Arg UGT1A8 rs34946978 Pro361Leu 
UGT1A1 
- Pro364Leu UGT1A8 rs55750087 Arg364Gly 
UGT1A1 
 VAR_012283 Arg367Gly UGT1A8 rs28934877 Asn396Asp 
UGT1A1 
 VAR_007704 Ala368Thr UGT1A8 rs34993780 Tyr483Asp 
UGT1A1 
 VAR_007705 Ser375Phe UGT1A9 rs4663870 Val264Glu 
UGT1A1 
 VAR_026144 His376Arg UGT1A9 rs17851756 Ile318Thr 
UGT1A1 
 VAR_026145 Gly377Val UGT1A9 rs34946978 Pro361Leu 
UGT1A1 
 VAR_007706 Ser381Arg UGT1A9 rs55750087 Arg364Gly 
UGT1A1 
 VAR_026146 Pro387Ser UGT1A9 rs28934877 Asn396Asp 
UGT1A1 
 VAR_026147 Gly395Val UGT1A9 rs34993780 Tyr483Asp 
UGT1A1 
 VAR_019412 Asn400Asp UGT1A10 - Ile211Thr 
UGT1A1 
 VAR_007707 Ala401Pro UGT1A10 rs17851756 Ile318Thr 
UGT1A1 
 VAR_026148 Arg403Cys UGT1A10 rs34946978 Pro361Leu 
UGT1A1 
 VAR_026149 Trp461Arg UGT1A10 rs55750087 Arg364Gly 
UGT1A1 
- Glu463Ala UGT1A10 rs28934877 Asn396Asp 
UGT1A1 
 VAR_026150 Ala478Asp UGT1A10 rs34993780 Tyr483Asp 
UGT1A1 
 VAR_007709 Tyr486Asp UGT2A1 rs4148301 Gly307Arg 
UGT1A1 
- Leu496Asn UGT2A2 rs4148301 Gly309Arg 
UGT1A3 rs45625338 Arg45Trp UGT2B4  VAR_011329 Phe396Leu 
UGT1A3 rs45595237 Arg49Trp UGT2B4 rs13119049 Asp457Glu 
UGT1A3 rs17851756 Ile322Thr UGT2B4 rs41298245 Cys511Arg 
UGT1A3 rs34946978 Pro365Leu UGT2B7 rs61361928 Leu46Pro 
UGT1A3 rs55750087 Arg368Gly UGT2B7 rs34620993 Ser299Phe 
UGT1A3 rs28934877 Asn400Asp UGT2B10 rs4095564 Ala381Thr 
UGT1A3 rs34993780 Tyr487Asp UGT2B10 rs3208727 Leu497Pro 
UGT1A4 rs17851756 Ile322Thr UGT2B11 rs7697037 Cys155Arg 
UGT1A4 rs28934877 Asn400Asp UGT2B11 rs3890590 Pro288Leu 
UGT1A4 
 VAR_009507 Tyr487Asp UGT2B11 rs11936018 Lys367Ile 
UGT1A5 rs28898602 Leu60His UGT3A2 rs2591714 Ala343Thr 
UGT1A5 rs41270755 Arg49Trp    
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2.4.4 Concordance analysis of predicted results by SIFT and PolyPhen 
 
Table 2-5 shows the concordance analysis between the functional consequences for 247 
nsSNPs predicted by SIFT and PolyPhen. Raw scores rather than arbitrarily defined 
categories were used for the correlation analysis. The row percentage of PolyPhen scores that 
falls into a SIFT category was calculated. Remarkably, 85.7% of “benign” predictions from 
PolyPhen falls into SIFT “tolerant” predictions and 84.2% of “probably damaging” 
predictions from PolyPhen falls into SIFT “intolerant” predictions. Scatter graphs plotted 
using 247 prediction scores from SIFT and PolyPhen showed negative correlation (Figure 
2-1). Spearman’s rank correlation coefficient ρ = -0.709 (P≤0.01) illustrate the significant 
concordance between the prediction scores from SIFT and PolyPhen algorithms.  
 
 
Table 2-5. Concordance analysis between the functional consequences of each nsSNP 
predicted by SIFT and Polyphen.  
 
  SIFT prediction 
  Tolerant borderline 
potentially 
intolerant intolerant Total 
  1.000~0.201 0.200~0.101 0.100~0.050 0.049~0.000  
Polyphen 
prediction 
      
benign 0.00~0.99 84 (85.7%) 5 (5.1%) 6 (6.1%) 3 (3.1%) 98 
borderline 1.00~1.24 17 (81%) 2 (9.5%) 2 (9.5%) 0 21 
potentially 
damaging 1.25~1.49 7 (53.8%) 3 (23.1%) 2 (15.4%) 1 (7.7%) 13 
possibly 
damaging 1.50~1.99 8 (24.2%) 8 (24.2%) 2 (6.1%) 15 (45.5%) 33 
Probably 
damaging ≥2.00 6 (7.3%) 5 (6.1%) 2 (2.4%) 69 (84.2%) 82 
Total  122 23 14 88 247 
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Figure 2-1. Scatter graph displaying the negative correlation between prediction scores for 
nsSNPs in human UGT genes using SIFT and PolyPhen programs (A & B). 
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2.4.5 Validation of the prediction results 
 
The confirmed phenotype of nsSNPs manifests as alteration of enzyme activity and 
susceptibility to diseases such as CN I and CN II and Gilbert’s Syndrome. Up to date, a total 
of 63 nsSNPs of human UGT genes are identified to demonstrate a relation to decreased 
activity, loss of enzyme activity, or susceptibility to diseases based on experimental and 
clinical studies. Using positive findings from the experiments, if the variants were predicted 
to be deleterious, it is considered a correct prediction. An incorrect/error prediction was 
considered when such nsSNPs were predicted as tolerant.  
 
The confirmed variants were collected from results derived from site-directed mutagenesis 
studies of the enzyme using biochemical characterization [134, 142-150] or clinical data from 
family-based and association studies [151-159]. The biochemical/ in vitro and in vivo UGT 
variants and the predictions for their functional impact scores by SIFT and PolyPhen are 
displayed in Table 2-7. If a confirmed UGT nsSNP was predicted as “intolerant” by SIFT and 
“probably damaging” by PolyPhen, then it is termed “true positive finding”. If a confirmed 
UGT nsSNP was predicted as “tolerated” by SIFT and “benign” by PolyPhen then it is termed 
“false negative finding”. According to these criteria, approximately 57 and 67% of 
characterised UGT nsSNPs were correctly predicted as deleterious and are “true positive 
predictions” by SIFT and PolyPhen, respectively (Table 2-6). SIFT predicted 27 confirmed 
UGT alleles as “tolerated” and Polyphen predicted 21 confirmed UGT alleles as “benign”,  
based on this finding, false negative error for SIFT and PolyPhen was 33 and 43%, 
respectively (Table 2-6).  97% of confirmed allelic variants of human UGTs were distributed 
in the UGT1A family, with 2 additional variants from the UGT2B family. Even more 
interesting is UGT1A1 alone contributes 74.6% of the confirmed allelic variants of human 
UGTs, this correlates with the fact that UGT1A1 was the top UGT gene with most frequent 
deleterious nsSNPs predicted by both SIFT and PolyPhen.  
60 
 
 
 
Table 2-6. Evaluation of predicting effect of SIFT and PolyPhen on confirmed human UGT 
nsSNPs.  
 
SIFT prediction 
 number % 
True positive predictions 
 
36 57% 
False negative predictions 27 43% 
Total 63  
  
PolyPhen prediction 
 number % 
True positive predictions 
 
42 67% 
False negative predictions 21 33% 
Total 63  
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Table 2-7. Confirmed allelic variants of human UGT genes using in vivo and in vitro studies. 
 
Enzyme Activity Site 
Directed 
Mutagenesis 
SIFT 
prediction 
score 
PolyPhen 
prediction score 
Reference Allele Name Residue 
1 
Position Residue 
2 
SNP Id Phenot
ype 
In Vitro In Vivo     
UGT1A1*3 Ser 375 Phe  VAR_007705 CN1 Inactive Inactive Yes 0.02 1.949 [134, 146] 
UGT1A1*6 Gly 71 Arg rs4148323  Reduced Reduced Yes 0.1 1.285 [148, 160] 
UGT1A1*7 Tyr 486 Asp  VAR_007709 CN2 Reduced Reduced Yes 0 3.39 
[148, 160, 
161] 
UGT1A1*8 Arg 209 Trp  VAR_007698 CN2 4.40% Reduced Yes 0 3.408 [162, 163] 
UGT1A1*9 Gln 331 Arg  VAR_007702 CN2 Reduced Reduced Yes 0 2.814 [133] 
UGT1A1*11 Gly 308 Glu  VAR_007701 CN1 Inactive Absent Yes 0 2.946 [146] 
UGT1A1*12 Leu 175 Gln  VAR_019411 CN2 38.40% Reduced Yes 0.1 1.547 [149] 
UGT1A1*14 Gly 276 Arg  VAR_007699 CN1 Inactive Inactive Yes 0 2.6 [149] 
UGT1A1*15 Cys 177 Arg  VAR_007697 CN1 Inactive Inactive Yes 0.14 2.739 [149] 
UGT1A1*16 Gln 357 Arg  VAR_007703 CN1 Absent Absent No 0.01 2.105 [147] 
UGT1A1*17 Ser 381 Arg  VAR_007706 CN1  Absent Absent No   0.01 1.507 [147] 
UGT1A1*18 Ala 401 Pro  VAR_007707 CN1  Absent Absent No  0.02 1.92 [147] 
UGT1A1*20 Ala 368 Thr  VAR_007704 CN1  Absent Absent No  0.01 1.957 [147] 
UGT1A1*22 Ala 291 Val  VAR_026138 CN1  Absent Absent No  0 2.766 [147] 
UGT1A1*23 Lys 428 Glu  VAR_007708 CN1  Absent Absent No  0.09 1.124 [147] 
UGT1A1*27 Pro 229 Gln  VAR_009505 Gilbert  Reduced Reduced No  0.3 0.759 [142] 
UGT1A1*29 Arg 367 Gly  VAR_012283 Gilbert  Reduced Reduced No   0 2.94 [142] 
UGT1A1*30 Leu 15 Arg  VAR_019410 CN2 Reduced Reduced Yes 0.16 no score [150] 
UGT1A1*31 Pro 387 Arg  VAR_026146 CN1 Absent Absent Yes 0 3.158 [144] 
UGT1A1*32 Arg 336 Trp  VAR_026142 CN1 0-10% Absent Yes 0 3.235 [143] 
UGT1A1*33 Ile 294 Thr  VAR_026139 CN2 40-55%  Yes 0 1.839 [143] 
UGT1A1*34 Met 310 Val - CN2 26%-51%  Yes 0.52 1.956 [145] 
UGT1A1*351 Ile 431 Thr - CN2 61%-81%  Yes 0.26 1.42 [145] 
UGT1A1*38 Asn 400 Asp VAR_019412 CN2   No  0.01 2.623 [155] 
UGT1A1*42 Glu 463 Ala - CN2   No  0 2.702 [151] 
UGT1A1*44 His 39 Asp  VAR_026135 CN1   Yes 0.01 3.673 [154] 
UGT1A1*51 His 376 Arg  VAR_026144 CN2   Yes 0.01 2.669 [154] 
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UGT1A1*52 Gly 377 Val  VAR_026145 CN2   Yes 0 2.847 [154] 
UGT1A1*55 Leu 496 Asn - CN1   Yes 0.01 2.375 [154] 
UGT1A1*62 Phe 83 Leu  VAR_026136 Gilbert   Yes 0.58 0.863 [159] 
UGT1A1*63 Pro 364 Leu - - Reduced - No  0.01 3.219 [153] 
UGT1A1*69 Ile 159 Thr - Gilbert - - Yes 0.2 1.46 [152] 
UGT1A1*70 Ala 321 Gly - Gilbert - - Yes 0.37 1.051 [152] 
UGT1A1*72 Asp 359 Asn - Gilbert - - Yes 0.05 2.45 [152] 
UGT1A1*73 Pro 364 Leu - Gilbert - - Yes 0.01 3.219 [152] 
UGT1A1*94 Trp 461 Arg  VAR_026149 CN1 - 
No detectable 
activity Yes 0 4.657 [156] 
UGT1A1*95 Arg 336 Gln  VAR_026141 CN1 - - Yes 0.11 1.445 [158] 
UGT1A1*96 Arg 336 Leu  VAR_026140 CN1 - - Yes 0 3.03 [158] 
UGT1A1*97 Gly 395 Val  VAR_026147 CN1 - - Yes 0.01 2.292 [158] 
UGT1A1*98 Pro 387 Ser  VAR_026146 CN1 - - Yes 0 3.158 [158] 
UGT1A1*101 Trp 354 Arg  VAR_026143 CN2 - - Yes 0 4.753 [158] 
UGT1A1*102 Pro 34 Gln  VAR_026134 CN2 - - Yes 0 2.803 [158] 
UGT1A1*103 Arg 403 Cys  VAR_026148 CN2 - - Yes 0 2.92 [158] 
UGT1A1*106 Ala 478 Asp  VAR_026150 CN2 - - Yes 0 2.149 [158] 
UGT1A1*107 Trp 40 Arg - CN2 - - Yes 0.14 4.05 [157] 
UGT1A1*109 Gln 18 Pro - CN2 - - Yes 0.03 1.535 [157] 
UGT1A1*113 Gly 493 Arg - CN2 - - No 0.23 2.086 [164] 
UGT1A3*4a Arg 45 Trp -   Low Yes 0.01 2.078 [165] 
UGT1A3*7a Phe 110 Ile -   Intermediate Yes 0.39 0.804 [166] 
UGT1A3*8a Ala 158 Val -   Low Yes 0.54 1.223 [166] 
UGT1A3*10a Val 47 Ala rs6431625   Intermediate Yes 0.1 0.726 [166] 
UGT1A4*2 Pro 24 Thr -   
Substrate-
dependent No  0.58 2.3 [167] 
UGT1A4*3b Leu 48 Val -   Low activity Yes 1 0.072 [168] 
UGT1A7*4 Trp 208 Arg rs11692021   Low   Yes  0.39 1.199 [169] 
UGT1A7*5 Gly 115 Ser -   Low   Yes 0.74 0.262 [170] 
UGT1A7*6 Glu 139 Asp -   High   Yes 0.59 0.318 [170] 
UGT1A8*3 Cys 277 Tyr  rs17863762   Severely reduced Yes 0 3.076 [171] 
UGT1A9*3a Met 33 Thr -   
Substrate-
dependent impact Yes 1 1.074 [170] 
UGT1A9*5 Asp 256 Asn -   Decreased activity Yes 0.61 0.994 [172] 
UGT1A10*6 Thr 202 Ile  VAR_018355   Reduced by 50% Yes  0.03 1.377 [172, 173] 
UGT1A10*7 Ile 211 Thr    No activity Yes 0.02 2.003 [174] 
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UGT2B10*2 Asp 67 Tyr - 
 
 
Associated with 
lower level of 
nicotine and 
cotinine 
glucuronidation in 
HLM No 0.08 0.524 [175] 
UGT2B15*2 Asp 85 Tyr  rs1902023 
 
 
Increased activity 
on androgens No 0.08 0.299 [176] 
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2.5 Discussion  
 
Based on the results of in vivo and in vitro research, among 63 functionally characterized 
nsSNPs in the UGTs, there were 24 showing altered enzyme expression/activities and 45 
associated with disease susceptibility. In agreement with earlier studies, reduced levels of 
UGT enzyme activities were observed in CN II and Gilbert’s syndrome, whilst absence of 
UGT enzyme activities were observed only in CN I patients. Additional deleterious nsSNPs 
of human UGT were predicted by SIFT and PolyPhen but the phenotypic prediction of these 
nsSNPs has not yet been confirmed using experiments. 
 
More than two-thirds of confirmed variants were UGT1A1 variants (Table 2-7). In the 
confirmed variants of UGT1A1, the associated phenotypes were CN I, CN II [131] and 
Gilbert’s syndrome [132] which are all closely related to bilirubin levels. To date, 47 mutant 
UGT1A1 alleles have been identified (Table 2-7). [133, 134, 142, 145-154, 156-161, 163] 
Many of these SNPs were predicted to have phenotypical effects by the algorithms and the 
correct prediction rates were 68% and 81% by SIFT and PolyPhen, respectively.  
 
A number of the confirmed allelic variants of UGT1A1 associated with Gilbert’s syndrome, 
including UGT1A1*27 (Pro229Gln), *29 (Arg367Gly), *62 (Phe83Leu), *69 (Ile159Thr), 
*70 (Ala321Gly), *72 (Asp359Asn) and *73 (Pro364Leu).  Both SIFT and PolyPhen 
correctly predicted the phenotype of Por364Leu. In addition, UGT1A1*7 (Tyr486Asp) and *9 
(Gln331Arg) closely associated with Crigler-Najjar II syndrome, [124, 134, 148, 161] were 
predicted as probably damaging with high PolyPhen scores. Furthermore, another UGT allelic 
variant UGT1A1*11 (Gly308Glu) identified in Crigler-Najjar I syndrome, [124, 146] was also 
correctly predicted by both SIFT and PolyPhen algorithms.  
Only two variant alleles of the human UGT2 mRNAs have been confirmed in the UGT2 gene 
family, which are Asp67Tyr and Asp85Tyr. [175, 176] Hyperbilirubinemia can be caused by 
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a number of reasons including liver disease and haemolysis. [177] Rate of production of 
bilirubin also needs to be considered when bilirubin level is abnormal, e.g. in inherited 
haemolytic syndromes such as glucose 6-phosphate dehydrogenase deficiency and sickle cell 
anaemia. UGT2B7 promoter variant 840G>A is associated with significantly reduced 
glucuronidation of morphine in sickle cell disease and contributes to the variability in hepatic 
clearance of morphine in these patients. [40] UGT2B15 variant (Asp85Tyr) have been shown 
to relate to prostate cancer risk. [140, 178]  
 
Humans have vast numbers of SNPs and presently there are more than a million SNPs in 
dbSNP that can be screened for association with diseases. Prediction tool SIFT  was tested 
against unbiased experimental datasets in which mutagenesis was performed throughout the 
entire protein, and both wild-type and negative phenotypes were assayed, only three datasets 
fit the criteria and the scarcity of unbiased data sets indicates how difficult characterization of 
mutant proteins on a large scale can be [112]. Therefore, determining disease causing SNPs 
via site directed mutagenesis experiments and gene knockout/knockin experiments is 
complex, lengthy and unrealistic taking into consideration the mass amount of SNPs. [179] 
Using bioinformatic tools to predict nsSNPs most likely to be damaging, this process acts as a 
filter and reduces the number of SNPs required to be screened for association with disease to 
those that most likely alter gene function [28, 29]. By predicting nsSNPs of UGT, we are able 
to distinguish mutations that are unlikely to affect protein function, [29] reducing the number 
of nsSNPs for experimentation thus saving time and resources. Based on prediction results of 
deleterious nsSNPs, on a much smaller scale we then via experiments and clinical studies are 
able to screen for polymorphisms of UGT that may potentially cause disease and increase 
drug toxicity. Moreover, the detection of individual single-nucleotide polymorphisms that 
alter enzyme function can be a useful tool for the identification of disease risk or to 
personalize drug regimens. [180, 181] 
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A total number of 248 nsSNPs were identified through the screening of 21 human UGT genes 
from NCBI dbSNP, Mutdb and Polydoms. However, according to published results from in 
vivo and in vitro studies, only about a quarter of nsSNPs in the dataset of validated human 
UGT genes were found to attribute to alteration of enzyme activity and correlation with 
diseases. These confirmed phenotypes of nsSNPs were related to reduced or absence of 
enzyme activity, and correlated to susceptibility to diseases such as CN, Gilbert’s syndrome 
and hyperbilirubinemia related to certain therapeutic drugs. 
 
There are 49 non-synonymous SNPs in exons 1-5 of UGT1A1 (Supplementary Table 1). To 
date, 47 mutant UGT1A1 alleles have been identified [133, 134, 142, 145-154, 156-161, 163]. 
Deleterious nsSNPs of UGT1A1 such as Ser375Phe, Gly308Glu, Ala291Val and His39Asp 
which are phenotypically presented as CN I were all correctly predicted by both SIFT and 
PolyPhen. The Tyr486Asp (UGT1A1*7) mutation in exon 1 and is the most abundant 
mutation in CN II in Japanese patients, [182] was correctly predicted as deleterious nsSNP by 
both SIFT and PolyPhen.  Variant UGT1A1*27 (Pro229Gln) identified in CN II  with reduced 
UGT enzyme activities in vitro and in vivo was not predicted to be deleterious by SIFT and 
PolyPhen. In 7 confirmed alleles associated with Gilbert’s syndrome (UGT1A1*27, *29, *62 
*69, *70, *72 and *73), only Arg367Gly and Pro364Leu were correctly predicted as 
deleterious nsSNPs of UGT1A1. Other examples of incorrect predictions includes UGT1A1*6 
(Gly71Arg) and UGT1A1*15 (Cys177Arg). Overall, SIFT and PolyPhen predicted UGT1A1 
SNPs to have phenotypical effects with correct prediction rates of 68% and 81%, respectively.  
 
SIFT and PolyPhen are in silico algorithm tools that use protein sequence alignment, 
physicochemical differences, mapping to know protein 3-D structures to predict the functional 
impact of nsSNPs on protein structure and activities [28, 29, 112, 114]. Even though SIFT 
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and PolyPhen employ different approaches and types of reference data for their predictions 
and different scales for scoring, there was significant concordance observed on functional 
consequences of each nsSNP prediction on human UGTs (Spearman’s ρ = -0.709, P ≤ 0.01). 
SIFT and PolyPhen can discriminate diseased variants from neutral variants, results from this 
study are consistent with reports by Ng and Henikoff [29] predicted 757 of 3084 or 25% 
nsSNPs from dbSNP to be damaging and having protein activity impacts. Ramensky et al. 
[28] correctly predicted 27.6% of nsSNPs to affect protein function in the human genome 
variation database. Xi et al [141] reported 30-50% of over 500 amino acid substitution 
variants identified in DNA repair genes were predicted to exhibit reduced activity. Zhang et 
al. [183] studied variants in H+/peptide cotransporter (PEPT1) involved in drug transportation, 
SIFT correctly predicted the SNP that reduced transport capacity to “affect protein function”, 
confirming the accuracy of SIFT on prediction of individual protein predictions. Our recent 
study on phenotype prediction of 791 validated nsSNPs in human cytochrome P450s using 
SIFT and PolyPhen, found that 70% of nsSNPs were correctly predicted as damaging [184]. 
 
Furthermore, the scatter graph plotted using functional consequence predictions from SIFT 
and PolyPhen showed negative correlation between the two sets of scores. Low scores from 
SIFT indicate an “intolerant” prediction, correlated with high scores from PolyPhen which 
indicates a “probably damaging” prediction. High scores from SIFT indicate a “tolerant” 
prediction, correlated with low scores from PolyPhen indicating a “benign” prediction. This 
correlation was further established by row percentage calculated between scores for each one 
of 247 nsSNPs predicted by SIFT and PolyPhen. The two algorithms show agreements at two 
extremes of the scores, a high percentage (85.7%) of “benign” predictions from PolyPhen was 
predicted “tolerant” by SIFT and a high percentage (84.2%) of “probably damaging” 
predictions from PolyPhen was predicted “intolerant” by SIFT. There were slight correlations 
for scores in between, showing a lack of agreement crossing different prediction categories of 
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the two algorithms, demonstrating a strong correlation in their predictions on potential effect 
of known human UGT nsSNPs on protein function. The concordance between SIFT and 
PolyPhen prediction scores suggest they can be used in combination in the future to improve 
accuracy of prediction studies.  
 
Although bioinformatics tools show their potential in reducing the number of nsSNPs for 
disease association studies by filtering nsSNPs that are most likely to be disease related, error 
predictions do occur. In this study, based on collected data from 63 in vitro and in vivo 
studies, the false negative predictions for SIFT and PolyPhen is 43% and 33%, respectively. 
There are several aspects affecting the prediction accuracy for prediction tools like SIFT and 
PolyPhen algorithms. Firstly SIFT and PolyPhen rely on several different databases for SNP 
information, polluted databases with erroneous SNP reports and bias of the data towards 
disease-related allelic variants are likely to lead to an over prediction of the number of 
deleterious nsSNPs [28]. For example, Ramensky et al. [28] compared a fraction of nsSNPs 
predicted to be damaging for HGVbase entries and found that the overall prediction rate for 
the category “Suspected” nsSNPs was 31.4%, for the category “Proven” nsSNPs was 28.9% 
and for “Proven” nsSNPs from systematic studies on healthy individual was 27.6%.  
Furthermore, programs identifying SNPs may detect base differences between the functional 
gene and a pseudogene and erroneously report these differences as SNPs in the function 
protein. Including nsSNPs erroneously mapped from pseudogenes in the SNP database will 
affect prediction accuracy on prediction tools using SNP information from these databases 
[29]. The growth of public SNP data and improvements of SNP database data will assist in 
acquiring correct information on SNPs to assist in improving prediction accuracy of 
bioinformatics tools. Secondly, SIFT has a weighted false positive error of 19% and PolyPhen 
9%, indicating that if all of the nsSNPs from dbSNP were functionally neutral,  19% or 9% 
would have been predicted as damaging by SIFT and PolyPhen, respectively [29]. 
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Additionally, there are factors overlooked when the predictions occurs, SIFT predicts on 
amino acid substitution in the protein product and does not take into account mutations that 
affect transcription, translation, splicing and other possible pretranslational alterations [29], 
erroneous predictions may then arise. Furthermore, the prediction might appear incorrect 
based on the lack of association with obvious altered phenotypes. SIFT and PolyPhen may be 
sensitive to a mutation and predict it to be damaging to protein function, but if the phenotype 
is undiagnosed, or hasn’t yet been assayed for therefore condemned an “error prediction”. On 
the other hand, SIFT and PolyPhen may predict a deleterious mutation to be “tolerated” and 
because it is not an obvious phenotype, we believe that it is a correct prediction whereas in 
actual fact it is a deleterious mutation that’s recessive or undiagnosed. Therefore it is 
important to identify the association of SNPs with various phenotype/diseases. Identifying 
deleterious nsSNPs using bioinformatics tools like SIFT and PolyPhen may lay the foundation 
and initiate the process of identifying SNPs that has clinical implications. There lies the 
ability to reduce the number and/or the field of possible deleterious nsSNPs that needs to be 
evaluated in clinical studies.  
 
In summary, in silico analysis predicted that 35.3-46% of over 200 amino acid substitution 
variants currently identified in the human UGT genes might cause reduced enzyme activity 
and/or elevated bilirubin levels. The identification of these variants using bioinformatic tools 
such as SIFT and PolyPhen narrows down study fields and is the first step of the progress to 
evaluate their possible phenotypic importance in costly clinical studies. 
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Chapter 3. Bioinformatics Study of Current and Future Therapeutic Targets of 
Rheumatoid Arthritis 
 
3.1 Introduction 
 
Rheumatoid arthritis (RA) is a chronic systematic autoimmune disease that involves the 
inflammation of multiple joints. In RA, the immune system targets the synovial membrane of 
joints which causes progressive and irreversible damage to the cartilage, joints and the bones. 
RA is a multifactorial disease with external and internal pathogens affecting the disease 
development although currently its etiology is still largely unknown.  
 
In RA, the pathological changes in the synovial membrane of the affected joints result in joint 
inflammation [185]. Common symptoms include morning stiffness in and around the affected 
joints, warmth and redness, pain on motion and local soft tissue swelling. This disease may 
also affect other organs of the body including the central nervous system, heart, kidneys, liver, 
lungs and the eyes [186]. Progression of RA can lead to deformities, reduced quality of life 
and in some cases, death. The clinical manifestations and course of RA are extremely 
variable, characterised by exacerbations and remissions, making this disease difficult to 
diagnose in the early stages as symptoms may vary greatly. The American College of 
Rheumatology has developed a set of criteria for diagnosing the disease [187].  
 
RA is a worldwide disease with an estimated prevalence of 1% [76]. Cooper et al. [188] 
recently reported prevalence data for autoimmune diseases by geographic area, which showed 
that RA in France, Hungary, Spain, Turkey, Greece and UK has a high occurrence rate of 
310-800 per 100,000. The average annual incidence in the United States is about 70 per 
100,000 annually. RA may present at any age, however most patients are first affected in their 
forties to sixties [189]. Prevalence of RA also increases with age, affecting 5% of women over 
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the age of 55. Data shows that both incidence and prevalence of RA is two to three times 
greater in women than in men, however, it tends to be more severe in men [186, 190].  
 
RA is a progressive disease with functional status decline. Patients diagnosed with RA may 
suffer from substantial physical deformation and can subsequently develop high levels of 
emotional stress due to unfavourable changes in lifestyle. More than half of all RA patients 
demonstrate severe disability 10 years after the onset of the disease [189]. Social impact is 
also of substantial consequence, figures show that tangible societal costs of RA in the US is 
$19.3 billion (in 2005 dollars) and intangible cost of $39.2 billion, this includes quality of life 
deterioration and premature mortality [191]. With a life expectancy decrease of 3 to 10 years, 
mortality rates of RA patients surpass those of the general population, the main causes of 
death in RA patients  are complications relating to the cardiovascular, haematological, 
gastrointestinal and pulmonary systems and infections [190].  
 
Previously, practitioners embraced a “go low, go slow” approach with RA treatment, 
consisting of a slow and gradual build-up of physical therapy and non-pharmacological 
interventions as the base, followed by the use of aspirin and other non-steroidal anti-
inflammatory drugs (NSAIDs), and later the introduction of a single disease modifying anti-
rheumatic drug (DMARD) [192]. This would continue for long periods of time without much 
change being achieved, often resulting in irreversible damage to the joint synovial membrane, 
cartilage and bones. However, treatment strategies for RA have changed dramatically in the 
past 2 decades. The current treatment strategy in early RA focuses on timely, aggressive and 
continuous treatments, using all available therapies either singularly and often in 
combinations to control inflammation as completely as possible [193].  
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RA is a complicated and progressive disease that leads to increased disability and mortality 
rates; it also causes suffering and reduced quality of life for RA patients. Furthermore, high 
costs of RA treatments create a large burden on society. This chapter aims to identify current 
therapeutic targets for RA based on data from the literature and several drug target related 
databases, identified targets were further analysed using a bioinformatics tool, PANTHER. 
PANTHER is a publicly available database that relates protein sequence evolution to 
evolution of protein functions and biological roles (http://www.pantherdb.org/). We also 
explored possible future therapeutic targets for RA and discussed the possibility of 
discovering novel drugs with improved efficacy and reduced toxicity for RA treatment. 
 
3.2 Methods 
 
3.2.1 Review of current therapies for RA 
 
In order to identify all the available RA therapeutic agents (“Approved” & “Investigational”), 
we systematically reviewed the published human studies on RA. Literature was searched 
mainly from Pubmed (from the respective inception to July 2010). Additionally, data from the 
US Food and Drugs Administration (FDA, www.fda.gov) and several online databases were 
extracted. Search items used in the databases include “rheumatoid arthritis” and “Anti-
rheumatic medication”. Only human data were included.  
 
3.2.2 Collection of current and investigational targets of RA 
 
Candidate targets of RA were extracted from three online databases: Drugbank, Therapeutic 
Target Database (TTD) and Potential Drug Target Database (PDTD).  
 
3.2.3 Analysis of current and investigational targets of RA 
 
After the collection of current approved drug targets, using target gene names via the 
“transcripts & protein” option on PANTHER for classifications. For those that did not have a 
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gene name on Panther and so could not be classified by Panther, search of the gene names 
was complete via NCBI and Uniprot for PANTHER classification.  
 
3.3 Review of current therapies of RA  
 
Immunopathogenesis of RA can be broadly classified into three phases: immunological 
abnormalities, inflammation and proliferation of the synovium, and then joint destruction and 
deformity that result in physical disability [194]. Individual RA patients have these phases 
mingled and mixed intricately. In early RA, the most noticeable feature in the affected joints 
is tissue oedema manifested as swelling and pain. This is followed by synovial lining 
hyperplasia due to vast infiltration of immune-mediating and inflammatory cells into the 
affected joints. The hypertrophy of the synovial lining becomes locally invasive at joint 
interface with cartilage and bone, forming a mass tissue called “pannus” which is the origin of 
joint erosion [195]. It is observed that the greater the inflammatory loads to which joints are 
exposed to, the more likely it is for structural damage to occur and the faster such damage will 
progress. Time is also another important contributory factor for damage progression, the 
longer the inflammation lasts, the more likely structural damage is to occur [196].  
 
Early and accurate diagnosis of the disease in combination with timely and effective 
treatments is critical in RA management. The frontline treatment of RA is currently anti-
rheumatic medication with the main goal to contain inflammation as effectively and as timely 
as possible. It is extremely important in early RA to achieve clinical remission in order to 
protect affected joints from structural damage and sustain quality of life for the patient [196, 
197].  Almost all anti-rheumatic agents used and developed for RA treatments have focused 
on reducing inflammation, relieve pain and most importantly to protect joint structures, by 
blocking proinflammatory molecules and inhibiting matrix-degrading factors. This can be 
achieved by blocking the target molecule itself, it’s receptors or it’s transcription factors; or 
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via the enhancement of it’s natural inhibitors and antagonists [198]. Therapeutic agents for 
RA can be generally categorised into 3 main groups: corticosteroids, NSAIDs and DMARDs.  
 
3.3.1  Corticosteroids 
 
Corticosteroids represent a group of therapeutic agents used in RA that have short term effect. 
These drugs controls systematic manifestation and provide rapid relief of joint symptoms such 
as joint swelling. However corticosteriods do not affect disease progression and provide no 
protection for the joint cavity or its surrounding cartilage or bone.  
 
3.3.2  NSAIDS 
 
NSAIDs have immediate analgesic and anti-inflammatory effects to treat pain and swelling 
associated with RA. NSAIDs inhibit cyclooxygense (COX) and reduce prostaglandin 
production, in turn diminishing inflammation and pain. Currently there are 3 forms of COXs, 
COX-1 is found in most normal tissues including the gastrointestinal tract, kidneys and 
platelets; COX-2, found particularly in the kidney, brain, bone and reproductive organs but 
increased substantially in any tissue with inflammation and injury; and COX-3, a newer 
identified COX found in the highest concentration in the brain and heart [199].  
 
COX-1 and COX-2 are clinically relevant to RA and they are the main therapeutic targets of 
NSAIDs. COX-1 is responsible for physiological functions such as protection of the gut 
mucosa, thus gastrointestinal toxicity is common amongst patients using non-selective 
NSAIDs. Gastric ulcers complicated with haemorrhage and perforation is an important health 
concern to non-selective NSAIDs users. The limitation of this group of drugs is reduced by 
the wider use of COX-2 selective NSAIDS. Moreover, COX-2 appears to be a more important 
mediator in inflammation and thus a key factor in arthritis pain, therefore the use of selective 
COX-2 NSAIDs with RA patients is increasingly popular [200]. However, selective COX-2 
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inhibitor related cardiovascular risks needs to be taken into consideration [189] and again, 
NSAIDs may not effect disease progression in RA.  
 
3.3.3  DMARDs 
 
DMARDs are the mainstay of RA therapy and are used in the early stages of RA treatment to 
prevent irreversible damage to joints. Among these, methotrexate (MTX, 4-amino-N10-
methylpteroyl glutamic acid) is the most  commonly used [201]. This group of drugs can 
modify the progression of RA and exhibit the ability to protect cartilage and bone.  
 
MTX is an analogue of folic acid and aminopterin (4-amino-pteroyl glutamic acid) [202]. 
MTX therapy has been used for the past 3 decades as the first choice in RA management, due 
to good efficacy, acceptable toxicity, low cost and vast patient availability [192]. Its 
popularity is also evident as MTX monotherapy and combination with other drugs has often 
been used in clinical studies to compare the effectiveness of different approaches of anti-
rheumatic agents. Whilst considered the anchor drug of other DMARDs, the 
pharmacodynamics and kinetics of MTX is still not fully understood, in particular the 
mechanism of inflammation modulation at a low dose in RA is unknown [202, 203]. Dose, 
route of administration and several pharmacokinetic profiles of MTX are listed in Table 3-1. 
MTX binds to and deactivates dihydrofolate reductase, an enzyme responsible for purine 
synthesis which is important for cell proliferation. However, the antiproliferative effect is not 
the main action of MTX in RA patients because a high dose is required to achieve this effect 
[202]. This suggests that the anti-inflammatory effects of MTX are more important than its 
effect on DNA prohibition. Furthermore, MTX modulates the cytokine network by inhibiting 
the intracellular expression of proinflammatory cytokines [e.g. interferon-γ (IFN-γ) and 
interleukin 4 (IL-4)) on peripheral CD45RO+CD4+ T-cells of patients with RA [204]. In 
addition, another study shows that MTX induced the secretion of IL-10 and inhibited the 
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production of nitric oxide in peripheral mononuclear cells derived from 28 active RA patients, 
suggesting that MTX immunosuppressive effect may be related to apoptosis via modulation 
of oxidative stress through the induction of IL-10 [205]. A randomised, double-blind, parallel 
designed clinical trial, macrophage numbers in 38 patients treated with MTX were 
significantly reduced in the intimal lining layer of the synovium; also present were reduced 
levels of T cell, vascular cell adhesion molecule-1 (VCAM-1) and  tumor necrosis factor-α 
(TNF-α) [206]. These studies suggest that MTX has important anti-inflammatory and 
immunosuppressant functions via its interaction with pro-inflammatory cytokines and 
lymphocytes. Other pharmacological mechanisms of MTX involves the promotion of 
adenosine release, suppression of lymphocyte proliferation, and neutrophil chemotaxis and 
adherence [202]. Frequently observed adverse events associated with MTX include 
hepatotoxicity (increased level of liver enzymes), GI symptoms (nausea, reduced appetite and 
stomatitis), these are observed in less than 5% of patients on MTX treatment. Very rarely, less 
than 1% of patients experience adverse effects related to the central nervous system, 
pulmonary toxicity, pancytopenia, liver cirrhosis, and nephrotoxicity [207].  
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Table 3-1. Pharmacokinetic profiles for MTX and leflunomide. 
 
Name Mechanism of 
action 
Indication Route of 
Administration 
Dose Cmax  t1/2β CL Bioavailability Toxicity Reference 
Leflunomide 
(Arava) 
Inhibition of 
dihydroorotate 
dehydrogenase 
and 
antiproliferative 
activity 
RA Oral Loading dose: 
one 100 mg 
tablet per day 
for 3 days 
Maintenance 
dose: 20 mg 
daily 
2.24 ± 
0.85 
µg/ml 
2 weeks 
(metabolite1) 
31ml/hr (IV) 80% The most frequent 
adverse events 
observed were 
diarrhea, 
abdominal pain, 
leukopenia, 
anemia and 
elevated liver 
function tests 
[208] 
MTX 
(Trexall) 
Inhibition of 
dihydrofolic acid 
reductase and 
interfereence with 
DNA synthesis, 
repair, and cellular 
replication 
RA, 
neoplastic 
diseases, 
psoriasis  
Intramuscular  
Intrathecal  
Intravenous  
Oral 
Adult RA: 
Single oral 
doses of 7.5 
mg once 
weekly 
Divided oral 
dose of 2.5 mg 
at 12 hour 
intervals for 3 
doses given as 
a course once 
weekly 
Juvenile RA: 
10 mg/m2 
given once 
weekly 
0,54 ± 
0.18 
µM 
3-10 hr 80–90 
ml/min/m2 
NA The most 
frequently 
reported adverse 
reactions include 
ulcerative 
stomatitis, 
leukopenia, 
nausea, and 
abdominal 
distress. Other 
frequently 
reported adverse 
effects are 
malaise, undue 
fatigue, chills and 
fever, dizziness 
and decreased 
resistance to 
infection 
[209, 210] 
Cmax, maximum plasma concentration; t½β, elimination half-life; CL, systematic clearance.
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Another DMARD leflunomide, is a RA specific drug that selectively inhibits de novo 
pyrimidine synthesis by blocking the rate-limiting enzyme dihydroorotate dehydrogenase 
[211, 212]. It acts on proliferating-activated CD4+ T cells, hindering the ability of 
lymphocytes to initiate pro-inflammatory processes in RA patients [211, 212]. The dose and 
routes of administration, pharmacokinetic parameters and toxicity of leflunomide are listed in 
Table 3-1. 
 
In recent years, a group of anti-rheumatic agents called biologics has emerged and is 
subsumed under DMARDs. The development of these new drugs is lead by much better 
molecular understanding of the disease pathogenesis and further advance of technology in 
drug discovery. Biologic agents refer to complex protein molecules that are created using 
molecular biology methods and are produced in prokaryotic or eukaryotic cell cultures. Their 
biological activities can be predefined, and are usually directed towards a specific cytokine or 
cell surface molecule, making it possible to predict a range of molecular activities [192].  
Biologic agents target immune effector cells (T-lymphocytes, B-lymphocytes and 
macrophages) and associated signalling molecules that are involved in the initiation and the 
progression of both immune and inflammation responses in RA. Therapeutic biologic 
DMARDs include TNF-α inhibitors, interleukin receptor antagonists, B cell depletion and 
other cytokine immunotherapies [212]. 
 
3.3.4  Anti-TNF-α agents 
 
Since their introduction in 1998, inhibitors of the proinflammatory cytokine TNF have had a 
dramatic impact on physicians’ therapeutic approach to patients with RA [213]. Anti-TNF-α 
agents represent an important class of biologics that inhibit TNF activities through different 
mechanisms (Table 3-2). TNF-α is an important inflammatory cytokine that plays a crucial 
role in the pathogenesis of RA and is a major mediator of structural damage in RA. 
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Monocytes (e.g. macrophages) are the major source of TNF-α, other cells such as T 
lymphocytes, neutrophils, mast cells and endothelium also contribute in different 
circumstances [76]. Clinical investigation  showed that TNF-α regulates IL-6, IL-8, monocyte 
chemoattractant protein-1, and VEGF production, recruitment of immune and inflammatory 
cells into joints, angiogenesis, and reduction of blood levels of matrix metalloproteinase 
(MMPs) (e.g. MMP-1, MMP-3) in RA [76]. These findings indicate the importance of TNF-α 
involvement in the pathophysiology of RA. TNF-α binds to its widely expressed receptors 
(type 1 (p55) and type 2 (p75)) and exists in soluble forms after cleavage [195], therefore 
TNF receptors also act as TNF antagonists. Presently, 5 anti-TNF-α biologics have been 
approved by the FDA for the clinical use in RA and have proven to be more effective when in 
combination with conventional DMARDs. Additionally, anti-TNF-α agents can be used in 
other autoimmune diseases as shown in Table 3-2.  
 
Infliximab is an anti-TNF-α monoclonal antibody which binds to soluble and membrane 
bound TNF-α, impairing the binding to its receptor and mediating killing of TNF-α 
expressing cells [212]. Infliximab has been shown to down regulate inflammatory cytokines 
IL-1β and IL-6 in osteoblastic cells, which play a crucial role in arthritis-related bone loss due 
to its involvement in osteoclast recruitment and activation [214]. Hence anti-TNF-α agents 
also have beneficial effects on protection of the bone in RA disease progression. Adalimumab 
is a recombinant human IgG1 monoclonal antibody that binds TNF-α, prohibiting its binding 
to TNF-α receptors. A study in RA patients showed that initial combination of MTX and 
adalimumab achieved a faster control of disease activity [215]. Etanercept is a soluble p75 
TNF receptor composed of 2 dimers, each with the ligand binding portion of p75 receptor 
linked to the Fc portion of human IgG1. Etanercept binds to both TNF-α and TNF-β, 
prohibiting the interaction with their respective receptors [212]. 
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Newer TNF inhibitors developed for the treatment of RA includes golimumab and 
certolizumab. Golimumab (CNT0-148) is a fully human anti-TNF-α IgG1 monoclonal 
antibody that targets and neutralizes both the soluble and the membrane-bound forms of TNF-
α [186, 189]. Certolizumab is a pegylated, Fab fragment of a humanized anti-TNF-α 
monoclonal antibody which binds with high affinity to TNF-α neutralizing its activity [189].   
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Table 3-2. Pharmacokinetics of anti-TNF-α agents. 
 
Name Mechanism of action Indication Route of 
Administration 
Dose Cmax  t1/2β CL Toxicity References 
Adalimumab   
(Humira) 
Binds specifically to 
TNF-α and blocks its 
interaction with the 
p55 and p75 cell 
surface TNF receptors 
RA, JIA, 
PA, AS, 
CD, PP 
 
SC 40 mg every other 
week 
4.7 ± 
1.6 
µg/ml  
131±52 
hr 
 12-17 
ml/hr  
Mild injection site 
reactions 
(erythema and/or 
itching, 
hemorrhage, pain 
or swelling). The 
most common 
adverse reactions 
are clinical flare 
reaction, rash and 
pneumonia 
[216, 217] 
Certolizumab 
(Cimzia) 
Anti-TNF-α 
monoclonal antibody; 
binds with high 
affinity to TNF-α 
neutralizing its 
activity 
RA, CD SC 400 mg SC at 
weeks 0, 2 and 4 
followed by 200 
mg every other 
week 
43-49 
µg/ml  
14 days IV: 9.21 
mL/hr to 
14.38 
ml/hr  
The most common 
adverse reactions 
are upper 
respiratory 
infections (18%), 
rash (9%) and 
urinary tract 
infections (8%) 
[218] 
Etanercept  
(Enbrel) 
Soluble form of p75 
TNF receptor that 
binds to TNF-α and 
TNF-β 
RA, JIA, 
PA, AS, PP 
SC 50 mg every week  SC 
25mg 
× 2: 
2.4 ± 
1.5 
µg/ml 
SC 
50mg 
× 1: 
2.6 ± 
1.2 
µg/ml 
102 ± 
30 hrs 
(SC 25 
mg) 
160 ± 80 
ml/hr 
Injection site 
reactions 
(erythema and/or 
itching, pain, or 
swelling) 
[219-221] 
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Golimumab 
(Simponi)  
Anti-TNF-α IgG1 
monoclonal antibody 
that targets and 
neutralizes both the 
soluble and 
membrane-bound 
form of TNF-α 
RA, PP, 
AS  
SC 50mg once a 
month 
2.5 
µg/ml 
2 weeks IV: 4.9 to 
6.7 
ml/day/kg 
The most common 
adverse reactions 
to golimumab 
include upper 
respiratory tract 
infection, sore 
throat and nasal 
congestion 
[222] 
Infliximab 
(Remicade) 
Neutralizes the 
biological activity of 
TNF-α by binding 
with high affinity to 
the soluble and 
transmembrane forms 
of TNFα and inhibits 
binding of TNFα with 
its receptors 
RA, CD, 
UC, AS, 
PA, AS, PP 
IV 3 mg/kg given as 
an intravenous 
induction regimen 
at weeks 0, 2, and 
6 weeks followed 
by a maintenance 
regimen of 3 
mg/kg every 8 
weeks  
118 
µg/ml 
at a 
dose of 
5 
mg/kg 
7.7-9.5 
days 
- Infusion-related 
reactions (e.g. 
dyspnea, flushing, 
headache and rash) 
[223, 224] 
AS, ankylosing spondylitis; Cmax, maximum concentration; CD, Crohn’s disease; CL, systematic clearance; IV, intravenous; JIA, juvenile idiopathic arthritis; PP, plaque psoriasis; 
PA, psoriatic arthritis; SC, subcutaneous injection; t½ β, elimination half-life; UC, ulcerative colitis.
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3.3.5  Other biologics 
 
T cells comprise approximately 40% of synovial tissue cells with CD4+ cells being 
predominant in the synovial sublining in RA [195]. CD4+ cells produce proinflammatory 
cytokines and help B cells divide [195]. Subsequently, activated B cells provide feedback and 
interact with T cells, followed by recruitment and activation of monocytes and macrophages 
leading to more production of proinflammatory cytokines (e.g. IL-6 and IL-1) in the synovial 
cavity [212, 225]. The dysregulation of B cells also produces rheumatoid factors  that activate 
chondrocytes and fibroblasts which release collagenases and metalloproteinases that 
contribute to tissue destruction [212]. Therefore, inhibition of T and B cells not only helps 
control inflammation, but also prevents tissue destruction, contributing significantly to disease 
control in RA. Biologics involving T cell and B cell inhibition have been developed. 
Abatacept was approved by FDA for RA treatment in 2005 [226]. It is a soluble selective T-
cell inhibitor that selectively modulates T cell activation via the CD80/CD86:CD28 pathway. 
Following 12 months' treatment, serum levels of IL-6, soluble IL-2 receptor, C-reactive 
protein, soluble E-selectin, and soluble intercellular adhesion molecule-1 were significantly 
lower in patients receiving abatacept  at 10 mg/kg versus placebo [227]. Rituximab is a B-cell 
depleting agent [228], blocking B-cell activity with anti-CD20 monoclonal antibody. It was 
approved in 2006 for RA patients failing TNF inhibitors. Rituximab induces C1q complement 
dependent cytotoxicity and antibody dependent cell mediated cytotoxicity through natural 
killer cells, macrophages and monocytes causing B-cell lysis as well as B-cell apoptosis 
[189].  
 
IL-1 is a pro-inflammatory cytokine present in the synovial lining in RA and is produced by 
activated monocytes and macrophages. IL-1 stimulates the release of MMP and increases 
bone resorption by effects on osteoclasts, therefore having a significant role in cartilage and 
bone erosion [212]. IL-1 receptor antagonist such as anakinra may benefit RA patients 
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through the down-regulation of  IL-1 actions. Anakinra is administered daily by subcutaneous 
injection.  Due to its unfriendly dosing and reduced effectiveness compared to anti-TNF 
biologic agents, this drug is infrequently used in RA [192]. It is also recommended that 
anakinra not used in combination with anti-TNF-α antagonists [212], this further limits the 
use of anakinra in the clinical setting. 
 
In January 2010, FDA approved tocilizumab which is the first humanised anti-IL-6 receptor 
monoclonal antibody that inhibits the signalling of IL-6 [186]. Tocilizumab is used to treat 
adults with moderate to severe RA who have not adequately responded to or cannot tolerate 
other approved drug classes for RA (www.fda.gov). A comparison study of 24 weeks 
demonstrates that tocilizumab monotherapy is better than MTX monotherapy, showing rapid 
improvement in RA signs and symptoms, and a favourable benefit-risk in RA patients 
compared to MTX treatment [229]. A summary of pharmacokinetic profiles of non-anti-TNF-
α agents is provided in Table 3-3. 
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Table 3-3. Pharmacokinetics of non-anti-TNF-α biologic agents. 
 
Name Mechanism of action Indication Route of 
Administration 
Dose Cmax  t1/2β CL Toxicity Reference 
Abatacept 
(Orencia) 
T cell inhibition by 
binding to CD80 and 
CD86, thereby blocking 
interaction with CD28 
RA, JIA IV <60 kg: 500 mg 
60 to100 kg: 750 
mg 
>100 kg:1000 mg  
 W0, W2, W4 
then every 4 
weeks thereafter 
295 (171-
398) µg/ml  
13.1 (8-25) days 0.22 (0.13-0.47) 
ml/hr/kg 
The most serious 
adverse reactions 
are serious 
infections and 
malignancies. 
The most 
commonly 
reported adverse 
events are 
headache, upper 
respiratory tract 
infection, 
nasopharyngitis, 
and nausea 
[230] 
Anakinra 
(Kineret) 
Blocks the biologic 
activity of IL-1 by 
competitively, inhibits IL-
1 binding to the IL-1 type 
I receptor (IL-1RI)  
RA  SC 100 mg daily - 4 to 6 hrs - Injection site 
reactions 
characterized by 
1 or more of the 
following: 
erythema, 
ecchymosis, 
inflammation, 
and pain 
[231, 232] 
Rituximab 
(Rituxan) 
Binds specifically to the 
antigen CD20 on B-cells 
and induces apoptosis 
RA, NHL, 
CLL 
IV Two-1000 mg IV 
separated by 2 
weeks 
2 × 500 mg: 
157 (± 46) 
µg/ml   
2 × 1000 mg: 
318 (± 86) 
µg/ml  
18.0 days (range: 
5.17-77.5 days) 
0.335 L/day Adverse reactions 
include infusion 
related reactions, 
upper respiratory 
tract infection, 
nasopharyngitis, 
urinary tract 
infection, and 
bronchitis. 
[233-235] 
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Tocilizumab 
(Actemra) 
Binds specifically to IL-6 
receptors (sIL-6R and 
mIL-6R), and inhibit IL-
6-mediated signaling 
through these receptors 
RA IV 4 mg/kg followed 
by an increase to 
8 mg/kg based on 
clinical response 
4 mg/kg: 
88.3 ± 41.4 
µg/ml 
8 mg/kg: 183 
± 85.6 µg/ml 
10 mg/kg: 151 ± 
59 hrs (6.3 days) 
10 mg/kg: 0.29 ± 
0.10 ml/hr/kg  
The most 
common serious 
adverse reactions 
are serious 
infections  
[236] 
Cmax, maximum plasma concentration; CL, systematic clearance; CLL, chronic lymphocytic leukemia; IL, interleukin; IV, intravenous; NHL, non-Hodgkin's lymphoma; SC, 
subcutaneous injection; t½β , elimination half-life
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It has been observed that combination therapy of biologics with MTX versus MTX 
monotherapy reduced the influence on health-related quality of life, home and work activities 
and productivity in patients with RA. [237-239]. Biological agents are also more effective and 
better tolerated when they are used in combination with other DMARDs besides MTX [189]. 
These productivity gains represent clinical benefits and suggest a substantial indirect cost gain 
might be achieved with combination therapy in RA patients. Moreover, patients can switch 
from one biologic to another due to nonresponse, loss of response, or adverse events. Results 
from an observatory study suggest  that a second TNF-blocking agent may be effective after 
failure of the first, regardless of the reason for discontinuation of the first TNF-blocking agent 
[240]. The development of biologics is a major advance for RA patients who have poor or 
incomplete response to MTX and/or other traditional DMARDs, this advance has provided 
more therapeutic options for many RA patients.  
 
Although there are a number of anti-rheumatic drugs available, patients often have 
unpredictable response to drugs, suffering severe side effects and toxicity associated with 
drug treatments. This suffering may be tolerable when the drugs are effective for RA, 
however, not all patients respond to treatments. Unsuccessful drug treatment is a major 
concern for RA patients; sometimes the medication is unresponsive, other times the effect of 
medicine simply wears off. Therefore, it requires the patient to switch to new drugs, this may 
cause the patients to experience anxiety and a high level of uncertainty [241]. For this reason, 
it is essential that the pathophysiological process of RA is better understood and new drugs 
with better efficacy and lesser toxicity are developed.  
 
During the last decade, important breakthroughs have been made in the treatment of RA. For 
instance, the recognitions of early immunomodulatory treatment as a crucial step for 
managing the disease to reduce the long-term destructive effect and the key role of TNF in 
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inflammation and matrix destruction, as well as the implementation of conventional disease-
modifying anti-rheumatic drugs and biologic agents as effective approaches. 
 
Although there are many impressive disease-modifying effects of biologic agents observed in 
the last decade, there is still a huge unmet need in the current management of RA. For 
example, not all RA patients respond to the treatment and some patients gradually lose 
response due to the development of anti-drug antibodies or escape mechanisms associated 
with the disease process. Besides, side-effects related to biologics are increasingly reported 
and the long term effects of these anti-rheumatoid agents are still uncertain. Thus, the need for 
additional agents in combination therapy for RA has been questioned [242-246], and there is 
definitely the need to find new therapeutic options including new targeted therapies to 
overcome shortages that exists in the current therapies. 
 
Table 3-4 shows new therapeutic strategies in RA targeting at cytokines, chemokines, 
signalling pathways, which are currently under pre-clinical or clinical investigations. New 
therapies to target TNF, interleukin and their related signalling pathways remain to be the 
preferences to control the disease. Agents interfering with B cells, T lymphocyte co-
stimulatory pathways and interleukin receptors combined with TNF blockers will provide 
new insights into the development of new targeted therapeutic strategies. In addition, there are 
potential approaches with uncertain clinical effects which need to be explored further in the 
future, such as targeting TNF-like ligand 1A, advanced glycation end-products, sphingosine 
1-phosphate, high mobility group box-1 protein, granulocyte-macrophage colony-stimulating 
factor, interleukin-1 receptor-associated kinase 4, allograft inflammatory factor-1, metastasis- 
promoting S100, IL-15, oncostatin M, epigenetic modifications of synovial cells, dendritic 
cells, chemokines, and signalling pathways.  
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Table 3-4. RA drugs and corresponding targets under investigation. 
 
Target ID Target Name Target Type Drug Drug Type 
TTDC00044 MAP kinase p38 clinical trial target VX-745 Discontinued 
TTDR00847 ADAM 17 Research target DPC-333 Discontinued 
TTDS00339 
Vascular endothelial growth 
factor     Successful N/A N/A 
TTDC00076 92 kDa type IV collagenase clinical trial target None for RA N/A 
TTDC00068 Cathepsin K clinical trial target None for RA N/A 
TTDC00222 
Inhibitor of nuclear factor κ-B 
kinase clinical trial target None for RA N/A 
TTDC00148 Integrin β-1 clinical trial target None for RA N/A 
TTDC00031 Integrin β-7 clinical trial target None for RA N/A 
TTDC00177 Interleukin-13 clinical trial target None for RA N/A 
TTDC00103 
Macrophage migration 
inhibitory factor clinical trial target None for RA N/A 
TTDC000201 
Mitogen-activated protein 
kinase 14 clinical trial target None for RA N/A 
TTDC00107 Toll-like receptor 9 clinical trial target None for RA N/A 
TTDR00277 αvβ3 integrin receptor Research target None for RA N/A 
TTDR01267 β-Lactoglobulin-1 Research target None for RA N/A 
TTDR00289 C-Jun N-terminal kinase Research target None for RA N/A 
TTDR01029 
CAMP-specific 3',5'-cyclic 
phosphodiesterase 7 Research target None for RA N/A 
TTDR00887 
CASP8 and FADD-like 
apoptosis regulator Research target None for RA N/A 
TTDR00975 Glandular kallikrein 1 Research target None for RA N/A 
TTDR00567 
Heparin-binding growth factor 
2 Research target None for RA N/A 
TTDR01206 
Inhibitor of nuclear factor κ B 
kinase β subunit Research target None for RA N/A 
TTDR00244 Integrin αvβ3 Research target None for RA N/A 
TTDR00141 Interleukin-2 Research target None for RA N/A 
TTDR00086 Interleukin-4 Research target None for RA N/A 
TTDR00422 Leukemia inhibitory factor Research target None for RA N/A 
TTDR00338 Matrix metalloproteinase Research target None for RA N/A 
TTDR00352 
Mitogen-activated protein 
kinase 11 Research target None for RA N/A 
TTDR01108 
Myeloid differentiation 
primary response protein 
MyD88 Research target None for RA N/A 
TTDR01266 Neutrophil collagenase Research target None for RA N/A 
TTDR00250 Nuclear factor NF-κ-B Research target None for RA N/A 
TTDR00458 Oncostatin M Research target None for RA N/A 
TTDR00161 Platelet activating factor Research target None for RA N/A 
TTDR00630 Prostaglandin E synthase Research target None for RA N/A 
TTDR00109 Proteinase activated receptor 2 Research target None for RA N/A 
TTDR00182 
T-cell receptor β-chain V 
region CTL-L17 Research target None for RA N/A 
TTDR00190 Tumor necrosis factor receptor Research target None for RA N/A 
TTDR01238 
Tumor necrosis factor receptor 
superfamily member 1B Research target None for RA N/A 
TTDR00926 
Vascular endothelial growth 
factor B Research target None for RA N/A 
TTDS00326 C-C chemokine receptor type 5 Successful AZD8566 Phase I 
TTDS00521 Interleukin-6 receptor  Successful SAR153191 Phase I 
TTDS00445 Integrin α-4     Successful CDP323 Phase I 
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TTDS00445 Integrin alpha-4     Successful R1295 Phase I 
TTDC00122 C-C chemokine receptor type 2 clinical trial target INCB-3284 Phase I 
TTDC00122 C-C chemokine receptor type 2 clinical trial target MLN1202 Phase I 
TTDC00214 Interleukin-17 clinical trial target AIN457 Phase I 
TTDC00129 Leukotriene B4 receptor 1 clinical trial target Amelubant Phase I 
TTDC00044 MAP kinase p38 clinical trial target KC706 Phase I 
TTDC00265 
T-cell surface glycoprotein 
CD4 clinical trial target Anti-CD4 Phase I 
TTDC00119 Transcription factor AP-1 clinical trial target T-5224 Phase I 
TTDC00215 C-C chemokine receptor type 1 clinical trial target AVE1701 Phase I  
TTDS00326 C-C chemokine receptor type 5 Successful AZD5672 Phase II 
TTDS00447 Interlukin 2 Successful Canakinumab Phase II 
TTDC00215 C-C chemokine receptor type 1 clinical trial target MLN3897 Phase II 
TTDC00122 C-C chemokine receptor type 2 clinical trial target INCB3284 Phase II 
TTDC00096 Interferon-γ clinical trial target Fontolizumab Phase II 
TTDC00300 Interleukin-1 clinical trial target AMG108 Phase II 
TTDC00300 Interleukin-1 clinical trial target K-832 Phase II 
TTDC00234 Interleukin-1 receptor, type II clinical trial target AMG108 Phase II 
TTDC00251 Interleukin-15 clinical trial target AMG-714 Phase II 
TTDC00044 MAP kinase p38 clinical trial target GSK-681323 Phase II 
TTDC00044 MAP kinase p38 clinical trial target R1503 Phase II 
TTDC00044 MAP kinase p38 clinical trial target SB681323 Phase II 
TTDC00218 P2X purinoceptor 7 clinical trial target AZD9056 Phase II 
TTDC00224 
Tumor necrosis factor ligand 
superfamily member 11 clinical trial target Denosumab Phase II 
TTDC00196 
Tumor necrosis factor ligand 
superfamily member 13B clinical trial target Atacicept Phase II 
TTDC00197 
Tumor necrosis factor ligand 
superfamily member 13B clinical trial target BR3-Fc Phase II 
TTDC00316 Tyrosine-protein kinase clinical trial target INCB28050 Phase II 
TTDC00187 Tyrosine-protein kinase JAK2 clinical trial target INCB18424 Phase II 
TTDC00187 Tyrosine-protein kinase JAK2 clinical trial target INCB28050 Phase II 
TTDC00084 Tyrosine-protein kinase JAK3 clinical trial target CP-690,550 Phase II 
TTDC00156 Tyrosine-protein kinase SYK clinical trial target R788 Phase II 
TTDC00033 Interleukin-12 clinical trial target ABT-874 Phase II/III 
TTDS00453 
T-lymphocyte activation 
antigen CD80    Successful RhuDex Phase IIa 
TTDC00221 Interleukin-18 clinical trial target IL-18BP Phase Iia 
TTDC00044 MAP kinase p38 clinical trial target SCIO-469 Phase IIa 
TTDC00044 MAP kinase p38 clinical trial target VX-702 
Phase IIa 
completed 
TTDS00189 Adenosine A3 receptor Successful CF101 Phase IIb 
TTDs00268 B-lymphocyte antigen CD20 Successful Orelizumab Phase III 
TTDs00268 B-lymphocyte antigen CD20 Successful Ofatumumab Phase III 
TTDS00059  
Dihydroorotate 
dehydrogenase, mitochondrial Successful Teriflunomide Phase III 
TTDS00131 Tumor necrosis factor Successful Certolizumab Phase III 
TTDS00131 Tumor necrosis factor Successful Golimumab Phase III 
TTDC00080 Interleukin-6 clinical trial target 
MRA 
atlizumab+tocilizumab 
actemra Phase III 
TTDC00046 Nuclear factor NF-κB clinical trial target Sulfasalizine Phase III 
TTDC00268 mRNA of TNF-α clinical trial target ISIS 104838 Phase III 
TTDS00041 Prostaglandin G/H synthase 2     Successful RPR 200765A Preclinical 
TTDC00122 C-C chemokine receptor type 2 clinical trial target MCP-1 Preclinical 
TTDR00451 C-C motif chemokine 2 Research target MCP-1 Preclinical 
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Currently, RA therapy has been innovated along with the introduction of biologic agents, 
which are used in combination with traditional DMARDs. This improved therapy has greatly 
changed the patients’ expectations to lead normal lives and provided new insights into the 
treatment of RA. The current RA therapeutics has raised the bar of effectiveness for the 
coming drugs. To develop new agents for RA treatment with therapeutic targets with a greater 
frequency of remission induction and less concerns about unwanted adverse effects remains 
an important goal. Lessons learned from the use of targeted therapies regarding the utility of 
animal model of RA, clinical trial design, pharmacodynamics, immunobiology and key 
pathogenic elements of the disease will pave the way for drug development. In addition, 
natural herb medicine is an alternative for RA treatment. Goldbach-Manshy et al. [247] 
conducted a randomized, double-blind clinical trial in 121 patients with RA to examine the 
effect of the standardized extract of Tripterygium wilfordii Hook compared with sulfasalazine. 
The observations showed that T. wilfordii Hook treatment produced rapid improvement in 
symptoms including swollen and tender joints, markers of inflammation, and overall patients’ 
functions. However, further studies are warranted to discover natural products as alternatives 
and investigate their underlying mechanisms. 
 
 
3.4 Current targets of RA 
 
In our literature search, we found 95 confirmed human therapeutic targets in RA as shown in 
Table 3-5. Using the PANTHER Classification System (described in Section 1.5.2.1), based 
on published scientific evidence and evolutionary relationships functional analysis of current 
RA therapeutic targets in humans was performed using three approaches: molecular function, 
biological process and pathway involvement Table 3-5. Distribution of human RA therapeutic 
targets varied in each of these functional classifications. 
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Table 3-5. Current therapeutic targets of RA. 
 
PANTHER  Classifications Target Name Gene 
Molecular 
function 
Biological process Pathway categories 
Associated 
drug(s) 
Related disease(s) 
3-Phosphoinositide-dependent 
protein kinase 1 
PDPK1 Protein kinase Protein phosphorylation,  
signal transduction,  
developmental process,  
cell structure 
PDGF signaling 
pathway, PI3 kinase 
pathway, Ras pathway, 
p53 pathway, p53 
pathway feedback loop 
Celecoxib Celecoxib is COX-2 
inhibitor used in the 
treatment of OA & 
RA 
5-Aminoimidazole-4-
carboxamidoribonucleotide 
transformylase 
ATIC Methyltransferase 
Other hydrolase 
Purine metabolism De novo purine 
biosynthesis 
Sulfasalazine Inflammatory bowel 
disease & RA 
72 kDa type IV collagenase MMP2 Metalloprotease & 
other extracellular 
matrix 
Proteolysis Alzheimer disease-
presenilin pathway 
Sulindac For acute or long-
term use in the relief 
of signs and 
symptoms of OA & 
RA 
Acetyl-CoA acetyltransferase 
(mitochondrial) 
ACAT1 Acetyltransferase Protein acetylation   Sulfasalazine For the treatment of 
CD and RA as a 
second-line agent 
Adenylosuccinate lyase ADSL Other lyase Purine metabolism De novo purine 
biosynthesis 
Azathioprine An 
immunosuppressive 
agent used in the 
treatment of RA 
Adenylosuccinate synthase ADSS Synthetase & other 
ligase 
Nucleoside, nucleotide and 
nucleic acid metabolism 
Wnt signaling pathway,  
De novo purine 
biosynthesis 
Azathioprine An 
immunosuppressive 
agent used in the 
treatment of RA 
Aldose reductase AKR1B1 Reductase Other metabolism N/A Sulindac For acute or long-
term use in the relief 
of signs and 
symptoms of OA & 
RA 
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Alkaline phosphatase, placental-
like 
ALPPL2 Other phosphatase Skeletal development N/A Levamisole This immune 
enhancer appears to 
be beneficial in RA 
Alpha-tocopherol transfer 
protein 
TTPA Unclassified Unclassified N/A Vitamin E It may be of limited 
benefit in some with 
asthma and RA 
Amidophosphoribosyltransferase PPAT Other transferase Monosaccharide metabolism De novo purine 
biosynthesis 
Azathioprine An 
immunosuppressive 
agent used in the 
treatment of RA 
AMP deaminase 1 AMPD1 Deaminase Purine metabolism Purine metabolism Azathioprine An 
immunosuppressive 
agent used in the 
treatment of RA 
AMP deaminase 2 AMPD2 Protein kinase Protein phosphorylation, 
signal transduction, 
developmental process,  
cell structure 
PDGF signaling 
pathway, PI3 kinase 
pathway, Ras pathway,   
p53 pathway, p53 
pathway feedback loops 
2 
Azathioprine An 
immunosuppressive 
agent used in the 
treatment of RA 
AMP deaminase 3 AMPD3 Deaminase Purine metabolism Purine metabolism Azathioprine An 
immunosuppressive 
agent used in the 
treatment of RA 
Annexin A1 ANXA1 Transfer/carrier 
protein 
annexin 
Fatty acid metabolism, cell 
surface receptor mediated 
signal transduction, cell 
motility 
N/A Methylprednis
olone 
Adjunctive therapy 
for short-term 
administration in 
RA 
Arachidonate 5-lipoxygenase ALOX5 Oxygenase Other lipid, fatty acid and 
steroid metabolism, immunity 
and defense 
N/A Leflunomide For the treatment of 
active RA 
B(0,+)-type amino acid 
transporter 1 
SLC7A9 Amino acid 
transporter 
Amino acid transport N/A L-Cystine L-cysteine has anti-
inflammatory 
properties, it can 
protect against 
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various toxins, and 
might be helpful in 
OA and RA 
Calcineurin subunit B isoform 2 PPP3R2 Protein 
phosphatase, 
calmodulin related 
protein 
Protein modification, calcium 
mediated signalling, other 
homeostasis activities 
Wnt signaling pathway Cyclosporine For treatment of 
transplant rejection, 
RA, severe psoriasis 
Calcium signal-modulating 
cyclophilin ligand 
CAMLG Unclassified Intracellular signaling 
cascade, T-cell mediated 
immunity 
N/A Cyclosporine For treatment of 
transplant rejection, 
RA, severe psoriasis 
Caspase-1 CASP1 Cysteine protease Proteolysis, apoptosis N/A Penicillamine It is used to reduce 
cystine excretion in 
cystinuria and to 
treat patients with 
severe, active RA 
unresponsive to 
conventional 
therapy. 
cGMP-dependent 3',5'-cyclic 
phosphodiesterase 
PDE2A Phosphodiesterase Metabolism of cyclic 
nucleotides, signal 
transduction 
N/A Sulindac For acute or long-
term use in the relief 
of signs and 
symptoms of OA & 
RA 
Chloride channel protein ClC-
Ka 
CLCNKA Anion channel Anion transport N/A Niflumic Acid An analgesic and 
anti-inflammatory 
agent used in the 
treatment of RA 
Complement C1q subcomponent 
subunit A 
C1QA Complement 
component 
Complement-mediated 
immunity 
N/A Etanercept For treatment of 
severe adult and 
juvenile RA 
Complement C1q subcomponent 
subunit B 
C1QB Complement 
component 
Complement-mediated 
immunity 
N/A Etanercept For treatment of 
severe adult and 
juvenile RA 
Complement C1q subcomponent 
subunit C 
C1QC Complement 
component 
Complement-mediated 
immunity 
N/A Etanercept For treatment of 
severe adult and 
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juvenile RA 
Complement C1r subcomponent C1R Serine protease, 
complement 
component 
Proteolysis,  
complement-mediated 
immunity 
N/A Etanercept For treatment of 
severe adult and 
juvenile RA 
Complement C1s subcomponent C1S Serine protease, 
complement 
component 
Proteolysis, complement-
mediated immunity 
N/A Etanercept For treatment of 
severe adult and 
juvenile RA 
Complement C5  C5 Complement 
component 
Complement-mediated 
immunity 
N/A Eculizumab RA 
Corticosteroid-binding globulin  SERPINA6 Serine protease 
inhibitor 
Proteolysis N/A Prednisolone Used to treat PA, 
RA, acute GA, AS, 
bursitis, and 
epicondylitis 
Cystine/glutamate transporter SLC7A11 Amino acid 
transporter 
Amino acid transport N/A Sulfasalazine, 
L-Cystine 
For the treatment of 
CD and RA as a 
second-line agent 
Cystinosin CTNS Amino acid 
transporter 
Amino acid transport, small 
molecule transport, other 
metabolism 
N/A L-Cystine L-cysteine has anti-
inflammatory 
properties, it can 
protect against 
various toxins, and 
it might be helpful 
in OA & RA 
Diacylglycerol kinase alpha DGKA Kinase Lipid metabolism, other 
intracellular signaling cascade 
N/A Vitamin E  It may be of limited 
benefit in some with 
asthma and RA 
Dihydrofolate reductase DHFR Unclassified Pyrimidine metabolism, DNA 
metabolism,  other carbon 
metabolism 
Formyltetrahydroformate 
biosynthesis, folate 
biosynthesis,   
 
MTX For the treatment of 
severe psoriasis and 
severe, active, 
classical or definite 
RA 
Dihydroorotate dehydrogenase, 
mitochondrial 
DHODH Dehydrogenase Pyrimidine metabolism De novo pyrmidine 
ribonucleotides 
Leflunomide For the treatment of 
active RA 
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biosythesis 
Epidermal growth factor /Pro-
epidermal growth factor 
EGF Growth factor Nucleoside, nucleotide and 
nucleic acid metabolism, 
receptor protein tyrosine 
kinase signaling pathway, 
ligand-mediated signalling,  
cell cycle control,  cell 
proliferation and 
differentiation 
N/A Sulindac For acute or long-
term use in the relief 
of signs and 
symptoms of OA & 
RA 
Fc gamma receptor III/ 
FcgammaRIIIb/CD16 
FCGR3B Immunoglobulin 
receptor family 
member, 
defense/immunity 
protein 
Other signal transduction, B-
cell- and antibody-mediated 
immunity, macrophage-
mediated immunity, natural 
killer cell mediated immunity 
N/A GMA-161 RA 
Glucocorticoid receptor NR3C1 Nuclear hormone 
receptor,  
transcription factor,  
nucleic acid 
binding 
Unclassified N/A Methylprednis
olone 
Adjunctive therapy 
for short-term 
administration in 
RA 
Glutathione S-transferase A2 GSTA2 Other transferase Detoxification N/A Chloroquine It has been used to 
treat RA 
GMP reductase 1 GMPR Reductase Purine metabolism N/A Azathioprine An 
immunosuppressive 
agent used in the 
treatment of RA 
GMP reductase 2 GMPR2 Reductase Purine metabolism N/A Azathioprine An 
immunosuppressive 
agent used in the 
treatment of RA 
GMP synthase [glutamine-
hydrolyzing] 
GMPS Synthase, other 
transferase 
Purine metabolism De novo purine 
biosynthesis 
Azathioprine An 
immunosuppressive 
agent used in the 
treatment of RA 
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GTPase HRas HRAS Small GTPase MAPKKK cascade, cell 
proliferation and 
differentiation, oncogene 
PI3 kinase pathway, 
inflammation mediated 
by chemokine and 
cytokine signaling 
pathway,  angiogenesis, 
integrin signalling 
pathway, VEGF 
signaling pathway, Ras 
pathway, FGF signaling 
pathway 
Sulindac For acute or long-
term use in the relief 
of signs and 
symptoms of 
osteoarthritis & RA 
Hemoglobin subunit alpha HBA1 Other 
transfer/carrier 
protein 
Transport, blood circulation 
and gas exchange 
N/A Chloroquine It has been used to 
treat RA 
High affinity immunoglobulin 
gamma Fc receptor I 
FCGR1A Immunoglobulin 
receptor family 
member, 
defense/immunity 
protein 
Other signal transduction, B-
cell- and antibody-mediated 
immunity, macrophage-
mediated immunity, natural 
killer cell mediated immunity 
N/A Etanercept For treatment of 
severe adult and 
juvenille RA 
Histidine ammonia-lyase HAL Unclassified Unclassified N/A L-Histidine L-histidine may be 
indicated for use in 
some with RA 
Histidine decarboxylase HDC Decarboxylase Other amino acid metabolism Adrenaline and 
noradrenaline 
biosynthesis, dopamine 
receptor mediated 
signaling pathway,  
5-hydroxytryptamine 
biosynthesis,  histamine 
synthesis 
L-Histidine L-histidine may be 
indicated for use in 
RA 
Histidyl-tRNA synthetase, 
cytoplasmic 
HARS Other RNA-
binding protein, 
aminoacyl-tRNA 
synthetase 
Amino acid activation N/A L-Histidine L-histidine may be 
indicated for use in 
RA 
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Hypoxanthine-guanine 
phosphoribosyltransferase 
HPRT1 Glycosyltransferase Purine metabolism Xanthine and guanine 
salvage pathway, 
adenine and 
hypoxanthine salvage 
pathway, xanthine and 
guanine salvage pathway 
Azathioprine An 
immunosuppressive 
agent used in the 
treatment of RA 
Inhibitor of nuclear factor κ-B 
kinase subunit beta 
IKBKB Non-receptor 
serine/threonine 
protein kinase 
Protein phosphorylation, NF-
kappaB cascade, 
cytokine/chemokine mediated 
immunity 
Inflammation mediated 
by chemokine and 
cytokine signaling 
pathway, interleukin 
signaling pathway, toll 
receptor signaling 
pathway, T cell 
activation, apoptosis 
signaling pathway 
Auranofin Used in the 
treatment of active, 
progressive or 
destructive forms of 
RA 
Inosine-5'-monophosphate 
dehydrogenase 1 
IMPDH1 Dehydrogenase Purine metabolism De novo purine 
biosynthesis 
Azathioprine An 
immunosuppressive 
agent used in the 
treatment of RA 
Inosine-5'-monophosphate 
dehydrogenase 2 
IMPDH2 Dehydrogenase Purine metabolism De novo purine 
biosynthesis 
Azathioprine An 
immunosuppressive 
agent used in the 
treatment of RA 
Integrin α-4     ITGA4 Other cell adhesion 
molecule 
Cell adhesion Integrin signalling 
pathway,  
inflammation mediated 
by chemokine and 
cytokine signaling 
pathway 
CDP323, 
R1295 
RA 
Interleukin-1β IL1B Interleukin Cytokine and chemokine 
mediated signaling pathway, 
ligand-mediated signalling, 
macrophage-mediated 
immunity, 
cytokine/chemokine mediated 
N/A Anakinra For the treatment of 
adult RA 
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immunity,  apoptosis, cell 
cycle control, cell 
proliferation and 
differentiation 
Interleukin-1 receptor type I IL1R1 Interleukin receptor Cytokine and chemokine 
mediated signaling pathway, 
immunity and defense 
p38 MAPK pathway-
>interleukin-1 receptor 
Anakinra For the treatment of 
adult RA 
Interleukin-1 receptor type II IL1R2 Interleukin receptor Cytokine and chemokine 
mediated signaling pathway 
N/A Anakinra For the treatment of 
adult RA 
Interleukin-6 receptor  IL6R Interleukin receptor Cytokine and chemokine 
mediated signaling pathway, 
MAPKKK cascade,  JAK-
STAT cascade,  ligand-
mediated signalling, immunity 
and defense, cell proliferation 
and differentiation 
Interleukin signaling 
pathway 
Tocilizumab RA unspecified  
Interleukin-8 IL-8 Chemokine Cytokine and chemokine 
mediated signaling pathway, 
calcium mediated signalling, 
NF-κ B cascade,  
ligand-mediated signalling, T-
cell mediated immunity, 
macrophage-mediated 
immunity, granulocyte-
mediated immunity, 
angiogenesis, cell 
proliferation and 
differentiation 
Inflammation mediated 
by chemokine and 
cytokine signaling 
pathway, interleukin 
signaling pathway 
Ketoprofen An ibuprofen-type 
anti-inflammatory 
analgesic and 
antipyretic. It is 
used in the 
treatment of RA and 
OA. 
Kallikrein KLKB1 Serine protease Proteolysis, other immune and 
defense, blood clotting 
Blood coagulation, blood 
coagulation 
  RA, asthma, 
pancreatitis 
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Low-affinity immunoglobulin-γ 
Fc region receptor II-a 
FCGR2A Immunoglobulin 
receptor family  
member, 
defense/immunity 
protein 
Other signal transduction, B-
cell- and antibody-mediated 
immunity, macrophage-
mediated immunity, natural 
killer cell mediated immunity 
N/A Etanercept For treatment of 
severe adult and 
juvenille RA 
Low-affinity immunoglobulin-γ 
Fc region receptor II-b 
FCGR2B Immunoglobulin 
receptor family 
member, 
defense/immunity 
protein 
Other signal transduction, B-
cell- and antibody-mediated 
immunity, 
macrophage-mediated 
immunity, 
natural killer cell mediated 
immunity 
N/A Etanercept For treatment of 
severe adult and 
juvenille RA 
Low-affinity immunoglobulin-γ 
Fc region receptor II-c 
FCGR2C Immunoglobulin 
receptor family 
member, 
defense/immunity 
protein 
Other signal transduction, B-
cell- and antibody-mediated 
immunity, 
macrophage-mediated 
immunity, 
natural killer cell mediated 
immunity 
N/A Etanercept For treatment of 
severe adult and 
juvenille RA 
Low-affinity immunoglobulin-γ 
Fc region receptor III-A 
FCGR3A Immunoglobulin 
receptor family 
member, 
defense/immunity 
protein 
Other signal transduction, B-
cell- and antibody-mediated 
immunity, 
macrophage-mediated 
immunity, 
natural killer cell mediated 
immunity 
N/A Etanercept For treatment of 
severe adult and 
juvenille RA 
Low-affinity immunoglobulin-γ 
Fc region receptor III-B 
FCGR3B Immunoglobulin 
receptor family 
member, 
defense/immunity 
protein 
Other signal transduction, B-
cell- and antibody-mediated 
immunity, 
macrophage-mediated 
immunity, 
natural killer cell mediated 
immunity 
N/A Etanercept For treatment of 
severe adult and 
juvenille RA 
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Lymphotoxin-α LTA Tumor necrosis 
factor family 
member 
Cytokine and chemokine 
mediated signaling pathway, 
ligand-mediated signalling, T-
cell mediated immunity, 
macrophage-mediated 
immunity,  
natural killer cell mediated 
immunity, 
cytokine/chemokine mediated 
immunity, granulocyte-
mediated immunity, induction 
of apoptosis 
Apoptosis signaling 
pathway 
Etanercept For treatment of 
severe adult and 
juvenille RA 
Lymphotoxin-β LTB Other cytokine Cytokine and chemokine 
mediated signaling pathway, 
ligand-mediated signalling, T-
cell mediated immunity,  
B-cell- and antibody-mediated 
immunity, macrophage-
mediated immunity, natural 
killer cell mediated 
immunity,cytokine/chemokine 
mediated immunity 
Apoptosis signaling 
pathway 
Infliximab For treatment of 
psoriasis,CD, RA 
and  AS 
Macrophage migration 
inhibitory factor 
MIF Cytokine Macrophage-mediated 
immunity 
N/A   Cancers, 
glomerulonephritis, 
inflammation, 
inflammatory lung 
disease, 
inflammatory 
neurological 
disease, 
inflammatory 
response in 
alcoholic liver 
disease, RA, sepsis, 
septic shock, SLE, 
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UC.  
Map kinase P38/mitogen-
activated protein kinase 14 
MAPK14 Non-receptor 
serine/threonine 
protein kinase 
Protein phosphorylation, 
MAPKKK cascade 
Alzheimer disease-
amyloid secretase 
pathway, EGF receptor 
signaling pathway, 
Parkinson disease, p38 
MAPK pathway, 
oxidative stress 
  Adult respiratory 
distress syndrome, 
Alzheimer's disease, 
crescentic 
glomerulonephritis, 
Crohn's disease, 
unspecified, insulin 
resistance, multiple 
myeloma, psoriasis, 
RA, skin diseases, 
cytokine-mediated 
diseases 
Mineralocorticoid receptor  NR3C2 Nuclear hormone 
receptor, 
transcription factor, 
nucleic acid 
binding 
Unclassified N/A Desoxycortico
sterone 
pivalate 
For treatment of 
adrenocortical 
insufficiency 
especially in 
multiple sclerosis, 
congenital cerebral 
palsy, polyarteritis 
nodosa, and RA 
Mitogen-activated protein kinase 
3 
MAPK3 Non-receptor 
serine/threonine 
protein kinase 
Protein phosphorylation, 
MAPKKK cascade 
Angiotensin II-
stimulated signaling 
through G proteins and 
β-arrestin, interleukin 
signaling pathway, Ras 
pathway, B cell 
activation 
Sulindac For acute or long-
term use in the relief 
of signs and 
symptoms of OA & 
RA 
Multidrug resistance protein 1 ABCB1 ATP-binding 
cassette (ABC) 
transporter 
Extracellular transport and 
import 
N/A Cyclosporine For treatment of 
transplant rejection, 
RA, severe psoriasis 
Neutral and basic amino acid 
transport protein rBAT 
SLC3A1 Amylase Glycogen metabolism N/A L-Cystine L-cysteine has anti-
inflammatory 
properties, it can 
protect against 
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various toxins, and 
it might be helpful 
in osteoarthritis & 
RA 
Orphan nuclear receptor PXR NR1I2 Nuclear hormone 
receptor, 
transcription factor, 
nucleic acid 
binding 
mRNA transcription 
regulation, steroid hormone-
mediated signaling 
Angiogenesis Vitamin E It may be of limited 
benefit in some with 
asthma & RA 
Peptidyl-prolyl cis-trans 
isomerase A 
PPIA Other isomerase Protein folding, nuclear 
transport, immunity and 
defense 
N/A Cyclosporine For treatment of 
transplant rejection, 
RA, severe psoriasis 
Peroxiredoxin-5, mitochondrial PRDX5 Peroxidase Antioxidation and free radical 
removal 
N/A Auranofin Used in the 
treatment of active, 
progressive or 
destructive forms of 
inflammatory 
arthritis, such as 
adult RA 
Peroxisome proliferator-
activated receptor delta 
PPARD Nuclear hormone 
receptor, 
transcription factor, 
nucleic acid 
binding 
Monosaccharide metabolism, 
regulation of lipid, fatty acid 
and steroid metabolism, 
mRNA transcription 
regulation, ligand-mediated 
signalling, stress response, 
developmental processes, cell 
proliferation and 
differentiation 
Wnt signaling pathway Sulindac For acute or long-
term use in the relief 
of signs and 
symptoms of OA 
and RA 
Prostacyclin synthase  PTGIS Oxidoreductase, 
isomerase 
Fatty acid biosynthesis, 
electron transport, regulation 
of vasoconstriction, dilation  
N/A Phenylbutazon
e 
It is useful in RA 
and Reiter's 
syndrome  
Prostaglandin G/H synthase 1 PTGS1 Synthase and 
synthetase, 
oxygenase 
Immunity and defense, cell 
proliferation and 
differentiation 
Inflammation mediated 
by chemokine and 
cytokine signaling 
pathway 
Piroxicam A cyclooxygenase 
inhibiting, NSAID 
for RA and OA  
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Prostaglandin G/H synthase 2 PTGS2 Synthase and 
synthetase, 
oxygenase 
Immunity and defense, cell 
proliferation and 
differentiation 
Endothelin signaling 
pathway, toll receptor 
signaling pathway, 
inflammation mediated 
by chemokine and 
cytokine signaling 
pathway 
Oxaprozin A non-narcotic 
NSAID used to 
relieve the 
inflammation, 
swelling, stiffness, 
and joint pain 
associated with OA 
and RA. 
Protein kinase Cα type PRKCA Transfer/carrier 
protein, non-
receptor 
serine/threonine 
protein kinase, 
calmodulin related 
protein, annexin 
Protein phosphorylation, 
calcium mediated signalling, 
cell proliferation and 
differentiation 
B cell activation-, Wnt 
signaling pathway, 
thyrotropin-releasing 
hormone receptor 
signaling pathway, 
inflammation mediated 
by chemokine and 
cytokine signaling 
pathway, T cell 
activation, Alzheimer 
disease 
Vitamin E  It may be of limited 
benefit in some with 
asthma and RA 
Protein kinase Cβ type PRKCB1 Transfer/carrier 
protein, non-
receptor 
serine/threonine 
protein kinase, 
calmodulin related 
protein, annexin 
Protein phosphorylation, 
calcium mediated signalling, 
cell proliferation and 
differentiation 
B cell activation-, Wnt 
signaling pathway, 
thyrotropin-releasing 
hormone receptor 
signaling pathway, 
inflammation mediated 
by chemokine and 
cytokine signaling 
pathway, T cell 
activation, Alzheimer 
disease 
Vitamin E  It may be of limited 
benefit in some with 
asthma and RA 
SEC14-like protein 2 SEC14L2 Other transporter, 
transfer/carrier 
protein 
Cholesterol metabolism, other 
transport 
N/A Vitamin E It may be of limited 
benefit in some with 
asthma and RA 
SEC14-like protein 3 SEC14L3 Other transporter, 
transfer/carrier 
Cholesterol metabolism, other 
transport 
N/A Vitamin E It may be of limited 
benefit in some with 
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protein asthma and RA 
SEC14-like protein 4 SEC14L4 Other transporter, 
transfer/carrier 
protein 
Cholesterol metabolism, other 
transport 
N/A Vitamin E It may be of limited 
benefit in some with 
asthma and RA 
Serine/threonine-protein 
phosphatase 2A catalytic subunit 
α isoform 
PPP2CA Protein 
phosphatase 
Unclassified p53 pathway, p53 
pathway feedback loop 
2, FGF signaling 
pathway, EGF receptor 
signaling pathway, p53 
pathway by glucose 
deprivation 
Vitamin E  It may be of limited 
benefit in some with 
asthma and RA 
Serine/threonine-protein 
phosphatase 2A catalytic subunit 
β isoform 
PPP2CB Protein 
phosphatase 
Unclassified p53 pathway, p53 
pathway feedback loop 
2, FGF signaling 
pathway, EGF receptor 
signaling pathway, p53 
pathway by glucose 
deprivation 
Vitamin E  It may be of limited 
benefit in some with 
asthma and RA 
Serum albumin ALB Other 
transfer/carrier 
protein 
Transport N/A Ketoprofen An ibuprofen-type 
anti-inflammatory 
analgesic and 
antipyretic  used in 
the treatment of RA 
and OA 
Solute carrier family 22 member 
6/Putative renal organic anion 
transporter 1 
SLC22A6/ 
Hroat1 
Other transporter Anion transport, small 
molecule transport, 
extracellular transport and 
import 
N/A Ketoprofen An ibuprofen-type 
anti-inflammatory 
analgesic and 
antipyretic  used in 
the treatment of RA 
and OA 
System N amino acid transporter 
1 
SLC38A3 Unclassified Unclassified N/A L-Histidine Indicated for use in 
some with RA 
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Thioredoxin reductase, 
cytoplasmic  
TXNRD1 Reductase Electron transport, other 
metabolism 
N/A Auranofin  RA  unspecified   
T-lymphocyte activation antigen 
CD80 
CD80 Immunoglobulin 
receptor family 
member, 
membrane-bound 
signaling molecule, 
defense/immunity 
protein 
Ligand-mediated signalling, 
T-cell mediated immunity 
T cell activation Abatacept For the second line 
reduction of the 
signs and symptoms 
of moderate-to-
severe active RA  
T-lymphocyte activation antigen 
CD86 
CD86 Immunoglobulin 
receptor family 
member, 
membrane-bound 
signaling molecule, 
defense/immunity 
protein 
Ligand-mediated signalling, 
T-cell mediated immunity, 
cell proliferation and 
differentiation  
  
T cell activation- Abatacept For the second line 
reduction of the 
signs and symptoms 
of moderate-to-
severe active RA 
Toll-like receptor 9 TLR9 Receptor, 
extracellular matrix 
Cytokine and chemokine 
mediated signaling pathway, 
developmental processes 
Toll receptor signaling 
pathway 
Chloroquine It has been used to 
treat RA 
Transthyretin TTR Unclassified Unclassified N/A Diclofenac For the acute and 
chronic treatment of 
signs and symptoms 
of RA and OA 
Tumor necrosis factor receptor 
superfamily member 1B 
TNFRSF1B Tumor necrosis 
factor receptor, 
defense/immunity 
protein 
Cytokine and chemokine 
mediated signaling pathway, 
other receptor mediated 
signaling pathway, 
cytokine/chemokine mediated 
immunity, developmental 
processes 
Apoptosis signaling 
pathway 
Etanercept For treatment of 
severe adult and 
juvenille RA 
Tumor necrosis factor/Tumor 
necrosis factor alpha 
TNF/ 
TNFA 
Tumor necrosis 
factor family 
member 
Cytokine and chemokine 
mediated signaling pathway, 
ligand-mediated signalling, 
immunity and defense, 
induction of apoptosis 
Wnt signaling pathway, 
apoptosis signaling 
pathway 
Chloroquine It has been used to 
treat RA 
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VEGF receptor/ FMS-related 
tyrosine kinase 1 
VEGFR1/ 
FLT1 
Tyrosine protein 
kinase receptor, 
protein kinase 
Protein phosphorylation, 
receptor protein tyrosine 
kinase signaling pathway, 
angiogenesis, cell 
proliferation and 
differentiation 
Angiogenesis, VEGF 
signaling pathway 
 - Breast cancer; 
cancers, ischemic 
heart disease, joint 
disorders, 
proliferative 
retinopathy, renal 
cell carcinoma, RA, 
superficial bladder 
tumors 
 
AS, ankylosing spondylitis; CD, Crohn’s disease; GA, gouty arthritis; OA, osteoarthris; PA, psoriasis arthritis; SLE, systemic lupus erythematosus; UC, ulcerative colitis
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As shown in Table 3-6, current anti-rheumatic drugs acts on various classes of molecular 
targets with a diverse range of molecular functions. The most common classes includes 
defence/immunity proteins, immunoglobulin receptor family members, complement 
component and transfer/carrier proteins. Overall, therapeutic targets from the 
defence/immunity protein classes were most targeted by current RA medications, these 
include tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), T-lymphocyte 
activation antigens CD80 and CD86 and few low affinity immunoglobulin γ Fc region 
receptors (FCGRs), namely I (FCGR1A), II-a (FCGR2A), II-b (FCGR2B), II-c (FCGR2C), 
IIIA (FCGR3A) and III-B (FCGR3B). Figure 3-1 shows various distributions of the most 
frequent occurring RA targets based on molecular function classifications. 
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Table 3-6. Distribution of current RA targets according to molecular function classification by 
PANTHER. 
 
PANTHER molecular function 
No. of 
targets 
PANTHER molecular 
function 
No. of 
targets 
Acetyltransferase 1 Other cell adhesion molecule 1 
Amino acid transporter 3 Other cytokine 1 
Aminoacyl-tRNA synthetase 1 Other extracellular matrix 1 
Amylase 1 Other hydrolase 1 
Anion channel 1 Other isomerase 1 
Annexin 3 Other ligase 1 
ATP-binding cassette (ABC) 
transporter 1 Other lyase 1 
Calmodulin related protein 3 Other phosphatase 1 
Chemokine 1 Other RNA-binding protein 1 
Complement component 6 Other transfer/carrier protein 2 
Cysteine protease 1 Other transferase 3 
Cytokine 1 Other transporter 4 
Deaminase 2 Oxidoreductase 1 
Decarboxylase 1 Oxygenase 3 
Defence/immunity protein 9 Peroxidase 1 
Dehydrogenase 3 Phosphodiesterase 1 
Extracellular matrix 1 Protein kinase 3 
Glycosyltransferase 1 Protein phosphatase 3 
Growth factor 1 Receptor 1 
Immunoglobulin receptor family 
member 8 Reductase 4 
Interleukin 1 Serine protease 3 
Interleukin receptor 3 Serine protease inhibitor 1 
Isomerase 1 Small GTPase 1 
Kinase 1 Synthase and synthetase 2 
Membrane-bound signalling 
molecule 2 Synthase 1 
Metalloprotease 1 Synthetase 1 
Methyltransferase 1 Transcription factor 4 
Molecular function unclassified 6 Transfer/carrier protein 6 
Non-receptor serine/threonine 
protein kinase 5 
Tumor necrosis factor family 
member 2 
Nuclear hormone receptor 4 Tumor necrosis factor receptor 1 
Nucleic acid binding 4 
Tyrosine protein kinase 
receptor 1 
  
110 
Figure 3-1. Distribution of most frequent current RA targets when classified by molecular function. 
       (The number at then end of the bar represents the number of targets)
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Based on the biological process classification of current RA targets (Table 3-7), those targets 
related to immunity pathways (B-cell and antibody-mediated, macrophage-mediated, natural-
killer cell mediated, and immunity and defence), cell proliferation processes (cell proliferation 
and differentiation), purine metabolism and inflammatory pathways (cytokine and chemokine 
mediated, ligand mediated) are the most recurrently involved. RA targets involved in immune 
pathways includes arachidonate 5-lipoxygenase (ALOX5), high affinity FCGR (FCGR1A), 
low affinity FCGRs (FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A and FCGR3B), ILs 
(IL1B & IL8), interleukin receptor (IL6R), lymphotoxin (LTA & LTB), macrophage 
migration inhibitory factor (MIF), peptidyl-prolyl cis-trans isomerase (PPIA), prostaglandin 
G/H synthase (PTGS1 & PTGS2) and TNF-α. Furthermore, therapeutic RA targets associated 
with inflammatory pathways included interleukins (IL-8 & IL-1β), ILRs (IL1R2, IL6R, & 
IL1R1), toll-like receptor 9 (TLR9), LT (LTA & LTB), TNF-α and TNF receptor 
(TNFRSF1B). Current RA targets also associates with cell proliferation process, these include 
GTPase HRas (HRAS), peroxisome proliferators-activated receptor (PPARD), epidermal 
growth factor (EGF), protein kinase C (PKCα & PKCβ1) and T-lymphocyte activation 
antigen CD86. Figure 3-2 shows various distributions of the most frequent occurring RA 
targets based on biological processes classification. 
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Table 3-7. Distribution of RA targets according to biological processes classified by PANTHER. 
 
Biological process No. of 
targets 
Biological process No. of 
targets 
Amino acid activation 1 MAPKKK cascade 4 
Amino acid transport 3 Metabolism of cyclic nucleotides 1 
Angiogenesis 2 Monosaccharide metabolism 2 
Anion transport 2 mRNA transcription regulation 2 
Antioxidation and free radical removal 1 Natural killer cell mediated immunity 8 
Apoptosis 2 NF-κB cascade 2 
B-cell- and antibody-mediated immunity 7 Nuclear transport 1 
Biosythesis  2 Nucleoside, nucleotide and nucleic acid metabolism 2 
Blood circulation and gas exchange 1 Oncogene 1 
Blood clotting 1 Other amino acid metabolism 1 
Calcium mediated signalling 4 Other carbon metabolism 1 
Cell adhesion 1 Other homeostasis activities 1 
Cell cycle control 2 Other immune and defence 1 
Cell motility 2 Other intracellular signalling cascade 1 
Cell proliferation and differentiation  12 Other lipid, fatty acid and steroid metabolism 1 
Cell structure 2 Other metabolism 3 
Cell surface receptor mediated signal transduction 1 Other receptor mediated signalling pathway 1 
Cholesterol metabolism 3 Other signal transduction 6 
Complement-mediated immunity 6 Other transport 3 
Cytokine and chemokine mediated signalling pathway 10 Protein acetylation 1 
Immunity and defence 1 Protein folding 1 
Cytokine/chemokine mediated immunity 5 Protein modification 1 
Detoxification 1 Protein phosphorylation 8 
Developmental processes 5 Proteolysis 6 
DNA metabolism 1 Purine metabolism 10 
Electron transport 2 Pyrimidine metabolism 2 
Extracellular transport and import 2 Receptor protein tyrosine kinase signalling pathway 2 
Glycogen metabolism 1 Regulation of lipid, fatty acid and steroid metabolism 1 
Granulocyte-mediated immunity 2 Regulation of vasoconstriction, dilation - 1 
Immunity and defence 6 Signal transduction 3 
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Induction of apoptosis 2 Skeletal development 1 
Intracellular signalling cascade 1 Small molecule transport 2 
JAK-STAT cascade 1 Steroid hormone-mediated signalling 1 
Ligand-mediated signalling 10 Stress response 1 
Lipid metabolism 1 T-cell mediated immunity 6 
Macrophage-mediated immunity 11 Transport 4 
  Unclassified 8 
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Figure 3-2. Distribution of most frequent current RA targets when classified by biological processes.  
       (The number on the right of the bar represents the number of targets
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According to the PANTHER Classification System (http://www.pantherdb.org/), current 
human RA therapeutic targets correlate with a mixture of biological pathways, such as 
inflammation mediated by chemokine and cytokine signalling pathway, angiogenesis, p53 
pathway, de novo purine biosynthesis, interleukin signalling pathway, T-cell activation, 
apoptosis signalling pathway, VEGF receptor signalling pathway and Wnt signalling pathway 
(Table 3-8). Figure 3-3 shows the distribution of the most frequent occurring RA therapeutic 
targets by known pathway category.  
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Table 3-8. Distribution of current RA targets according to molecular pathways classified by 
PANTHER. 
 
Pathway categories No. of targets 
5-HT2 type receptor mediated signalling pathway 2 
5-HT biosynthesis 1 
Adenine and hypoxanthine salvage pathway 1 
Adrenaline and noradrenaline biosynthesis 1 
Alpha adrenergic receptor signalling pathway 2 
Alzheimer disease 6 
Angiogenesis 8 
Angiotensin II-stimulated signalling through G proteins and β-arrestin 3 
Apoptosis signalling pathway 7 
B cell activation 6 
Blood coagulation 2 
De novo purine biosynthesis 9 
De novo pyrmidine ribonucleotides biosythesis 1 
Dopamine receptor mediated signalling pathway 1 
EGF receptor signalling pathway 7 
Endothelin signalling pathway  4 
FGF signalling pathway 7 
Folate biosynthesis 2 
Formyltetrahydroformate biosynthesis 1 
Heterotrimeric G-protein signalling pathway-Gq α and Go α mediated pathway 2 
Histamine H1 receptor mediated signalling pathway  2 
Histamine synthesis 1 
Inflammation mediated by chemokine and cytokine signalling pathway 13 
Insulin/IGF pathway 3 
Integrin signalling pathway  4 
Interferon-gamma signalling pathway 2 
Interleukin signalling pathway 7 
JAK/STAT signalling pathway 1 
Metabotropic glutamate receptor group I pathway  2 
Muscarinic acetylcholine receptor 1 and 3 signalling pathway  2 
Oxidative stress response 1 
Oxytocin receptor mediated signalling pathway  2 
p38 MAPK pathway  5 
p53 pathway feedback loops 2 12 
Parkinson disease  3 
PDGF signalling pathway 6 
PI3 kinase pathway 7 
Purine metabolism  2 
Ras Pathway 5 
T cell activation 7 
TGF-β signalling pathway- 4 
Thyrotropin-releasing hormone receptor signalling pathway- 2 
Toll receptor signalling pathway 6 
Unknown 53 
VEGF signalling pathway 7 
Wnt signalling pathway 8 
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Figure 3-3. Distribution of most frequent current RA targets when classified by molecular pathways.  
       (The number on the right of the bar represents the number of targets) 
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Cytokines are local protein mediators that are involved in almost all important biological 
processes, including cell growth and activation, cell differentiation, inflammation and 
immunity [248]. They are considered local messenger molecules that involves in the 
intercellular communication network of the immune system. In RA, activated antigen 
presenting cells (e.g. macrophages) produce a range of cytokines. Analysis of cytokine 
mRNA and protein revealed that many proinflammatory cytokines such as TNF-α, IL-1, IL-6, 
granulocyte-macrophage colony-stimulating factor (GM-CSF) are present in RA tissues 
[248]. The expression level of IL-18 is increased in synovial tissues of RA patients and 
correlates directly with RA disease activity [249, 250]. A novel cytokine IL-32 is positively 
correlated with levels of TNF-α, IL-1β, IL-6, and chemokines; immunohistochemistry 
revealed that IL-32 is highly expressed in RA synovial tissue biopsies but not in synovial 
tissues from patients with osteoarthritis [251].  A study using quantitative reverse 
transcriptase-polymerase chain reaction assay found that the expression of IFN-γ, IL-10 and 
IL-12 mRNA was increased in synovial fluid mononuclear cells compared with RA peripheral 
blood mononuclear cells [252]. Proinflammatory cytokines IL-1 and TNF-α activate 
macrophages and fibroblasts which after activation produces MMPs, these enzymes are 
considered to be responsible for cartliage destruction seen in RA [253]. TNF-α, IL-1β, and 
monocyte chemoattractant protein 1 (MCP-1) involves in leukocyte trafficking which is 
implicated in the pathogenesis of RA [254]. Hence the involvement of cytokines in RA is 
broad with complex interactions, creating a huge cytokine network that makes RA 
pathogenesis a complicated but intricate process. Interestingly, many cytokines with 
proinflammatory features also have anti-inflammatory aspects (e.g. IFN-γ), and those with 
mostly antiimmune/inflammatory features, such as TGF-β or IL-10, also have 
proinflammatory effects and hence are potentially pathogenic [253]. 
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A group of chemotactic cytokines or chemokines act as important mediators with chemotactic 
effects of certain leukocyte populations in the inflammation processes. Chemokine families 
are structurally identified according to the location of two of four highly conserved cysteine 
amino acid residues. The first two amino-terminal cysteines in one family are separated by an 
additional nonconserved amino acid in a strict C-X-C motif, and the other family possesses a 
conserved C-C motif near the amino terminus [255]. In general, the C-X-C (α) chemokines 
such as IL-8, and epithelial neutrophil activating peptide 78 (ENA 78), all have chemotactic 
activity or attraction for neutrophils [255, 256]. On the other hand, the C-C (β) chemokines 
such as RANTES (regulated upon activation normal T cell expressed and secreted), MCP-1, 
and macrophage inflammatory protein 1α (MIP-1α) mainly recruit mononuclear leukocytes (T 
cells and monocytes) [255, 256]. Analysis of mRNA  revealed abundant IL-8 in RA tissue 
[248]. Chemokines can also be categorized into homeostatic or inflammatory according to the 
function.  Homeostatic chemokines are continuously expressed exerting housekeeping 
functions whereas the inflammatory chemokines are involved in inflammation processes 
[257]. The two types of chemokines have some overlap in functions and are implicated in the 
pathogenesis of RA [258, 259]. Chemokine secretion and chemokine receptor expression can 
be mediated by other inflammatory regulators [260]. An increase in chemokine production is 
associated with autoantibody productions in RA [261]. Considering the substantial role played 
by proinflammatory chemokines in the inflammation in RA, the inhibition of chemokine 
production and chemokine production-associated pathways would play an important part in 
bringing a halt to the disease progression in RA. Besides being involved in the inflammatory 
process of RA, cytokines and chemokines are also engaged in other important pathological 
pathways such as cell expression and angiogenesis (see below). Therefore, further advance 
the knowledge in this area may help to discover novel therapeutic targets for RA.  
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Angiogenesis is an important metabolic pathway that is responsible for the formation of new 
capillaries. In early RA, angiogenesis is observed on arthroscopy and synovial lining 
hyperplasia begins to develop [195], this is driven by increased metabolic demands and 
hypoxia led by the infiltration of various types of cells into the synovial lining, mainly 
consisting of macrophages, T lymphocytes, and plasma cells [76]. Current RA medications 
inhibit or modulate the activity of various therapeutic targets involved in angiogenesis 
pathways, such as mitogen-activated protein kinases (MAPK3 and MAPK14), PKC (PKC 
and PKC1), Ras (HRAS) and VEGF.  
 
The angiogenesis pathway in RA can also be modulated by cytokines. Pro-inflammatory 
cytokine IL-18 significantly enhanced the secretion of angiogenic factors stromal cell–derived 
factor 1α (SDF-1α), monocyte chemoattractant protein 1 (MCP-1), and VEGF in RA synovial 
tissue fibroblasts via distinct pathways [262]. VEGF levels were significantly enhanced 
mainly via JNK-2, PKCα, and NF-κB [262].  
 
The de novo purine biosynthesis pathway is another commonly involved pathway by RA 
therapeutic targets. Purine, a building block for DNA and RNA, also a signalling molecule is 
crucial for cell proliferation and cell differentiation in the immune and inflammatory 
processes of RA. Hence agents targeting de novo purine biosynthesis pathway are appropriate 
candidates for RA drugs. For example, MTX significantly decreases the purine enzyme 
activities of adenosine-deaminase, purine-nucleoside-phosphorylase, and hypoxanthine-
guanine-phosphoribosyltransferase [263]. Purine analog azathioprine is an effective RA agent 
and reduces the activity of purine enzymes [264].  
 
Apoptosis is important in the down-regulation of  immune responses after the activation and 
proliferation of T and B cells in RA [202]. Over expression of p53 has been described in 
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many inflammatory conditions including RA [265] and Figure 3-3 shows that p53 pathway is 
commonly associated in RA. Activated p53 protein is a transcription factor that initiates cell 
cycle arrest, cellular senescence or apoptosis [266]. The process of apoptosis plays an integral 
role in RA via the elimination of immune and inflammatory cells therefore prohibiting disease 
progression.  
 
It is widely recognized that T lymphocytes act as important effector cells exhibiting an 
essential role in the immunopathogenesis of RA. T cell depletion has shown to be a  
promising therapeutic approach for RA treatment. Direct targeting of T cell populations did 
not succeed clinically as a result of non-specific T cell depletion related toxicity. Thus, 
targeting T cell activation is an alternative strategy to control the disease. The process of T 
cell activation requires two distinct signals, which are the cognate interaction between T cell 
receptor and antigen, along with their co-stimulation. Antigen presenting cells and their 
costimulation is essential for T cell activation and presumably play a central role in triggering 
RA. Targeting T cell activation via these two signalling pathways rather than decreasing the 
absolute number of T cells may be an effective option to RA therapy. 
 
 
 
3.5 Future targets and therapies of RA 
 
3.5.1 TNF-like Ligand 1A  
 
The production of various cytokines within the synovium has an essential role in the 
inflammatory process. TNF-like Ligand 1A (TL1A), a member of the TNF superfamily of 
cytokines, is the ligand for DR3 and DcR3. Initially, TL1A was thought to be generated only 
by endothelial cells induced by TNF-α and IL-1β [267], further studies reported that several 
types of cells, such as CD4 and CD8 cells, monocytes, dendritic cells are also capable of 
generating this cytokine [268, 269]. Recently, Zhang et al. [270]  demonstrated that TL1A 
increased TNF-α and IL-17 productions and Th17 differentiation in T cells in vitro, which 
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worsened collagen-induced arthritis in mice in vivo with multiple enlarged germinal centers in 
the spleen and boosted serum anti-collagen Ab titers after TL1A administration [270]. They 
also showed that human RA synovial fluids had elevated TL1A titers, and human 
chondrocytes and synovial fibroblasts were capable of secreting TL1A upon TNF-α or IL-1β 
stimulation. These observations indicate that TL1A might exert a role in RA initiation via the 
induction of autoantibody production; moreover, inflammatory cytokines inducing TL1A 
secretion in RA joints suggest a vicious cycle that exacerbates RA pathogenesis. Taken 
together, TL1A may be a potential therapeutic target in the treatment of RA.. 
 
3.5.2 Advanced glycation end-products  
 
RA-induced systemic osteoporosis is an important factor contributing to RA related morbidity 
and mortality [271]. Despite the availability of preventative therapeutic drugs, they are still 
insufficient to prevent generalized bone loss in RA.  Advanced glycation end-products 
(AGEs) are products of nonenzymatic glycation and oxidation of proteins and lipids. Several 
studies show that AGEs affected osteoclasts (bone resorption) and osteoblasts (bone 
formation), which indicates that AGEs might play an important role in the pathogenesis of 
osteoporotic bone diseases [272, 273]. Miyata et al. [274] demonstrates that AGEs increased 
in patients with RA and the concentration of AGEs was correlated with RA disease activity. 
AGEs impaired bone remodelling and were increased in serum and synovial fluid from RA 
patients, which indicates that AGEs may play a part in the pathogenesis of osteoporosis 
leading to bone loss in RA patients. Thus, AGE-lowering agent may provide a potential 
therapeutic strategy for RA therapy.  
 
3.5.3 Sphingosine 1-phosphate  
 
Sphingosine 1-phophate (S1P) is involved in various pathologic conditions and has been 
implicated as an important mediator of angiogenesis, inflammation, cancer, and 
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autoimmunity. In RA synoviocytes, it is suggested that S1P signalling pathway via S1P 
receptors plays a significant role in cell proliferation and inflammatory cytokine-induced 
COX-2 expression and PGE2 production [275]. In addition, S1P(1), S1P(2) and S1P(3) had 
essential roles in the pathogenesis of RA by modulating fibroblast-like synoviocytes 
migration, cytokine/chemokine production, and cell survival [276]. Taken together, regulation 
of S1P/S1P1 signalling pathway may represent a novel therapeutic target in RA.  
 
3.5.4 High mobility group box-1 protein  
 
High mobility group box-1 (HMGB 1) protein, originally known as a DNA binding protein 
which facilitates DNA replication and repair has been implicated in the pathogenesis of RA in 
both animal and human studies as a pro-inflammatory cytokine with pleiotropic activity. 
HMGB 1 has been detected with a stronger expression profile in synovial fluid of RA patients 
than that of osteoarthritis patients and was found to promote the release of pro-inflammatory 
cytokines such as TNF-α, IL-1β and IL-6 [277].  Recently, Sundberg et al. [278] suggests that 
the activity of HMGB1 might be independent of TNF during chronic inflammation. Hence, 
HMGB1 represents a TNF-independent molecule acting as a target for future therapeutic 
intervention in RA. 
 
3.5.5 Granulocyte-macrophage colony-stimulating factor signalling 
 
Many studies showed that fibroblast-like synoviocytes are involved in the development of 
sustained inflammation and angiogenesis in arthritic joints whilst several cytokines and 
rheumatoid factors stimulate their overgrowth [279-281]. Recently, Ha et al. [282] found that 
both transcriptional and post-translational control lead to Granulocyte-macrophage colony-
stimulating factor (GM-CSF)-mediated metastatic lymph node 51 (MLN51) up-regulation in 
RA fibroblast-like synoviocytes. They also observed the involvement of p38 MAPK in up-
regulating MLN51. Moreover, the proliferation of fibroblast-like synoviocytes was induced 
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due to upregulation of FLICE-inhibitory protein in response to GM-CSF.  The observations 
suggest that the GM-CSF signalling pathway could cause fibroblast-like synoviocyte 
hyperplasia in RA through activating MAPK and increasing MLN51 and FLICE-inhibitory 
protein. This signalling indicates a potential therapeutic target for the treatment of RA.  
 
3.5.6 Interleukin-1 receptor-associated kinase 4  
 
Interleulin-1 receptor-associated kinase 4 (IRAK-4), a member of a family of protein kinases 
which also include IRAK-1, IRAK-2 and IRAK-M, is an important factor in the activation of 
toll-like receptor (TLRs) pathway which regulates the production of cytokines, chemokines 
and immune responses. There are reports showing that IRAK-4 acted a crucial role in the 
signalling pathway of IL-1 and IL-18 receptors and it is required for the activation of all the 
TLRs except for TLR-3 [283-285]. Recently, Koziczak-Holbro et al. [286]  examined the role 
of IRAK-4 in the pathogenesis of RA and suggested that inhibition of IRAK-4 activities is a 
possible therapeutic target for RA treatment. 
 
3.5.7 Allograft inflammatory factor-1  
 
Allograft inflammatory factor-1 (AIF-1) is a cytokine originally identified and cloned from rat 
allografts undergoing chronic rejection as well as tissue inflammation in various autoimmune 
diseases [287]. AIF-1 is a Ca2+-binding protein and might be involved in the regulation of 
cell cycle progression and cellular activation status due to Ca2+ being an important second 
messenger in cellular signaling. AIF-1 is expressed in various human tissues and cells 
including immune organs [288]. Kimura et al. [289] observed that AIF-1 was strongly 
expressed in infiltrating mononuclear cells and synovial in RA compared to OA.  It stimulates 
the proliferation of cultured synovial cells and augmented IL-6 productions from synovial 
fibroblasts and peripheral blood mononuclear cells. In addition, concentrations of AIF-1 and 
IL-6 were significantly correlated. Taken together, these findings indicate a close relationship 
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between AIF-1 and the pathogenesis of RA; and suggest that AIF-1 is a new member of the 
cytokine network involved in the immunological processes underlying RA, which provides a 
potential target for RA therapy. 
 
 
3.5.8 Metastasis-promoting S100  
 
The metastasis-promoting protein S100 is a family of small acidic calcium-binding proteins 
consisting of over 20 members [290]. It is suggested that S100A8, S100A9 and S100A12 
exert their proinflammatory function in the extracellular in chronic inflammatory diseases 
including RA [291]. Foell et al. [292] demonstrates that the level of S100A12 in inflamed 
synovial tissue and the serum levels are associated with RA disease activity [292]. The 
association of S100A4 with inflammation was also observed, showing an increase in S100A4 
messenger RNA in patients with RA [293]. This finding indicates that S100A4 plays a role in 
pathogenesis of RA. Therefore, to target metastasis-promoting protein S100 will be a 
potential approach for RA treatment in the future.  
 
 
3.6 Conclusion and future perspectives 
 
At present, combinations of anti-inflammatory and anti-rheumatic medications are the full 
front treatment for RA patients. Corticosteriods and NSAIDs are used mainly to target 
inflammation in RA, with slight effect on disease progression. DMARDs are important 
disease modifying drugs for RA, with the ability not only to delay RA disease progression but 
also having the potential to protect the cartilage and bone. RA medication has a wide range of 
targets in the human body. Molecular structures that are involved in the process or associated 
pathways involving in immune response, inflammatory cascades, angiogenesis, cell 
proliferation and apoptosis are largely targeted by RA medication. In the last couple of 
decades, the development of biologics such as anti-TNF-α agents, interleukin inhibitors, B-
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cell inhibitors has emerged. This development was innovated by novel therapeutic targets that 
have opened new doors for RA medications and expanding avenues of treatment approaches 
for RA patients.  
Regardless of recent development and increased availability of RA medication, patients still 
suffer from undesired side effects and toxicity brought on by current medical treatments. 
Therefore further research is warranted in the area of identifying novel therapeutic targets of 
RA, in order to achieve maximal medical benefits for RA patients, in turn improving patient’s 
quality of life.  
 
The future goals of the therapy of RA should aim to: 
• develop new agents for managing inflammation, controlling disease process and 
halting disease progression. 
• discover new agents for interrupting osteoclast activation, reducing osteoporosis in 
RA patients. 
• determine the suitable time for biologics introduction in RA treatment. 
• gain more information about the effectiveness and safety of biologics. 
• fulfil individualized therapy.  
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Chapter 4. Bioinformatics Study of Current and Future Therapeutic Targets of Non-
Insulin Dependent Diabetes Mellitus 
 
4.1 Introduction 
 
Diabetes mellitus is a major health problem around the world, with continued expansion of 
disease associated morbidity, mortality, reduced quality of life and increased health care costs.  
Despite extensive research into diabetes and ongoing education on diabetes prevention, its 
prevalence is still on the rise. The International Diabetes Federation forecasts by the year 
2030, the total number of people with diabetes to be 440 million worldwide 
(www.diabetesatlas.org).  
 
Non-insulin dependent diabetes mellitus (NIDDM) is characterised by insulin resistance in 
peripheral tissues (such as liver and muscle), accompanied by β-cell dysfunction in the 
pancreas [294]. Insulin is a vital hormone produced by the pancreas that allows blood glucose 
passage into the body’s cells, fuelling the body’s systems. Without insulin, excess glucose 
builds up in the bloodstream leading to hyperglycaemia (high blood glucose), which is a 
hallmark metabolic abnormality associated with NIDDM. If untreated or not well managed, 
long term hyperglycaemia can lead to increased risk of macrovasulcar (cardiovascular, 
cerebrovascular and peripheral vascular disease) and microvasulcar (nephropathy, 
neuropathy, and retinopathy) complications. 
 
Hyperglycaemia being the key factor underlying complications of NIDDM, to reduce high 
blood glucose level and  reach target blood glucose level is a critical aim in NIDDM treatment 
[295]. This can be accomplished through the promotion of insulin levels in the body or an 
increase of insulin sensitivity of target cells, or via other glucose metabolism associated 
pathways. These therapeutic effects can be achieved through insulin sensitisers (e.g. 
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biguanides), insulin secretagogues (e.g. sulfonylureas and meglitinides) and external insulin 
delivery (insulin analogues). 
 
Despite the fact that a variety of antidiabetic agents are available for NIDDM patients, there 
are still shortcomings in diabetes treatment presently and the search for optimal therapy is 
necessary. Putting aside common side effects such as weight gain and hypoglycemia, current 
diabetes therapies do not address the key driver of this condition, β-cell dysfunction [296, 
297] and does not alter  the progressive nature of insulin secretory deficit [298]. Additionally, 
the pathophysiology of the disease is only partially understood [297], and there are currently 
no anti-diabetic agents that can effectively reduce excessive cardiovascular risk associated 
with NIDDM [299].  
 
This chapter aims to review current available therapies for NIDDM, investigate therapeutic 
targets and explore possible new classes of therapies for NIDDM using a bioinformatics 
approach.  
 
 
4.2 Methods 
 
4.2.1 Review of current available therapies for NIDDM 
 
In order to identify all the available NIDDM therapeutic agents (“Approved” & 
“Investigational”), we systematically reviewed published human studies on NIDDM. 
Literature was searched mainly from Pubmed (from the respective inception to July 2010). 
Additionally, data from the US Food and Drugs Administration (FDA, www.fda.gov) and 
several online databases were extracted. 
 
Search items used in the databases include “non-insulin diabetes mellitus”, “type-2 diabetes” 
and “anti-diabetic medication”. Only human data were included.  
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4.2.2 Collection of current and investigational targets of NIDDM 
 
Candidate targets of NIDDM were extracted from three online databases: Drugbank, 
Therapeutic Target Database and Potential Drug Target Database. 
 
4.2.3 Analysis of current and investigational targets of NIDDM 
 
After the collection of current approved drug targets, using target gene names via the 
“transcripts & protein” option on PANTHER to extract classification details. For those that 
did not have a gene name on Panther and so could not be classified by Panther, search of the 
gene names were done via NCBI and Uniprot for PANTHER classification.  
 
 
4.3 Review of current NIDDM drugs 
 
Effectiveness of NIDDM treatment therapy is often determined by indicators such as 
glycosylated haemoglobin (HbA1C) levels. The American Diabetes Association  recommends 
a HbA1C target level of less than or equal to 7% in diabetic patients. HbA1C levels are also a 
major determining factor for selecting which class of anti-diabetic drugs is suitable for 
treatment. When levels of glycemia are high (e.g., HbA1C >8.5%), classes with greater and 
more rapid glucose-lowering effect are selected [300]. On the other hand, when glycemic 
levels are closer to target HbA1C levels (e.g., <7.5%), agents with lesser potential to lower 
glycemia and/or a slower onset of action may be used [300]. HbA1C levels are also used to 
decide if combination therapy is required, for example,  if HbA1C levels rise above 7% in 
metformin treated patients, in addition to sulfonylurea, a thiazolidinedione may be added 
[299].  
 
The following section outlines different classes of antidiabetic medicines on the market that 
lowers blood glucose to reach goal HbA1C levels through a variety of mechanisms. 
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4.3.1 α- Glucosidase inhibitors  
 
α-glucosidase inhibitors (AGIs) are oral antidiabetic agents that delay the breakdown of 
complex carbohydrates in the small intestine, slowing down glucose absorption, which leads 
to a slower rise in blood glucose level, primarily targeting postprandially hyperglycemia [301, 
302]. Compared to metformin or the sulfonylureas, AGIs are less effective in lowering 
glycemia, reducing HbA1C levels by 0.5-0.8% [303]. Hypoglycemia is not often observed in 
AGIs as they do not increase insulin secretion, however increased delivery of carbohydrate to 
the colon commonly results in increased gas production and gastrointestinal symptoms such 
as flatulence and diarrhea [300]. Acarbose is a first-line drug for treating NIDDM that is 
insufficiently controlled by diet alone [304]. All AGIs act on alpha-glucosidase enzymes, 
however, acarbose is most effective on glucoamylase inhibition whilst another AGI miglitol is 
a more potent inhibitor of disaccharide-digesting enzymes [305, 306]. Interestingly, AGIs are 
frequently prescribed as first-line agents in Asian countries with diet rich in complex 
carbohydrates, but are seldom prescribed in the USA and Europe with protein and fat rich 
diet.  
 
4.3.2 Biguanides 
 
Biguanides are oral drugs for the management of mild to moderately severe NIDDM patients 
to overcome insulin resistance, especially in obese patients who fail diet and exercise therapy 
[307, 308]. Biguanides has a two-fold mechanism of action: it enhances the peripheral muscle 
glucose uptake and utilization (by making muscle and fat cells more sensitive to available 
insulin) and inhibits hepatic glucose output (by preventing the liver from making excess 
glucose) [307].  
 
Biguanides are known to cause vomiting, nausea, abdominal cramps, gastrointestinal 
intolerance, anorexia, epigastric fullness, photosensitivity, dyspepsia, and dysgeusia (metallic 
  131 
taste), confusion, and lethargy [307]. In contrast to SUs, one major advantage of biguanides is 
they usually do not cause hypoglycemia, even in overdose due to the fact that  insulin 
secretion is not promoted [311].  
 
Phenformin is a biguanide that was introduced in the United States in 1957 to treat NIDDM 
then removed from the market by the FDA in 1977 due to high incidence of lactic acidosis, 
which is a metabolic aberration that results in mortality in 50-75% of cases [49, 307]. All 
biguanides can cause lactic acidosis but the incident is highest in patients using phenformin, 
one in 4,000 patients taking phenformin develops lactic acidosis; compared with one in 
40,000 to 80,000 in patients taking metformin or buformin [309]. The therapeutic dose of 
phenformin was 50-200 mg per day and patients developing lactic acidosis took an average of 
123 mg per day [308].  
 
Another biguanide metformin was approved by the FDA in 1994 and has been used as the 
backbone therapy of NIDDM since. Metmorfin effectively lowers blood glucose level, as well 
as blood cholesterol and triglyceride levels, this reduces diabetic complications in the long 
run. Another benefit of metformin treatment is that it does not cause weight gain like other 
anti-diabetic agents. Overweight, high cholesterol and high triglyceride levels all increase the 
risk of developing heart disease, which is the leading cause of death in people with NIDDM. 
An additional advantage of metformin is that it does not cause hypoglycemia (low blood 
glucose) as it does not increase insulin secretion. Metformin effectively decreases HbA1C 
levels by ~1% to 2% [310]. The most common side effects of metformin are nausea and 
diarrhea, which usually go away over time. 
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4.3.3 Insulin 
 
Despite vigorous treatment with oral hypoglycemic agents, the progressive nature of NIDDM 
and the rising incidence of the disease world wide means that more and more people will 
require insulin therapy overtime, which is inevitably a last resort for NIDDM treatment. The 
American Diabetes Association recommends that analogue insulin therapy be initiated when 
patient’s HbA1C levels reach >8.5% [312]. Insulin is the most effective at lowering 
hyperglycemia and when used in appropriate doses, can decrease any level of elevated HbA1C 
to or close to, the therapeutic goal [300].  
 
Insulin formulations not only need to match the action of endogenous insulin as closely as 
possible, but must also be formulated and delivered to encourage patient adherence [312]. 
Patient compliance is an issue with insulin therapy, patients often raise concerns including 
time-consumption, dosage adjustment, pain and discomfort from injections. Although there 
are continuous effort to improve insulin delivery, a good delivering device is yet to be 
produced to provide NIDDM patients with optimal insulin dosage and minimise the risk of 
hypoglycaemia, one of the most concerning side effects of insulin therapy [312].  
 
There is a wide range of insulin replication available. When compared to human insulin, 
rapid-acting insulin analogues (lispro, aspart and glulisine) are suited for the control of 
postprandial hyperglycemia. In addition to greater flexibility in timing and dosing of insulin, 
they are rapidly absorbed, lowering post-prandial blood glucose (1-2 hrs) in a timely fashion 
and possible late post-prandial hypoglycaemia [313]. Insulin lispro was the first insulin 
analogue, which was prepared by recombinant DNA technology. Longer-acting, basal insulin 
analogues (e.g., detemir, glargine) provide concomitant improvements in safety, efficacy and 
variability of glycaemic control, with low risks of hypoglycaemia [314].  
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4.3.4 Meglitinides 
 
Meglitinides share similar mechanism of action with the sulfonylureas (discussed in Section 
4.3.5). They both stimulate rapid insulin secretion from β-cells by inhibiting ATP-sensitive K+ 
channels, activating the Ca++ channels leading to increase in calcium, thereby releasing insulin 
[315]. However, meglitinides act on a non-sulfonylurea binding site on the pancreatic β-cell 
[316]. 
 
Repaglinide, a benzoic acid derivative, was the first meglitinide analogue available [317]. The 
rapid onset of action, glucose-dependent insulin secretion effect of repaglinide makes this 
agent suitable for pre-prandial administration. In addition,  repaglinide targets early-phase 
insulin secretion which allows patients to have flexible mealtimes without increasing the risk 
of hypoglycaemia or compromising glycemic control [318]. Other meglitinide analogues 
include nateglinide (a d-phenylanaine derivative) and mitiglinide. 
 
4.3.5 Sulfonylureas  
 
Sulfonylureas (SUs) are insulin secretagogues that bind to sulfonylurea receptor on functional 
β-cells, causing the closure of ATP-sensitive potassium channels, which leads to 
depolarisation, an influx of calcium ions, and insulin secretion [52, 317, 319]. They 
exclusively act on β-cells and do not address the secretion defect of α-ells [302]. SUs can 
reduce HbA1C levels by ~1.5%, which is comparable to that of metformin [320, 321].  
 
Due to low specificity of the biological action, delayed time of onset, the long duration of the 
effect, major side effects induced by this class of agents include hypoglycemia and binding to 
cardiac receptors, resulting in failure of coronary vasodilatation and subsequent deleterious 
cardiac effects [319]. Various side effects represented the major limitations of the first 
generation SUs such as tolbutamide and chlorpropamide [319]. Second generation SUs (e.g. 
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glyburide and glipzide) exhibits a safer and better biological profile accomplished by selective 
binding and rapid onset of actions [319]. These improvements will attend to sulfonylurea-
induced hypoglycemia and cardiovascular side effects.  
 
4.3.6 Thiazolidinediones  
 
Thiazolidinediones (TZDs) are insulin sensitisers that increase insulin sensitivity of target 
tissues to the effects of endogenous and exogenous insulin, by increasing the number of 
glucose transporters in insulin-resistant tissues [322]. The TZDs are also potent and selective 
agonists of the peroxisome proliferator-activated receptor gamma (PPAR-γ) which play a role 
in the production, transport, and utilization of glucose and in the regulation of fatty acid 
metabolism [310]. In addition, they control adipocyte differentiation, therefore increasing the 
subcutaneous adipose tissue mass while decreasing abdominal adipose tissue mass [322], 
which helps with weight control in patients with NIDDM. An older TZD troglitazone was 
withdrawn from the market in March 2000 due to fatal idiosyndratic hepatotoxicity [52]. 
Other TZDs rosiglitazone and pioglitazone have not shown the same problems but patients are 
still closely monitored for liver problems. Hypoglycemia associated with TZD (rosiglitazone) 
is low (≤2%) because they do not stimulate insulin secretion [323], this is similar in 
biguanides.  
 
4.4 Current NIDDM targets 
 
In our literature search, we found 38 confirmed therapeutic targets of NIDDM in humans as 
shown in Table 4-1. Previously, we identified 96 therapeutic targets of rheumatoid arthritis, 
which is more than double the number of targets identified in this study. Using the 
PANTHER Classification System (http://www.pantherdb.org/, described in Section 1.5.2.1), 
based on published scientific evidence and evolutionary relationships, functional analysis of 
current NIDDM therapeutic targets in humans was performed using three approaches: 
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molecular function, biological process and pathway involvement (Table 4-1). Distribution of 
human NIDDM therapeutic targets varied in each of these functional classifications. 
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Table 4-1. Current therapeutic targets of NIDDM 
 
PANTHER Classifications Target Name Target 
Gene Molecular function Biological process Pathway categories 
Drug Name Related Diseases 
5'-AMP-activated protein 
kinase catalytic subunit α-1 
PRKAA1 Non-receptor 
serine/threonine protein 
kinase 
Gluconeogenesis, protein 
phosphorylation,  stress 
response 
p53 pathway by glucose 
deprivation 
Phenformin NIDDM 
5'-AMP-activated protein 
kinase subunit β-1 
PRKAB1 Kinase modulator Gluconeogenesis, cholesterol 
metabolism, protein 
phosphorylation, stress 
response 
p53 pathway by glucose 
deprivation 
Metformin NIDDM 
Adenosine A1 receptor  ADORA1 Protein coupled 
receptor 
G-protein mediated signaling, 
ligand-mediated signaling, 
phagocytosis, macrophage-
mediated immunity, other 
immune and defence, 
granulocyte-mediated 
immunity, nerve-nerve 
synaptic transmission, muscle 
contraction, induction of 
apoptosis, vision, regulation of 
vasoconstriction, dilation 
Heterotrimeric G-protein 
signaling pathway-Giα 
and Gsα mediated 
pathway 
 Caffeine Analgesics, asthma, 
cardiac arrhythmias, 
chronic ileitis, 
inflammation, 
inflammatory bowel 
disease, insulin resistance 
(obesity-related), 
NIDDM, pain, renal 
failure    
Aldose reductase     AKR1B1 Reductase   Other metabolism N/A Epalrestat  Analgesics, diabetic 
complications, diabetic 
neuropathy, diabetic 
retinopathy, neuropathic 
pain, NIDDM 
α2 adrenergic receptor  ADRA2A Protein coupled 
receptor 
G-protein mediated signaling  N/A   Alzheimer's disease, 
analgesics, DM, erectile 
dysfunction, 
gastrointestinal 
disturbances, heart 
failure, hypertension, 
ischemic heart disease, 
mechanical allodynia 
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associated with 
neuropathic pain of spinal 
origin, nasal congestion, 
open-angle glaucoma, 
peri-operative ischemia, 
prefrontal cognitive 
deficits, spasticity 
associated with cerebral 
or spinal damage, 
systemic sclerosis, 
tachycardia, unspecified, 
vasospastic attacks 
associated with idiopathic 
Raynaud's disease 
ATP-binding cassette 
transporter subfamily C 
member 8 
ABCC8 Other transporter  Carbohydrate metabolism, 
small molecule transport, 
extracellular transport and 
import, detoxification  
N/A Nateglinide NIDDM 
ATP-sensitive inward 
rectifier potassium channel 
1 
KCNJ1 Voltage-gated 
potassium channel  
Cation transport  N/A Glimepiride NIDDM 
ATP-sensitive inward 
rectifier potassium channel 
11 
KCNJ11 Voltage-gated 
potassium channel  
Cation transport  N/A Glimepiride NIDDM 
ATP-sensitive K+ channel   KCNJ5 Voltage-gated 
potassium channel  
Cation transport, muscle 
contraction  
N/A Glibenclamide  Hypertonicity of bladder, 
NIDDM 
Carnitine O-
palmitoyltransferase I  
CPT1A Acetyltransferase, 
acyltransferase  
Amino acid metabolism, fatty 
acid metabolism 
Muscarinic acetylcholine 
receptor 2 and 4 signaling 
pathway 
  NIDDM, obesity 
Dipeptidyl peptidase IV      DPP4 Serine protease  Proteolysis, cell surface 
receptor mediated signal 
transduction, T-cell mediated 
immunity  
N/A  Autoimmune diseases, 
DM, malignancies, 
obesity  
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Equilibrative nucleoside 
transporter 1 
SLC29A1 Other transporter  Nucleoside, nucleotide and 
nucleic acid transport, 
transport, cell proliferation and 
differentiation  
N/A Troglitazone NIDDM 
Fructose-1,6-
bisphosphatase 
FBP1 Carbohydrate 
phosphatase  
Carbohydrate metabolism  N/A  Diabetes 
Glucagon receptor GCGR G-protein coupled 
receptor  
G-protein mediated signaling, 
glucose homeostasis  
N/A  Hyperglycemia, T1DM, 
NIDDM, lipid 
metabolism disorders, 
obesity 
 
Glucagon-like peptide 1 
receptor 
GLP1R G-protein coupled 
receptor  
G-protein mediated signaling, 
glucose homeostasis  
N/A  Central nervous system 
diseases, diabetic 
neuropathy, obesity, 
NIDDM 
Glucokinase GCK Carbohydrate kinase  Glycolysis  Pentose phosphate 
pathway, glycolysis, 
fructose galactose 
metabolism 
 NIDDM 
Glycogen synthase kinase-3     GSK3A Non-receptor 
serine/threonine protein 
kinase 
Other polysaccharide 
metabolism, glycogen 
metabolism, protein 
phosphorylation, other receptor 
mediated signaling pathway, 
other intracellular signaling 
cascade, embryogenesis, 
segment specification, 
neurogenesis, mesoderm 
development, mitosis, cell 
proliferation and 
differentiation 
Ras Pathway, PDGF 
signaling pathway, 
heterotrimeric G-protein 
signaling pathway-Gi 
alpha and Gs alpha 
mediated pathway, Wnt 
signaling pathway, 
insulin/IGF pathway-
protein kinase B signaling 
cascade, angiogenesis,  
hedgehog signaling 
pathway, interleukin 
signaling pathway, 
Alzheimer disease-
presenilin pathway, 
cadherin signaling 
 Alzheimer's disease, 
bipolar affective disorder, 
cancer, unspecific, 
chronic inflammatory 
diseases, stroke, 
traumatic head injury, 
NIDDM 
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pathway, PI3 kinase 
pathway 
Hexokinase D GCK Carbohydrate kinase  Glycolysis  Pentose phosphate 
pathway, glycolysis, 
fructose galactose 
metabolism 
 NIDDM 
Insulin receptor   INSR Tyrosine protein kinase 
receptor, protein kinase 
Regulation of carbohydrate 
metabolism, protein 
phosphorylation, receptor 
protein tyrosine kinase 
signaling pathway, ligand-
mediated signaling, inhibition 
of apoptosis, other 
developmental process, 
embryogenesis, cell cycle 
control, cell proliferation and 
differentiation 
Insulin/IGF pathway-
protein kinase B signaling 
cascade, insulin/IGF 
pathway-mitogen 
activated protein kinase 
kinase/MAP kinase 
cascade, PI3 kinase 
pathway 
 Diabetes Mellitus 
Integrin α4 ITGA4 Other cell adhesion 
molecule  
Cell adhesion  Integrin signalling 
pathway, inflammation 
mediated by chemokine 
and cytokine signaling 
pathway 
 Allergic rhinitis, 
unspecified, allergy, 
unspecified, asthma, 
chronic experimental 
allergic 
encephalomyelitis, 
diabetes mellitus, 
inflammatory bowel 
disease, multiple 
sclerosis, predominantly 
eosinophil mediated 
disease states, rheumatoid 
arthritis, unspecified 
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Lipase/Pancreatic lipase PNLIP Lipase  Lipid metabolism  N/A  Acne, alzheimer's 
disease, dermatitis, 
hyperlipidemia, obesity, 
skin rash, NIDDM 
Long-chain fatty acid CoA 
ligase 4 
ACSL4 Other ligase   Fatty acid metabolism N/A Troglitazone NIDDM 
Lysosomal α-glucosidase GAA Glucosidase  Glycogen metabolism  N/A Acarbose NIDDM 
Maltase-glucoamylase, 
intestinal 
MGAM Glucosidase   N/A N/A Acarbose NIDDM 
Pancreatic α-amylase AMY2A Amylase Glycogen metabolism  N/A Acarbose NIDDM 
Pepsin 3A PGA5 Aspartic protease  Proteolysis  N/A  Barrett esophagus, 
duodenal ulcer, NIDDM 
 
 
Peroxisome proliferator 
activated receptor α     
PPARA Nuclear hormone 
receptor, transcription 
factor, nucleic acid 
binding 
Monosaccharide metabolism, 
regulation of lipid, fatty acid 
and steroid metabolism, 
mRNA transcription 
regulation, ligand-mediated 
signaling, stress response, 
developmental processes, cell 
proliferation and 
differentiation 
N/A   Bladder cancer, diabetes 
mellitus 
Peroxisome proliferator 
activated receptor δ 
PPARD Nuclear hormone 
receptor, transcription 
factor, nucleic acid 
binding 
Monosaccharide metabolism, 
regulation of lipid, fatty acid 
and steroid metabolism, 
mRNA transcription 
regulation, igand-mediated 
signaling, stress response, 
developmental processes, cell 
proliferation and 
differentiation 
Wnt signaling pathway  Atherosclerosis, 
inflammation, metabolic 
syndrome X, obesity, skin 
diseases, NIDDM  
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Peroxisome proliferator-
activated receptor γ 
PPARG Nuclear hormone 
receptor, transcription 
factor, nucleic acid 
binding 
Monosaccharide metabolism, 
regulation of lipid, fatty acid 
and steroid metabolism, 
mRNA transcription 
regulation, ligand-mediated 
signaling, stress response, 
developmental processes, cell 
proliferation and 
differentiation 
N/A Troglitazone NIDDM 
Plasminogen activator 
inhibitor 1 
SERPIN
E1 
Serine protease 
inhibitor  
Proteolysis  p53 pathway, blood 
coagulation, plasminogen 
activating cascade 
Troglitazone NIDDM 
 
Prostacyclin receptor     
PTG1R G-protein coupled 
receptor 
G-protein mediated signaling  N/A    
Protein kinase Cβ PRKCB1 Transfer/carrier protein, 
non-receptor 
serine/threonine protein 
kinase, calmodulin 
related protein, annexin 
Protein phosphorylation, 
calcium mediated signaling, 
cell proliferation and 
differentiation 
B cell activation, Wnt 
signaling pathway, 
thyrotropin-releasing 
hormone receptor 
signaling pathway, 
inflammation mediated by 
chemokine and cytokine 
signaling pathway, 
T cell activation, 
Alzheimer disease-
amyloid secretase 
pathway, EGF receptor 
signaling pathway, alpha 
adrenergic receptor 
signaling pathway, 
angiotensin II-stimulated 
signaling through G 
proteins and beta-arrestin, 
muscarinic acetylcholine 
receptor 1 and 3 signaling 
  B-lineage malignancies, 
diabetes mellitus, diabetic 
retinopathy, macular 
edema.  
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pathway, histamine H1 
receptor mediated 
signaling pathway, 
angiogenesis,  
VEGF signaling pathway, 
heterotrimeric G-protein 
signaling pathway-Gq 
alpha and Go alpha 
mediated pathway, FGF 
signaling pathway, 
metabotropic glutamate 
receptor group I pathway, 
oxytocin receptor 
mediated signaling 
pathway, endothelin 
signaling pathway, 
apoptosis signaling 
pathway, 5HT2 type 
receptor mediated 
signaling pathway, PDGF 
signaling pathway, 
inflammation mediated by 
chemokine and cytokine 
signaling pathway  
Retinoic acid receptor 
(RXRα) 
RXRA Nuclear hormone 
receptor, transcription 
factor, nucleic acid 
binding 
Regulation of lipid, fatty acid 
and steroid metabolism, 
mRNA transcription 
regulation, vitamin 
metabolism, signal 
transduction 
N/A  Adrenocorticotrophic 
hormone-secreting 
pituitary tumors, 
atherosclerosis, atopic 
dermatitis, autoimmune 
diseases, bladder cancer, 
chronic inflammatory 
diseases, Crohn's disease, 
diabetes mellitus, 
inflammation, 
inflammatory bowel 
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disease, insulin 
resistance, prostate cancer 
Serum albumin ALB Other transfer/carrier 
protein 
Transport N/A Gliclazide  
Sucrase-isomaltase, 
intestinal 
SI Glucosidase  unclassified  N/A Acarbose  
Tumor necrosis factor-α TNFA Tumor necrosis factor 
family member 
Cytokine and chemokine 
mediated signaling pathway, 
ligand-mediated signaling, 
immunity and defence, 
induction of apoptosis 
Wnt signaling pathway, 
apoptosis signaling 
pathway 
 Asthma, Behcet's disease, 
chronic inflammatory 
diseases, congestive heart 
failure, Crohn's disease, 
unspecified, heart failure, 
rheumatic diseases, 
rheumatoid arthritis, 
unspecified, solid tumor, 
hyperimmunoglobulinemi
a D, periodic fever 
syndrome, NIDDM 
Vascular endothelial 
growth factor A 
VEGFA Growth factor Receptor protein tyrosine 
kinase signaling pathway, 
MAPKKK cascade, ligand-
mediated signaling, stress 
response, angiogenesis, cell 
proliferation and 
differentiation, other 
oncogenesis 
Angiogenesis, VEGF 
signaling pathway 
Gliclazide  
Voltage-dependent T-type 
calcium channel α-1G 
subunit     
CACNA1
G 
Voltage-gated calcium 
channel  
Cation transport, 
neurotransmitter release, 
muscle contraction  
Endogenous cannabinoi 
signaling,  GABA- 
B_receptor_II_signaling 
 Analgesics, angina 
pectoris, cardiac 
dysrhythmias, 
cardiovascular disease, 
unspecified, epilepsy, 
heart failure, 
hypertension, 
hypoinsulinaemia, 
neuropathic pain  
  144 
Based on molecular function analysis by PANTHER, current NIDDM medications act on 
various classes of molecular targets in humans (Table 4-2). The most commonly involved 
classes include molecular targets from classifications of nuclear hormone receptors and 
nucleic acid binding (PPARA, PPARD, PPARG, RXRA), transcription factors (PPARA, 
PPARD, PPARG), voltage gated potassium channel (KCNJ1, KCNJ5, KCNJ11), glucosidase 
(GAA, MGAM, SI), G-protein coupled receptor (PTG1R, GCGR, GLP1R) and non-receptor 
serine/threonine protein kinase (PRKAA1, GSK3A, PRKCB1).  
 
 
 
Table 4-2. Distribution of current NIDDM targets according to molecular function 
classification by PANTEHR. 
 
PANTHER molecular function 
No. of 
targets PANTHER molecular function 
No. of 
targets 
Acetyltransferase 1 Other cell adhesion molecule  1 
Acyltransferase  1 Other ligase   1 
Amylase 1 Other transfer/carrier protein 1 
Annexin 1 Other transporter  2 
Aspartic protease  1 Protein coupled receptor 2 
Calmodulin related protein 1 Protein kinase 1 
Carbohydrate kinase  2 Reductase   1 
Carbohydrate phosphatase  1 Serine protease  1 
Glucosidase  3 Serine protease inhibitor  1 
G-protein coupled receptor  3 Transcription factor 4 
Growth factor 1 Transfer/carrier protein 1 
Kinase modulator 1 Tumor necrosis factor family member 1 
Lipase  1 Tyrosine protein kinase receptor 1 
Non-receptor serine/threonine protein 
kinase 
3 Voltage-gated calcium channel  1 
Nuclear hormone receptor 4 Voltage-gated potassium channel  3 
Nucleic acid binding 4   
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We also classified current NIDDM therapeutic targets according to biological processes using 
PANTHER. Present NIDDM therapeutic targets correlate with varied biological processes, 
most frequently involved including cell proliferation and differentiation processes, ligand-
mediated signaling, stress response process, protein phosphorylation, and regulations of lipid, 
fatty acids, steroid metabolism and mRNA transcription (Table 4-3). NIDDM targets involved 
in cell proliferation and differentiation processes include peroxisome proliferator activated 
receptor, alpha, delta and gamma (PPARA, PPARD, PPARG), glycogen synthase kinase 3 
(GSK3A), protein kinase C, beta type (PRKCB1), vascular endothelial growth factor A 
(VEGFA), equilibrative nucleoside transporter 1 (SLC29A1) and insulin receptor (IR). 
NIDDM targets involved in ligand-mediated signaling include peroxisome proliferator 
activated receptor, alpha, delta and gamma (PPARA, PPARD, PPARG), vascular endothelial 
growth factor A (VEGFA), insulin receptor (IR), tumour necrosis factor alpha (TNFA) and 
adenosine A1 receptor (ADORA1). NIDDM targets related to stress response include 
peroxisome proliferator activated receptor, alpha, delta and gamma (PPARA, PPARD, 
PPARG), vascular endothelial growth factor A (VEGFA), 5’-AMP-activated protein kinase 
catalytic subunit alpha-1 (PRKAA1) and 5’-AMP-activated protein kinase subunit beta-1 
(PRKAB1).  
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Table 4-3. Distribution of current NIDDM targets according to biological processes 
classification by PANTHER. 
 
PANTHER biological processes 
No. of 
targets PANTHER biological processes 
No. of 
targets 
Amino acid metabolism 1 Monosaccharide metabolism 3 
Angiogenesis 1 mRNA transcription regulation 4 
Calcium mediated signalling 1 Muscle contraction 3 
Carbohydrate metabolism  2 Nerve-nerve synaptic transmission 1 
Cation transport 4 Neurogenesis 1 
Cell adhesion  1 Neurotransmitter release 1 
Cell cycle control 1 
Nucleoside, nucleotide and nucleic acid 
transport 1 
Cell proliferation and differentiation 8 Other developmental process 1 
Cell surface receptor mediated signal 
transduction 1 Other immune and defence 1 
Cholesterol metabolism 1 Other intracellular signalling cascade 1 
Cytokine and chemokine mediated 
signalling pathway 1 Other metabolism 1 
Detoxification  1 Other oncogenesis 1 
Developmental processes 3 Other polysaccharide metabolism 1 
Embryogenesis 2 
Other receptor mediated signalling 
pathway 1 
Extracellular transport and import 1 Phagocytosis 1 
Fatty acid metabolism 2 Protein phosphorylation 5 
Gluconeogenesis 2 Proteolysis  3 
Glucose homeostasis  2 
Receptor protein tyrosine kinase 
signalling pathway 2 
Glycogen metabolism  2 Regulation of carbohydrate metabolism 1 
Glycolysis  2 
Regulation of lipid, fatty acid and 
steroid metabolism 4 
G-protein mediated signalling 5 
Regulation of vasoconstriction and 
dilation 1 
Granulocyte-mediated immunity 1 Segment specification 1 
Immunity and defence 1 Signal transduction 1 
Induction of apoptosis 3 Small molecule transport 1 
Ligand-mediated signalling 7 Stress response 6 
Lipid metabolism  1 T-cell mediated immunity  1 
Macrophage-mediated immunity 1 Transport 2 
MAPKKK cascade 1 Unclassified 2 
Mesoderm development 1 Vision 1 
Mitosis 1 Vitamin metabolism 1 
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The most common pathways targeted by current anti-diabetic agents according to PANTHER 
classifications are a number of signalling pathways (Table 4-4), including Wnt signaling 
pathway, apoptosis signalling pathway and heterotrimeric G-protein signaling pathway. 
Insulin and glucose related pathways targeted by current anti-diabetic agents are insulin/IGF 
pathways and p53 pathway by glucose deprivation. Other common pathways include 
inflammation mediated by chemokine and cytokine signaling pathway and angiogenesis 
pathways.
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Table 4-4. Pathway category classifications of current NIDDM targets according to 
PANTHER 
Pathway categories No. of 
Targets 
5HT2 type receptor mediated signaling pathway 1 
αAdrenergic receptor signaling pathway 1 
Alzheimer disease 2 
Angiogenesis 3 
Angiotensin II-stimulated signaling through G proteins and β-arrestin 1 
Apoptosis signaling pathway 2 
B cell activation 1 
Blood coagulation 1 
Cadherin signaling pathway 1 
EGF receptor signaling pathway 1 
Endogenous cannabinoid signaling 1 
Endothelin signaling pathway 1 
FGF signaling pathway 1 
Fructose galactose metabolism 2 
GABA-B receptor II signaling 1 
Glycolysis 2 
Hedgehog signaling pathway 1 
Heterotrimeric G-protein signaling pathway 4 
Histamine H1 receptor mediated signaling pathway 1 
Inflammation mediated by chemokine and cytokine signaling pathway 3 
Insulin/IGF pathway 3 
Integrin signalling pathway 1 
Interleukin signaling pathway 1 
Metabotropic glutamate receptor group I pathway 2 
Muscarinic acetylcholine receptor 2 and 4 signaling pathway 1 
Oxytocin receptor mediated signaling pathway 1 
p53 pathway by glucose deprivation 3 
PDGF signaling pathway 2 
Pentose phosphate pathway 2 
PI3 kinase pathway 2 
Plasminogen activating cascade 1 
Ras Pathway 1 
T cell activation 1 
Thyrotropin-releasing hormone receptor signaling pathway 1 
VEGF signaling pathway 2 
Wnt signaling pathway 4 
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This section outlines important targets of current anti-diabetic agents, their relevant pathways, 
corresponding therapeutic agents and related future targets.  
 
PANTHER analysis revealed that peroxisome proliferator activated receptors (PPARs) are 
important targets of antidiabetic agents. PPARs are ligand-activated transcription factors of 
the nuclear hormone receptor superfamily. They are clinically validated targets for treatment 
of insulin resistance. The 3 PPAR isoforms (alpha, delta/beta and gamma) are known to 
control many physiological functions including glucose absorption, lipid balance, and cell 
growth and differentiation [324]. The 3 PPAR isoforms are each encoded by a separate gene: 
PPARα (PPARA), PPARδ (PPARD) and PPARγ (PPARG). PPARs function through the 
formation of heterodimers with the coreceptor 9-cis retinoic acid receptor (RXR) and dock to 
promoter regions of genes, which regulates transcription in a ligand-dependent manner 
through the differential recruitment of co-activators and corepressors [325]. Activation of 
different downstream coactivators and corepressors will have different physiologic effects.   
 
Fibrates are PPARα activators used to improve the dyslipidemia component of metabolic 
syndrome, which is characterised by elevated triglyceride and low high-density lipoprotein 
levels, wheareas TZDs are PPARγ activators that improve insulin resistance in NIDDM [326].  
Because of different activation of downstream coactivators and end products and effects, dual 
PPARα/γ agnosits may have the ability to create a synergistic effect on insulin resistance and 
metabolic syndrome.  
 
PPAR- γ, a nuclear transcription factor is predominantly expressed in adipose tissue and after 
activation, plays a role in the production, transport, and utilization of glucose and in the 
regulation of fatty acid metabolism. TZDs are a class of anti-diabetic drugs which are PPARγ 
agonists. They achieve their hypoglycaemic effects by increasing glucose sensitivity in target 
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tissues, particularly muscle [327]. After TZDs bind to the transcription factor, it is activated 
and attaches to genes that have a recognition site for the activated PPAR-γ complex. The 
genes are either stimulated or inhibited to transcribe their mRNA depending on the particular 
gene and the specific tissue. The genes specifically regulated are those involved in modulating 
lipid metabolism, adipose tissue differentiation, and insulin action [328]. TZDs affinity for -
PPAR-γ correlates with their ability to reduce blood glucose [329] 
 
Another group of molecular targets that are commonly targeted by anti-diabetic agents are the 
sulfonylurea receptors. Sulfonylurea receptors are located on pancreatic β-cells membrane, 
and are composed of 2 units: an inwardly pore-forming ion channel (Klr 6.2) and regulatory 
subunits and ATP/ADP sensor (SUR1) [330]. 
 
The sulfonylureas are popular anti-diabetic agents that promote insulin secretion by binding to 
the sulfonylurea receptor type 1 [331]. Increase in intracellular glucose concentrations result 
in the increased production of ATP pancreatic β-cells, which is followed by closure of ATP-
dependent potassium (K+-ATP) channels [332]. Cell membrane depolarization and opening 
of voltage-sensitive calcium channels follows. An influx of Ca2+ is then followed by the 
depolarization of the cell membrane which induces the degranulation of insulin-containing 
vesicles and are followed by  insulin release and hypoglycaemic effects [319, 322, 333].  
 
Different SUs attach to multiple or different locations on  regulatory subunits of the 
sulfonylurea receptor [322]. Popular sulfonylurea agent repaglinide binds to up to 3 different 
receptors on pancreatic β-cells, one of them being the sulfonylurea receptor, resulting in 
closure of the K+ -ATP channels [334]. Whilst glyburide attaches to a 140-kD protein subunit 
and glimepiride attaches to a 65-KD subunit.  
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Lipids play a crucial role in the pathogenesis of metabolic diseases [335]. Fatty acids are 
implicated in the development of insulin resistance via several mechanisms, such as glucose 
oxidation reduction, insulin signalling inhibition and insulin receptor signalling changes, 
which all lead to reduced glucose uptake and insulin resistance [336]. Free fatty acid receptors 
are human cell surface receptors that are specifically activated by medium to long-chain free 
fatty acids [337]. Novel therapeutic targets related to free fatty acid levels in NIDDM and 
fatty acid receptors are discussed in the following sections (4.5.3 and 4.5.10).   
 
 
 
4.5 Future NIDDM drugs and targets 
 
4.5.1 11β-Hydroxysteroid dehydrogenase type 1 inhibitors 
 
Glucocorticoids are important regulators of glucose and lipid homeostasis, acting largely via 
intracellular glucocorticoid receptors in the liver, adipose tissue, and muscle. In addition, high 
levels of glucocorticoids can result in dyslipidemia, and a redistribution of fat to visceral 
depots which are associated with increased cardiovascular risk [338].  
 
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a NADPH-dependent enzyme that 
catalyses the conversion of the inactive 11-keto forms of glucocorticoids (cortisone, 11-
dehydrocorticosterone) to their active forms (cortisol, corticosterone) in several tissues [339], 
particularly in the liver. 11β-HSD1 amplifies local glucocorticoid hormone action in target 
tissues for insulin action and has been suggested to play a regulatory role in glucose 
homeostasis [340, 341]. Excess glucocorticoid levels cause glucose intolerance and insulin 
resistance, leading to NIDDM. 
 
It is found that 11β-HSD1 mRNA level is significantly higher in patients with NIDDM than 
controls in both visceral and subcutaneous adipose tissues [342]. Additionally, in 
subcutaneous adipose tissues, mRNA levels of 11β-HSD1 is higher in patients with type 2 
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diabetes compared to patients with impaired or normal glucose tolerance (P<0.0001) [343]. 
11β-HSD1 knockout animals demonstrated increased hepatic and adipose insulin sensitivity, 
improved glucose tolerance, a favourable lipoprotein profile, and reduced hemostatic factor 
synthesis [338]. Supporting the notion of a favourable metabolic profile, selective 11β-HSD1 
inhibitor BVT.2733 given to hyperglycaemic KKAy mice lowered blood glucose and insulin 
concentrations [340].  These data indicate that pharmacological inhibition of 11β-HSD1 
activity may result in the reduction of glucocorticoid signalling pathway. 
 
Administration of selective 11βHSD1 inhibitor (INCB13739, phase II) in NIDDM patients 
resulted in significant reductions in HbA1C (−0.6%), fasting plasma glucose (−24 mg/dl) 
compared with placebo. Total cholesterol, low density lipoprotein (LDL) cholesterol and 
triglycerides were all significantly decreased in hyperlipidemic patients. Adverse events were 
similar across all treatment groups [344]. Data from in vitro and in vivo studies show that 
11βHSD1 inhibition offers a new potential approach to control glucose and cardiovascular 
risk factors in type 2 diabetes although further clinical studies are warranted. 
 
4.5.2 Apelin 
 
Apelin was first isolated from bovine stomach extracts in 1998 [345]. In humans, apelin is 
expressed in several tissues, including the central nervous system, placenta, lung, kidney, 
heart and mammary gland [345]. Apelin may play a relevant role in the regulation of 
cardiovascular functions in diabetic cardiomyopathy as diabetic mice treated with apelin 
reportedly increased vasodilating response to acetylcholine through P13k/Akt/eNos pathway 
[346]. However, the expression of apelin receptor in the pancreatic islet cells suggests that the 
pancreatic islets are targets for apelin. The administration of apelin-36 inhibited glucose-
stimulated insulin secretion both in vivo and in vitro [347]. The inhibiting action of apelin on 
glucose-stimulated insulin secretion may be a burden in future apelin therapy. Based on these 
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findings, further studies are warranted to explore the possibility of apelin to regulate vascular 
functions in diabetes without compromising insulin secretion.  
 
4.5.3 Fatty acid receptors 
 
Free fatty acid receptors are human cell surface receptors that are specifically activated by 
medium to long-chain free fatty acids [337]. In this section, we will discuss 3 fatty acid 
receptors that have been found to be involved in NIDDM.  
 
In early NIDDM, elevated levels of fatty acids stimulate G-protein coupled receptor 40 
(GPR40), and chronic over stimulation of GPR40 leads to impaired β-cell function, 
hypoinsulinaemia and diabetes [294]. Therefore, GPR40 plays an important role in the chain 
of events linking obesity and NIDDM. GPR40 has been detected in the human pancreatic β-
cells and insulinomas, with ~20-fold enrichment reported in human islets [348-350]. 
Interestingly, the level of expression of GPR40 mRNA is comparable to that of sulofonylurea 
receptor and glucagon-like peptide 1 receptor, which are known to be abundantly expressed in 
pancreatic β-cells and are closely related to anti-diabetic treatment therapies [350]. Taken 
together, either antagonist of GPR40 or down regulation of GPR40 could be a potential 
strategy to combat NIDDM. A remarkable finding show that current anti-diabetic agents 
TZDs also activate GPR40 [337], suggesting that the combination of TZDs and anti-GPR40 
therapy may have synergistic clinical effects and could be useful in future diabetes treatment.  
 
Another G-protein coupled receptor- GPR119, is expressed predominantly in the pancreas and 
gastrointestinal tract in humans [351]. GSK-1292263, a novel GPR119 agonist has shown to 
increase levels of circulating glucagon-like peptide 1, gastric inhibitory polypeptide, peptide 
YY and glucagon in GSK-1292263 treated rats than controls. Increases of these 
gastrointestinal peptides have beneficial effects on insulin secretion [352]. Further, GSK-
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1292263 treated Zucker diabetic fatty rats was associated with a statistically significant 
increase in insulin immunoreactivity in pancreatic sections, compared with control animals 
[352].  
 
Recently, the safety, tolerability, pharmacokinetics and pharmacodynamics of single and 
multiple oral doses of GSK-1292263 in healthy volunteers (n=69) were reported. GSK-
1292263 has a mean half-life of 12-18 hours following once-daily dosing (5 days) and a dose-
dependent increase in glucose AUC (0-3 h) during oral glucose tolerance test was observed 
[353]. GSK-1292263-related side effects include mild headache, dizziness, hyperhidrosis, 
flushing and post-OGTT hypoglycaemia [353]. Co-administration with sitagliptin led to 
increases in the plasma concentrations of active GLP-1 but reduced the levels of total GLP-1, 
gastric inhibitory polypeptide and peptide YY [353]. Sitagliptin also affected the exposure of 
GSK-1292263 (50% increase) but GSK-1292263 did not affect sitagliptin exposure [353]. 
Hence, future studies are warranted for drug-drug interactions of GSK-1292263 and other oral 
antidiabetic agents to avoid unwanted side effects.   
 
GPR120 is an orphan G-protein coupled receptor abundantly expressed in the human 
intestinal tract, when activated by unsaturated fatty acids, it leads to the secretion of the 
incretin glucagon-like peptide 1 (GLP-1) in vitro and in vivo [354]. Increased levels of GLP-1 
has proven to promote glucose tolerance, hence GPR120 benefit stimulates insulin secretion 
by the increase of GLP-1 levels. This mechanism of action by adopted by GLP-1 analogues 
and DPP-4 inhibitors has already been proven to be effective for NIDDM, indicating that 
future therapies using GPR120 activation may be a promising treatment option for NIDDM.  
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4.5.4 Ghrelin 
 
Ghrelin is a novel peptide releasing growth hormone that is produced primarily by the 
enteroendocrine cells in the gastric mucosa [355]. In vitro, ghrelin inhibits glucose-stimulated 
insulin secretion in a dose-dependent manner from cultured pancreata [356], isolated 
pancreatic islets [357, 358], and β-cell cell lines [357]. These results demonstrate that ghrelin 
acts directly on β-cells. The same effect has also been seen in mice [358].  These findings 
suggest that ghrelin inhibition may possibly restore glucose stimulated insulin secretion, and 
indirectly preserving β-cells functions. However, in normal volunteers, intravenous 
administration of ghrelin leads to increased gastric emptying rate [359], which can have 
unwanted effect on glucose homeostasis in NIDDM patiens. Therefore, only improved 
understanding of the relationship between ghrelin, and insulin secretion and insulin resistance 
can designate the potential for ghrelin treatment in insulin resistance and NIDDM.  
 
4.5.5 Glucagon receptor antagonists 
 
Glucagon is released by pancreatic α-cells, it increases hepatic glucose output through its 
receptor and therefore is responsible for increased blood glucose levels particularly 
postprandially [360]. In NIDDM patients, relative glucagon hypersecretion in the fasted state 
and a lack of suppression of postprandial glucagon secretion contribute to the increased rate 
of hepatic glucose output [361]. High-affinity monoclonal antibodies targeting the glucagon 
receptor in diet-induced obese mice reduced fasting blood glucose without inducing 
hypoglycemia, reversible α-cell hyperplasia was observed and pancreatic β-cell function was 
preserved [362]. A glucagon antagonist has shown to reduce the glucagon-stimulated glucose 
production in healthy humans and showed good safety profiles [363]. Therefore, glucagon 
receptor antagonists that are able to block glucagon might have a lowering effect on fasting 
hyperglycaemia in NIDDM. 
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4.5.6 Glucokinase activators 
 
Glucokinase (GK) is a key enzyme that regulates glucose induced insulin secretion in 
pancreatic β-cells and glucose homeostasis in the liver via the catalysis of glucose to glucose-
6-phosphate [364, 365]. GK is selectively expressed in pancreatic β-cells and liver 
parenchymal cells, both of which are known to play crucial roles in blood glucose 
homeostasis in the body [366]. In humans, mutation of the GK gene has shown to impair the 
enzyme function causing type 2 maturity onset diabetes of young [367]. In addition, GK 
mutations increase insulin levels that cause hyperinsulinemic hypoglycemia [368].  
 
In vitro data show that GK activator (LY2121260) increases GK protein levels and stimulate 
insulin secretion in a glucose-dependent manner in pancreatic β-cells and increases glucose 
use in rat hepatocytes [365]. Animals treated with LY2121260 showed improved glucose 
tolerance after oral glucose challenge [365]. Current SUs treatment is vulnerable to secondary 
failure through β-cell desensitization due to stimulate insulin secretion via a glucose-
independent mechanism. GK activator retained full glucose-lowering efficacy in glimepiride-
desensitized rats, and significantly increased pancreatic insulin content, compared with 
controls [369]. Further, initial phase I results of glucokinase activator, MK-0599, 
demonstrated lowering of plasma glucose levels in healthy, nondiabetic volunteers [370]. This 
suggests that future GK activator therapy can be useful in NIDDM patients that no longer 
respond to SUs. 
 
4.5.7 Incretin therapy 
 
Incretins glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide 
(GIP) are intestinal peptide hormones released in response to food ingestion [371]. They 
enhance meal-related insulin secretion and promote glucose tolerance, a phenomenon called 
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the incretin effect. In NIDDM patients the incretin effect is reduced, thus researchers have 
adopted the “incretin concept” in attempts to develop incretin based therapeutic agents.   
 
Besides insulin secretion enhancement, GLP-1 also suppress glucagon secretion from alpha 
cells also in a glucose-dependent matter, glucagon secretion is inhibited under 
hyperglycaemic conditions and even increased under hypoglycemia [302, 372]. Moreover, 
GLP-1 slows gastric emptying and gastrointestinal motility [373], slowing down the rise of 
blood glucose level, all of which result in a glucose-lowering effect. It also acts a mediator of 
satiety in the hypothalamus. In healthy and NIDDM subjects, these actions are responsible for 
decreased caloric intake and consecutive weight loss followed by GLP-1 infusions [374, 375].  
GLP-1 also promotes β-cell regeneration [294], which provide hope for preservation of β-cell 
functions in NIDDM patients.  
 
Endogenously released GLP-1 has a short biological half-life of 1.5-5 minutes [376] and the 
serum half life of GIP is approximately 7 minutes [377]. Upon secretion, GLP-1 and GIP are 
rapidly degraded and inactivated by the enzyme dipeptidyl peptidase 4 (DPP-4) [378]. Hence 
to exploit the incretin-based therapy, DPP-4 resistant GLP-1 analogues have been produced in 
attempts to raise GLP-1 concentrations into the pharmacological range [297]. On the other 
hand, incretin enhancers (DPP-4 inhibitors) are used to prevent degradation of endogenously 
released GLP-1 and GIP, and consequently enhancing plasma level of active incretins in 
circulation, prolonging the actions of the incretins, consequently leading to increased insulin 
levels [297]. Currently there are only 2 classes of incretin-based therapies as mentioned. 
Additional effects and consequences of these drugs remain to be elucidated.  
 
GLP-1 mimetics are long-acting GLP-1 receptor agonists that are injectable compounds. So 
far, there are 2 GLP-1 analogues approved by the FDA. Exenatide (Byetta) was the first GLP-
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1 analogue launched; it was approved by FDA in 2005 and European Medicines Agency in 
2006. It’s developed from exendin-4, found in the saliva of the gila monster lizard [379] and 
has approximately 50% homology with human GLP-1 [380]. Liraglutide (Victoza) has 97% 
homology with GLP-1 and was approved by the FDA on Jan 25, 2010. Two more GLP-
analogues, albiglutide and taspoglutide (Phase III clinical trial) are currently under 
development.  
 
Sitagliptin is the first DPP-4 inhibitor launched and was approved in October 2006 by the 
FDA. In healthy subjects, sitagliptin markedly and dose-dependently inhibited approximately 
80% of plasma DPP-IV activity over 24 hours and produced an approximately 2-fold increase 
in post meal active GLP-1 level compared to placebo [381, 382]. Sitagliptin was well 
tolerated and was not associated with hypoglycemia [381, 382]. Further, a fixed-dose 
combination tablet containing both sitagliptin and metformin was approved by the FDA in 
April 2007 [383]. Another DPP-4 inhibitor saxagliptin was approved in 2009 under the trade 
name of Onglyza. Other DPP-4 inhibitors alogliptin, linagliptin are waiting for approval or 
under development. Pharmacokinetic profiles of FDA approved GLP-1 agonists and DPP-4 
inhibitors are presented in Table 4-5. 
 
The insulin-release effects of the incretins are glucose-dependent and have no insulinotropic 
activity at lower glucose concentrations (less than 4 mM), therefore reducing the chance of 
hypoglycemia, one of the major concern of other anti-diabetic drug classes [384].  
Furthermore, DPP-4 inhibitors are the first substances having a glucose-dependent dual action 
on pancreatic α- and β- cell functions stimulating insulin secretion and suppressing glucagon 
secretion under hyperglycaemic conditions. This dual action leads to an improved time course 
of islet hormone secretion after a meal and hyperglycaemia [302]. Taken together, the 
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discovery and advances of incretin therapy may help overcome the limitations of the classical 
treatment options of NIDDM. 
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Table 4-5. Pharmacokinetics of GLP-1 analogues and DPP4 inhibitors. 
 
Name 
(Brand 
name) 
Mechanis
m of action 
Indication Route of 
Administration  
Dose Cmax  t1/2β Tmax CL Reductions in 
HbA1C values 
Bioavailability  Toxicity Reference 
Exenatide 
(Byetta) 
 
 
 
 
 
 
 
GLP-1 
analogue 
NIDDM SC 5 or 10 µg 
twice daily 
 
119 
pg/ml (5 
µg)  
3.4-4 
hr 
2.1 hr 
 
 1% (10 µg 
twice daily)  
13 L/hr (5µg)  Mild gastro- 
intestinal 
adverse 
effects such 
as nausea, 
abdominal  
distension and 
vomiting 
[385-
388] 
Liraglutide 
(Victoza) 
GLP-1 
analogue 
NIDDM SC Initial dose 
of 0.6 mg 
per day for 
one week, 
then increase 
to 1.2 mg 
once daily  
 13 hr 9-12 hr    Mild 
gastrointestin
al symptoms 
[389] 
Sitagliptin 
(Januvia) 
DPP4 
inhibitor 
NIDDM Oral 100 mg daily 
as single 
agent; 50 mg 
sitagliptin/50
0 mg 
metformin 
and 50 mg 
sitagliptin/10
00 mg 
metformin, 
twice daily  
 8-14 hr   Plasma 
CL: 416 
ml/min ; 
renal CL: 
388 
ml/min  
0.79%  87%  Gastrointestin
al adverse 
events such as 
diarrhea and 
nausea  
 
[381, 
390-392] 
Vildagpliti
n (Galvus) 
DPP4 
inhibitor 
NIDDM Oral 50mg once 
or twice 
daily 
397±92 
ng/ml 
(100 mg 
2 hr                                                                                                       1.5-2hr  Renal 
CL: 13 
l/hr  
85%  [393-
395] 
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dose)  
Saxagliptin 
(Onglyza) 
DPP4 
inhibitor 
NIDDM Oral 5mg daily   2.2-3.8 
hr  
2 hr  Renal 
CL: 230 
ml/min 
0.7-0.9%   Headache, 
nasopharyngit
is, upper 
respiratory 
tract 
infections, 
and urinary 
tract 
infections 
[396, 
397] 
 
 
 
Cmax, maximum plasma concentration; CL, systematic clearance; IV, intravenous; SC, subcutaneous injection; t½β , elimination half-life.
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4.5.8 Sirtuins 
 
Silent Information Regulator Two (Sir2) proteins or sirtuins are enzymes that have NAD-
dependent deacetylase activity and are essential in longevity in yeast [398]. Mammalian 
SIRT1, a class III histone/protein deacetylase is the most closely related homolog of the SIR2 
gene [399].   
 
In NIDDM rat, SIRT1 knockdown lowered fasting glucose concentration and hepatic glucose 
production, also producing a decrease in plasma total cholesterol which is attributed to 
increased cholesterol uptake and export from the liver [400]. Also observed was increased 
acetylation of transcription factors STAT3, FOXO1and PGC-1α, resulting in 25%, 51%, and 
49% decrease in transcription in key gluconeogenic enzymes, namely, phosphoenolpyruvate 
carboxylase kinase (PEPCK), fructose-1,6-bisphosphatase (FBPase), and glucose-6-
phosphatase (G6Pase) [400]. 
 
Pharmacological activators of SIRT1 have been reported to have improved glucose tolerance 
in vitro and in vivo. Resveratrol, a natural plant product present in grapes and red wine, is 
known to be a potent activator of SIRT1 [401]. In human adipocytes, resveratrol stimulated 
basal and insulin-stimulated glucose uptake [401]. Results from the same study also showed 
that de novo lipogenesis was inhibited in parallel with a down-regulation of lipogenic gene 
expression. These findings suggest that SIRT activators implicate in lipogenesis and may play 
a role in the development of cardiovascular complications in NIDDM. Zucker fatty rats 
treated with a SIRT1 activator showed great improvement in glucose tolerance, reduced 
hyperinsulinemia, and enhanced systemic insulin sensitivity during glucose clamp studies 
[402]. Current experimental data show favorable outcomes in glucose tolerance related to 
SIRT1 activators. Sirtris Pharmaceutical is currently evaluating SRT2104 in a Phase II 
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clinical trial of NIDDM, indicating a great potential of SIRT1 therapy becoming successful in 
the future of NIDDM treatment.    
 
Another sirtuins SIRT4 is also known to be involved in insulin secretion and β-cell survival 
[403]. SIRT4 is different to SIR1 as it does not possess deacetylase activity but instead uses 
NAD to transfer ADP-ribose to its substrate protien [403] and is selectively expressed in the 
pancreatic β-cells. SIRT4 inhibits the activity of ADP-ribosylating GDH and blocks the 
conversion of glutamate to the tricarboxylic acid cycle intermediate, α-ketoglutarate, which 
can exert a negative effect on insulin secretion [404]. SIRT4 knockout experiment in 
insulinoma cells and mice triggered insulin hypersecretion [405]. Abundant expression of 
SIRT4 in the pancreas along with its insulin secretion related activities makes SIRT4 a 
promising therapeutic target for NIDDM treatment. 
 
4.5.9 Sodium-glucose transporter-2 inhibitors 
 
Sodium-glucose transporter-2 (SGLT-2) mediates approximately 90% of active renal glucose 
reabsorption in the renal proximal tubule [406]. Inhibitors of this transporter blocks glucose 
reabsorption and therefore promote glycosuria [407]. Increased urinary output of glucose will 
lower serum glucose, so SGLT-2 inhibitors may help reduce blood sugar levels in NIDDM. In 
addition, because SGLT-2 is expressed exclusively in the kidneys, inhibition of this 
transporter ought not to affect other tissues or organs. Moreover, SGLT-2 can reduce blood 
glucose level without inducing insulin secretion, hence reducing the risks of hypoglycemia. 
Overall, SGLT-2 inhibitors are promising agents in the treatment of NIDDM. Two agents 
from this class of drugs, sergliflozin and dapagliflozin are both currently in Phase III clinical 
trials.  
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In healthy volunteers and NIDDM patients, oral administration of sergliflozin produces rapid 
and sustained suppression of renal glucose reabsorption and dose-dependant glucosuria [408, 
409]. In healthy obese subjects, dose-related reduction in body weight through increase in 
urinary calorie loss rather than through osmotic diuresis [408]. Single and multiple doses of 
sergliflozin are well tolerated with no clinically significant adverse events identified. Glucose 
excretion induced by sergliflozin does not affect glucose level, insulin level or electrolyte 
balance [408-410]. 
 
Dapagliflozin doses of approximately 20-50 mg provides close-to-maximal SGLT2 inhibition 
for at least 24 h and sustains dose-dependent glucosuria over 24 hours, which indicates that it 
is suitable for administration in once-daily doses [411]. In both healthy subjects and NIDDM 
patients, dapagliflozin produces a dose-dependent increase of glucosuria [411, 412].  In a 14-
day study, NIDDM patients shows clinically meaningful changes in the reduction in fasting 
serum glucose and improvements in oral glucose tolerance test [412]. In a well designed 
multi-centre trial, in 71 NIDDM patients with poor hyperglycemic control with high insulin 
doses, dapagliflozin decreased HbA1C, produced better fasting plasma glucose and 
postprandial glucose levels, and lowered weight more than placebo [413]. Overall, adverse 
events were balanced across all groups, although more genital infections occurred in the 20-
mg dapagliflozin group than in the placebo group [413]. Available pharmacokinetic profiles 
of sergliflozin and dapagliflozin are provided in Table 4-6.
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Table 4-6. Pharmacokinetics of SGLT-2 inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
t½β , elimination half-life;Tmax, time to maximum plasma concentration 
 
Name  Status Manufacturer Mechanism 
of action 
Indication Route of 
Administration 
Dose t1/2β Tmax Toxicity Reference 
Sergliflozin Phase 
III 
GlaxoSmithKline Inhibits 
renal 
glucose 
reabsorption  
NIDDM Oral 5-500 
mg  
0.5-
1 hr  
30-45 
min 
No 
significant 
adverse 
events 
identified  
[409] 
Dapagliflozin Phase 
III 
Bristol-Myers 
Squibb & 
AstraZeneca 
Inhibits 
renal 
glucose 
reabsorption  
NIDDM Oral 20-50 
mg 
17 
hr 
 Increased 
incidence 
of genital 
infections  
[411, 413] 
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4.5.10 Stearoly-CoA desaturase 1 inhibitors 
 
Lipids play a crucial role in the pathogenesis of metabolic diseases and enzymes regulating 
lipid metabolism has recently been proposed as therapeutic targets [335]. Increasing evidence 
suggests that stearoly-CoA desaturase 1 (SCD1), the rate-limiting enzyme of 
monounsaturated fatty acid (substrates for the synthesis of triglycerides) biosynthesis from 
saturated fatty acyl-CoAs, is an important factor in the pathogenesis of lipid-induced insulin 
resistance [414, 415].  
 
In SCD1-/- mice, an increase of glucose transporter GLUT4 levels led to a pronounced 
elevation of glucose uptake into cells [415]. After a 30-min glucose load, SCD1-/- mice 
showed greater glucose tolerance and have lower plasma glucose levels compared with wild-
type mice [415]. Based on these results, it is evident that SCD1 has a critical role in insulin 
signal transduction in mice muscles. 
 
Although the precise mechanism of SCD1 action on insulin signalling remains to be clarified, 
current findings on SCD1 point to a very promising novel target for the treatment of insulin 
resistance [414]. Further, it is also proposed that SCD1 inhibitor compounds maybe 
successfully used in combination with one or more other drugs (e.g., PPARγ agonists, insulin 
or insulin mimetics), this can provide a promising future combination therapies in NIDDM 
[416]. Inhibition of SCD1 expression or activity as drug actions is a novel approach for 
NIDDM treatment; however the effect of SCD1 inhibitors on glucose uptake in humans is still 
to be elucidated.  
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4.6 Conclusions 
 
Current therapies of NIDDM aim to achieve and maintain glycemic goals (e.g., HbA1C <7%) 
to control glucose level and reduce the long term complications associated with this disease.  
Present anti-diabetic agents act to reduce blood glucose levels via different mechanisms, such 
as promoting insulin secretion (SUs and meglitinides), increasing insulin sensitivity 
(biguanides and TZDs), inhibition of hepatic glucose output (biguanides) and decrease of 
glucose absorption from the small intestines (AGIs).  
 
Overall, current diabetes therapies can effectively reduces blood glucose level and manage 
NIDDM.  However, the key driver of this condition- β-cell dysfunction is not addressed and 
the progressive nature of indulin secretion deficit in NIDDM cannot be altered by current 
anti-diabetic agents [296-298]. Additionally, the pathophysiology of the disease is only 
partially understood [297]. Furthermore, no current anti-diabetic agents can effectively reduce 
excessive cardiovascular risk [299].  
 
Therefore, further research is warranted in the area of identifying novel therapeutic targets of 
NIDDM, in order to achieve maximal medical benefits for NIDDM patients, in turn 
improving patient’s quality of life. The future goals of the therapy of NIDDM should aim to 
develop new agents that effectively manage blood glucose levels without inducing 
hypoglycaemia. New agents should also aim to reverse pancreatic β-cell damage and halt 
disease progression. In the long run, reduce NIDDM associated complications such as 
cardiovascular risks. 
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Chapter 5. A Bioinformatic Study of Berberine Targets 
 
5.1 General introduction 
 
Berberine (Figure 5-1, molecular formula C20H19NO5 and a molecular weight of 353.36) is an 
isoquinoline alkaloid found in many medicinal plants [417]. It is a major constituent of many 
medicinal plants of families Papaveraceae, Berberidaceae, Fumariaceae, Menispermaceae, 
Ranunculaceae, Rutaceae and Annonaceae [418]. It is present in Hydrastis Canadensis 
(goldenseal), Coptis chinensis (Coptis or goldenthread), Berberis aquifolium (Oregon grape), 
Berberis vulgaris (barberry), and Berberis aristata (tree turmeric). The berberine alkaloid can 
be found in the roots, rhizomes, and stem bark of the plants.  
 
Berberine is one of the main alkaloids found in the Chinese herb Huang lian (Rhizoma 
Coptidis, Figure 5-2) [419]. Huang Lian has traditionally been used to treat diarrhoea and 
diabetes. In China, berberine has been manufactured into the over-the-counter drug Huang 
Lian Su Pian (Figure 5-3), also known as Coptis Extract Tablets for the treatment of traveler’s 
diarrhoea [417, 420]. 
 
In recent years, there has been a growing interest in the pharmacological activities of 
berberine and many studies have been carried out to elucidate the mechanisms of action of 
berberine. This study aims to review molecular targets of berberine based on in vitro studies. 
Berberine has shown to have good hypoglycaemic effects, so we also reviewed the effects of 
berberine in animal and human studies, with a focus on diabetes mellitus.  
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Figure 5-1. Chemical structure of berberine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2. Chinese herb Huang Lian (Coptidis rhizome) 
 
 
 
 
 
Figure 5-3. Huang Lian Su Pian used to treat traveller’s diarrhoea in China.  
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5.2  Analysis of berberine targets in vitro 
 
5.2.1 Berberine targets in vitro  
  
In vitro studies related to berberine and its targets were searched using Pubmed (from 
inception to June 2011). Serarch terms used were a combination of “berberine”, “in vitro”, 
“human cell” and “mechanism”. Only studies using human cell lines were used to extract 
current berberine targets (Table 5-1). Studies using animal cell lines or berberine derivatives 
or is in a language other than English were excluded. Information extracted from these studies 
includes molecular targets of berberine (name and gene symbols), cell type, effects of 
berberine and possible clinical applications (Table 5-1). 
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Table 5-1. Potential targets of berberine.  
 
Target Names Target Gene 
Symbol 
Cells Effects Possible clinical 
applications 
References 
72 kDa type IV collagenase MMP2 HUVECs, tongue cancer 
SCC-4 cells, gastric 
carcinoma SNU-5 cells, lung 
cancer A549 cells, U-87 
glioma cells 
Down regulation of MMP2 mRNA 
and protein expression, reduced 
MMP-2 levels 
Anti-metastatic  [421-425] 
Acetyl-Coenzyme A 
carboxylase α 
ACACA HepG2 hepatoma cells Phosphorylation Anti-hyperlipidemic [426] 
Alpha fetoprotein AFP HepG2 hepatoma cells Reduced secretion of alpha 
fetoprotein 
Apoptosis [427] 
Amyloid beta (A4) precursor 
protein (peptidase nexin-II, 
Alzheimer disease) 
APP Neuroglioma H4 cells Reduces amyloid-beta peptide 
(Abeta) levels via modulation of 
APP 
Alzheimer disease [428] 
Apoptosis regulator Bcl-X BCL2L1 Colonic carcinoma cells, 
HepG2 cells/ A549 cells, 
prostate carcinoma cells 
(DU145 and PC-3, LNCaP), 
Jurkat cells 
JNK/p38 pathway and induction of 
ROS production. Decreased 
expression  
Cell apoptosis, anti-cancer, 
anti-inflammatory  
[429-434] 
Arylamine N-
acetyltransferase 1 
NAT Leukemia HL-60 cells, colon 
tumour cells, brain tumour 
cells (G95/VGH and GBM 
8401) 
Decrease in  N-acetyltransferase 
(NAT) protein and expression of 
mRNA  
Anti-cancer (leukemia, colon 
cancer, brain tumour etc) 
[435-437] 
ATP-binding cassette sub-
family G member 2 
ABCG2 MCF-7 breast cancer cells Decrease in ABCG2 expression Breast cancer [438] 
Baculoviral IAP repeat-
containing protein 2 ( anti-
apoptosis factor c-IPA-1) 
BIRC2  Jurkat cells, colonic 
carcinoma cells (SW620) 
Suppresses expression of anti 
apoptosis factor IAP1 
Anticancer  [429, 434] 
Baculoviral IAP repeat-
containing protein 3 
BIRC3 Jurkat cells Suppresses expression of  anti 
apoptosis factor IAP2 
Anticancer  [434] 
Baculoviral IAP repeat-
containing protein 5 
(Survivin) 
BIRC5 Jurkat cells Suppresses expression of survivin Anticancer and anti-
inflammatory agent 
[434] 
B-cell CLL/lymphoma 2 BCL2 HepG2 cells, oral squamous 
cell carcinoma, tongue 
cancer SCC-4 cells, colonic 
carcinoma cells, lung cancer 
cells, brest cancer MCF-7 
(estrogen receptor+) cells, 
prostate carcinoma cells 
(DU145 and PC-3, LNCaP) 
Bcl-2 downregulation Cell apoptosis, Cancer, ER 
antagonist adjuvant therapy  
[429, 431-
433, 439-
442] 
B-cell lymphoma 3-encoded 
protein 
Bcl-3 Gastric carcinoma SNU-5 
cells  
Downregulation of Bcl-3 Gastric cancer [443] 
Bcl2 antagonist of cell death BAD Human oral squamous cell 
carcinoma 
Increased expression of 
proapoptotic BAD protein 
Anti-tumour  [441] 
BCL2-associated X protein BAX Gastric carcinoma SNU-5 
cells, prostate carcinoma 
cells (DU145, PC-3, LNCaP 
and PWR-1E), leukemia HL-
60, tongue cancer SCC-4 
, lung cancer cells  
 Upregulation of Bax, increased 
expression. G2/M phase arrest 
Cell apoptosis, gastric cancer [422, 431-
433, 443-
445] 
BH3-interacting domain 
death agonist p11 
BID Colonic carcinoma cells/ 
HepG2 cells 
JNK/p38 pathway and induction of 
ROS production 
Induction of apoptosis  [429, 430] 
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C/EBP homologous protein 
(CHOP) or  growth arrest- 
and DNA damage-inducible 
gene 153 (GADD153) or 
DNA damage-inducible 
transcript 3 
GADD153/ 
DDIT3 
Cervical cancer Ca Ski cells  Induced expression of GADD153  Cervical cancer  [446] 
CASP8 and FADD-like 
apoptosis regulator subunit 
p12 
CFLAR/cFLI
P 
Jurkat cells Suppresses expression of cFLIP Anticancer and anti-
inflammatory  
[434] 
Caspase 3, apoptosis-related 
cysteine peptidase 
CASP3 Tongue cancer SCC-4 cells, 
neuroblastoma (SK-N-SH), 
glioblastoma T98G cells, 
gastric carcinoma SNU-5 
cells, HL-60 cells,  prostate 
carcinoma cells (DU145, 
PWR-1E, PC-3 and LNCaP), 
colonic carcinoma cells, 
hepatoma cells, oral 
squamous cell carcinoma, 
promonocytic U937 cells, 
lung cancer A549, H1301 
cells 
Activation of caspase-3, G2/M 
phase arrest 
Anti-cancer [422, 429-
433, 441, 
443, 447-
451] 
Caspase 8, apoptosis-related 
cysteine peptidase 
CASP8 Tongue cancer SCC-4 cells, 
colonic carcinoma cells, 
hepatoma cells, oral 
squamous cell carcinoma 
Activated caspase 8  Anti-cancer [422, 429, 
430, 441] 
aspase 9, ap ptosis- elated 
cysteine peptidase 
C SP9 Tongue cancer SCC-4 cel s,
glioblastoma T98G, oral 
squamous carcinoma, 
promonocytic U937 cells, 
prostate carcinoma cells 
(DU145 and PC-3, LNCaP) 
Activation of ca pase 9 ll apoptosis, anti-cancer 22, 432, 
433, 441, 
448-450, 
452] 
Cdc42 effector protein 1 CDC42EP1 Nasopharyngeal carcinoma 
(HONE1) cells 
Suppression of Rho GTPases 
activation (Cd 42) 
Cancer metastasis inhibition [453] 
Cell division protein kinase 
6 
CDK6 Prostate carcinoma cells 
(DU145 and PC-3, LNCaP) 
Decrease in Cdk6 Cell apoptosis, cancer [432, 433] 
Cellular tumor antigen p53 TP53 Gastric carcinoma SNU-5 
ells, Osteosarcoma 
Increased expression of p53 protein, 
cell cyle arrest at G1G2/M phase 
arrest 
Anti-cancer (gastric cancer, 
osteosarcoma) 
[443, 454] 
Chemokine (C-C motif) 
ligand 2 (monocyte 
chemotactic protein-1) 
CCL2 Retinal pigment epithelial 
cell line 
Inhibits CCL2 (MCP-1) expression Anti-inflammatory [455] 
Cyclic AMP-dependent 
transcription factor ATF-3 
ATF3 Colerectal cancer cells Induces ATF3 expression Colorectal cancer  [456] 
Cyclin dependant kinase 
1/Cell division control 
protein 2 homolog 
CDK1/CDC2 HL-60 cell, Gastric 
carcinoma SNU-5 cells  
Inactivation of Cdc2 (CDK1) or 
decreased protein expression  
Anti-proliferative and pro-
apoptotic 
[443, 457] 
Cyclin E1 CCNE1 Neuroblastoma (SK-N-SK), 
glioblastoma T98G cells 
Decrease Anti cancer  [447, 452] 
Cyclin-dependent kinase 2 CDK2 Neur blastoma (SK-N-SK), 
glioblastoma T98G cells, 
prostate carcinoma cells 
(DU145 and PC-3, LNCaP) 
Decrease in Cdk2 Cell apoptosis, anti-cancer [432, 433, 
447, 452] 
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Cyclin-dependent kinase 4 CDK4 Neuroblastoma (SK-N-SK), 
glioblastoma T98G cells, 
prostate carcinoma cells 
(DU145 and PC-3, LNCaP) 
Decrease in Cdk4 Cell apoptosis, anti-cancer [432, 433, 
447, 452] 
Cyclin-dependent kinase 
inhibitor 1 
(p21) 
CDKN1A Brest cancer MCF-7 
(estrogen receptor+)cells, 
Epidermoid carcinoma A431 
cells 
Increased expression of p21 Breast cancer, ER antagonist 
adjuvant therapy  
[432, 433, 
442] 
Cyclin-dependent kinase 
inhibitor 1B (P27/KIP1) 
CDKN1B Epidermoid carcinoma A431 
cells 
Increased expression of Cdki 
proteins  
Cell apoptosis, cancer [432, 433] 
Cytochrome c-1 CYC1 Tongue cancer SCC-4 cells, 
colonic carcinoma cells, 
promyelocytic leukemia HL-
60 cells 
Release of cytochrome c-1 Anti-cancer [422, 429, 
445, 448] 
CYP2C9 CYP2C9 Recombinant CYP Inhibition of CYP2C9 Drug interactions [458] 
CYP2D6 CYP2D6 Recombinant CYP Inhibition of CYP2D6 Drug interactions [458] 
CYP3A4 CYP3A4 Caco-2 cells, patients CYP3A4 down regulation and 
inhibition  
Drug interactions [459, 460] 
Dipeptidyl-peptidase 4 
(CD26, adenosine deaminase 
complexing protein 2) 
DPP4 Recombinant DPP4 Inhibition of DPP4  -- [461] 
Early activation antigen 
CD69 
CD69 Human peripheral 
lymphocytes  
Reduced expression of CD69  Immunosuppressive agent [462] 
Epidermal growth factor 
receptor 
EGFR Brest cancer MCF-7 
(estrogen receptor+)cells 
EGFRdownregulated Breast cancer, ER antagonist 
adjuvant therapy  
[442] 
Ezrin EZR Nasopharyngeal carcinoma 
5-8F cells 
Ezrin inhibition Anti cancer  [463] 
G1/S-specific cyclin-D1 CND1 Giant cell carcinoma cell 
line, HL-60 cell, Prostate
carcinom  cells (DU145 and 
PC-3, LNCaP), Jurkat cells,
neuroblastoma (SK-N-SK) 
Inhibits xpression of cyclin D1 Anti-pr liferative and pro-
apoptotic, anti-cancer, anti-
inflammatory  
-434, 
7,
464] 
G1/S-specific cyclin-D2 CCND2 Prostate carcinoma cells 
(DU145 and PC-3, LNCaP) 
Decrease in cyclin D2 Cell apoptosis, cancer [432, 433] 
G1/S-specific cyclin-E1 CCNE1 Prostate carcinoma cells 
(DU145 and PC-3, LNCaP) 
Decrease in cyclin E Cell apoptosis, cancer [432, 433] 
G2/mitotic-specific cyclin-
B1) 
CCNB1  Gastric carcinoma SNU-5 
cells  
Decreased cyclin B, G2/M phase 
arrest 
Cell apoptosis, anti-cancer [443] 
Glucagon-like peptide  
(GCG/GLP-1/GLP-2) 
GCG NCI-H716 cells Enchanced glucagon-like pepetide 
(GLP)-1  
Antidiabetic agent [465] 
Growth/differentiation factor 
15 (NAG-1) 
GDF15 Colerectal cancer cells Induces NAG-1  expression Colorectal cancer  [456] 
Hypoxia-inducible factor 1α HIF1A HUVECs, HepG2 cells Prevention and reduction of  HIF-1 
alpha expression 
Tumour angiogenesis [ 66, 467] 
Induced myeloid leukemia 
cell differentiation protein 
Mcl-1 
MCL1 Oral cancer cells Inhibition of  Mcl-1 expression Induced apoptosis [468] 
Inhibitor of nuclear f ctor 
κB kinase subunit α 
(IκB kinase) 
CHUK(IKK) Jurkat cells Inhibition of IkappaB kinase (IKK) Anticancer and anti-
inflammatory agent 
[434] 
Interferon-β IFNB1 Brest cancer CF-7 
(estrogen receptor+)cells 
IFN- beta upregulated  Breast cancer, ER antagonist 
adjuvant therapy  
[442] 
Interleukin 8 IL8 Retinal pigment epithelial 
cell line 
Inhibits IL-8 expression nti-inflammatory [455] 
Interleukin-1β IL1B Fibroblasts (HFL1) Induces IL-1B productions Pulmonary inflammation [469] 
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Interleukin-2 receptor α 
chain 
IL2RA/CD25 Human peripheral 
lymphocytes  
Reduced expression of CD25 Immunosuppressive agent [462] 
Interleukin-6 IL6 Keratinocytes Reduces and IL-6 expression Anti-skin ageing agent [470] 
Low density lipoprotein 
receptor (familial 
hypercholesterolemia) 
LDLR HepG2 cells Increased mRNA and protein 
expression 
Hyperlipidemia  [471, 472] 
Matrix metallopeptidase 1 
(27 kDa interstitial 
collagenase) 
MMP1 Dermal fibroblasts, U-87 
glioma cells 
MMP-1 expression  decreased  Anti-skin ageing agent, anti-
cancer  
[423, 473] 
Matrix metallopeptidase 9 
(gelatinase B, 92kDa 
gelatinase, 92kDa type IV 
collagenase) 
MMP9 Tongue cancer SCC-4 cells, 
keratinocytes, gastric 
carcinoma SNU-5 
Inhibition Anti-cancer [423, 440, 
470] 
Matrix metalloproteinase-16 MMP16 Jurkat cells Suppresses expression of MMP-16 Anticancer and anti-
inflammatory agent 
[434] 
Mitogen-activated protein 
kinase 3 
ERK1/MAPK
3 
Peripheral blood monocytes 
(PBMC) 
 ERK1 protein expression inhibition Anti-atherosclerotic effects [474] 
Mitogen-activated protein 
kinase 4 
ERK2/MAPK
4 
Peripheral blood monocytes 
(PBMC) 
 ERK2 protein expression inhibition Anti-atherosclerotic effects [474] 
Mitogen-activated protein 
kinase 8 
(JNK) 
MAPK8 Peripheral blood monocytes 
(PBMC) 
 Jun N-terminal kinase (JNK) 
protien expression inhibited at high 
levels of BBR 
Anti-atherosclerotic effects [429, 474] 
M-phase inducer 
phosphatase 1 
CDC25A HL-60 cell  Phosphorylation and degradation of 
Cdc25A 
Anti-proliferative and pro-
apoptotic 
[457] 
Tumour cell lines  Significant inhibited P-gp 
mulitidrug resistance (MDR) 
activity  
MDR activity reversal [475] Multidrug resistance protein 
1(Pgp, Pgp-170) 
ABCB1 
Hepatoma HepG2 cells Upregulated multidrug resistance 
transporter (pgp-170) expression 
Reduced retention of 
chemotherapeutic agents 
[476] 
Myc proto-oncogene protein MYC U-87 glioma c lls Myc level decreased Malig ant glioma and cancer 
development  
24
NF-κB inhibitor α NFKBIA Lung epithelial cells (A-549) Inhibition of kappaB-alpha 
phosphorylation and degradation  
Pulmonary inflammation [469] 
Nuclear factor NF-kappa-B 
p50 subunit 
 (NF-κB) 
NFKB1 Jurkat cells, ostoblastic cells, 
HepG2 cells 
Inhibit NF-kappaB production and 
suppress NF-kappa B  
Anticancer and anti-
inflammatory agent, alcohol 
liver disease, osteoclast 
formation  
[434, 477, 
478] 
Nuclear receptor subfamily 
3, group C, member 1 
(glucocorticoid receptor) 
NR3C1 Hep G2 cells Reduced GR levels Cell growth arrest  [427] 
Nuclophosmin (nucleolar 
phosphoprotein B23) and 
telomerase 
NPM1 Leukemia HL-60 cells  Down regulation of 
nuclophosmin/B23 and telomerase 
activity  
Cancer  [479] 
Peroxisome proliferator-
activated receptor gamma 
PPARG Free-fatty-acid-induced 
insulin ersistance muscle 
cells-L6 myotubes 
Decreased expression Anti-diabetic  [480] 
Platelet glycoprotein 4 CD36/FAT Free-fatty-acid-induced 
insulin ersistance muscle 
c lls-L6 myotubes 
Decreased expression Anti-diabetic  [480] 
Poly (ADP-ribose) 
polymerase family, member 
1 
PARP HepG2 cells/ hepatoma cells, 
colonic carcinoma cells, 
prostate cancer cells (PC-3), 
prostate carcinoma cells 
(DU145 and PC-3, LNCaP) 
Cleavege of poly (ADP-ribose) 
polymerase. Activation of PARP 
Cell apoptosis, anti cancer  [429, 430, 
432, 433, 
439, 450] 
Potassium voltage-gated 
channel subfamily H 
member 2 
KCNH2/HER
G1  
Leukemic stem cells (LSCs) Inhibits HERG1 K (+) channels of 
leukemic cells  
Inhibits AML cell migration  [481] 
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Processed sterol regulatory 
element-binding protein 2 
SREBP2 HepG2 cells Reduction of  SREBP2 Hyperlipidemia [466] 
Proprotein convertase 
subtilisin/kexin type 9 
PCSK9 HepG2 cells  Suppression of  PCSK9 mRNA and 
protein levels 
Hyperlipidemia  [466, 472] 
Prostaglandin G/H synthase 
2 
PTGS2/COX2 Peripheral blood monocytes 
(PBMC), oral cancer cell 
lines OC2 and KB cells, 
brest cancer MCF-7 
(estrogen receptor+)cells, 
Jurkat cells, colon cancer 
cells 
Decrease of Cox-2 mRNA and 
protien expression. 
Anti-atherosclerotic effects, 
anti-inflammatory, anti-
cancer, breast cancer ER 
antagonist adjuvant therapy , 
anti cancer 
[434, 442, 
468, 474, 
482, 483] 
Liver cells Increased InsR mRNA and protein 
expression through protein kinase C 
activation 
Increase insulin sensitivity in 
Diabetes mellitus 
[484] Protein Kinase C 
U-87 glioma cells Protein kinase C activation 
decreased 
Malignant glioma and cancer 
development  
[424] 
Proto-oncogene tyrosine-
protein kinase ROS 
ROS1 HUVECs Inhibition of ROS generation Protects LDL oxidation and 
prevent ox-LDL-induced 
cellular dysfunction 
[429, 485] 
Ras-related C3 botulinum 
toxin substrate 1 
RAC1 Nasopharyngeal carcinoma 
(HONE1) cells 
Suppression of Rho GTPases 
activation (Rac1) 
Cancer metastasis inhibition [453] 
Receptor tyrosine-protein 
kinase erbB-2  
ERBB2 / 
HER2 
Brest cancer MCF-7 
(estrogen receptor+)cells 
HER2downregulated Breast cancer, ER antagonist 
adjuvant therapy  
[442] 
Rho-associated protein 
kinase 1 
ROCK1/RHO Nasopharyngeal carcinoma 
5-8F cells 
Suppression of Rho kinase activity  Anti cancer  [453] 
Runt-related transcription 
factor 2 
RUNX2 Osteoblast cells Promotes transcritptional activity of 
Runx2 
Osteoblast differentiation and 
bone formation in 
Osteoperosis 
[486] 
SDF-1-α (SDF-1) CXCL1 Acute mye oid leukemia 
(AML) 
es SDF-1 chemokine  Inhibits AML cell migration  81
Sucrase-isomaltase (α-
glucosidase) 
SI Caco-2 cells Inhibit alpha-glucosidase Anti-hyperglycaemic [487] 
Topoisomerase (DNA) I Top1 Recombinant human 
topoisomerase I 
Top1 inhibition Anti-cancer [488] 
Transcription factor AP-1 AP-1 Hepatoma cells, MDA-MB-
231 breast cancer cells, giant 
cell carcinoma cell line, 
colon cancer cells, U-87 
glioma cells 
Inhibition of AP-1 activity, AP-1 
DNA suppression  
Antitumor activity, anti 
cancer 
[424, 464, 
482, 483, 
489, 490] 
Transforming protein RhoA RHOA Nasopharyngeal carcinoma 
(HONE1) cells 
Suppression of Rho GTPases 
activation (RhoA) 
Cancer metastasis inhibition [453] 
Tumor necrosis factor/ 
Tumor necrosis factor α 
TNFA Macrophages, fibroblasts 
(HFL1) 
Inhibitiono of TNFa Anti-inflammatory [469, 491] 
Urokinase-plasminogen 
activator 
PLAU Lung cancer A549 cells, 
tongue cancer SCC-4 cells  
Reduced urokinase-plasminogen 
activa or (u-PA) 
Anti-metastatic, anti cancer [425, 440] 
Vascular endothelial growth 
factor A 
VEGFA HUVECs Prevention of VEGF expression Tumour angiogenesis [467] 
Wee1-lik  protein ki ase Wee1 G tric carcinoma SNU-5 
cells  
Increased expressi n of 
Wee1protein, G2/M phase arrest 
G stric cancer 4  
  176 
A total of 90 berberine targets were identified in our literature search, as shown in Table 5-1. 
Extensive research has been carried out to study the effects of berberine on cancer cells in 
vitro. This may be related to recent discovery of anti-cancer drugs with natural compound 
origin, e.g, paclitaxel and topotecan.  
 
Various human cancer cell lines were used to demonstrate the anti-cancer effects of berberine 
in vitro. These include cancer cell lines of the tongue, stomach, lung, colon, liver, breast, 
prostate, nasopharyngeal, neurones, epidermal and blood [422, 429, 431, 432, 439, 441, 443, 
447, 463, 482, 492]. Berberine has shown to induce cancer cell death via several mechanisms 
such as regulation of apoptosis proteins and cell cycle arrest.   
 
Berberine treatment increased the expression of apoptotic cell death proteins, promotes cell 
cycle arrest and induces cell death in human cancer cell lines. For instance, in human prostate 
epithelial cells (PWR-1E), berberine treatment increased expression of B-cell CLL/lymphoma 
2 (BCL2)-associated X protein (Bax) was observed after berberine treatment, inducing cell 
death and demonstrates pro-apoptotic properties [444]. Similar effects of berberine were 
observed in prostate carcinoma cells (DU145, PC-3 and LNCaP) [432, 433]. Berberine also 
increased levels of Bax in promyelocytic leukemia cells [493], gastric carcinoma cells [443] 
and lung cancer cells [431]. 
 
Berberine can also promote cell death by the regulation of anti-apoptotic proteins. Decreased 
expression of anti-apoptotic Bcl-2 protein was observed in human oral squamous cell 
carcinoma after berberine treatment [441]. Studies done in other cancer cell lines such as lung 
cancer, gastric cancer and prostate cancer also showed reduced levels of Bcl-2 after berberine 
treatment [431-433, 443]. Cell cycle arrest at different phases has also been observed in 
human cancer cell lines after treatment with berberine. In giant cell carcinoma and prostate 
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carcinoma cells, berberine also decreased G0/G1 phase associated cyclins (D1, D2, E, Cdk2, 
Cdk4 and Cdk6), inducing G0/G1 arrest and suppressing cell proliferation [432, 433, 447, 
464]. Further, in hepG2 cells, berberine acted on BCL2, procaspase -3 and -9, and poly (ADP-
ribose) polymerase (PARP), induced cell cycle arrest at G2/M phase and inhibited cell 
proliferation [439].  
 
Berberine can promote cell death via the regulation of pro- and anti-apoptotic proteins. In 
addition to this, berberine can also promote apoptosis via mitochondrial/caspase pathway. In 
cancer cell lines (tongue cancer, oral squamous cell carcinoma and prostate epithelial) [422, 
441, 444, 449]. Activations of caspases-3, -9 promotes G1 cell cycle arrest in different human 
cancer cell lines (lung, stomach and prostate) [431-433, 443, 449].  
 
Berberine also showed anti-metastic properties in several cancer cell lines, acting on 72 kDa 
type IV collagenase (MMP2), Cdc42 effector protein 1 (CDC42EP1) and ras-related C3 
botulinum toxin substrate 1 (RAC1), transforming protein RhoA (RHOA) and urokinase-
plasminogen activator A (PLAU) [440, 481]. Further, berberine showed anti-topoisomerase I 
properties [494], this observation can be useful as topoisomerase I is responsible for DNA 
replication and anti-topoisomerase I compounds can be effective in cancer treatments.   
 
In addition to its effects on cancer cells, berberine also acts on molecular targets related to 
insulin resistance. In free fatty acid induced insulin resistance muscle cells, berberine 
improves insulin resistance and improves glucose uptake by decreasing PPARgamma and 
FAT/CD36 protein expression [480]. Another study reported increased insulin receptor (InsR) 
mRNA and protein expression increases insulin sensitivity in liver cells after berberine 
treatment [484]. In caco-2 cells, berberine inhibited alpha-glucosidase and disaachardisases 
activities, as a result reducing glucose levels [487]. In Hep G2 cells, berberine also improved 
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insulin signal transduction through various mechanisms such as decreased phosphorylation of 
PERK and eLF2 alpha, increased phosphorylation of IRS-1 tyr and AKT ser [495]. In 
intestinal NCI-H716 cells, berberine enhanced glucagon-like peptide 1 (GLP-1) release and 
promotes proglucagon mRNA expression [496]. These results demonstrate that berberine has 
great potential for insulin resistance treatment and should be explored further in animal and 
human studies.  
 
5.2.2 Analysis of berberine targets in vitro by PANTHER 
 
Using the PANTHER Classification System (described in Section 1.5.2.1), in vitro berberine 
targets were analysed using three approaches: molecular function, biological process and 
pathway involvement (Table 5-2). Distribution of berberine therapeutic targets in vitro varied 
in each of these functional classifications.  Table 5-4 and Table 5-5 shows various 
distributions of the most frequent occurring berberine targets in vitro based on molecular 
functions, biological processes and pathways, respectively.
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Table 5-2. Berberine’s target classication based on PANTHER. 
 
Target Names Target Gene 
Symbol 
PANTHER molecular 
function 
Biological process Pathway categories 
Multidrug resistance protein 
1(Pgp, Pgp-170) 
ABCB1 ATPase activity, coupled to 
transmembrane movement of 
substances, transmembrane 
transporter activity 
Immune system process, 
extracellular transport, 
carbohydrate metabolic process, 
response to toxin 
ATP-binding cassette (ABC) 
transporter 
ATP-binding cassette 
subfamily G member 2 
ABCG2 ATPase activity, coupled to 
transmembrane movement of 
substances, transmembrane 
transporter activity, anion 
channel activity 
Immune system process, anion 
transport, lipid transport, oxygen 
and reactive oxygen species, 
metabolic process, lipid metabolic 
process, response to stress 
N/A 
Acetyl-Coenzyme A 
carboxylase-α 
ACACA Other ligase Gluconeogenesis, monosaccharide 
metabolism, fatty acid biosynthesis, 
coenzyme metabolism 
N/A 
α-Fetoprotein AFP Other transfer/carrier protein  Transport, mesoderm development, 
oncogenesis  
N/A 
Transcription factor AP-1 AP-1 DNA binding, transcription 
factor activity 
Cell cycle, intracellular signaling 
cascade, nucleobase, nucleoside, 
nucleotide and nucleic acid, 
metabolic process, cell cycle, signal 
transduction 
Toll receptor signaling pathway, 
inflammation mediated by chemokine 
and cytokine signaling pathway, 
apoptosis signaling pathway, oxidative 
stress response,  angiogenesis, TGF-
beta signaling pathway, T cell 
activation, B cell activation, Ras 
Pathway, FAS signaling pathway, 
PDGF signaling pathway 
 
Β-Amyloid (A4) precursor 
protein (peptidase nexin-II, 
Alzheimer disease) 
APP Other signaling molec Other signal transduction, cell 
communication, other intracellular 
protein traffic 
Alzheimer disease-amyloid secretase 
pathway, Alzheimer disease-presenilin 
pathway, blood coagulation, Alzheimer 
disease-presenilin pathway, Alzheimer 
disease-amyloid secretase pathway 
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Cyclic AMP-dependent 
transcription factor ATF-3 
ATF3 DNA binding, transcription 
factor activity 
Transcription factor activity, 
immune system process, 
neurological system process, 
induction of apoptosis, nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolic process 
Apoptosis signaling pathway 
Bcl2 antagonist of cell death BAD N/A N/A PDGF signaling pathway, apoptosis 
signaling pathway , angiogenesis, PI3 
kinase pathway, VEGF signaling 
pathway, interleukin signaling pathway 
BCL2-associated X protein BAX Other signaling molecule Induction of apoptosis, 
ametogenesis, hematopoiesis, cell 
cycle control, cell proliferation and 
differentiation, tumor suppressor 
p53 pathway, apoptosis signaling 
pathway, Huntington disease 
B-cell CLL/lymphoma 2 BCL2 Other signaling molecule Inhibition of apoptosis, oncogenesis Oxidative stress response,  apoptosis 
signaling pathway 
Apoptosis regulator Bcl-X BCL2L1 Receptor binding Gamete generation, induction of 
apoptosis, negative regulation of 
apoptosis,cell cycle, mesoderm 
development, hemopoiesis, 
Apoptosis signaling pathway 
B-cell lymphoma 3-encoded 
protein 
Bcl-3 N/A Nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process 
Inflammation mediated by chemokine 
and cytokine signaling pathway 
 BH3-interacting domain 
death agonist p11 
BID N/A N/A Apoptosis signaling pathway, FAS 
signaling pathway 
Baculoviral IAP repeat-
containing protein 2 ( anti-
apoptosis factor c-IPA-1) 
BIRC2 N/A N/A Apoptosis signaling pathway  
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Baculoviral IAP repeat-
containing protein 3 
BIRC3 N/A N/A Apoptosis signaling pathway  
Baculoviral IAP repeat-
containing protein 5 
(Survivin) 
BIRC5 N/A N/A Angiogenesis 
Caspase 3, apoptosis-related 
cysteine peptidase 
CASP3 Cysteine protease Proteolysis, apoptosis Huntington disease, FAS signaling 
pathway, apoptosis signaling pathway 
Caspase 8, apoptosis-related 
cysteine peptidase 
CASP8 Cysteine protease Proteolysis, apoptosis   
 
Apoptosis signaling pathway, FAS 
signaling pathway, Huntington disease 
Caspase 9, apoptosis-related 
cysteine peptidase 
CASP9 Cysteine protease Proteolysis, apoptosis Angiogenesis, apoptosis signaling 
pathway, FAS signaling pathway, 
VEGF signaling pathway, PI3 kinase 
pathway 
Chemokine (C-C motif) 
ligand 2 (monocyte 
chemotactic protein-1) 
CCL2 Non-receptor serine/threonine, 
protein kinase  
Protein phosphorylation, cell cycle 
control, mitosis  
N/A 
G2/mitotic-specific cyclin-
B1) 
CCNB1 Protein binding, kinase 
activator activity, kinase 
regulator activity 
Mitosis Cell cycle, p53 pathway 
G1/S-specific cyclin-D1 CCND1 Protein binding, kinase 
activator activity, kinase 
regulator activity 
Spermatogenesis, mitosis PI3 kinase pathway, cell cycle, Wnt 
signaling pathway 
G1/S-specific cyclin-D2 CCND2 Protein binding, kinase 
activator activity, kinase 
regulator activity 
Spermatogenesis, mitosis PI3 kinase pathway, cell cycle 
Cyclin E1 CCNE1 Kinase activator Cell cycle control, mitosis, cell 
proliferation and differentiation  
p53 pathway, cell cycle, Parkinson 
disease, p53 pathway feedback loops 2 
G1/S-specific cyclin-E1 CCNE1 Protein binding, kinase 
activator activity, kinase 
regulator activity 
Mitosis p53 pathway, cell cycle, Parkinson 
disease, p53 pathway feedback loops 2 
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Interleukin-2 receptor α 
chain 
IL2RA/CD25 Cytokine receptor activity Immune system process, cell 
surface receptor linked signal 
transduction, intracellular signaling 
cascade, cell-cell signalling, signal 
transduction, cell-cell signalling, 
cellular defense response 
Interleukin signaling pathway 
Platelet glycoprotein 4 CD36/FAT Receptor activity Macrophage activation, lipid 
transport, apoptosis, signal 
transduction, cell adhesion, lipid 
metabolic process, signal 
transduction, cell adhesion, cellular 
component, morphogenesis 
N/A 
Early activation antigen 
CD69 
CD69 Receptor activity,receptor 
binding 
B cell mediated immunity, natural 
killer cell activation, cellular 
defense response 
Membrane-bound signaling molecule 
M-phase inducer 
phosphatase 1 
CDC25A Hydrolase activity, acting on 
ester bonds, phosphatase 
activity 
Phosphatase activity cell cycle,  
phosphate metabolic process, 
protein metabolic process, cell 
cycle  
p53 pathway 
Cdc42 effector protein 1 CDC42EP1 N/A N/A N/A 
Cyclin dependant kinase 
1/Cell division control 
protein 2 homolog 
CDK1/CDC2 Kinase activity Immune system process, mitosis, 
intracellular signaling cascade, 
protein metabolic process, cell 
motion, mitosis, signal 
transduction, response to stress 
p53 pathway 
Cyclin-dependent kinase 2 CDK2 Non-receptor serine/threonine 
protein kinase  
Protein phosphorylation, cell cycle 
control, mitosis  
p53 pathway, p53 pathway feedback 
loops 2 
Cyclin-dependent kinase 4 CDK4 Non-receptor serine/threonine 
protein kinase  
Protein phosphorylation, cell cycle 
control, mitosis  
N/A 
Cell division protein kinase 
6 
CDK6 Kinase activity Immune system process, mitosis, 
intracellular signaling cascade, 
protein metabolic process, cell 
motion, mitosis, signal 
transduction, response to stress 
N/A 
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Cyclin-dependent kinase 
inhibitor 1 
(p21) 
CDKN1A Protein binding, kinase 
inhibitor activity, kinase 
regulator activity 
 
Cell cycle 
Interleukin signaling pathway, p53 
pathway feedback loops 2, p53 pathway 
Cyclin-dependent kinase 
inhibitor 1B (P27/KIP1) 
CDKN1B Protein binding, kinase 
inhibitor activity, kinase 
regulator activity 
Cell cycle Interleukin signaling pathway 
CASP8 and FADD-like 
apoptosis regulator subunit 
p12 
CFLAR/cFLIP Peptidase activity, protein 
binding, peptidase inhibitor 
activity 
Apoptosis, protein metabolic 
process 
 
Apoptosis signaling pathway, FAS 
signaling pathway  
Inhibitor of nuclear factor- 
κB kinase subunit α 
(IκB kinase) 
CHUK(IKK) Kinase activity Immune response, intracellular 
signaling cascade, protein 
metabolic process, signal 
transduction, response to stimulus 
Interleukin signaling pathway, 
apoptosis signaling pathway, T cell 
activation, toll receptor signaling 
pathway, B cell activation 
 
SDF-1-α (SDF-1) CXCL12 N/A N/A Axon guidance mediated by Slit/Robo 
Cytochrome c-1 CYC1 Reductase  Oxidative phosphorylation  FAS signaling pathway, ATP synthesis, 
Huntington disease 
CYP2C9 CYP2C9 Oxygenase  Fatty acid metabolism, steroid 
metabolism, electron transport  
 
N/A 
CYP2D6 CYP2D6 Oxygenase  Other lipid, fatty acid and steroid 
metabolism, steroid metabolism, 
electron transport 
 
Vitamin D metabolism and pathway 
CYP3A4 CYP3A4 Oxygenase  Steroid hormone metabolism, 
electron transport  
N/A 
Dipeptidyl-peptidase 4 
(CD26, adenosine deaminase 
complexing protein 2) 
DPP4 Serine protease  Proteolysis, cell surface receptor 
mediated signal transduction, T-cell 
mediated immunity  
 
N/A 
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Epidermal growth factor 
receptor 
EGFR Kinase activity,transmembrane 
receptor protein tyrosine 
kinase activity, transmembrane 
receptor protein kinase 
activity, receptor binding 
Female gamete generation, immune 
system process, negative regulation 
of apoptosis, cell cycle, cell surface 
receptor linked signal transduction, 
intracellular signaling cascade,  
cell-cell signalling, cell-cell 
adhesion, protein metabolic 
process, cell motion, cell cycle 
signal transduction, cell-cell 
signalling, dorsal/ventral axis 
specification, ectoderm 
development, mesoderm 
development, embryonic 
development, nervous system 
development 
 
EGF receptor signaling pathway, 
cadherin signaling pathway 
Receptor tyrosine-protein 
kinase erbB-2  
ERBB2 / HER2 Kinase activity,transmembrane 
receptor protein tyrosine 
kinase activity, transmembrane 
receptor protein kinase 
activity, receptor binding 
Female gamete generation, immune 
system process, negative regulation 
of apoptosis, cell cycle, cell surface 
receptor linked signal transduction, 
intracellular signaling cascade,  
cell-cell signalling, cell-cell 
adhesion, protein metabolic 
process, cell motion, cell cycle 
signal transduction, cell-cell 
signalling, dorsal/ventral axis 
specification, ectoderm 
development, mesoderm 
development, embryonic 
development, nervous system 
development 
EGF receptor signaling pathway, 
cadherin signaling pathway 
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Mitogen-activated protein 
kinase 3 
ERK1/MAPK3 Kinase activity Immune system process, mitosis, 
cell surface receptor linked signal 
transduction, intracellular signaling 
cascade, carbohydrate metabolic 
process, protein metabolic process, 
cell motion, signal transduction, 
segment specification, ectoderm 
development, mesoderm 
development, embryonic 
development, nervous system 
development, response to stress 
Apoptosis signaling pathway, 
Alzheimer disease-amyloid secretase 
pathway, B cell activation, Ras 
Pathway, interleukin signaling pathway, 
angiogenesis, T cell activation, toll 
receptor signaling pathway, insulin/IGF 
pathway-mitogen activated protein 
kinase kinase/MAP kinase cascade, 
FGF signaling pathway, Parkinson 
disease, PDGF signaling pathway, 
inflammation mediated by chemokine 
and cytokine signaling pathway, VEGF 
signaling pathway, interferon-gamma 
signaling pathway, endothelin signaling 
pathway, angiogenesis, TGF-beta 
signaling pathway, integrin signalling 
pathway, EGF receptor signaling 
pathway 
Mitogen-activated protein 
kinase 4 
ERK2/MAPK4 Kinase activity Immune system process, mitosis, 
cell surface receptor linked signal 
transduction, intracellular signaling 
cascade, carbohydrate metabolic 
process, protein metabolic process, 
cell motion, mitosis, signal 
transduction, segment specification, 
ectoderm development, mesoderm 
development, embryonic 
development, nervous system 
development, response to stress 
lzheimer disease-amyloid secretase 
pathway, interleukin signaling pathway, 
angiogenesis, VEGF signaling pathway, 
integrin signalling pathway 
Ezrin EZR Structural constituent of 
cytoskeleton 
Cellular component, morphogenesis N/A 
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C/EBP homologous protein 
(CHOP) or  growth arrest- 
and DNA damage-inducible 
gene 153 (GADD153) or 
DNA damage-inducible 
transcript 3 
GADD153/ 
DDIT3 
N/A N/A Oxidative stress response 
Glucagon-like peptide  
(GCG/GLP-1/GLP-2) 
GCG Receptor binding Signal transduction, cell-cell 
signalling, ccarbohydrate metabolic 
process, lipid metabolic process, 
signal transduction, cell-cell 
signalling, cellular glucose 
homeostasis 
Peptide hormone 
Growth/differentiation factor 
15 (NAG-1) 
GDF15 Receptor binding Female gamete generation, cell 
surface receptor linked signal 
transduction, signal transduction, 
ectoderm development, mesoderm 
development, skeletal system 
development, heart development, 
muscle organ development 
TGF-beta signaling pathway 
Hypoxia-inducible factor 1α HIF1A DNA binding, transcription 
factor activity 
Nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process, 
ectoderm development, nervous 
system development 
Hypoxia response via HIF activation, 
VEGF signaling pathway, angiogenesis 
Interferon-β IFNB1 Receptor binding Response to interferon-gamma, 
induction of apoptosis, negative 
regulation of apoptosis, cell surface 
receptor linked signal transduction, 
intracellular signaling cascade, cell-
cell signalling, signal transduction 
cell-cell signalling, cellular defense 
response 
Toll receptor signaling pathway 
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Interleukin-1β IL1B Receptor binding Immune response, macrophage 
activation, cell surface receptor 
linked signal transduction, cell-cell 
signalling, signal transduction, cell-
cell signalling, response to stimulus 
Inflammation mediated by chemokine 
and cytokine signaling pathway 
Interleukin-6 IL6 Receptor binding Immune system process, negative 
regulation of apoptosis, cell surface 
receptor linked signal transduction, 
intracellular signaling cascade, cell-
cell signalling signal transduction, 
cell-cell signaling 
Inflammation mediated by chemokine 
and cytokine signaling pathway, 
interleukin signaling pathway 
Interleukin 8 IL8 Chemokine Cytokine and chemokine mediated 
signaling pathway, calcium 
mediated signalling, NF-kappaB 
cascade, ligand-mediated 
signalling, T-cell mediated 
immunity, macrophage-mediated 
immunity, granulocyte-mediated 
immunity, angiogenesis, cell 
proliferation and differentiation, 
cell motility 
Inflammation mediated by chemokine 
and cytokine signaling pathway, 
interleukin signaling pathway 
Potassium voltage-gated 
channel subfamily H 
member 2 
KCNH2/HERG1 Receptor activity, cation 
transmembrane transporter 
activity, voltage-gated 
potassium channel activity, 
cation channel activity,cyclic 
nucleotide-gated ion channel 
activity 
Cation transport, signal 
transduction 
Ligand-gated ion channel 
Low density lipoprotein 
receptor (familial 
hypercholesterolemia) 
LDLR Other receptor Oogenesis Alzheimer disease-presenilin pathway 
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Mitogen-activated protein 
kinase 8 
(JNK) 
MAPK8 Kinase activity Immune system process, mitosis, 
cell surface receptor linked signal 
transduction, intracellular signaling 
cascade, carbohydrate metabolic 
process, protein metabolic process, 
cell motion, mitosis, signal 
transduction, segment specification, 
ectoderm development, mesoderm 
development, embryonic 
development, nervous system 
development, response to stress 
Alzheimer disease-amyloid secretase 
pathway, Ras Pathway, EGF receptor 
signaling pathway, Parkinson disease, 
angiogenesis, FGF signaling pathway, 
FAS signaling pathway, toll receptor 
signaling pathway, TGF-beta signaling 
pathway, PDGF signaling pathway, 
Huntington disease, integrin signalling 
pathway, T cell activation, B cell 
activation, interferon-gamma signaling 
pathway, oxidative stress response, 
apoptosis signaling pathway, integrin 
signalling pathway 
Induced myeloid leukemia 
cell differentiation protein 
Mcl-1 
MCL1 Receptor binding Gamete generation, induction of 
apoptosis, negative regulation of 
apoptosis, cell cycle, mesoderm 
development, hemopoiesis 
Apoptosis signaling pathway 
Matrix metallopeptidase 1 
(27 kDa interstitial 
collagenase) 
MMP1 Peptidase activity Protein metabolic process Plasminogen activating cascade, 
Alzheimer disease-presenilin pathway, 
plasminogen activating cascade 
Matrix metalloproteinase-16 MMP16 Peptidase activity  Protein metabolic process  Alzheimer disease-presenilin pathway 
72 kDa type IV collagenase MMP2 Metalloprotease, other 
extracellular matrix 
Proteolysis Alzheimer disease-presenilin pathway 
Matrix metallopeptidase 9 
(gelatinase B, 92kDa 
gelatinase, 92kDa type IV 
collagenase) 
MMP9 Metalloprotease, other 
extracellular matrix 
Proteolysis  Alzheimer disease-presenilin pathway, 
plasminogen activating cascade 
Myc proto-oncogene protein MYC DNA binding, transcription 
factor activity 
Induction of apoptosis, cell cycle, 
nucleobase, nucleoside, nucleotide 
and nucleic acid, metabolic process, 
cell cycle 
Oxidative stress response, p53 pathway 
feedback loops 2, Wnt signaling 
pathway, interleukin signaling pathway, 
PDGF signaling pathway 
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Arylamine N-
acetyltransferase 1 
NAT Acyltransferase activity Metabolic process Acetyltransferase 
Nuclear factor NF-κB p50 
subunit 
 (NF-κB) 
NFKB1 DNA binding, transcription 
factor activity 
B cell mediated immunity, negative 
regulation of apoptosis, intracellular 
signaling cascade, nucleobase, 
nucleoside,  ucleotide and nucleic 
acid, metabolic process, signal 
transduction, cellular defense 
response 
T cell activation, B cell activation, toll 
receptor signaling pathway, 
inflammation mediated by chemokine 
and cytokine signaling pathway, 
apoptosis signaling pathway 
NF-κB inhibitor alpha NFKBIA Protein binding Immune system process, 
intracellular protein transport 
apoptosis, intracellular signaling 
cascade, nucleobase, nucleoside, 
nucleotide and nucleic acid 
metabolic process, signal 
transduction, response to stress 
Apoptosis signaling pathway, toll 
receptor signaling pathway, 
inflammation mediated by chemokine 
and cytokine signaling pathway, T cell 
activation, B cell activation 
Nuclophosmin (nucleolar 
phosphoprotein B23) and 
telomerase 
NPM1 N/A  
Nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process  
N/A 
Nuclear receptor subfamily 
3, group C, member 1 
(glucocorticoid receptor) 
NR3C1 Nuclear hormone receptor, 
transcription factor, nucleic 
acid binding 
N/A N/A 
Poly (ADP-ribose) 
polymerase family, member 
1 
PARP Glycosyltransferase  
DNA repair, protein ADP-
ribosylation, stress response 
 
FAS signaling pathway 
Proprotein convertase 
subtilisin/kexin type 9 
PCSK9 Serine protease   Proteolysis N/A 
Urokinase-plasminogen 
activator 
PLAU Peptidase activity  
Immune system process, signal 
transduction, protein metabolic 
process, cell motion, signal 
transduction, blood coagulation 
Blood coagulation, plasminogen 
activating cascade 
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Peroxisome proliferator-
activated receptor-γ 
PPARG Nuclear hormone receptor, 
transcription factor, nucleic 
acid binding 
 
Monosaccharide metabolism, 
regulation of lipid, fatty acid and 
steroid metabolism, mRNA 
transcription regulation, ligand-
mediated signalling, stress 
response, developmental processes, 
cell proliferation and differentiation 
 
N/A 
Prostaglandin G/H synthase 
2 
PTGS2/COX2 Oxidoreductase activity  
Immune system process 
Endothelin signaling pathway, toll 
receptor signaling 
pathwayInflammation mediated by 
chemokine and cytokine signaling 
pathway 
 
 
Ras-related C3 botulinum 
toxin substrate 1 
RAC1 GTPase activity, protein 
binding 
Intracellular protein transport, 
endocytosis, cell surface receptor 
linked signal transduction, 
intracellular signaling cascade, 
signal transduction 
Axon guidance mediated by Slit/Robo, 
integrin signalling pathway, 
inflammation mediated by chemokine 
and cytokine signaling pathway, 
Huntington disease, axon guidance 
mediated by Slit/Robo, FGF signaling 
pathway, T cell activation, axon 
guidance mediated by netrin, EGF 
receptor signaling pathway, 
inflammation mediated by chemokine 
and cytokine signaling pathway, 
cytoskeletal regulation by Rho GTPase, 
aAxon guidance mediated by 
semaphorins, cytoskeletal regulation by 
Rho GTPase, B cell activation, Ras 
pathway 
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Rho-associated protein 
kinase 1 
ROCK1/RHO Kinase activity Mitosis, intracellular signaling 
cascade, cell adhesion, protein 
metabolic process, cell motion, 
mitosis, signal transduction, cell 
adhesion, embryonic development 
Inflammation mediated by chemokine 
and cytokine signaling pathway, 
cytoskeletal regulation by Rho GTPase 
Transforming protein RhoA RHOA GTPase activity, protein 
binding 
Intracellular protein transport, 
endocytosis, cell surface receptor 
linked signal transduction, 
intracellular signaling cascade, 
signal transduction 
Axon guidance mediated by Slit/Robo, 
angiogenesis, heterotrimeric G-protein 
signaling pathway-Gq alpha and Go 
alpha mediated pathway, axon guidance 
mediated by semaphorins, inflammation 
mediated by chemokine and cytokine 
signaling pathway, integrin signalling 
pathway, Ras Pathway, cytoskeletal 
regulation by Rho GTPase, PDGF 
signaling pathway 
Proto-oncogene tyrosine-
protein kinase ROS 
ROS1 Kinase activity, 
transmembrane receptor 
protein tyrosine kinase activity, 
transmembrane receptor 
protein kinase activity, 
receptor binding 
Female gamete generation, immune 
system process, visual perception, 
sensory perception, negative 
regulation of apoptosis, cell cycle, 
cell surface receptor linked signal 
transduction, intracellular signaling 
cascade, cell-cell signalling, cell-
cell adhesion, protein metabolic 
process, cell motion, cell cycle, 
signal transduction, ectoderm 
development, mesoderm 
development, embryonic 
development, nervous system 
development 
N/A 
Runt-related transcription 
factor 2 
RUNX2 DNA binding, transcription 
factor activity 
Mesoderm development, skeletal 
system development, hemopoiesis 
N/A 
Sucrase-isomaltase (α-
glucosidase) 
SI hydrolase activity, hydrolyzing 
O-glycosyl compounds 
Carbohydrate metabolic process, 
protein metabolic process 
N/A 
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Processed sterol regulatory 
element-binding protein 2 
SREBP2 DNA binding, transcription 
factor activity 
Nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process, 
lipid metabolic process 
Basic helix-loop-helix transcription 
factor 
Tumor necrosis factor/ 
Tumor necrosis factor-α 
TNFA Tumor necrosis factor family 
member 
Cytokine and chemokine mediated 
signaling pathway, ligand-mediated 
signalling, mmunity and defense, 
induction of apoptosis 
Wnt signaling pathway, apoptosis 
signaling pathway 
Topoisomerase (DNA) I Top1 DNA topoisomerase DNA replication, general mRNA 
transcription activities 
DNA replication 
Cellular tumor antigen p53 TP53 DNA binding, transcription 
factor activity 
Induction of apoptosis, cell cycle, 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process, 
cell cycle 
Apoptosis signaling pathway, 
Huntington disease, P53 pathway 
feedback loops 1, p53 pathway, p53 
pathway by glucose deprivation, p53 
pathway feedback loops 2, Wnt 
signaling pathway 
Vascular endothelial growth 
factor A 
VEGFA Receptor binding Immune system process, cell cycle, 
cell surface receptor linked signal 
transduction, intracellular signaling 
cascade, cell-cell signalling, cell 
cycle 
signal transduction, mesoderm 
development, angiogenesis, 
response to stress 
Angiogenesis,VEGF signaling pathway 
Wee1-like protein kinase Wee1 Kinase activity Mitosis, protein metabolic process Protein kinase 
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As shown in Table 5-3 below, berberine acts on a diverse range of molecular targets in vitro. 
The most common classes of molecular functions include receptor binding, kinase activity, 
protein binding, transcription activity, DNA binding and kinase regulator activity. Known 
berberine targets in vitro from the receptor binding class includes epidermal growth factor 
receptor (EGFR), vascular endothelial growth factor A (VEGFA), interleukin-1 beta (IL1B) 
and interleukin-6 (IL6), growth/differentiation factor 15 (NAG-1) and glucagon-like peptide 
(GLP1).  
 
Table 5-3. Distribution of berberine targets in vitro according to molecular functions.  
PANTHER molecular function No. of targets Panther molecular function No. of 
targets 
Acyltransferase activity 1 Nucleic acid binding 2 
Anion channel activity 1 Other extracellular matrix  2 
ATPase activity, coupled to 
transmembrane movement of 
substances 
2 Other ligase 1 
Cation channel activity 1 Other receptor 1 
Cation transmembrane transporter 
activity 
1 Other signaling molecule 3 
Chemokine 1 Other transfer/carrier protein  1 
Cyclic nucleotide-gated ion channel 
activity 
1 Oxidoreductase activity 1 
Cysteine protease 3 Oxygenase  3 
Cytokine receptor activity 1 Peptidase activity 4 
DNA binding 9 Peptidase inhibitor activity 1 
DNA topoisomerase 1 Phosphatase activity 1 
Glycosyltransferase 1 Protein binding 10 
GTPase activity 2 Receptor activity 3 
Hydrolase activity, acting on ester 
bonds 
1 Receptor binding 12 
Hydrolase activity, hydrolyzing O-
glycosyl compounds 
1 Reductase  1 
Kinase activator 1 Serine protease  2 
Kinase activator activity 4 Structural constituent of 
cytoskeleton 
1 
Kinase activity 11 Transmembrane transporter 
activity 
2 
Kinase inhibitor activity 2 Transcription factor 2 
Kinase regulator activity 6 Transcription factor activity 9 
Metalloprotease 2 Transmembrane receptor 
protein kinase activity 
3 
Not classified 10 Transmembrane receptor 
protein tyrosine kinase 
activity 
3 
Non-receptor serine/threonine protein 
kinase  
3 Tumor necrosis factor family 
member 
1 
Nuclear hormone receptor 2 Voltage-gated potassium 
channel activity 
1 
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 Based on the biological process classification of in vitro berberine targets, those targets 
related to signal transduction, intracellular signalling cascade, cell surface receptor linked 
signal transduction, cell motion, cell cycle control, immunity system process and protein 
metabolic process are most frequently involved (Table 5-4).  In vitro berberine targets 
involved signal transduction include cyclin dependant kinases (CDK1 & CDK6), inhibitor of 
nuclear factor κB kinase subunit alpha (CHUK), epidermal growth factor receptor (EFGR), 
receptor tyrosine-protein kinase (ERBB2), glucagon-like peptide (GCG), 
growth/differentiation factor 15 (GDF15), interferon-β (IFNB1), interleukins (IL1B, IL2RA & 
IL6), potassium voltage-gated channel subfamily H member 2 (KCNH1), mitogen-activated 
protein kinases (ERK1, ERK2 & MAPK8), nuclear factor-κB p50 subunit (NFKB1), NF-κB 
inhibitor-α (NFKB1A), urokinase-plasminogen activator (PLAU), Ras-related C3 botulinum 
toxin substrate 1 (RAC1), Rho-associated protein kinase 4 (RHO), transforming protein RhoA 
(RHOA), proto-oncogene tyrosine-protein kinase ROS (ROS1), vascular endothelial growth 
factor A (VEGFA). 
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Table 5-4. Distribution of berberine targets in vitro by biological functions classified by PANTHER. 
 
 
PANTHER biological functions No. of targets PANTHER biological functions No. of targets 
Angiogenesis 2 Induction of apoptosis 9 
Anion transport 1 Intracellular protein transport 3 
Apoptosis 6 Intracellular signaling cascade 18 
B cell mediated immunity 2 Ligand-mediated signaling 3 
Blood coagulation 1 Lipid metabolic process 4 
Calcium mediated signaling 1 Lipid transport 2 
Carbohydrate metabolic process 7 Macrophage activation 2 
Cation transport 1 Macrophage-mediated immunity 1 
Cell adhesion 3 Mesoderm development 12 
Cell communication 1 Metabolic process 1 
Cell cycle 11 Mitosis 4 
Cell cycle control 5 Monosaccharide metabolism 2 
Cell cycle intracellular signaling cascade 1 mRNA transcription regulation 1 
Cell cycle signal transduction 1 Muscle organ development 1 
Cell motility 1 Not classified 9 
Cell motion 10 Natural killer cell activation 1 
Cell proliferation and differentiation 3 Negative regulation of apoptosis 8 
Cell proliferation and differentiation  1 Nervous system development 7 
Cell surface receptor linked signal transduction 14 Neurological system process 1 
Cell surface receptor mediated signal transduction 1 NF-κB cascade 1 
Cell-cell adhesion 3 Nucleobase, nucleoside, nucleotide and nucleic acid 
metabolic process 
10 
Cell-cell signaling 9 Oncogenesis 3 
Cellular component morphogenesis 2 Other intracellular protein traffic 1 
Cellular defense response 4 Other lipid, fatty acid and steroid metabolism 1 
Cellular glucose homeostasis 1 Other signal transduction 1 
Coenzyme metabolism 1 Oxidative phosphorylation  1 
Cytokine and chemokine mediated signaling pathway 2 Oxygen and reactive oxygen species metabolic process 1 
Developmental processes 1 Phosphatase activity cell cycle 1 
DNA repair 1 Phosphate metabolic process 1 
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DNA replication 2 Protein ADP-ribosylation 1 
Dorsal/ventral axis specification 1 Protein metabolic process 17 
Ectoderm development 1 Protein phosphorylation 3 
Ectoderm development 8 Proteolysis 7 
Electron transport 3 Regulation of lipid, fatty acid and steroid metabolism 1 
Embryonic development 7 Response to interferon-gamma 1 
Endocytosis 2 Response to stimulus 2 
Extracellular transport 2 Response to stress 8 
Fatty acid biosynthesis 1 Response to toxin 2 
Fatty acid metabolism 1 Segment specification 3 
Female gamete generation 4 Sensory perception 1 
Gamete generation 2 Signal transduction 25 
Gametogenesis 1 Skeletal system development 2 
General mRNA transcription activities 1 Spermatogenesis 2 
Gluconeogenesis 1 Steroid hormone metabolism 1 
Granulocyte-mediated immunity 1 Steroid metabolism 2 
Heart development 1 Stress response 2 
Hematopoiesis 1 T-cell mediated immunity 2 
Hemopoiesis 3 Transcription factor activity immune system process 1 
Immune response 2 Transport 1 
Immune system process 16 Tumor suppressor 1 
Immune system processMitosis 1 Visual perception 1 
Immunity and defense 1   
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According to the PANTHER Classification System, in vitro berberine targets correlate with a 
mixture of biological pathways, such as Alzheimer disease-presenilin and secretase pathways, 
angiogenesis, apoptosis signaling pathway, FAS signaling pathway, Hungtington disease, 
inflammation mediated by chemokine and cytokine signaling pathway, interleukin signaling 
pathway and p53 pathways (Table 5-5). 
 
Compared to RA and NIDDM therapeutic targets, in vitro targets of berberine distributed 
across a far larger number of PANTHER classifications of molecular functions, biological 
processes and pathways. This can be an advantage in terms of drug discovery using berberine. 
Given that berberine targets are involved in a wide range of molecular activities altering many 
pathological states of the body, berberine can be explored for the treatment of different 
diseases. On the other hand, the nature of multi-targeting of berberine lack in target 
specificity, which can become difficult for drug design. Further, because berberine can have 
interactions with so many molecular structures and involve in different pathways, much 
attention must be paid to avoid interactions with other therapeutic drugs. 
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Table 5-5. Distribution of berberine targets in vitro according to pathway categories by PANTHER classifications.  
 
 
PANTHER pathway categories No. of 
targets 
PANTHER pathway categories No. of 
targets 
Acetyltransferase 1 Integrin signalling pathway 6 
Alzheimer disease-amyloid secretase pathway 11 Interferon-gamma signaling pathway 2 
Alzheimer disease-presenilin pathway 14 Interleukin signaling pathway 10 
Angiogenesis 11 Ligand-gated ion channel 1 
Apoptosis signaling pathway 21 Membrane-bound signaling molecule 1 
ATP synthesis 1 Pathway unclassified 19 
ATP-binding cassette (ABC) transporter 2 Oxidative stress response 5 
Axon guidance mediated by netrin 1 p53 pathway 12 
Axon guidance mediated by semaphorins 1 p53 pathway by glucose deprivation 1 
Axon guidance mediated by Slit/Robo 4 p53 pathway feedback loops 1 
B cell activation 7 P53 pathway feedback loops 1 1 
Basic helix-loop-helix transcription factor 1 p53 pathway feedback loops 2 4 
Blood coagulation 3 Parkinson disease 3 
Cadherin signaling pathway 2 PDGF signaling pathway 6 
Cell cycle 4 Peptide hormone 1 
Cytoskeletal regulation by Rho GTPase 3 PI3 kinase pathway 4 
DNA replication 2 Plasminogen activating cascade 8 
EGF receptor signaling pathway 4 Protein kinase 1 
Endothelin signaling pathway 2 Ras Pathway 5 
FAS signaling pathway 13 T cell activation 7 
FGF signaling pathway 4 TGF-β signaling pathway 4 
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway 1 Toll receptor signaling pathway 9 
Huntington disease 9 VEGF signaling pathway 7 
Hypoxia response via HIF activation 1 Vitamin D metabolism and pathway 1 
Inflammation mediated by chemokine and cytokine signaling pathway 13 Wnt signaling pathway 4 
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade 1   
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5.3 Effects of berberine in vivo and in humans with a focus on diabetes mellitus  
 
In China, Huang Lian (Rhizoma Coptidis) has been used to treat diabetes for more than 1400 
years [419]. Berberine is one of the main active alkaloids present in Rhizoma Coptidis. As 
discussed in Section 5.2.1, berberine has shown to have good hypoglycaemic effects in vitro 
[465, 480, 484, 487]. Further, the chemical structure of berberine is different from commonly 
used hypoglycaemic agents such as sulfonylureas, biguanides, TZDs or acarbose [417].  Thus 
it is meaningful to investigate the efficacy and safety of berberine treatments for diabetes 
mellitus to confirm the possibility of berberine serving as a new class of anti-diabetic 
medications. Extensive research has been done to investigate the hypoglycaemic effects of 
berberine in animal models. This section will highlight the effects of berberine in diabetic 
animal studies, focusing on different mechanisms of actions of berberine.  
 
Hyperglycemia is a hallmark metabolic abnormality associated with metabolic diseases such 
as type 2 diabetes. Berberine has shown to significantly decrease fasting blood glucose levels 
in diabetic rats (diet or drug induced), this has been observed in a number of studies [497-
500]. Berberine can reduce fasting blood glucose level via different mechanisms. For 
example, Liu et. al [497] reported that berberine reduced fasting blood glucose levels by 
inhibiting intestinal disaccharidases down regulate SI complex mRNA expression in a 
concentration-dependent manner. Xia et. Al [500] reported berberine reduced fasting glucose 
level via the inhibition of gluconeogenesis, via decreased PEPCK and G6Pase genes in the 
liver, reduced hepatic steatosis and inhibition of FAS expression.  
 
Current diabetes therapies does not address the key driver of this condition, β-cell dysfunction 
[296, 297] and does not alter  the progressive nature of insulin secretory deficit [298]. 
Berberine increased pancreatic β-cell numbers and β-cell mass in streptozotocin-induced 
diabetic rats [496, 501]. It also reversed pathological changes of pancreatic beta cells in 
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diabetic rats induced by streptozotocin and diet [502]. Further, in berberine treated diabetic 
rats, the pancreatic and plasma insulin levels increased after glucose load, reducing blood 
glucose levels [496, 501]. These observations are significant as berberine may be explored 
further as an additional therapy to existing antidiabetic drugs to effectively preserve β-cell 
functions, reverse β-cell damage and promote insulin secretion in diabetes patients.  
 
Further to β-cell dysfunction and insulin secretory deficit in diabetes, defects in insulin 
receptor expression or function cause insulin resistance and diabetes mellitus [503]. Thus, 
regulation of InsR expression may improve insulin resistance in diabetes mellitus. Berberine 
increases InsR mRNA and protein expression in human liver cells and in animal model in a 
dose- and time-dependent manner [484]. Berberine up-regulates InsR and leads to enhanced 
insulin signalling pathway, confirming berberine as an insulin sensitiser. 
 
Incretins glucagon-like peptide 1 (GLP-1) is an intestinal peptide hormone released in 
response to food ingestion [371]. GLP-1 enhances meal-related insulin secretion and 
promotes glucose tolerance. In streptozotocin-induced rats, berberine enhanced GLP-1 release 
and promotes proglucagon mRNA expression, increased beta cell mass and pancreas insulin 
levels after glucose load [496]. This observation was in line with the groups  previous 
experiments in vitro. Lu et. Al [501] also reported that berberine increased proglucagon 
mRNA expression and plasma insulin levels in streptozotocin-induced diabetic rats. The 
glucagon gene encodes GLP-1 and the increased expression of proglucagon mRNA assists in 
controlling the blood glucose homeostasis.  This observation may be significant in diabetes 
therapy. 
 
Berberine also reduced body weight and caused a significant improvement in glucose 
tolerance without altering food intake in db/db mice [504]. Oral glucose tolerance 
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improvement in diabetic rats after berberine treatment has also been observed in other studies 
[505, 506]. 
 
Long term hyperglycaemia can lead to increased risk of cardiovascular complications. In 
hyperglycemia and hypercholesterolemia rats with injured cardiac functions, berberine (15, 
30mg/kg/day, i.g for 6 weeks) increased cardiac output, left ventricular systolic pressure and 
+dp/dtmax by 64, 16 and 79%, but decreased left ventricular end diastolic pressure and -
dp/dtmax by 121 and 61% in the rats receiving HSFD/streptozotocin, respectively, when 
compared with the untreated rats of hyperglycemia and hypercholesterolemia [507]. Berberine 
caused significant increase in cardiac fatty acid transport protein-1 (159%), fatty acid 
transport proteins (56%), fatty acid beta-oxidase (52%), as well as glucose transporter-4. 
These results demonstrate the cardioprotective functions of berberine in 
hyperglycemia/hypercholesterolemia through alleviating cardiac lipid accumulation and 
promoting glucose transport 4 [507]. Another study also showed improved vasorelaxation in 
impaired aorta in diabetic rats after berberine treatment (100mg/kg/day, 8 weeks) [499]. Thus, 
in addition to its hypoglycaemic effects, berberine can also be investigated for 
cardiomyopathy in diabetes.  
 
Berberine also regulates lipid metabolism which is closely related to diabetes. In rats with 
induced diabetic hyperlipidemia, berberine (75, 150, 300 mg/kg/day for 16 weeks) effectively 
reduced liver weight and liver/body weight ratio, levels of total cholesterol, triglycerides and 
low density lipoprotein-cholesterol  [508]. In rats with a high fat diet, berberine significantly 
reduced body weight, alleviated liver steatosis and improved insulin resistance [509]. This 
observation indicates that berberine can be an effective treatment for diabetes with obesity.  
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Clinically,  preeminent factors for monitoring glycaemia and evaluating the risks of 
complications of diabetes include fasting blood glucose (FBG), haemoglobin A1C (HbA1C) 
[510]. Triglyceride synthesis is closely associated with glucose metabolism so serum 
triglyceride levels are determined. Clinical studies often measure FBG, HbA1C and 
triglyceride levels, along with other factors to study the hypoglycaemic effects of berberine. 
The efficacies of berberine in type 2 diabetes patients have been reported. Through literature 
search, key clinical studies on berberine effects on type 2 diabetes patients are summarised.  
 
Zhang et al [511] conducted a randomized, double-blind, placebo-controlled multicenter trial 
(n=116). The authors found that when berberine (1.0 g daily) was administered for 3 months 
in type 2 diabetes patients with dyslipidemia, the fasting and post load plasma glucose levels 
decreased from 7.0±0.8 to 5.6±0.9 and from 12.0±2.7 to 8.9±2.8 mM/L, HbA1C from 
7.5±1.0% to 6.6±0.7%.  Further, in the treatment group, triglyceride levels were reduced from 
2.51±2.04 to 1.61±1.0 mM/L, total cholesterol from 5.31±0.98 to 4.35±0.96 mM/L, and LDL-
cholesterol from 3.23±0.81 to 2.55±0.77 mM/L. Results from the treatment group was 
significant compared to the control group. In the treatment group, patient’s body weight was 
also significantly reduced. Mild to moderate constipation was reported in 5 patients from the 
treatment group and 1 patient from the control group, however this finding was not 
statistically significant. No other adverse events were reported. At 3 months, berberine was 
found to be effective in lowering blood glucose, lipids, body weight and blood pressure with a 
good safety profile.  
 
Yin et. Al reported a 3 months study comparing berberine to anti-diabetic drug metformin 
(0.5 g t.i.d) [417]. In this study, berberine exhibited identical effect as metformin in the 
regulation of glucose metabolism, significant decreases in HbA1C (by 2%, P<0.01), FBG (by 
3.8 mM/L; P<0.01) and postprandial blood glucose (PBG) (by 8.8 mM/L; P<0.01). Further, 
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the regulation of lipid metabolism was better in the berberine group than the metformin group. 
Triglycerides and total cholesterol levels were significantly lower than in the metformin group 
(P<0.05). At the same time, the same group of researchers used berberine as a combination 
therapy to evaluate its additive or synergistic effects of on the commonly used hypoglycemic 
agents, such as sulfonylureas, biguanides, thiazolidinediones and acarbose. Patients were 
given 500 mg berberine three times daily for 3 months in addition to their previous treatment. 
At week 5, berberine significantly (P<0.01) reduced levels of HbA1C (from 8.1% to 7.3%), 
FBG, PBG and fasting insulin levels. Blood lipids including triglyceride, total cholesterol and 
LDL-cholesterol decreased significantly lowered compared to baseline. In both studies, 
incidences of gastrointestinal adverse events were observed, including diarrhea, constipation, 
flatulence and abdominal pain. Interestingly, patients did not suffer from severe 
gastrointestinal adverse events when berberine was used alone and in combination therapy, 
adverse effects disappeared after berberine dosage was reduced. No pronounced elevation in 
liver enzymes or creatinine was observed, suggesting that berberine did not cause damage to 
the liver or kidneys. 
 
 
Another clinical study [512] randomly divided 97 T2DM patients into berberine treatment 
(1g/day) for 2 months, using metformin therapy (1.5 g/day) and rosiglitazone group (4 
mg/b.i.d) as reference groups. Blood samples were taking before and after treatments to 
measure FBG, HbA1C, triglyceride and serum insulin levels. Compared to values prior to 
treatment, berberine significantly lowered FBG by 25.9% (P< 0.001), HbA1C by 18.1% 
(P<0.00), and triglycerides by 17.6% (P<0.01). The hypoglycaemic effects of berberine were 
comparable to metformin and rosiglitazone. Serum insulin level were declined significantly 
(P<0.01) by 28.2%, this indicates increased insulin sensitivity in peripheral tissues by 
berberine treatment. Peripheral blood lymphocytes from berberine treated patients were 
  204 
isolated to examine the InsR expression. The surface expression of InsR significantly elevated 
by 3.6-fold after berberine treatment.  
 
Metformin and rosiglitazone are not recommended for use in diabetic patients with liver 
function damage [504, 513]. So the effect of berberine was tested in hyperglycaemic patients 
with hepatitis. Hepatitis B and C patients with hyperglycaemia received berberine at 1g/day 
for 2 months. In both diabetic hepatitis B and C patients, berberine significantly reduced FBG 
and triglyceride levels. Berberine treatment also reduced the elevated Alanine transaminase  
and aspartate aminotransferase levels in these patients. Overall, berberine is safe and effective 
in hyperglycaemic patients with liver function damage.  
 
Table 5-6 compares clinical studies of berberine in diabetes patients. Across the studies, 
berberine has shown to significantly reduce FBG, PBG and HbA1C levels. Berberine also 
demonstrated the ability to reduce triglyceride and cholesterol levels. Minimal gastrointestinal 
side effects were shown but no liver or kidney damage was observed. These observations in 
diabetes patients demonstrate that berberine is a safe and effective anti-diabetic agent. 
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Table 5-6. Comparison of clinical studies of berberine in diabetes patients.  
 
 
 
b.i.d, twice daily; t.i.d, three times daily; HOMA-IR, Homeostasis Model of Assessment-Insulin Resistance. 
Study type Study subjects Berberine dosage Control 
treatment 
Major findings Side effects Reference 
Randomised, 
double-blind, 
placebo-
controlled, 
multiple-center 
Type 2 diabetes 
and 
dyslipidemia 
(n=116) 
0.5g, b.i.d for 3 
months 
Placebo  • Significantly reduced fasting and 
post load plasma glucose, HbA1C.  
• Significantly reduced triglyceride, 
total cholesterol and LDL-
cholesterol. 
 
Mild to moderate 
constipation in 5 
patients 
[511] 
Type 2 diabetes 
(n=36) 
0.5g, t.i.d for 3 
months 
Metformin (0.5g 
t.i.d) 
• Significantly reduced FBG, PBG 
and HbA1C. 
• Significantly reduced plasma 
triglycerides. 
 
Randomised, 
blinded, 
placebo-
controlled 
Type 2 diabetes 
poorly 
controlled 
(n=48) 
0.5g, t.i.d for 3 
months 
Existing anti-
diabetic treatment 
• Lowered FBG and PBG. 
• Significantly decreased HbA1C.  
• Significantly reduced fasting 
plasma insulin and HOMA-IR. 
Transient 
gastrointestinal 
adverse effects. No 
liver or kidney 
damage 
[417] 
Type 2 diabetes 
(n=97) 
1g/day for 2 months Metformin (1.5 
g/day); 
Rosiglitazone (4 
mg/day) 
• Significantly reduced FBG, 
HbA1C and triglycerides.  
• Serum insulin level were declined 
significantly (P<0.01), increased 
insulin sensitivity in peripheral 
tissues.  
• Significantly elevated surface 
expression of InsR by 3.6-fold. 
Randomised 
Type 2 diabetes 
with chronic 
hepatitis C virus 
infection (n=35) 
1 g/day for 2 months N/A • Significantly reduced FBG and 
triglyceride levels. 
• Reduced the elevated ALT and 
aspartate aminotransferase levels. 
No adverse events [512] 
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5.4 Potential of drug discovery from berberine  
 
In cell based studies, berberine has shown effects on multiple molecular targets and alters 
various biological pathways. Berberine associates with a range of conditions, particularly 
diabetes, hyperlipidemia and cancer. Many in vitro studies showed potent anticancer 
properties of berberine against various cancer cells. Berberine may have the potential of 
becoming an anticancer agent, like other natural compounds (taxol, camptothecin) that have 
been developed and used as anticancer agents.  
 
Diabetes mellitus is a major health problem around the world and its prevalence is on the rise. 
Diabetes mellitus drug therapy is limited by availability of effective medications, as existing 
oral hypoglycaemic agents often have side effects  and fails in long term administration [417]. 
Berberine has shown significant results in fasting blood glucose levels reduction, increase in 
insulin sensitivity and improvement in insulin resistance in vitro, in diabetic animal models 
and in diabetic patients. Further, berberine shows mechanism that current anti-diabetic drugs 
do not have. For instance, berberine has shown effects on pancreatic β-cell number and mass 
improvement [496, 501, 502]. In addition, berberine has a good safety profile and does not 
show side effects such as hypoglycaemia, weight gain or liver, kidney damage. Metformin 
and rosiglitazone are not recommended for use in diabetic patients with liver function damage 
[504, 513]. Berberine has shown to be effective in the reduction of blood glucose level and is 
safe in diabetic patients with viral hepatitis [512]. Berberine can therefore be investigated as 
an effective diabetes therapy with patients with liver function damage.  
 
In addition to its hypoglycemic effects in diabetic patients, berberine also reduced triglyceride 
and cholesterol levels. Abnormalities in lipid metabolism often deteriorate diabetes and cause 
complications. The regulation of lipid metabolism in diabetes patients by berberine may have 
clinical significance in managing diabetic patients with hyperlipidemia.   
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In China, berberine has been manufactured into the over-the-counter drug Huang Lian Su 
Pian, also known as Coptis Extract Tablets for the treatment of traveler’s diarrhoea [417, 
420]. However, in vitro and in vivo studies have shown that berberine has potent anti-cancer, 
anti-diabetic, anti-lipidemic and anti-inflammatory effects. Therefore, further clinical studies 
are warranted to investigate the potential of berberine in the application of cancer and diabetes 
treatments in the future.  
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Chapter 6. Drug and Herbal Target Database Construction: A Pilot Study 
 
6.1 Introduction 
 
As mentioned in Section 1.5.2.1, databases are a key component of bioinformatics. Databases 
allow researchers to deposit their findings in a place that allow other researchers and the 
public to access easily. Further, the accumulation of large amounts of data is valuable in 
modern research of drug discovery.  
 
This chapter outlines and discusses about current available drug target databases and herbal 
target databases, along with the strength and limitations. Then we propose to construct a 
database that contains rich data on drugs and drug targets, herbs and herb targets.  
 
6.2 Drug target databases 
 
Public accessible databases such as DrugBank (http://www.drugbank.ca/), Therapeutic Target 
Database (http://bidd.nus.edu.sg/group/cjttd/ttd.asp ) and Potential Drug Target Database 
(http://www.dddc.ac.cn/pdtd/) have been developed to facilitate the access of information 
about therapeutic targets. In this section, DrugBank, TTD and PDTD will be briefly 
introduced.  
 
6.2.1 Drugbank  
 
DrugBank was constructed in the effort to link drug knowledge accumulated in the past half 
century and todays rich electronic sequence/structure data. DrugBank was first released in 
2006, it is a database that links sequence, structure and mechanistic data about both drug and 
large biotech drugs [514]. Data in DrugBank was compiled after molecules and their drug 
targets [515]. It has a strong focus on quantitative, analytic or molecular information about 
both drugs and drug targets [516]. In addition, DrugBank contains extensive data on the 
nomenclature, ontology, chemistry, structure, function, action, pharmacology, 
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pharmacokinetics, metabolism and pharmaceutical properties of both small molecule the 
access, search, comparison of more than a dozen textbooks, several hundred journal articles, 
nearly 30 different electronic databases and at least 20 web-based programs [516]. DrugBank 
can be accessed at http://www.drugbank.ca/ (Figure 6-1). 
 
DrugBank is a fully searchable web-enabled resource with many built-in tools and features for 
viewing, sorting and extracting drug or drug target data, it allows educators and researchers 
from diverse backgrounds (academic, industrial, clinical, non-clinical) to conduct in silico 
learning and discovery [516]. DrugBank data can be browsed through by 6 categories: drug 
browse, pharma browse, geno browse, pathway browse, class browse and associate browse.  
 
Drugs in DrugBank are divided into 4 major categories to facilitate more targeted research:  
1. FDA-approved small molecule drugs (no.= 1424) 
2. FDA-approved biotech drugs (132 entries) 
3. Nutraceuticals or micronutrients such as vitamins and metabolites (no.=82) 
4. Experimental drugs, including unapproved drugs, de-listed drugs, illicit drugs 
(no.=5,467) 
 
Each drug has its own DrugCard in DrugBank, which provides not only comprehensive 
numeric, sequence and textual data, it also contains hyperlinks to other databases, abstracts, 
digital images and interactive applets for molecular structure viewing [516]. In DrugBank 
version 1.0, each DrugCard contained more than 80 data fields with half dedicated to 
information on drugs and half to drug targets [516]. The latest version of DrugBank has 148 
data fields for each DrugCard [514]. A summary table of data fields found in each DrugCard 
is provided (Table 6-1), a more complete listing can be found on the DrugBank website. The 
DrugCard for Abacavir, a drug used for HIV and aids, is shown in DrugBank has separate 
  210 
categories of data for the drug and has produced links named “Taxonomy, Pharmacology, 
Pharmacoeconomics, References, Interaction and Comments” on top of the page, viewers can 
click on these tabs at any time of the search to view data that is of their particular interest 
(Figure 6-1). Further,  to the left hand of the screen there is a tab linking to “Targets” and 
“Enzyme” which takes viewers to detailed information on its drug targets and metabolising 
enzymes (Figure 6-2). As we can see from the comparison table (Table 6-2), the number of 
drugs and data field for each drug has increased over the development of DrugBank versions 
1, 2 and 3, making DrugBank more comprehensive and more complete.  
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Figure 6-1. a) DrugBank home page; b) Drug card for Abacavir.      
a) DrugBank home page.      b) Drug card for Abacavir.  
 
   
 
 
Figure 6-2. Detailed information of Abacavir targets and metabolising enzymes. 
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Table 6-1. Summary of the data fields or data types found in each DrugCard in DrugBank version 3.0 
       [Adapted from Knox, C., et al. (2011). Nucleic Acids Research 39 (Database issue): D1035-1041.] 
 
Drug or compound information Drug target or receptor information 
Generic name Target name 
Accession number Target synonyms 
Type (small molecule/biotech/nutraceutical) Target protein sequence 
Groups (approved/illicit/withdrawn) Target no. of residues 
Description Target molecular weight 
Chemical Structure Target pI 
Brand names/synonyms Target gene ontology 
Molecular weight Target general function 
SMILES string Target pathways 
Taxonomy Target reactions 
Pharmacology Target Pfam domains 
Pharmacoeconomics Target signal sequences 
Properties Target transmembrane regions 
References Target essentiality  
KEGG/PubChem/ChemSpider/ChEBI/CheMBL links Target GenBank Protein ID 
TTD/PharmGKB/DrugProductDatabase/RxList/Drugs.com/PDRhealth/Wikipedia Links Target UniProt ID 
ATC, AHFS codes Target PDB ID 
PDB entries link Target PDB file 
FDA label link Target 3D structure 
MSDS link Target cellular location 
Drug interactions Target gene sequence 
Food interactions Target GenBank Gene ID 
Target information Target GeneCard ID 
Enzyme information Target GenAtlas ID 
Comments Target HGNC ID 
 Target HPRD ID 
 Target chromosome location 
 Target locus 
 Target SNPs 
 Target References 
 Target related drugs 
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Table 6-2. Comparison between the coverage of DrugBank 1.0, 2.0 and DrugBank 3.2.  
[Adapted from Knox, C., et al. (2011). Nucleic Acids Research 39 (Database issue): D1035-1041.] 
 
Category 1.0 2.0 3.2 
No. of data fields  88 108 148 
No. of search types  8 12 16 
No. of drug-action pathways  0 0 223 
No. of drugs with metabolizing enzyme data  0 0 762 
No. of drug metabolites  0 0 811 
No. of drugs with drug transporter data  0 0 516 
No. of SNP-associated drug effects  0 0 113 
No. of drugs with patent/pricing/manufacturer data  0 0 1208 
No. of food–drug interactions  0 714 1039 
No. of drug–drug interactions  0 13242 13795 
No. of ADMET parameters (Caco-2, LogS)  0 276 890 
No. of QSAR parameters per drug  5 6 14 
No. of FDA-approved small molecule drugs  841 1344 1424 
No. of biotech drug 113 123 132 
No. of nutraceutical drugs 61 69 82 
No. of withdrawn drugs  0 57 68 
No. of illicit drugs  0 188 189 
No. of experimental drugs 2894 3116 5210 
Total No. of experimental and FDA small molecule 
drugs  3796 4774 6684 
Total No. of experimental and FDA drugs  3909 4897 6816 
No. of names/brands/synonyms  18304 28447 37171 
No. of approved-drug drug targets (unique)  524 1565 1768 
No. of all drug targets (unique)  2133 3037 4326 
No. of approved-drug enzymes/carriers (unique)  0 0 164 
No. of all drug enzymes/carriers (unique)  0 0 169 
No. of external database links  12 18 31 
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6.2.2 Therapeutic Target Database 
 
To build a public accessible database that provides comprehensive information about 
therapeutic targets, researchers at the Department of Computational Science at the National 
University of Singapore introduced a Therapeutic Target Database (TTD) [84]. Information on 
therapeutic targets was collected from a search of pharmacology textbooks and review 
articles.  In the first release of TTD, there were 433 entries of protein and nucleic acid targets 
in TTD, along with 125 diseases and 809 drugs [84]. An updated version of TTD was 
complete with 358 successful targets, 251 clinical and 1254 research targets, 560 diseases and 
5028 drugs [517]. TTD can be accessed at http://bidd.nus.edu.sg/group/cjttd/TTD_HOME.asp.  
 
TTD data can be accessed via a generalised search through the TTD home page; any search 
can be performed by specifying full name or any part of the name in a text field via the drug 
list or target list. A search of targets for type 2 diabetes mellitus is used to illustrate this 
process. Firstly, enter search term “type 2 diabetes mellitus” into the query box under “Search 
results in terms of target list” as shown in (Figure 6-3). The list of targets for type 2 diabetes 
mellitus will appear as shown (Figure 6-3). Specific target information can be accessed by 
clicking on “Target info” on the left hand column, here, comprehensive data on a target is 
presented (Figure 6-3). Data fields accessible include TTD target ID, name, type of target, 
synonyms, diseases, drug, antibody, binder, inhibitor, pathway, related US patent, cross 
references and relevant literature. The target sequence is cross linked to the Universal Protein 
Resource (UNI-PROT) database. The available 3D structure of the target can be accessed 
through cross link to the Protein Data Bank database. For an enzymatic target, it can be cross 
linked to Expasy database. Relevant literatures of the target are cross linked to the PubMed 
database. 
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Besides a general search, TTD data can also be accessed by keyword or customised search. 
Customised search fields include target name, drug name, disease indication, target 
biochemical class, target species, drug therapeutic class and drug mode of action [517]. 
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Figure 6-3. General search on TTD homepage using search term “type 2 diabetes mellitus”.  
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6.2.3 Potential Drug Target Database  
 
Potential Drug Target Database (PDTD) has dual functions of querying drug target 
information and identifying the potential binding proteins of an active compound or an 
existing drug by using reverse docking approach. Accordingly, PDTD contains one structural 
sub-database and one informatics sub-database [518]. PDTD can be accessed at 
http://www.dddc.ac.cn/pdtd/ (Figure 6-4). 
 
PDTD currently contains 1207 entries covering 841 known and potential drug targets with 
structures from the PDB. This number increased from >1100 entries covering information of 
>800 known drug targets in 2008 [518]. The targets in PDTD were selected from literatures 
and some online databases such as TTD [84] and DrugBank [516]. Because PDTD is 
designed to search the probable binding proteins for new active compounds or existing drugs, 
it only contains the proteins with known 3D structures determined experimentally by the X-
ray crystallographic or nuclear magnetic resonance methods [518]. According to therapeutic 
areas, drug targets in PDTD may be categorised into 15 types (Figure 6-4). The distribution of 
biochemical classification is shown in Figure 6-4.  
 
PDTD targets can be either browsed or searched (Figure 6-5). Detailed PDTD target 
information page (Figure 6-6.) includes basic information such as, PDB ID, biochemical type, 
therapeutic area, target name, related disease and source of protein. Links to PDB, UniProt, 
KEGG and EC is also available. A PDB and mol2 file of each protein or target is stored in the 
structural sub-database and can be accessed on individual target page.  
 
PDTD also provides hyperlinks to databases such as TTD and DrugBank, this allow easy 
navigation for more information about target structure, source and function [518]. In addition, 
the classified target structures and all target files are downloadable for all PDTD users from 
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the “Download” page [518]. Finally, in conjunction with TarFisDock, PDTD is also designed 
for target identification.   Users can also use reverse docking program to search PDTD for 
finding the possible binding protein(s) of a small molecule [518].   
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Figure 6-4. PDTD homepage.  
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Figure 6-5. a) PDTD browse page; b) PDTD search page. 
 
a) PDTD browse page 
 
 
 
 
b) PDTD search page.  
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Figure 6-6. PDTD target page.  
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6.3 Herb databases 
 
With the increased popularity of CHM use, it is no surprise that a number of databases on 
CHM have emerged in the past couple of decades. The following section wii breifely 
introduce some CHM databases.  
 
Traditional Chinese Medicine Database organised information in three parts: Chinese 
medicines, original plants and bioactive components [109].  A summary of data fields is 
shown in Table 6-3, they include basic data, chemical components, molecular structures and 
bioactive data. The molecular structure part of the database contains more than 1,540 species 
of natural products used as Traditional Chinese medicine (TCM) and 6,800 compounds that 
are isolated from plants, herbs, animals, fungi, etc [109]. The application is divided in 3 
components: TCM data queries, chemical data queries and multiple-entry queries. Users can 
request data by any of the query modes.  
 
 
 
Table 6-3. Summary of data fields in Traditional Chinese Medicine Database. 
 
Chinese Medicine Original Plants Bioactive Compounds 
• Name and synonyms  
• Codes of TCM 
• Effective species 
• Property 
• Flavour 
• Channel tropism 
• Effects 
• Indications 
• Clinical applications  
• Pharmaceutical 
functions 
• Annotations 
• References 
• Name and synonyms 
• Medicinal parts 
• Collection and 
process of the plants 
 
• Chemical formulas 
• 2D chemical structure 
• 3D chemical structure 
• Molecular weight 
• CAS registry number 
• Physiochemical properties  
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Traditional Chinese Medicine Information Database (TCM-ID) provides comprehensive 
information about all aspects of TCM including prescriptions, constituent herbs, herbal 
ingredients, molecular structure and functional properties of active ingredients, therapeutic 
and side effects, clinical indication and application, plus more related matters. Information in 
TCM-ID was manually collected from TCM books and papers in Medline [108]. TCM-ID can 
be accessed at http://bidd.nus.edu.sg/group/TCMsite/Default.aspx (Figure 6-7). Data can also 
be searched by formula, herb or compound, other input such as disease name or therapeutic 
effect can also be used to perform a search. Up to date, TCM-ID contains information for 
1,197 Chinese herbal formulas, 1,102 herbs, 12,120 herbal compounds, and the 3D structure 
of 3,725 herbal ingredients [108]. Data in TCM-ID has shown to be valuable when used to 
assess whether problems such as TCM mechanism studies and validation of TCM multi-herb 
preparations can be solved. Using the 3D structure of Genistein, INVDOCK was used to 
search for its molecular targets, some identified potential therapeutic targets reported to be 
inhibited by Genistein, and some reports showed that Genistein affected the activity or 
expression levels of identified targets [108]. As illustrated, data presented in TCM-ID is 
useful in in silico studies of mechanisms of herbal compounds.  
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Figure 6-7. Detailed information on a) a TCM prescription; b) a single herb and c) herbal 
compound in TCM-ID.  
 
a) TCM prescription 
 
   
 
b) Herb target information  
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A 3D structure database of components from CHM paid special attention to 3D structure of 
components from TCM herbs. The database was designed to aim primarily at drug designers 
wanting to speed up the process of lead compounds and phytomedicine researchers [110]. 
Data in this database were selected from three categories (Table 6-4)[110]. First category 
comprised of herb basic information, including common name, standard name, formula, 
weight, CAS entry number and physical properties. Second category is structural information, 
including 2D and 3D structures and various molecular properties. Last category is information 
on source herbs, including Latin name, family, effective parts and curative effects. Currently, 
there are 10,564 herbal component records and 2,073 TCM herb records collected in the 
database [110].  
 
 
Table 6-4. Data fields in 3D Structure database of components from CHM.  
 
Basic molecular information Structural information Source herb information 
• Common name 
• Standard name 
• Formula 
• Weight 
• CAS entry number 
• Physical properties 
• 2D chemical structure 
• 3D chemical structure 
• Molecular structural 
properties 
• Latin name 
• Family  
• Effective parts 
• Curative effects 
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In the construction of Phytochemical databases of CHM constituents with target specificities, 
two databases were constructed.  The first database, Chinese Herbs Compound Database 
(CHCD), covers details on chemical constituents of major herbs used in TCM. The other 
database, Bioactive Plant Compound Database (BPCD), provides information on 
phytochemical compounds with known activity against targets. CHCD and BPCD were 
constructed containing details on 8264 compounds found in 240 of the most commonly used 
herbs in Chinese medicine and a total of 78 targets is covered [94].  A summary of 
information provided in CHCD and BPCD can be found in Table 6-5.  
 
 
 
 
 
Table 6-5. Summary table of contents for CHCD and BPCD.  
Contents Details 
Structure  • 2D (MDL mol format) 
• 3D confirmations 
SMILES code - 
Compound names • Trivial or common names 
• Systematic name 
Compound class and skeletal type - 
Chirality - 
CAS registry number - 
Pharmacology - 
Toxicology - 
Herb names • Botanical species (Latin) 
• Common herb names (pinyin) 
Part of plant where compound is found - 
Chemical reference(s) - 
TCM categories - 
Target(s) - 
Ligand type - 
Inhibition - 
Botanical species - 
Further details • Protein subunit information 
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6.4 Database proposal 
 
6.4.1 Aim of proposed database  
 
Currently, a number of databases available on CHM and compounds have been 
developed, but only one database contains limited information on herbal targets.   
 
The mapping of this database is to construct a database that contains comprehensive data 
not only on pharmaceutical drug targets, but also herbal compound targets. The 
completion of this database will be a highlight in the combining of traditional medicine 
and modern science. The proposed database aims to be a “one-stop-shop” for researchers 
who would like to gain knowledge of drug, drug targets, herbs, herb targets and their 
interactions.  
 
6.4.2 Methods 
6.4.2.1 Logical design 
 
The proposed database plans to include extensive data on diseases, drugs, drug/herbal 
targets, herbal compounds and herbal formula. Each section will hold comprehensive 
data and the list of items included under each section is decided based on literature. A 
small scaled search using ‘menoapuse’ will be used to establish the relationship of 
different sections of information. The search and data extration was complete by the 
candidate. Logical design validated relationships and interconnections between separate 
sections. Through discussion and with assistance from information technology experts, 
this process was completed. 
6.4.2.2 Data collection  
 
Data on diseases, drugs and drug targets were collected from 3 databases: DrugBank, 
TTD and PDTD. For each drug, information including drug name, synonym, drug type, 
brand name, chemical formula, chemical structure, drug category, pharmacological 
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properties, toxicity and interactions were collected. For each drug targets, information 
including target name, synomym, gene name, protein name, mokecular weight and 
function were collected. Collected data were tabulated, duplicates were cross checked 
then deleted.  
 
Data on herbal formula, herbs, herbal compounds and herbal targets will be collected 
from various databases and books including TCM-ID, CHCD, BPCD. Databases such as 
Pubmed and PDB will be systematically searched to compile an up to date and 
comprehensive list of herbal targets. Collected data will be tabulated and duplicates will 
be deleted.  
 
6.4.2.3 Interface design 
 
After all data is available, collaborating technicians will be contacted to design a web 
interface that is appealing and easy to use.  
 
6.4.3 What has been completed so far 
 
This database will contain comprehensive data on separate sections: disease, drugs, drug 
targets/herbal targets, herbal compounds and herbal formula. In each section, we propose 
to include several data fields to hold comprehensive data. The layout of each section and 
information that will be included in the database is outlined in Figure 6-8. To ensure the 
success of the database, the potential relationships between drug targets, herbal targets 
and disease must be established. A detailed diagram showing the relationship between 
disease-drug-target-herbal compound-herb-formula and disease is shown in Figure 6-8. 
 
A small scaled search using “menopause” was carried out. Details of menopause drug 
therapy and herbal therapy were extracted. This demonstrated the relationships of herbal 
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compounds with targets that can be linked to therapeutic drugs for the same disease. 
More specifically, an overall link was established through the relationship of various 
sections of the database: disease and drug, drug and target, target and compound, 
compound and herb, herb and formula, formula and disease (Figure 6-9). 
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Figure 6-8. Outline of proposed database, establishing a relationship between various 
sections of information.  
 
 
  231 
 
 
Figure 6-9. Using menopause as an example to demonstrate the relationship of disease-
drug-target-herbal compound-herb-formula and disease. 
 
 
 
Drug 
 
Diethylstilbestrol 
 
Drug_Disease 
 
Drug: Diethylstilbestrol 
Disease: Menopause 
Disease_Formula 
 
Disease: Menopause 
Formula: Tian Wang Bu Xin Dan
  
Compound_Herb 
 
Compound: Ginsenoside Rb1 
Herb: Ren shen 
Disease 
 
Menopause 
Formula_Herb 
 
Formula: Tian Wang Bu Xin Dan 
Herb: Ren shen 
Formula 
 
Tian Wang Bu Xin Dan 
Compound 
 
Ginsenoside Rb1 
Target_Compound 
 
Target: Estrogen receptor  
Compound: Ginsenoside Rb1 
Herb 
 
Ren shen 
Target 
 
Estrogen receptor 
Drug_Target 
 
Drug: Diethylstilbestrol 
Target: Estrogen receptor  
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The relationship between disease-drug-target-herbal compound-herb-formula and disease has 
been established by the “Menopause- Diethylstilbestrol-Estrogen receptor- Ginsenoside Rb1- 
Ren shen- Tian Wang Bu Xin Dan- Menopause” model.  
 
After this, we need to populate data. To do so, extensive data mining must be carried out to 
collect data to complete the various sections of the database. Due to time constraint, only a 
comprehensive list of drug targets has been completed. Current drug targets were extracted 
from Drugbank, TTD and PDTD databases. Only confirmed and human data were included. 
Drug targets from 3 databases were cross examined to eliminate duplicates, databases such as 
Pubmed and PDB was often used to cross examine targets. The comprehensive list of current 
drug targets is presented in Supplementary Table 2. 
 
Some problems arised during the target collection process,  common issues are summarised 
below and examples are given.  
 
1. Same drug target with different IDs within the database.   
e.g. acetylcholinesterase in DrugBank was “Target ID 624” and “Target ID 2549”.  
Cross examination of the target name, gene name and protein sequence confirmed that 
the targets were the same. Duplicates were deleted from the final list of targets.  
 
2. Same target under different names.  
e.g.  carbonic andydarase 2 was found in DrugBank but carbonic anhydrase, type IV, 
II was found in PDTD. 
Cross examination of the target name, gene name and protein sequence confirmed that 
the targets were the same. Therefore, we chose one target name for our database. 
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3. One target name including a few targets.  
e.g. In TTD, 30S ribosomal subunit was targeted by Amikacin. However, in 
DrugBank 30S ribosomal subunit S12 is targeted by Amikacin.  
Therefore, subunits must be listed separately, this has been done in the final target list.  
 
4. In some databases, abbreviation of the target was used instead of the full name.  
e.g. ACAT = Acetyl-CoA acetyltransferase, mitochondrial 
Abbreviation was deleted after cross examination of gene name and protein sequence. 
 Only full names of target were included in our list.  
 
5. Incomplete target names.  
e.g. in DrugBank, we found “Coagulation factor VII”, whereas the target is under 
“Coagulation factor VIIa” in PDTD.  
Cross examination of target name, gene name and protein sequence confirmed that it 
was the same target. Then the more comprehensive target name was included in our 
list of targets.  
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6.5 Discussion and future perspectives 
 
Currently there are many databases available that focuses on different areas of science. There 
are databases that contain sequence and sequence annotation information; such as GenBank, 
Ensembl, EntrezGene, SwissProt and UniProt. There are databases that hold vast amount of 
data on SNPs and mutations, such as dbSNP, OMIM and HGMD. There are also databases 
available that contains drug metabolism and interaction data, for instance DrugBank. 
Researchers have used these databases to gather information, to find useful data, to identify 
what has already been accomplished and what aspects of research still needs attention and 
inquisition.  
 
Chinese Herbal Medicine is an increasingly popular form of treatment in the west and is 
becoming more involved in our lives. This increase in popularity is closely related to its 
proven effectiveness in clinical practice over the past centuries. However, this form of 
medicine has left many researchers curious and wondering about how it interacts with the 
human body at a molecular level that leads to its effectivess. Information on herbal 
compounds which integrate chemical structure, pharmacology, molecular targets and 
botanical sources including patterns of traditional usage, are of interest in terms of drug 
discovery and in furthering our understanding of herbal medicine.  
 
Some excellent work has put together databases that contain basic information related to the 
herb, its original plants, bioactive compounds, therapeutic indications and clinical applications 
[108-111]. However, they contain little data on herbal targets. Bioactive Plant Compound 
Database (BPCD) contains a total of 78 herbal targets information [94]. Therefore, a database 
with comprehensive data on herbal targets is much needed.  
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Further, despite the extensive use of herbal medicine in the modern society, and the few 
existing Chinese herbal medicine databases, it is difficult to point out an outstanding database 
that has comprehensive and detailed information about herbs, herbal compounds and herb 
targets. In addition, a database that links and relates herbal medicine information with 
therapeutic drugs is non-existent.  
 
A number of good pharmaceutical databases such as DrugBank and TTD already exist. One 
way of building a comprehensive pharmaceutical and herbal medicine database can be 
incorporating herbal medicine data into an existing database. This sounds like a good plan that 
saves resources and time. However, the process of logical design, data collection, merge and 
verification is complex and lengthy; dispute in data requires further cross checks which takes 
up time. In addition, each database have different focus of interest and may not contain data 
which we propose to include. In all, constructing a new database in an efficient manner will 
not waste more resources and time than incoporating data into an existing database. 
 
So, we proposed to construct a database that contains comprehensive data on pharmaceutical 
drug and drug targets, herbs, herbal compound and herb targets. The focus is to provide 
comprehensive and up-to-date data of drugs, herbs, and drug and herb targets. To our 
knowledge, this will be the first database of its kind. 
 
The first step of logical design has completed. The relationship between disease and drug, 
drug and target, target and compound, compound and herb, herb and formula, formula and 
disease has been successfully established. This ensures the possibility of combining this 
information into one refined database for future research. 
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After logical design, the next steps are populating the database and design an interface that is 
appealing and easy to manoeuvre. Unfortunately, due to time constraint this was not possible 
during this study. We were only able to extract a comprehensive list of current drug targets. In 
the future, we plan to use 12 months time to finish data collection of herbal targets, 
compounds and formula. Data related to herbal compounds and formula will be collected 
from various databases and books including TCM-ID, CHCD, BPCD. Databases such as 
Pubmed and PDB will be systematically searched to compile an up to date and comprehensive 
list of herbal targets. This is an ongoing project, we do look forward to completing the next 
few steps of constructing the database in the future.  
 
In general, when compared with pharmaceutical drugs, the quality of data on herbal medicine 
is poor. To ensure the high quality and accuracy of data on herbal medicine and relate targets 
in our database, we plan to cross check herbal medicine data from various CHM databases, 
verify data on herbal functions with literature and only include herbal target information 
obtained from in vitro or in vivo experiments.   
 
This proposed database may be of value in future understanding of herbal medicine at a 
molecular level. By linking herbal targets and drug targets, this may assist in the 
understanding of some clinical herb-drug interactions. Furthermore, to help discover new 
target classes from herbal targets.
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Chapter 7. General Discussion 
 
7.1 Major achievements of this study 
 
First, we used 2 algorithms, SIFT and PolyPhen in an attempt to predict the genotype-
phenotype relationship of an important drug metabolising enzyme called UDP 
glucuronosyltransferases (UGT). We have identified a total of 248 nsSNPs in a screening of 
21 human UGT genes. SIFT classified 88 out of 248 (35.5% ) identified UGT nsSNPs as 
“deleterious”; while PolyPhen identified 114 out of 248 (46.0%) identified UGT nsSNPs as 
“potentially damaging” and “damaging”.  Spearman’s rank correlation coefficient ρ = -0.709 
(P≤0.01) illustrates a significant concordance between the prediction scores from SIFT and 
PolyPhen algorithms. Among 63 functionally characterized nsSNPs in the UGTs, 24 showed 
altered enzyme expression/activities and 45 were associated with disease susceptibility. 
Results showed that SIFT and PolyPhen are good prediction tools with correct prediction 
rates of 57.1% and 66.7%, respectively. Using this method, we can screen for polymorphisms 
of various genes that may potentially cause disease and increase drug toxicity.  
 
Further to this, we used PANTHER to classify human therapeutic targets of RA and NIDDM. 
RA and NIDDM are two common diseases that have high prevalence and affect quality of life 
for patients. Current drug therapies offer symptomatic relief but does not alter the progressive 
nature of the diseases. Side effects associated with current RA and NIDDM therapies are also 
concerning. Thus more effective drugs with improved safety profiles are required. These 
studies identified which classes of molecular targets are most targeted by current medications 
for the 2 conditions. In our literature search, we found 95 confirmed human therapeutic 
targets in RA. Overall, the most targeted proteins include tumor necrosis factor receptor 
superfamily member 1B (TNFRSF1B), T-lymphocyte activation antigens CD80 and CD86 
and few low affinity immunoglobulin Fc region receptors (FCGRs), namely I (FCGR1A), II-a 
(FCGR2A), II-b (FCGR2B), II-c (FCGR2C), IIIA (FCGR3A) and III-B (FCGR3B). As for 
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NIDDM, we found 38 confirmed therapeutic targets in humans. The most commonly targets 
includes molecular targets from classifications of nuclear hormone receptors and nucleic acid 
binding (PPARA, PPARD, PPARG, RXRA), transcription factors (PPARA, PPARD, 
PPARG), voltage gated potassium channel (KCNJ1, KCNJ5, KCNJ11), glucosidase (GAA, 
MGAM, SI), G-protein coupled receptor (PTG1R, GCGR, GLP1R) and non-receptor 
serine/threonine protein kinase (PRKAA1, GSK3A, PRKCB1). The results from these studies 
give us a focus on chief target classes and can be useful in the future to identify new 
therapeutic targets. 
 
Additionally, we explored targets that are associated with herbal medicine compounds. Using 
berberine as an example, a total of 90 berberine targets in vitro were identified in our 
literature search. Using available human target data and the application of PANTHER 
software analysis, we identified major target classes of berberine according to molecular 
functions, biological processes and pathway classifications. One of the most common classes 
of molecular targets acted on by berberine is the receptor binding class. Molecular targets of 
berberine from this class  includes epidermal growth factor receptor (EGFR), vascular 
endothelial growth factor A (VEGFA), interleukin-1β (IL1B) and interleukin-6 (IL6), 
growth/differentiation factor 15 (NAG-1) and glucagon-like peptide (GLP1). Berberine has 
shown significant results in fasting blood glucose levels reduction, increase in insulin 
sensitivity and improvement in insulin resistance in vitro, in diabetic animal models and in 
diabetic patients. Further, berberine shows mechanism that current anti-diabetic drugs do not 
have. Together with target analysis and known clinical effects of berberine, the identification 
of new areas of therapeutic targets and the development of new anti-diabetic drugs using 
herbal targets may be possible. 
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Finally, we proposed to construct a database that contains comprehensive data on 
pharmaceutical drug and targets, as well as herbs, herbal compounds and their targets. The 
first step of logical design has been completed. The relationship between disease and drug, 
drug and target, target and compound, compound and herb, herb and formula, formula and 
disease has been successfully established. Current drug targets has also been extracted and 
examined. Due to time constraint, we were not able to move onto data population and 
interface design.   
 
To conclude, our studies showed a promising future for the use of bioinformatic tools in 
identifying new therapeutic targets and exploration of novel drugs. This is intended to 
improving drug efficacy and safety profiles to benefit patients.  
 
7.2 Genotype-phenotype relationship of human UGT genes 
 
Genetic variations between individuals can affect individual responses to medicines. 
Deleterious nsSNPs of the UGT genes have been reported to associate with disease 
disposition (Gilbert’s syndrome & CN syndrome) and biochemical abnormalities in 
individuals. The identification of deleterious nsSNPs relates human phenotypes to variation at 
the DNA level and links genetic and phenotypic differences in individuals. This is a very 
important step in preventing unwanted altered drug responses and is a crucial step in the 
progress towards individualised medicine and care. However, because there are vast numbers 
of SNPs deposited in the SNP databases, identification of potentially damaging nsSNPs using 
laboratory approach is expensive, time-consuming and unrealistic. On the other hand, 
predicting the phenotypic consequences of nsSNPs using algorithms in silico provides the 
potential to reduce the number of SNPs that may need to be validated in the laboratory setting 
and clinical studies. In this project, we used predictive bioinformatics tools to investigate the 
potential effect of known human UGT nsSNPs on protein function.  
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Different in silico tools apply different methods to make predictions. SIFT predicts the effect 
of an amino acid substitution on protein function according to sequence homology and the 
physical properties of amino acids. It can be applied to large numbers of proteins as it does 
not require the knowledge of protein structural or functional information but instead examines 
sequence similarity among related genes [29]. Another prediction software PolyPhen is a 
structure-sequence based amino acid substitution prediction method. It predicts whether an 
amino acid replacement to a known 3D structure is likely to destroy the hydrophobic core of a 
protein, electrostatic interactions, interactions with ligands or other important features of a 
protein [28, 114].  
 
Even though SIFT and PolyPhen employ different approaches and types of reference data for 
their predictions and different scales for scoring, in this study, there was significant 
concordance observed on functional consequences of each nsSNP prediction on human UGTs 
(Spearman’s ρ = -0.709, P≤0.01). Low scores from SIFT indicate an “intolerant” prediction, 
correlated with high scores from PolyPhen which indicates a “probably damaging” prediction. 
In addition to the concordance test, the scatter graph plotted using functional consequence 
predictions from SIFT and PolyPhen showed negative correlation between the two sets of 
scores. This correlation was further established by row percentage calculated between scores 
for each one of 247 nsSNPs predicted by SIFT and PolyPhen. The two algorithms show 
agreements at two extremes of the scores (damaging or tolerant), demonstrating a strong 
correlation in their predictions on potential effect of known human UGT nsSNPs on protein 
function. Although SIFT and PolyPhen apply different prediction methods, this study showed 
strong concordance in their prediction scores. In the future, they may be used in combination 
to improve accuracy of prediction studies.  
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We also investigated the prediction accuracy of SIFT and PolyPhen algorithms based on a 
number of site-directed mutagenesis studies of the UGT enzyme and clinical data from 
family-based and association studies. Thes studies confirmed functional effects of the UGT 
nsSNPs, including altered enzyme activities, metabolic dysfunctions or disease correlations.  
 
Using in silico prediction tools, prediction of potential deleterious nsSNPs that may be 
clinically significant can be carried out. On a broader level, this process allows us to relate 
genetic variations of important genes in our body to a phenotypic level. Also it provides the 
potential to reduce the number of SNPs that may need to be validated in the laboratory setting 
and clinical studies, saving time and resources. On a personal level, identification of 
deleterious nsSNPs related to important drug metabolising enzymes is a very important step 
in the preventing unwanted altered drug responses. The success and accuracy of predictions 
brings us one step closer towards individualised medicine and care. 
 
 
7.3 Bioinformatics studies of therapeutic targets 
 
Therapeutic targets are molecular structures in our body that react with drugs to produce 
pharmacodynamic effects. Information of various aspects of known targets including 
molecular mechanism of their binding agents and related adverse effects is useful for finding 
clues to new target identification [84]. 
 
In this project, we used a bioinformatics approach to study current therapeutic targets of RA 
and NIDDM. Bioinformatics tool PANTHER classified RA and NIDDM therapeutic targets 
according to different categories: molecular functions, biological process and pathways.  
 
Using PANTHER, the analysis of current therapeutic targets of RA showed the most popular 
targets of the current anti-rheumatic agents was inflammation by chemokine and cytokines 
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pathways. This trend is followed by current investigational targets and therapies of RA. Via 
literature search, we found that newer targets of RA that are under investigation are mostly 
chemokines and cytokines related to inflammation, these include TL1A, SIP, HMGB1, 
IRAK4 and AIF. As for NIDDM, our literature review found that current NIDDM therapies 
do not address β- cell dysfunction, which is the key driver of this condition. However, this is a 
focal point for some new anti-diabetic agents. Glucokinase activator and GLP-1 attend to 
desensitization and preservation of β-cells. Our study further demonstrated that information 
on known therapies and their targets is useful for finding clues to new targets and new 
therapies.  
 
Overall, therapeutic targets greatly assist with the molecular dissection of the mechanism of 
action of drugs. Further, knowledge on drug targets makes it possible to use disease specific 
targets to design more desirable drugs with increased specificity and efficacy. With the in-
depth knowledge of known drug targets and disease, a focused target selection that are disease 
specific increases the chance of successful new drug development. Additionally, disease 
focused target selection can ensure that time and resources are used efficiently.  
 
In recent years, herbal compounds have been source of new drugs [94]. To name a few, 
Taxol, irinotecan and topetecan were all successfully derived from plants. Therefore, we used 
PANTHER to analyse targets of berberine, an herbal compound derived from the Chinese 
herb Huang Lian. Compared to RA and NIDDM therapeutic targets, in vitro targets of 
berberine distributed across a far larger number of PANTHER classifications of molecular 
functions, biological processes and pathways. This can be an advantage in terms of drug 
discovery using berberine. Since berberine targets are involved in a wide range of molecular 
activities, in turn, can alter many pathological states of the body. Thus berberine can be 
explored for the treatment of various diseases. On the other hand, the nature of multi-targeting 
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of berberine lacks in target specificity which can become difficult for drug design. Further, 
our literature search of berberine in vitro and in vivo studies showed that it has promising anti-
cancer and anti-diabetic effects. This is encouraging for researchers who plan to explore the 
potential of berberine becoming a successful commercial drug in the future.  
  
The modern world is witness to emerging innovative technologies. In drug discovery, 
technology has taken the industry to places that were not imaginable 20 years ago. Today, the 
success of developing effective agents from plant compounds or their derivatives has shed a 
new light on target discovery. Plant compounds exhibit enormous structural diversity and 
should be  explored for its pharmacological potential [94]. Mother nature will no doubt bring 
more delightful surprises to us with her enriched natural resources.   
 
 
7.4 Innovative database construction 
 
Modern technology has allowed us to create databases that contain rich information and allow 
users to access useful data freely. Database is a space where scientists across the world can 
deposit their findings, share their knowledge, search for relevant data and retrieve useful 
information that is most relevant to their research. Databases with specific genres can be great 
tools for researchers in specific fields.  
 
Databases related to pharmaceutical drugs centrally deliver information on the drug, drug 
metabolising enzymes and drug targets. Some excellent drug databases include DrugBank, 
TTD and PDTD. Herbal databases are emerging gradually as a result of its widespread use.  
 
Our study aimed to develop an innovative database that contains comprehensive data on drugs 
and targets, herbs, herbal compounds and relevant targets. After logical design, the 
relationship between disease and drug, drug and target, target and compound, compound and 
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herb, herb and formula, formula and disease has been successfully established. This ensures 
the possibility of combining this information into one refined database for future research. 
 
The future completion of this database has the potential to establish a link between herbal 
targets and drug targets. This may assist in the understanding of some clinical herb-drug 
interactions and also help discovery of  new target classes from herbal targets.  
 
 
7.5 Limitations of this study  
 
Bioinformatics studies offer to bring researchers convenience to data access, retrieval and 
analysis. However, these studies rely heavily on available data. Therefore, quality of data in 
databases is very important. If the quality of data is poor, then the interpretation and analysis 
of the data will be poor and hence any predictions or interpretation based upon the faulty data. 
In our study, we used SIFT and PolyPhen to make predictions of human UGT nsSNPs on 
protein effects. SIFT and PolyPhen rely on several different databases for SNP information, 
so polluted databases with erroneous SNP reports and bias of the data towards disease-related 
allelic variants are likely to lead to an over prediction of the number of deleterious nsSNPs 
[28]. For example, Ramensky et al. [28] compared a fraction of nsSNPs predicted to be 
damaging for HGVbase entries and found that the overall prediction rate for the category 
“Suspected” nsSNPs was 31.4%, for the category “Proven” nsSNPs was 28.9% and for 
“Proven” nsSNPs from systematic studies on healthy individual was 27.6%.  Generally 
speaking, data quality is difficult to monitor in bioinformatics and is among the most 
expensive and manual intensive aspects of database operation [105]. However, high quality 
data is crucial for predictions or interpretations; therefore, databases should ensure that only 
high quality data are deposited into the database. This should not be overlooked in future 
bioinformatic studies.  
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Further, genetic basis of any disease is often multifactorial, and the complexity of the 
biological system can not be fully reproduced by mathematical equations, hence the relevance 
of any gene, SNP or genotype cannot always be predicted based on genetics analysis alone 
[66]. For instance, programs identifying SNPs may detect base differences between the 
functional gene and a pseudogene and erroneously report these differences as SNPs in the 
function protein. Including nsSNPs erroneously mapped from pseudogenes in the SNP 
database will affect prediction accuracy on prediction tools using SNP information from these 
databases [29]. Furthermore, there are factors overlooked when the predictions occurs. SIFT 
predicts on amino acid substitution in the protein product and does not take into account 
mutations that affect transcription, translation, splicing and other possible pretranslational 
alterations [29]. As a result, erroneous predictions may arise. Therefore, although predictions 
using in silico tools can give a fair indication of SNPs that may be damaging,  results from 
prediction tools still need to be validated using mechanistic studies, animal models and 
clinical trials.  
 
In addition, bioinformatic tools have their shortcomings. Although SIFT and PolyPhen show 
their potential in reducing the number of nsSNPs for disease association studies by filtering 
nsSNPs that are most likely to be disease related, error predictions do occur. This could be 
due to poor quality data as we mentioned earlier, or false positive error predictions.  SIFT has 
a weighted false positive error of 19% and PolyPhen 9%, indicating that if all of the nsSNPs 
from dbSNP were functionally neutral,  19% or 9% would have been predicted as damaging 
by SIFT and PolyPhen, respectively [29]. Further, PANTHER classifications of proteins are 
based on published scientific evidence and evolutionary relationships [107]. Hence, 
PANTHER classifications can only be as comprehensive and accurate as published scientific 
data that it uses.  
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This study used berberine to study its herbal targets. For current bio-information on herbal 
medicines, there are also shortcomings evident. Currently, only a small number of databases 
with herbal medicine information are available. Within these databases, only limited 
information on herbal compounds and targets are presented. Quality of data is also not 
consistently reliable. Taken together, these inadequacies make it tricky to do predictions and 
analysis using bioinformatic softwares.  
 
Finally, there is an enormous amount of biological data available. For instance, in February 
2011, there were approximately 124,277,818,310 bases, from 132,015,054 reported sequences 
in Genbank. The latest release (April 2011) of GenBank contains 126,551,501,141 bases in 
135,440,924 sequence records (http://www.ncbi.nlm.nih.gov/genbank/).  A new release is 
made every 2 months and the data is updated regularly. In just 2 months period, the number of 
sequence recorded in Genbank increased by more than 2 million. Therefore, to produce timely 
analysis for future work using bioinformatic tools, it is important to keep up to date with the 
latest data.  
 
7.6 Future perspectives 
 
Our findings from this project suggest that: a) predicting the phenotypic consequence of 
nsSNPs in human UGTs using computational algorithms may provide further understanding 
of genetic differences in susceptibility to diseases and drug response and would be useful to 
guide the direction of future genotype-phenotype studies; and b) target studies using 
bioinformatics approach can show the focus of current targets and give directions for future 
exploring of targets. This process can reduce the time and cost for the drug discovery process. 
Further benchmarking studies are warranted to verify our prediction data for UGTs; to explore 
new targets; to translate this knowledge into drug development setting.  
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In the future, data collected on human biological, genetic, metabolic information can be 
incorporated to benefit the future development of personalised medicine and individualised 
therapy. Further, valuable data and bioinformatic tools can be useful in terms of drug target 
identification and ADR predictions. Additionaly, improvements on data quality and 
availability of herbal targets surely will increase the value of herbal targets which may 
contribute significantly to the drug development process. Improvements in quality of data and 
bioinformatic tools will allow more accurate predictions and interpretations in the future. This 
will reduce the likelihood of toxicity and drug candidate failure. Hence, producing effective 
and safe new drug products in a timely manner, this will in turn benefit patients and the 
society. Bioinformatics is developing at a rapid pace, and we watch with anticipation and 
excitement as technology tranforms and advances the art of science as we know it.  
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Supplementary Table 1. Predictions scores from SIFT and PolyPhen for UGTs. 
 
 
MW (Da) 
No. of 
amino 
acids Source ID 
SNP position 
in gene 
AA 
Position WT  MT 
SIFT 
Score 
SIFT 
Prediction 
PolyPhen(PSIC 
Score)  PolyPhen Prediction 
59591 533 SWISS:VAR_019410 44T>G 15 Leu Arg 0.16 Tolerated no score Benign 
59591 533 SWISS:VAR_026134 111C>A 34 Pro Gln 0 Deleterious 2.803 Prob Damaging 
59591 533 SWISS:VAR_026135 115C>G 39 His Asp 0.01 Deleterious 3.673 Prob Damaging 
59591 533 - 118T>C 40 Trp Arg 0.14 Tolerated 4.05 Prob Damaging 
59591 533 rs4148323 211(G>A) 70 Gly Arg 0.1 Tolerated 1.285 Benign 
59591 533 SWISS:VAR_026136 247T>C 83 Phe Leu 0.58 Tolerated 0.863 Benign 
59591 533 - 476T>C 159 Ile            Thr 0.2 Tolerated 1.46 Benign 
59591 533 SWISS:VAR_019411 524T>A 175 Leu Gln 0.1 Tolerated 1.547 Poss Damaging 
59591 533 SWISS:VAR_007697 529T>C 177 Cys Arg 0.14 Tolerated 2.739 Prob Damaging 
59591 533 - 554A>C 185 Gln       Pro 0.013 Deleterious 1.535 Poss Damaging 
59591 533 SWISS:VAR_007698 625C>T 209 Arg Trp 0 Deleterious 3.408 Prob Damaging 
59591 533 SWISS:VAR_026137 674T>G 225 Val Gly 0.31 Tolerated 0.123 Benign 
59591 533 SWISS:VAR_009505 686C>A 229 Pro Gln 0.3 Tolerated 0.759 Benign 
59591 533 rs57307513  763T>C 250 Ser Pro 0.22 Tolerated 0.09 Benign 
59591 533 SWISS:VAR_007699 826G>C 276 Gly Arg 0 Deleterious 2.6 Prob Damaging 
59591 533 SWISS:VAR_026138  - 291 Glu Val 0 Deleterious 2.766 Prob Damaging 
59591 533 SWISS:VAR_007700  872C>T 292 Ala Val 0.13 Tolerated 1.465 Benign 
59591 533 SWISS:VAR_026139 881T>C 294 Ile Thr 0 Deleterious 1.839 Poss Damaging 
59591 533 SWISS:VAR_007701 923G>A 308 Gly Glu 0 Deleterious 2.946 Prob Damaging 
59591 533 - 928A>G 310 Met Val 0.52 Tolerated 1.956 Poss Damaging 
59591 533 - 962C>G 321 Ala       Gly 0.37 Tolerated 1.051 Benign 
59591 533 rs17851756 980T>C 322 Ile Thr 0.01 Deleterious 2.067 Prob Damaging 
59591 533 SWISS:VAR_007702 991C>T 331 Gln Arg 0 Deleterious 2.814 Prob Damaging 
59591 533 SWISS:VAR_026140 1007G>T 336 Arg Leu 0 Deleterious 3.03 Prob Damaging 
59591 533 SWISS:VAR_026141 1007G>A 336 Arg Gln 0.11 Tolerated 1.445 Benign 
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59591 533 SWISS:VAR_026142 1006C>T 336 Arg Trp 0 Deleterious 3.235 Prob Damaging 
59591 533 SWISS:VAR_026143 1060T>C 354 Trp Arg 0 Deleterious 4.753 Prob Damaging 
59591 533 SWISS:VAR_007703 1069C>T 357 Gln Arg 0.01 Deleterious 2.105 Prob Damaging 
59591 533 - 1075G>A 359 Asp       Asn 0.05 Tolerated 2.45 Prob Damaging 
59591 533 rs34946978 1091C>T 364 Pro           Leu 0.01 Deleterious 3.219 Prob Damaging 
59591 533 SWISS:VAR_012283 1099C>G 367 Arg Gly 0 Deleterious 2.94 Prob Damaging 
59591 533 SWISS:VAR_007704 
Ala368Thr/ 
1102G>A 368 Ser Thr 0.01 Deleterious 1.957 Prob Damaging 
59591 533 SWISS:VAR_007705 1124C>T 375 Ser Phe 0.02 Deleterious 1.949 Poss Damaging 
59591 533 SWISS:VAR_026144 1127A>G 376 His Arg 0.01 Deleterious 2.669 Prob Damaging 
59591 533 SWISS:VAR_026145 1130G>T 377 Gly Val 0 Deleterious 2.847 Prob Damaging 
59591 533 SWISS:VAR_007706 1143C>G 381 Ser Arg 0.01 Deleterious 1.507 Poss Damaging 
59591 533 SWISS:VAR_026146 1159C>T 387 Pro Ser 0 Deleterious 3.158 Prob Damaging 
59591 533 SWISS:VAR_026147 1184G>T 395 Gly Val 0.01 Deleterious 2.292 Prob Damaging 
59591 533 SWISS:VAR_019412 1213A>G 400 Asn Asp 0.01 Deleterious 2.623 Prob Damaging 
59591 533 SWISS:VAR_007707 1201G>C 401 Ala Pro 0.02 Deleterious 1.92 Poss Damaging 
59591 533 SWISS:VAR_026148 1207C>T 403 Arg Cys 0 Deleterious 2.92 Prob Damaging 
59591 533 rs36076514  1246G>T 411 Val Leu 0.62 Tolerated 0.737 Benign 
59591 533 SWISS:VAR_007708 
Lys426Glu/ 
1282A>G 428 Lys Glu 0.09 Tolerated 1.124 Benign 
59591 533  1292T>C 431 Ile Thr 0.26 Tolerated 1.42 Benign 
59591 533 SWISS:VAR_026149 1381T>C 461 Trp Arg 0 Deleterious 4.657 Prob Damaging 
59591 533  1388A>C 463 Glu Ala 0 Deleterious 2.702 Prob Damaging 
59591 533 SWISS:VAR_026150 1433C>A 478 Ala Asp 0 Deleterious 2.149 Prob Damaging 
59591 533 SWISS:VAR_007709 1456(T>G) 486 Tyr Asp 0 Deleterious 3.39 Prob Damaging 
59591 533 - 1477G>C 493 Gly Arg 0.23 Tolerated 2.086 Prob Damaging 
59591 533 - 1487T>A 496 Leu Asn 0.01 Deleterious 2.375 Prob Damaging 
59591 533 rs1042709 1546G>C 510 Ala Pro 0.11 Tolerated 1.593 Poss Damaging 
60338 534 rs28898617 17A>G 5 Gln Arg 0.65 Tolerated 0.145 Benign 
60338 534 rs3821242  31T>C 10 Trp Arg 0.6 Tolerated 0.6 Benign 
60338 534 rs45625338 133C>T 45 Arg Trp 0.01 Deleterious 2.078 Prob Damaging 
60338 534 rs6431625  140T>C 46 Val Ala 0.1 Tolerated 0.726 Benign 
60338 534 rs45595237 145C>T 49 Arg Trp 0 Deleterious 2.083 Prob Damaging 
60338 534 rs28898618 233C>T 77 Thr Ile 0.22 Tolerated 1.155 Benign 
60338 534    110 Phe Ile 0.39 Tolerated 0.804 Benign 
60338 534 rs28898619 342G>A 113 Met Ile 0.42 Tolerated 1.173 Benign 
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60338 534 rs13406898 431C>T 143 Thr Ile 0.02 Deleterious 0.107 Benign 
60338 534  473C>T 158 Ala Val 0.51 Tolerated 1.223 Benign 
60338 534 rs45547931 676G>A 226 Ala Thr 0.39 Tolerated 0.543 Benign 
60338 534 rs28898620 782T>C 260 Phe Ser 0.4 Tolerated 3.031 Prob Damaging 
60338 534 rs45449995 808A>G 270 Met Val 0.61 Tolerated 1.927 Poss Damaging 
60338 534 rs17851756 968T>C 322 Ile Thr 0.01 Deleterious 2.067 Prob Damaging 
60338 534 rs34946978 1094C>T 365 Pro Leu 0.01 Deleterious 3.187 Prob Damaging 
60338 534 rs55750087 1102C>G 368 Arg Gly 0.01 Deleterious 2.92 Prob Damaging 
60338 534 rs28934877   400 Asn Asp 0.01 Deleterious 2.211 Prob Damaging 
60338 534 rs36076514 1234G>T 412 Val Leu 0.59 Tolerated 0.583 Benign 
60338 534 rs34993780 1459T>G 487 Tyr Asp 0.01 Deleterious 3.342 Prob Damaging 
60338 534 rs1042709 1534G>C 511 Ala Pro 0.11 Tolerated 1.593 Poss Damaging 
60025 534 rs6755571 70C>A 24 Pro Thr 0.58 Tolerated 2.3 Prob Damaging 
60025 534 - 142T>G 48 Leu Val 1 Tolerated 0.072 Benign 
60025 534 rs45510694  179G>C 50 Glu Asp 0.47 Tolerated 1.405 Benign 
60025 534 rs45621441  231C>T 68 His Tyr 1 Tolerated 0.322 Benign 
60025 534 SWISS:VAR_009506   132 Leu Pro 0.11 Tolerated 2.388 Prob Damaging 
60025 534 rs45540231  555A>T 176 Ile Phe 0.7 Tolerated 0.046 Benign 
60025 534 SWISS:VAR_007710   332 Gln Arg 0.27 Tolerated 2.732 Prob Damaging 
60025 534 rs34946978  1123C>T 365 Pro Leu 0.01 Deleterious 3.187 Prob Damaging 
60025 534 rs55750087 1131C>G 368 Arg Gly 0.01 Deleterious 2.878 Prob Damaging 
60025 534 SWISS:VAR_007711   376 Ser Phe 0.56 Tolerated 1.926 Poss Damaging 
60025 534 rs36076514 1263G>T 412 Val Leu 0.62 Tolerated 0.65 Benign 
60025 534 SWISS:VAR_009507 1488T>G 487 Tyr Asp 0.00 Deleterious 3.355 Poss Damaging 
60071 534 rs45441297  127A>G 43 Ser Gly 0.38 Tolerated 0.366 Benign 
60071 534 rs3755323 143T>C 47 Leu Ser 0.02 Deleterious 0.885 Benign 
60071 534 rs41270755 145C>T 49 Arg Trp 0 Deleterious 1.923 Poss Damaging 
60071 534 rs3755322 150C>G 50 
       
Asp         Glu 1 Tolerated 1.40 Benign 
60071 534  rs28898602 182T>A 60 Leu His 0.00 Deleterious 2.194 Prob Damaging 
60071 534  rs3755321 188T>C 62 Leu Pro 1 Tolerated 1.794 Poss Damaging 
60071 534  rs17874940 219C>A 72 Asn Lys 0.91 Tolerated 0.173 Benign 
60071 534  rs28946880 296C>T 98 Ser Leu 0.24 Tolerated 0.411 Benign 
60071 534  rs17864694 316C>T 105 Leu Phe 0.8 Tolerated 0.704 Benign 
60071 534  rs28946881 323T>A 107 Met Lys 0.94 Tolerated 0.311 Benign 
60071 534  rs28946882 326A>C 108 Lys Thr 0.56 Tolerated 0.022 Benign 
  291 
60071 534  rs17864695 335G>A 111 Arg Lys 0.95 Tolerated 0.203 Benign 
60071 534  rs28946883 339A>T 112 Arg Ser 0.84 Tolerated 0.54 Benign 
60071 534  rs28946884 349A>T 116 Met Leu 0.88 Tolerated 0.266 Benign 
60071 534  rs3755320 424C>A 141 His Asn 0.31 Tolerated 0.132 Benign 
60071 534  rs28946885 430A>T 143 Thr Ser 0.76 Tolerated 0.893 Benign 
60071 534  rs12475068  473C>G 157 Ala Gly 1 Tolerated 1.137 Benign 
60071 534  rs17862867 673C>T 224 His Tyr 0.27 Tolerated 0.831 Benign 
60071 534  rs28946887 722G>C 240 Arg Thr 0.61 Tolerated 0.729 Benign 
60071 534  rs2012736 742C>A 247 Leu Ile 0.54 Tolerated 0.058 Benign 
60071 534  rs17862868  745G>C 248 Val Leu 1 Tolerated 0.75 Benign 
60071 534  rs3892170 776G>C 258 Gly Arg 0.09 Tolerated 0.134 Benign 
60071 534  rs17851756 968T>C 322 Ile Thr 0.01 Deleterious 2.067 Prob Damaging 
60071 534  rs28934877   400 Asn Asp 0.01 Deleterious 2.211 Prob Damaging 
60071 534  rs1042709 1534G>C 511 Ala Pro 0.11 Tolerated 1.593 Poss Damaging 
60751 532  rs6759892 19T>G 6 Ser Ala 1 Tolerated 0.302 Benign 
60751 532 rs45547342  203G>T 22 Gly Cys 0.09 Tolerated 0.418 Benign 
60751 532  rs1042708 348C>A 69 Ser Tyr 0.01 Deleterious 1.963 Poss Damaging 
60751 532  rs2070959  541A>G 180 Thr Ala 0.69 Tolerated 0.6 Benign 
60751 532  rs1105879  552A>C 183 Arg Ser 0.12 Tolerated 1.119 Benign 
60751 532  rs17851756 1101T>C 320 Ile Thr 0.01 Deleterious 2.067 Prob Damaging 
60751 532  rs28934877   398 Asn Asp 0.01 Deleterious 2.211 Prob Damaging 
60751 532 rs34993780  1592T>G 485 Tyr Asp 0 Deleterious 3.426 Prob Damaging 
60751 532  rs1042709 1667G>C 509 Ala Pro 0.11 Tolerated 1.593 Poss Damaging 
59819 530  rs1042581   68 Arg Lys 0.37 Tolerated 0.215 Benign 
59819 530 rs45437497  274G>A 92 Val Ile 0.29 Tolerated 0.393 Benign 
59819 530 - 343G>A 115 Gly Ser 0.74 Tolerated 0.268 Benign 
59819 530  rs17868323 387T>G 128 Asn Lys 0.96 Tolerated 0.146 Benign 
59819 530  rs17868324   130 Arg Gln 0.28 Tolerated 0.324 Benign 
59819 530 SWISS:VAR_015557 392G>A 131 Arg Lys 1 Tolerated 0.723 Benign 
59819 530 - 417G>C 139 Glu Asp 0.59 Tolerated 0.318 Benign 
59819 530  rs1042594   169 Ala Thr 0.28 Tolerated 0.037 Benign 
59819 530 rs1042595  - 173 Phe Val 0.49 Tolerated 0.879 Benign 
59819 530  rs11692021  622T>C 207 Trp Arg 0.39 Tolerated 1.199 Benign 
59819 530  rs28969713   231 Ser Thr 0.45 Tolerated 0.629 Benign 
59819 530  rs17851756 956T>C 318 Ile Thr 0.01 Deleterious 2.067 Prob Damaging 
59819 530  rs28934877   396 Asn Asp 0.01 Deleterious 2.211 Prob Damaging 
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59819 530  rs1042709 1522G>C 507 Ala Pro 0.11 Tolerated 1.593 Poss Damaging 
59742 530  rs1126783 107C>G 14 Ser Cys 0.35 Tolerated 1.45 Benign 
59742 530 rs45504099  220C>A 53 His Asn 0.03 Deleterious 2.67 Prob Damaging 
59742 530  rs1042581   67 Lys Arg 0.37 Tolerated 0.215 Benign 
59742 530  rs1126785 346G>C 94 Asp         His 0.47 Tolerated 0.401 Benign 
59742 530  rs1126788 376T>A 104 Leu Met 0.35 Tolerated 0.693 Benign 
59742 530  rs1126792 390T>A 108 Phe Leu 1 Tolerated 0.062 Benign 
59742 530  rs1126793 391C>A 109 Leu Met 0.27 Tolerated 1.058 Benign 
59742 530  rs1126798 415A>G 117 Asn Asp 0.69 Tolerated 0.143 Benign 
59742 530 SWISS:VAR_015543   132 Lys Arg 0.25 Tolerated 1.598 Poss Damaging 
59742 530  rs17862841 494C>T 143 Ala Val 1 Tolerated 0.204 Benign 
59742 530  rs1042593 517G>A 151 Ala Thr 0.36 Tolerated 0.189 Benign 
59742 530 SWISS:VAR_015544   154 Gly Ala 0.05 Tolerated 1.039 Benign 
59742 530  rs1042594   168 Ala Thr 0.28 Tolerated 0.037 Benign 
59742 530  rs1042597  581C>G 172 Ala Gly 0.05 Tolerated 0.016 Benign 
59742 530  rs1042597 581C>T 172 Ala Val 0.8 Tolerated 0.016 Benign 
59742 530 SWISS:VAR_015546   202 Thr Ala 0.01 Deleterious 1.642 Poss Damaging 
59742 530  rs1126802 685C>T 207 Arg Trp 0.2 Tolerated 1.193 Benign 
59742 530  rs1126803 697A>G 211 Met Val 0.57 Tolerated 1.148 Benign 
59742 530 SWISS:VAR_015547   212 Met Leu 0.61 Tolerated 1.263 Benign 
59742 530  rs1126804 711A>C 215 Glu Asp 0.52 Tolerated 1.048 Benign 
59742 530 rs45568432 745C>A 228 Leu Ile 0.21 Tolerated 0.206 Benign 
59742 530  rs17863762 893G>A 276 Cys Tyr 0 Deleterious 3.706 Prob Damaging 
59742 530  rs17851756 1019T>C 318 Ile Thr 0.01 Deleterious 2.067 Prob Damaging 
59742 530 rs34946978  1145C>T 361 Pro Leu 0.01 Deleterious 3.2 Prob Damaging 
59742 530 rs55750087  1153C>G 364 Arg Gly 0.02 Deleterious 2.94 Prob Damaging 
59742 530  rs28934877   396 Asn Asp 0.01 Deleterious 2.211 Prob Damaging 
59742 530 rs36076514  1285C>T 408 Val Leu 0.66 Tolerated 0.686 Benign 
59742 530 rs34993780  1510T>G 483 Tyr Asp 0 Deleterious 3.491 Prob Damaging 
59742 530  rs1042709 1585G>C 507 Ala Pro 0.11 Tolerated 1.593 Poss Damaging 
59941 530 - 98T>C 33 Met Thr 1 Tolerated 1.074 Benign 
59941 530  rs28946876 424A>T 128 Lys Asn 0.53 Tolerated 0.168 Benign 
59941 530 - 803G>A 256 Asp         Asn 0.61 Tolerated 0.994 Benign 
59941 530  rs4663870 831T>A 264 Val Glu 0.01 Deleterious 1.91 Poss Damaging 
59941 530  rs17851756 993T>C 318 Ile Thr 0.01 Deleterious 2.067 Prob Damaging 
59941 530 rs34946978 1119C>T 361 Pro          Leu 0.02 Deleterious 3.128 Prob Damaging 
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59941 530 rs55750087 1127C>G 364 Arg           Gly 0.03 Deleterious 2.894 Prob Damaging 
59941 530  rs28934877   396 Asn Asp 0.01 Deleterious 2.211 Prob Damaging 
59941 530 rs36076514 1259G>T 408 Val Leu 0.63 Tolerated 0.755 Benign 
59941 530 rs34993780 1484T>G 483 
   
Tyr         Asp 0 Deleterious 3.426 Prob Damaging 
59941 530  rs1042709 1559G>C 507 Ala Pro 0.11 Tolerated 1.593 Poss Damaging 
59810 530 SWISS:VAR_018354 177G>A 59 Met Ile 0.28 Tolerated 0.021 Benign 
59810 530  rs28969679 303A>T 85 Gln Leu 0.71 Tolerated 0.344 Benign 
59810 530  rs28969680 321T>A 91 Val Asp 0.22 Tolerated 0.037 Benign 
59810 530  rs28969681 329C>G 94 His Asp 0.64 Tolerated 0.401 Benign 
59810 530 rs45538634  351C>T 102 Ala Val 0.64 Tolerated 0.009 Benign 
59810 530 rs45473304  354A>G 103 Gln Arg 0.69 Tolerated 0.531 Benign 
59810 530 rs45484192  359A>T 105 Ile Leu 0.60 Tolerated 0.013 Benign 
59810 530 rs45618733  373A>T 109 Leu Phe 0.69 Tolerated 0.37 Benign 
59810 530  rs28969682 374A>C 110 Met Leu 0.68 Tolerated 1.058 Benign 
59810 530  rs28969683 387G>A 113 Ser Asn 0.59 Tolerated 0.601 Benign 
59810 530 rs45507501  395C>T 117 Leu Phe 0.75 Tolerated 0.713 Benign 
59810 530 rs45458396  398G>A 118 Asp Asn 0.5 Tolerated 0.197 Benign 
59810 530  rs10187694  461G>A 138 Glu Lys 0.19 Tolerated 0.881 Benign 
59810 530 SWISS:VAR_018355 605C>T 202 Thr Ile 0.03 Deleterious 1.377 Benign 
59810 530 - 622T>C 211 Ile Thr 0.02 Deleterious 2.003 Prob Damaging 
59810 530 rs45563247  759C>T 238 Pro Leu 0.30 Tolerated 2.662 Prob Damaging 
59810 530  rs28969685  730C>A 243 Leu Ile 0.14 Tolerated 0.188 Benign 
59810 530 rs45574333  810C>T 255 Thr Met 0.11 Tolerated 0.232 Benign 
59810 530  rs17851756 1002T>C 318 Ile Thr 0.02 Deleterious 2.067 Prob Damaging 
59810 530 rs34946978  1128C>T 361 Pro Leu 0.01 Deleterious 3.224 Prob Damaging 
59810 530 rs55750087  1136C>G 364 Arg Gly 0.01 Deleterious 2.88 Prob Damaging 
59810 530  rs28934877   396 Asn Asp 0.01 Deleterious 2.211 Prob Damaging 
59810 530 rs36076514  1268C>T 408 Val Leu 0.51 Tolerated 0.686 Benign 
59810 530 rs34993780  1493T>G 483 Tyr Asp 0 Deleterious 3.462 Prob Damaging 
59810 530  rs1042709 1568G>C 507 Ala Pro 0.11 Tolerated 1.593 Poss Damaging 
59872 527  rs1347046 287G>A 74 Arg Lys 0.38 Tolerated 1.107 Benign 
59872 527 rs55864295  625T>C 188 Tyr His 0.25 Tolerated 1.13 Benign 
59872 527 rs41292307  653T>C 197 Leu Ser 0.34 Tolerated 0.78 Benign 
59872 527  rs4148301 985G>A 307 Gly Arg 0 Deleterious 2.285 Prob Damaging 
59872 527  rs4148304 1234G>A 390 Val Ile 0.99 Tolerated  0.378 Benign 
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 528 rs28404221 173C>T 58 Ala                    Val 0.46 Tolerated 0.134 Benign 
 528 rs4148301 925G>A 309 Gly Arg 0 Deleterious 2.69 Prob Damaging 
 528 rs4148304 1174G>A 392 Val Ile 1 Tolerated 0.507 Benign 
60284 527  rs13128286 1515G>A 496 Ala Thr 0.36 Tolerated 0.127 Benign 
60513 528 rs41299974 167G>C 40 Lys       Asn 0.34 Tolerated 0.655 Benign 
60513 528 rs41299976 279C>A 78 Pro       Thr 0.46 Tolerated 1.23 Benign 
60513 528 rs41299978 285T>C 80 Ser Pro 0.59 Tolerated 0.166 Benign 
60513 528 SWISS:VAR_011328 325T>C 109 Phe Leu 0.64 Tolerated 0.902 Benign 
60513 528 rs41300004 876G>A 277 Val Ile 0.92 Tolerated 0.252 Benign 
60513 528 SWISS:VAR_011329   396 Phe Leu 0.01 Deleterious 1.522 Poss Damaging 
60513 528  rs13119049 1421T>A 457 Asp Glu 0 Deleterious 1.836 Poss Damaging 
60513 528 SWISS:VAR_007712 1422C>A 458 Asp Glu 0.02 Deleterious 0.951 Benign 
60513 528 rs41298245  1578T>C 511 Cys Arg 0.03 Deleterious 2.765 Prob Damaging 
60695 529 rs58632287 136C>T 41 Thr Ile 0.24 Tolerated 0.172 Benign 
60695 529 rs61361928 151T>C 46 Leu      Pro 0 Deleterious 2.913 Prob Damaging 
60695 529  rs12233719 225G>T 70 Ala Ser 0.74 Tolerated 0.346 Benign 
60695 529 rs61154511 228C>T 72 Leu     Phe 0.7 Tolerated 0.37 Benign 
60695 529 rs60103519  552C>T 179 Thr Ile 0.23 Tolerated 0.542 Benign 
60695 529  rs7439366 816T>C 267 
       
Tyr         His 0.07 Tolerated 1.296 Benign 
60695 529 rs34620993 910C>T 299 Ser Phe 0 Deleterious 1.708 Prob Damaging 
60695 529 rs35590824 1147A>G 378 Asn Ser 0.48 Tolerated 1.847 Poss Damaging 
60695 529 rs34308305 1240G>A 409 Arg     Lys 0.36 Tolerated 0.079 Benign 
60695 529 rs34851008 1302A>C 430 Lys      Gln 0.49 Tolerated 0.855 Benign 
60774 528  199G>T 67 Asp       Tyr 0.08 Tolerated 0.524 Benign 
60774 528  rs1976666 856C>G 282 Pro Ala 0.12 Tolerated 2.558 Prob Damaging 
60774 528  rs4095564 1153G>A 381 Ala Thr 0.02 Deleterious 1.835 Poss Damaging 
60774 528 rs13111837  - 399 Pro       Ser 0.4 Tolerated 1.603 Poss Damaging 
60774 528 rs13118363  - 410 Ala       Thr 0.11 Tolerated 0.755 Benign 
60774 528 rs3208727 1502T>C 497 Leu       Pro 0.01 Deleterious 2.407 Prob Damaging 
61038 529  rs7697482   69 Ser Pro 0.2 Tolerated 0.001 Benign 
61038 529  rs7688262 311G>A 100 Arg Gln 0.47 Tolerated 0.479 Benign 
61038 529  rs7697037 475T>C 155 Cys Arg 0 Deleterious 3.977 Prob Damaging 
61038 529  rs3890590 875C>T 288 Pro Leu 0.01 Deleterious 2.102 Prob Damaging 
61038 529 rs11936018 -  367 Lys       Ile 0.01 Deleterious 2.799 Prob Damaging 
61038 529  - 458 Asp Glu 0.65 Tolerated 1.228 Benign 
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60988 530  rs1902023 291T>G 84 Try Asp 0.08 Tolerated 0.299 Benign 
60988 530  rs4148269 1606A>C 522 Lys Thr 0.32 Tolerated 0.157 Benign 
60906 529  rs4235127 1096T>A 364 Leu His 1 Tolerated 2.761 Prob Damaging 
60906 529 rs41292949 1324A>G 441 Asn Ser 0.24 Tolerated 1.434 Benign 
60906 529  rs6843900 1342T>G 446 Ile Arg 0.68 Tolerated 1.565 Poss Damaging 
60906 529  rs6828191 1374C>G 457 His Asp 1 Tolerated 0.799 Benign 
60906 529 rs45582032 1534T>G 511 Phe       Cys 1 Tolerated 1.127 Benign 
59151 523  rs3756669 518T>G 120 Cys Gly 0.1 Tolerated 4.163 Prob Damaging 
59547 523  rs2197514 313T>A 74 
       
Tyr         Asn 0.09 Tolerated 1.793 Poss Damaging 
59547 523  rs2591714 1123G>A 343 Ala Thr 0.04 Deleterious 1.576 Poss Damaging 
61456 541  rs4148254 1191C>T 226 Pro Leu 0.32 Tolerated 1.455 Benign 
61456 541  rs11098261 1618A>G 368 Ile        Met 1 Tolerated 0.745 Benign 
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Supplementary Table 2. Comprehensive list of current drug targets 
 
 [Citrate [pro-3S]-lyase] ligase Cysteine dioxygenase type 1  Integrin β-2  Probable glutamyl-tRNA 
1,3-β-Glucan synthase   Cysteine sulfinic acid decarboxylase Integrin β-3  
Probable glutamyl-tRNA synthetase, 
mitochondrial  
10-Formyltetrahydrofolate dehydrogenase 
Cysteine sulfinic acid decarboxylase-related 
protein 1  Integrin-linked kinase 
Probable leucyl-tRNA synthetase, 
mitochondrial  
11-cis-Retinol dehydrogenase  Cysteinyl leukotriene receptor 1  Intercellular adhesion molecule 1  
Probable low molecular weight protein-
tyrosine-phosphatase epsP  
14-3-3 protein zeta/delta /14-3-3 θ isoform  
(A,B,C,D) Cysteinyl leukotriene receptor 2  Interferon-γ Probable phospholipid-transporting ATPase IA  
15-Hydroxyprostaglandin dehydrogenase 
[NAD+]  Cysteinyl-tRNA synthetase, cytoplasmic  Interferon-α β receptor α chain  
Probable prolyl-tRNA synthetase, 
mitochondrial  
16S rRNA   
Cystic fibrosis transmembrane conductance 
regulator  Interferon-α β receptor β chain  Probable pyruvate-flavodoxin oxidoreductase  
17 α-Hydroxylase-C17, 20-lyase   Cystine glutamate transporter  Interferon-γ receptor alpha chain  
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 1  
17-β-Hydroxysteroid-Dehydrogenase Type 1 Cystinosin  Interferon-γ receptor beta chain  
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 2  
1-deoxy-D-xylulose-5-phosphate 
reductoisomerase   Cytidine deaminase Interleukin-1   
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 3  
23S rRNA   Cytochrome b  Interleukin-1β Pro-epidermal growth factor  
23S rRNA methylase leader peptide Cytochrome b5  Interleukin-1 receptor type I  Progesterone receptor  
25-Hydroxyvitamin D-1α hydroxylase, 
mitochondrial  Cytochrome c  Interleukin-1 receptor type II  Prolactin receptor  
26S Proteasome non-ATPase regulatory 
subunit 1  Cytochrome c oxidase subunit 1  Interleukin-10 receptor Proline oxidase, mitochondrial  
26S Proteasome non-ATPase regulatory 
subunit 2  Cytochrome P450 11B1, mitochondrial  Interleukin-11 receptor α chain  
Proline synthetase co-transcribed bacterial 
homolog protein  
28 kDa Heat- and acid-stable phosphoprotein  Cytochrome p450 121   Interleukin-2 receptor α chain Prolyl 3-hydroxylase 1  
2-Amino-3-ketobutyrate coenzyme A ligase, 
mitochondrial Cytochrome P450 17A1  Interleukin-2 receptor subunit β  Prolyl 3-hydroxylase 2  
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2-Amino-4-hydroxy-6-
hydroxymethyldihydropteridine 
pyrophosphokinase Cytochrome P450 19   Interleukin-3  Prolyl 3-hydroxylase 3  
2-Oxoglutarate and iron-dependent oxygenase 
domain containing 1  Cytochrome P450 19A1  Interleukin-3 receptor α chain  Prolyl 4-hydroxylase subunit α-1  
2-Oxoglutarate dehydrogenase E1 component, 
mitochondrial  Cytochrome P450 1B1  Interleukin-5  Prolyl 4-hydroxylase subunit α-2  
3β-Hydroxysteroid dehydrogenase Delta 5-- Cytochrome P450 27, mitochondrial  Interleukin-6  Prolyl endopeptidase  
3' Histone mRNA exonuclease 1  Cytochrome P450 2A6  Interleukin-8  
Propionyl-CoA carboxylase α chain, 
mitochondrial 
30S Ribosomal protein S10  Cytochrome P450 2B4  
Intermediate conductance calcium-activated 
potassium channel protein 4  
Propionyl-CoA carboxylase β chain, 
mitochondrial  
30S Ribosomal protein S12  Cytochrome P450 2D6  Interphotoreceptor retinoid-binding protein  Prostacyclin receptor  
30S Ribosomal protein S4  Cytochrome P450 2R1 Interstitial Collagenase Prostacyclin synthase 
30S Ribosomal protein S9  Cytochrome P450 3A3  Intestinal Glcnac-6-sulfotransferase Prostaglandin D2 receptor  
3-Hydroxy-3-methylglutaryl-coenzyme A 
reductase Cytochrome P450 3A4  Islet amyloid polypeptide  Prostaglandin E2 receptor, EP1 subtype  
3-Hydroxyacyl-CoA dehydrogenase type-2  Cytochrome P450 3A5  
Isocitrate dehydrogenase [NAD] subunit α, 
mitochondrial Prostaglandin E2 receptor, EP2 subtype  
3-Hydroxyisobutyrate dehydrogenase, 
mitochondrial Cytochrome P450 4A11  
Isocitrate dehydrogenase [NAD] subunit β, 
mitochondrial Prostaglandin E2 receptor, EP3 subtype  
3-keto-Steroid reductase  Cytochrome P450 51 
Isocitrate dehydrogenase [NAD] subunit γ, 
mitochondrial Prostaglandin E2 receptor, EP4 subtype 
3-Methyl-2-oxobutanoate dehydrogenase 
(Lipoamide) Cytochrome P450 51A1  Isoleucine-tRNA synthetase Prostaglandin F2-α receptor  
3-Oxo-5-α-steroid 4-dehydrogenase 1  Cytochrome P450-cam  Isoleucyl-tRNA synthetase Prostaglandin G H synthase 1  
3-Oxo-5-α-steroid 4-dehydrogenase 2 Cytokine receptor common β chain  Isoleucyl-tRNA synthetase, cytoplasmic  Prostaglandin G H synthase 2  
3-Oxoacyl-[acyl-carrier-protein] synthase 1  Cytokine receptor common γ chain  Isoleucyl-tRNA synthetase, mitochondrial  Prostatic acid phosphatase 
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3-Oxoacyl-[acyl-carrier-protein] synthase 2 Cytosolic phospholipase A2 Itk tyrosine kinase Protachykinin 1  
3-Oxoacyl-[acyl-carrier-protein] synthase 3  Cytosolic purine 5'-nucleotidase  Jak2 tyrosine kinase Protease  
3-Phosphoinositide-dependent protein kinase 
1  D1A dopamine receptor Jak3 tyrosine kinase Proteasome subunit beta type 1  
4-Aminobutyrate aminotransferase, 
mitochondrial  D1B dopamine receptor 
Jumonji ARID domain-containing protein 
1D  Proteasome subunit beta type 2  
4-Hydroxyphenylpyruvate dioxygenase  D2 dopamine receptor Jun N-terminal kinase Proteasome subunit beta type 5  
4-Trimethylaminobutyraldehyde 
dehydrogenase  D3 dopamine receptor Kallikrein Protein arginine deiminase IV 
5,10-Methylenetetrahydrofolate reductase  D4 dopamine receptor Kallikrein-1  Protein kinase Cα type  
50S Ribosomal protein L10 
D1 dopamine receptor-interacting protein 
calcyon  Kappa-type opioid receptor Protein kinase Cβ type  
50S Ribosomal protein L22  D-3-phosphoglycerate dehydrogenase  Karyopherin beta 2 Protein NOV homolog  
50S Ribosomal protein L3 D-Alanyl--D-alanine ligase A Keratin, type II cytoskeletal 8  Protein S100-A1  
50S Ribosomal protein L4  D-Alanyl-D-alanine carboxypeptidase  KIAA0251 protein  Protein S100-A12  
5-α-Reductase   
D-β-Hydroxybutyrate dehydrogenase, 
mitochondrial  Kinesin-like protein KIF11 Protein S100-A13 
5-aminolevulinate synthase, erythroid-
specific, mitochondrial Death-associated protein kinase Kininogen-1 Protein S100-P  
5-aminolevulinate synthase, nonspecific, 
mitochondrial  
Dehydrogenase reductase SDR family 
member 4  Kit tyrosine kinase Protein tyrosine kinase 
5'-AMP-activated protein kinase catalytic 
subunit α-1  δ1-Pyrroline-5-carboxylate synthetase  Kynureninase  Protein Tyrosine Phosphatase 1b 
5'-AMP-activated protein kinase subunit β-1  
δ1-Pyrroline-5-carboxylate dehydrogenase, 
mitochondrial  
Kynurenine α-aminoadipate 
aminotransferase mitochondrial  Protein-arginine deiminase type-1  
5'-AMP-activated protein kinase subunit beta-
2 δ6-Fatty acid desaturase  Kynurenine-oxoglutarate transaminase 1  Protein-arginine deiminase type-2  
5-Hydroxytryptamine 1A receptor  δ-Aminolevulinic acid dehydratase Kynurenine-oxoglutarate transaminase 3  Protein-arginine deiminase type-3  
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5-Hydroxytryptamine 1B receptor δ-Opioid receptor  Lactotransferrin  Protein-arginine deiminase type-4  
5-Hydroxytryptamine 1D receptor  Deoxyhypusine synthase  Lactoylglutathione lyase Protein-arginine deiminase type-6  
5-Hydroxytryptamine 1E receptor  D-Glucose 6-phosphotransferase Laminin subunit α-1  Proteinase-activated receptor 1 
5-Hydroxytryptamine 1F receptor  Diacylglycerol kinase-α Laminin subunit α-3  Protein-glutamine gamma-glutamyltransferase 2  
5-Hydroxytryptamine 2 receptor   Diacylglycerol kinase-β Laminin subunit α-5  Protein-glutamine gamma-glutamyltransferase 4  
5-Hydroxytryptamine 2A receptor  Diacylglycerol kinase-δ Laminin subunit β-1  Protein-glutamine gamma-glutamyltransferase 5  
5-Hydroxytryptamine 2B receptor  Diacylglycerol kinase-γ Laminin subunit γ-1  Protein-glutamine gamma-glutamyltransferase 6  
5-Hydroxytryptamine 2C receptor  Diamine acetyltransferase 1  
Large neutral amino acids transporter small 
subunit 2  
Protein-glutamine gamma-glutamyltransferase 
E  
5-Hydroxytryptamine 3 receptor  Diamine acetyltransferase 2  Large structural protein  
Protein-glutamine gamma-glutamyltransferase 
K  
5-Hydroxytryptamine 4 receptor  Diaminopimelate decarboxylase  Lck tyrosine kinase 
Protein-glutamine gamma-glutamyltransferase 
Z  
5-Hydroxytryptamine 6 receptor  Dihydrofolate reductase  Lecithin retinol acyltransferase Prothrombin  
5-Hydroxytryptamine 7 receptor Dihydrolipoyl dehydrogenase, mitochondrial  Leucine carboxyl methyltransferase 1  Proton-coupled amino acid transporter 1  
5'-Nucleotidase  
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase 
complex, mitochondrial  Leucine carboxyl methyltransferase 2  
Proto-oncogene serine threonine-protein kinase 
Pim-1  
5-Oxoprolinase  
Dihydroorotate dehydrogenase homolog, 
mitochondrial  Leucyl-tRNA synthetase, cytoplasmic Proto-oncogene tyrosine-protein kinase ABL1  
6,7-Dimethyl-8-ribityllumazine synthase  Dihydroorotate dehydrogenase, mitochondrial  Leukocyte antigen  Proto-oncogene tyrosine-protein kinase Fyn 
72 kDa type IV collagenase Dihydropterate synthase Leukocyte elastase  Proto-oncogene tyrosine-protein kinase LCK  
73-kDa molecular chaperone HSP73   Dihydropteridine reductase  Leukotriene A4 hydrolase 
Proto-oncogene tyrosine-protein kinase receptor 
ret  
  300 
78 kDa Glucose-regulated protein  Dihydropteroate synthase  Leukotriene C4 synthase  Proto-oncogene tyrosine-protein kinase Src  
7-Dehydrocholesterol reductase  Dihydropteroate synthase 1  Lipoic acid synthetase, mitochondrial  Proto-oncogene tyrosine-protein kinase Yes  
85 kDa Calcium-independent phospholipase 
A2  Dihydropteroate synthase 2  Lipoprotein lipase  P-selectin  
A G-specific adenine glycosylase  Dihydropyrimidine dehydrogenase [NADP+] Lipoyltransferase 1, mitochondrial  P-selectin cytoplasmic tail-associated protein  
ABC transporter G family protein  
Dimethyl sulfoxide trimethylamine N-oxide 
reductase  LIR-1 Purine nucleoside phosphorylase  
Acetoin utilization protein  Dipeptidase Liver X receptor-α Purine nucleoside phosphorylase deoD-type  
Acetylcholine receptor subunit α-type unc-63  Dipeptidase 1  Liver X receptor-β Purine trans deoxyribosylase  
Acetylcholine-binding protein  Dipeptidyl peptidase 4 (DPP4) L-lactate dehydrogenase A chain  Putative HIF-prolyl hydroxylase PH-4  
Acetylcholinesterase  Discs large homolog 4  L-lactate dehydrogenase A-like 6A  Putative L-Dopa decarboxylase  
Acetyl-CoA acetyltransferase, mitochondrial 
(ACAT) Divalent-cation tolerance protein cutA  L-lactate dehydrogenase A-like 6B Putative renal organic anion transporter 1  
Acetyl-CoA carboxylase  D-lactate dehydrogenase L-lactate dehydrogenase B chain Putative selenocysteine lyase  
Acetyl-CoA carboxylase 1  DNA   L-lactate dehydrogenase C chain  Pyridoxal kinase  
Acetyl-CoA carboxylase 2 DNA (cytosine-5)-methyltransferase 1 Long-chain fatty-acid CoA ligase 1 Pyridoxal phosphate phosphatase  
Acetyl-coenzyme A synthetase 2-like, 
mitochondrial  DNA gyrase subunit A  Long-chain fatty-aci CoA ligase 3  Pyridoxine-5'-phosphate oxidase  
Acetyl-coenzyme A synthetase, cytoplasmic  DNA gyrase subunit B  Long-chain fatty-acid CoA ligase 4  Pyrin  
Acriflavine resistance protein B  DNA ligase 1  
Low affinity immunoglobulin γ Fc region 
receptor II-a  Pyrroline 5-carboxylate reductase isoform  
Actin, alpha skeletal muscle  DNA ligase 3  
Low affinity immunoglobulin gamma Fc 
region receptor II-b  Pyrroline-5-carboxylate reductase 1  
Activated Akt/protein kinase B DNA polymerase  
Low affinity immunoglobulin γ Fc region 
receptor II-c  Pyrroline-5-carboxylate reductase 2  
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Activated CDC42 kinase 1 DNA polymerase (HSV)   
Low affinity immunoglobulin γ Fc region 
receptor III-A  Pyrroline-5-carboxylate reductase-like  
Activin receptor type 1B DNA polymerase alpha catalytic subunit  
Low affinity immunoglobulin γ Fc region 
receptor III-B Pyruvate carboxylase, mitochondrial  
Activin receptor type-1  DNA polymerase-β 
Low molecular weight phosphotyrosine 
protein phosphatase  Pyruvate dehydrogenase [cytochrome]  
Acyl carrier protein, mitochondrial  DNA polymerase I  
Low-affinity cationic amino acid transporter 
2  Pyruvate dehydrogenase [NADP+]  
ADAM-33 DNA polymerase subunit α B  Low-density lipoprotein receptor 
Pyruvate dehydrogenase E1 component alpha 
subunit, somatic form, mitochondrial  
Adenine phosphoribosyltransferase DNA replication licensing factor MCM6  
Low-density lipoprotein receptor-related 
protein 1  
Pyruvate dehydrogenase E1 component 
αsubunit, testis-specific form, mitochondrial 
Adenine phosphoribosyltransferase  DNA replication licensing factor MCM7  
Low-density lipoprotein receptor-related 
protein 2 
Pyruvate dehydrogenase E1 component subunit 
β, mitochondrial  
Adenosine A1 receptor DNA topoisomerase 4 subunit A L-serine dehydratase  Pyruvate dehydrogenase kinase-2 
Adenosine A2a receptor  DNA topoisomerase I 
Lutropin-choriogonadotropic hormone 
receptor  Pyruvate kinase isozymes M1/M2 
Adenosine A2b receptor  DNA topoisomerase I, mitochondrial  Lymphotoxin-α  Pyruvate kinase isozymes R L  
Adenosine A3 receptor  DNA topoisomerase II   Lymphotoxin-β  Quinone oxidoreductase  
Adenosine deaminase  DNA topoisomerase II, alpha isozyme   lyso-PAF: acetyl-CoA acetyltransferase   Quinone reductase-2 
Adenylate cyclase type 1  DNA-(apurinic or apyrimidinic site) lyase Lysophospholipase RAC-α serine threonine-protein kinase  
Adenylate cyclase type 7 DNA-directed RNA polymerase α chain  Lysosomal α-glucosidase 
RAF proto-oncogene serine threonine-protein 
kinase  
Adenylosuccinate lyase  DNA-directed RNA polymerase β chain  Lysozyme  Ran-GPPNHP-RanBP1-RanGAP 
Adenylosuccinate synthetase  Dopamine β-hydroxylase Lysozyme C  
Ras-binding domain of the serine/threonine 
kinase C-Raf1 
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Adenylosuccinate synthetase isozyme 1  Dopamine D1 receptor   Lysyl-tRNA synthetase  Ras-Ras Gap 
Adenylosuccinate synthetase isozyme 2  Dopamine receptor   
Macrophage colony-stimulating factor 1 
receptor  Ras-related C3 botulinum toxin substrate 1  
ADP ATP translocase 1 Dopamine re-uptake   Macrophage metalloelastase  Receptor activity-modifying protein 1 
ADP ATP translocase 2 Dr hemagglutinin structural subunit  Macrophage migration inhibitory factor Receptor activity-modifying protein 2  
ADP ATP translocase 3  
Dual specificity mitogen-activated protein 
kinase kinase 7  Major prion protein  Receptor activity-modifying protein 3  
Adrenocorticotropic hormone receptor  
Ectonucleotide pyrophosphatase 
phosphodiesterase family member 1  Malate dehydrogenase Receptor tyrosine-protein kinase erbB-2 
Adrenodoxin, mitochondrial  Egl nine homolog 1  Malate dehydrogenase, cytoplasmic  Regulatory protein E2  
AFG3-like protein 1  Egl nine homolog 2  Malate dehydrogenase, mitochondrial  Renin  
AFG3-like protein 2  Egl nine homolog 3  Maleylacetoacetate isomerase RET proto-oncogene  
Alanine aminotransferase 1 
Elongation of very long chain fatty acids 
protein 4  
Malonyl-CoA:acyl carrier protein 
transacylase   Retinal dehydrogenase 1 
Alanine aminotransferase 2  
Endoplasmic reticulum-Golgi intermediate 
compartment protein 2  Maltase-glucoamylase, intestinal  Retinal dehydrogenase 2 
Alanine racemase Endoplasmin  Mannan-binding lectin serine protease-2 Retinoblastoma-associated protein  
Alanine-glyoxylate aminotransferase 2, 
mitochondrial Endosialin  Mannitol dehydrogenase  Retinoic acid receptor-α  
Alanine-glyoxylate aminotransferase 2-like 2  Endothelial protein C receptor  
Mannose-6-phosphate receptor-binding 
protein 1  Retinoic acid receptor-β  
Alanine-glyoxylate aminotransferase homolog  Endothelin B receptor  MAO B Retinoic acid receptor γ-1 
Alanyl-tRNA synthetase, cytoplasmic  Endothelin-1 receptor Map Kinase P38 Retinoic acid receptor γ-2  
Alcohol dehydrogenase 1A  
Enoyl-[acyl-carrier-protein] reductase 
[NADH]  MAPKAPK2 Retinoic acid receptor responder protein 1 
Alcohol dehydrogenase 1B  Enoyl-ACP reductase   Mast stem cell growth factor receptor  Retinoic acid receptor RXR-α 
  303 
Alcohol dehydrogenase 1C  Envelope glycoprotein  Matrilysin Retinoic acid receptor RXR-β 
Alcohol dehydrogenase 4  Envelope glycoprotein GP220  Matrix metalloproteinase-9  Retinoic acid receptor RXR-γ  
Alcohol dehydrogenase class 3  Envelope glycoprotein GP340 Matrix protein 2 Retinoic acid-induced protein 3 
Alcohol dehydrogenase class 4 mu Σ chain Enzyme Melatonin receptor type 1A  Retinoid-binding protein 7 
Alcohol dehydrogenase E chain  Eosinophil cationic protein  Melatonin receptor type 1B  Retinol dehydrogenase 11  
Aldehyde dehydrogenase 1A3 Ephrin type-A receptor 2  Memapsin 2 (β-Secretase) Retinol dehydrogenase 12 
Aldehyde dehydrogenase 3B1  Epidermal growth factor receptor Membrane copper amine oxidase  Retinol dehydrogenase 13  
Aldehyde dehydrogenase 3B2  Epididymal secretory glutathione peroxidase Metabotropic glutamate receptor 1 Retinol dehydrogenase 14  
Aldehyde dehydrogenase X, mitochondrial  
Epithelial discoidin domain-containing 
receptor 1  Metabotropic glutamate receptor 2  Retinol-binding protein I, cellular  
Aldehyde dehydrogenase, dimeric NADP-
preferring  Epoxide hydrolase 2  Metabotropic glutamate receptor 3  Retinol-binding protein II, cellular 
Aldehyde dehydrogenase, mitochondrial ERGIC-53 protein  Metabotropic glutamate receptor 4 Retinol-binding protein III, cellular 
Aldehyde Reductase Ergosterol biosynthetic protein 28  Metabotropic glutamate receptor 5  Reverse Transcriptase 
Aldo-keto reductase family 1 member C1  Erythropoietin receptor  Metabotropic glutamate receptor 7 Rhinovirus 14 (HRV14) 
Aldo-keto reductase family 1 member C2  E-selectin Metabotropic glutamate receptor 8  Rho 
Aldo-keto reductase family 1 member C3  Estradiol 17-β-dehydrogenase 1  Metalloprotease 3 Rhodopsin  
Aldo-keto reductase family 1 member C4  Estradiol 17-β-dehydrogenase 2 Metalloprotease 8 Riboflavin kinase  
Aldose reductase  Estradiol 17-β-dehydrogenase 3  Metalloproteinase  Riboflavin kinase FMN adenylyltransferase  
Aldosterone receptor   Estradiol 17-β-dehydrogenase 8  
Methionine adenosyltransferase 2 subunit 
beta  Riboflavin synthase alpha chain  
ALK tyrosine kinase receptor  Estrogen receptor  Methionine aminopeptidase Ribonuclease pancreatic  
Alkaline phosphatase, placental-like  Estrogen receptor-β Methionine aminopeptidase 2  Ribonuclease U2  
All-trans-retinol 13,14-reductase  Estrogen Sulfotransferase Methionine decarboxylase 
Ribonucleoside-diphosphate reductase large 
subunit  
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α1 Antitrypsin 
Estrogenic 17-β hydroxysteroid 
dehydrogenase Methionine synthase Ribosome-inactivating protein α-trichosanthin  
αAdrenergic receptor   Estrogen-related receptor-γ 
Methionine synthase reductase, 
mitochondrial Ribosome-inactivating protein momordin I  
α-Chain Evolved beta-galactosidase subunit-α Methionine-R-sulfoxide reductase  
Ribosyldihydronicotinamide dehydrogenase 
[quinone]  
αPlatelet-derived growth factor receptor  Excitatory amino acid transporter 1  Methionine-R-sulfoxide reductase B2  Ricin  
α-1A Adrenergic receptor  Excitatory amino acid transporter 2  
Methionyl-tRNA formyltransferase, 
mitochondrial  RNA-directed DNA Polymerase 
α1-Acid glycoprotein 1  Excitatory amino acid transporter 3  Methionyl-tRNA synthetase, cytoplasmic 
RNA-directed DNA polymerase reductase 
(NADPH/NADH)   
α1B Adrenergic receptor Excitatory amino acid transporter 4  Methionyl-tRNA synthetase, mitochondrial  
RNA-directed RNA polymerase catalytic 
subunit  
α1D Adrenergic receptor Excitatory amino acid transporter 5  
Methylated-DNA-protein-cysteine 
methyltransferase  RNase P RNA   
α2A Adrenergic receptor  Extracellular calcium-sensing receptor Methyl-CpG-binding domain protein 2 ROCK I/Rho-associated protein kinase 1 
α2-Antiplasmin  Factor VIII 
Methylcrotonoyl-CoA carboxylase beta 
chain, mitochondrial Ryanodine receptor 1 
α2B Adrenergic receptor  Factor XIII 
Methylcrotonoyl-CoA carboxylase subunit 
alpha, mitochondrial  
S-adenosylmethionine decarboxylase 
proenzyme 
α2C Adrenergic receptor  Farnesoid X receptor Methylenetetrahydrofolate reductase  
S-adenosylmethionine synthetase isoform type-
1  
α2-Macroglobulin  Farnesyl diphosphate synthase  
Methylenetetrahydrofolate reductase 
intermediate form  
S-adenosylmethionine synthetase isoform type-
2  
α-Aminoadipic semialdehyde dehydrogenase Farnesyl pyrophosphate synthetase 
Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondrial  Scavenger receptor class B member 1  
α-Aminoadipic semialdehyde synthase, 
mitochondrial  Fatty acid synthase 
Methylmalonic aciduria and homocystinuria 
type C protein  SCLY protein  
α-Ketoglutarate-dependent dioxygenase alkB 
homolog 2  Fatty acid synthase subunit-β   
Methylmalonic aciduria type A protein, 
mitochondrial  SEC14-like protein 2  
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α-Ketoglutarate-dependent dioxygenase alkB 
homolog 3  Fatty acid-binding protein, brain  Methylmalonyl-CoA mutase, mitochondrial SEC14-like protein 3  
α-N-acetylglucosaminidase  Fatty aldehyde dehydrogenase  Microsomal glutathione S-transferase 1  SEC14-like protein 4  
α-Synuclein  Fatty-acid amide hydrolase  Microsomal glutathione S-transferase 2  Secretin receptor  
α-Tocopherol transfer protein Ferrichrome-iron receptor  Microsomal glutathione S-transferase 3  Seed lectin subunit I  
AMBP protein  Ferritin heavy chain  
Microsomal triglyceride transfer protein 
large subunit  Selenocysteine lyase variant  
Amidophosphoribosyltransferase  Ferritin light chain Microtubule-associated protein 1A  Sentrin specific protease-1 
Amiloride-sensitive amine oxidase [copper-
containing]  FGF-4 receptor Microtubule-associated protein 2  Serine dehydratase-like  
Amiloride-sensitive cation channel 1, 
neuronal  Fibrinogen α chain  Migration-inducing protein 4  Serine hydroxymethyltransferase 1  
Amiloride-sensitive cation channel 2, 
neuronal  
Fibrinogen β chain [Contains: Fibrinopeptide 
B]  Mineralocorticoid receptor  Serine hydroxymethyltransferase 2  
Amiloride-sensitive sodium channel subunit-α  Fibrinogen γ chain  
Mitochondrial aspartate-glutamate carrier 
protein  Serine hydroxymethyltransferase, cytosolic  
Amiloride-sensitive sodium channel subunit-β Fibroblast growth factor 4  
Mitochondrial carnitine acylcarnitine carrier 
protein Serine hydroxymethyltransferase, mitochondrial  
Amiloride-sensitive sodium channel subunit-δ Fibroblast Growth Factor Receptor 1 
Mitochondrial carnitine acylcarnitine carrier 
protein CACL Serine palmitoyltransferase 1  
Amiloride-sensitive sodium channel subunit-γ Fibroblast Growth Factor Receptor 2 Mitochondrial dicarboxylate carrier  Serine palmitoyltransferase 2 
Amine oxidase [flavin-containing] A  Fibroblast growth factor receptor 3  Mitochondrial folate transporter carrier Serine protease hepsin  
Amine oxidase [flavin-containing] B  Fibroblast growth factor receptor 4  Mitochondrial glutamate carrier 1  Serine proteinase α-thrombin 
Aminoacylase-1 Fibronectin  Mitochondrial glutamate carrier 2  Serine racemase  
Aminolevulinate, δ-, synthase 2  Fk506 binding protein (Fkbp) Mitochondrial ornithine transporter 1  Serine threonine-protein kinase ALS2CR7  
Aminomethyltransferase, mitochondrial  FK506-binding protein 1A Mitochondrial ornithine transporter 2  Serine threonine-protein kinase receptor R3  
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Aminopeptidase N  FK506-binding protein 4  Mitogen-activated protein kinase 1  Serine threonine-protein kinase SKY1  
Amnionless protein  
FKBP12-rapamycin complex-associated 
protein  Mitogen-activated protein kinase 3  
Serine threonine-protein phosphatase 2A 
catalytic subunit α isoform  
AMP deaminase 1  Fkbp-rapamycin associated protein 
Mitogen-activated protein kinase kinase 2 
(MEK2) 
Serine threonine-protein phosphatase 2A 
catalytic subunit beta isoform  
AMP deaminase 2 
FKBP-type peptidyl-prolyl cis-trans isomerase 
fkpA  MMP Serine-pyruvate aminotransferase  
AMP deaminase 3 FL cytokine receptor MMP8 Serotonin re-uptake   
AMT protein Flavin reductase  MNK2 protein kinase Serotonin transporter   
Amylase Flavodoxin  Molybdenum cofactor sulfurase  Serotransferrin  
Androgen receptor  fMet-Leu-Phe receptor  Monocarboxylate transporter 1 Serpin B6  
Angiogenin Folate receptor-β Monocarboxylate transporter 2  Serum albumin  
Angiopoietin 1 receptor Folate receptor-γ  Monocarboxylate transporter 3  Serum amyloid A protein  
Angiotensin-converting enzyme 2  
FolC bifunctional protein [Includes: 
Folylpolyglutamate synthase Monocarboxylate transporter 4  Serum deprivation-response protein  
Angiotensin-converting enzyme, somatic 
isoform  Follicle-stimulating hormone receptor  Monocarboxylate transporter 5  Serum paraoxonase arylesterase 1  
Angiotensin-converting enzyme, testis-
specific isoform  Folylpolyglutamate synthase, mitochondrial  Monocarboxylate transporter 6  Serum protein 
Angiotensinogen  Formimidoyltransferase-cyclodeaminase Monocarboxylate transporter 7  Serum retinol binding protein 
Annexin A1  Free fatty acid receptor 1  Monocarboxylate transporter 8  Seryl-tRNA synthetase, cytoplasmic 
Annexin A10 Fructose-1,6-bisphosphatase 1  MTA SAH nucleosidase  Sex hormone-binding globulin 
Annexin A2  Fumarate reductase flavoprotein subunit  Mu opioid receptor S-formylglutathione hydrolase  
Annexin A3 Fusion glycoprotein F0 Mucin-2 SHMT2 protein  
Annexin A8 
G protein-activated inward rectifier potassium 
channel 1 Mucosal addressin cell adhesion molecule-1 
Short branched chain specific acyl-CoA 
dehydrogenase, mitochondrial  
Anti-muellerian hormone type-2 receptor 
G protein-activated inward rectifier potassium 
channel 2  Mu-crystallin homolog  Short-chain dehydrogenase reductase 3  
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Antithrombin-III  
G protein-activated inward rectifier potassium 
channel 4  Multidrug resistance protein 1  
Short-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
Antiviral protein I  G1 S-specific cyclin-D1  Multidrug resistance-associated protein 1 Sialidase-1  
Antiviral protein S  GABA-A receptor subunit  Multidrug resistance-associated protein 4  Sigma 1-type opioid receptor  
Apolipoprotein B-100  GABA-gated chloride channel subunit 
Multifunctional protein ADE2 [Includes: 
Phosphoribosylaminoimidazole- 
succinocarboxamide synthase  
Signal transducer and activator of transcription 
1-α/β 
Apolipoprotein E  GAD1 protein  
Multiple coagulation factor deficiency 
protein 2  
Signal transducer and activator of transcription 
5B 
Apolipoprotein(a) Gag-Pol polyprotein Murine Double Minute-2 (MDM2) Small inducible cytokine A2 
Apoptosis regulator Bcl-2  Galectin-10 Muscarinic acetylcholine receptor M1  Small inducible cytokine A23  
Apoptotic protease-activating factor 1  Galectin-3 Muscarinic acetylcholine receptor M2  S-Methyl-5-thioadenosine phosphorylase  
Aquaporin-1 Galectin-4 Muscarinic acetylcholine receptor M3  
Sodium- and chloride-dependent creatine 
transporter 1  
Arachidonate 15-lipoxygenase  Galectin-7 Muscarinic acetylcholine receptor M4  
Sodium- and chloride-dependent GABA 
transporter 1  
Arachidonate 5-lipoxygenase  
γ-Aminobutyric acid type B receptor, subunit 
1  Muscarinic acetylcholine receptor M5  
Sodium- and chloride-dependent glycine 
transporter 1  
A-Raf proto-oncogene serine threonine-
protein kinase  
γ-Aminobutyric acid type B receptor, subunit 
2  Mu-type opioid receptor  
Sodium- and chloride-dependent glycine 
transporter 2  
Arginase  γ-Aminobutyric acid uptake   Myeloid cell surface antigen CD33  
Sodium- and chloride-dependent neutral and 
basic amino acid transporter B(0+) 
Arginase-1  γ-Aminobutyric-acid receptor subunit alpha-1 Myeloperoxidase  Sodium calcium exchanger 1  
Arginase-2, mitochondrial γ-Aminobutyric-acid receptor subunit α-2  Na+-H+ ion exchange Sodium channel protein type 1 subunit α 
Arginine decarboxylase  γ-Aminobutyric-acid receptor subunit α-3 N-Acetylgalactosamine-6-sulfatase Sodium channel protein type 10 subunit α  
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Argininosuccinate lyase  γ-Aminobutyric-acid receptor subunit alpha-4  N-Acetylglucosamine kinase  Sodium channel protein type 11 subunit α 
Argininosuccinate synthase γ-Aminobutyric-acid receptor subunit α-5  
N-Acetylglucosamine-1-phosphodiester 
alpha-N-acetylglucosaminidase  Sodium channel protein type 2 subunit α  
Aromatic-L-amino-acid decarboxylase  γ-Aminobutyric-acid receptor subunit α-6 N-Acetylglutamate synthase, mitochondrial  Sodium channel protein type 3 subunit α  
Arsenical pump-driving ATPase γ-Aminobutyric-acid receptor subunit β-1  N-Acylglucosamine 2-epimerase Sodium channel protein type 4 subunit α  
Aryl hydrocarbon receptor γ-Aminobutyric-acid receptor subunit β-2  NAD(P) transhydrogenase, mitochondrial Sodium channel protein type 5 subunit α  
Arylamine N-acetyltransferase  γ-Aminobutyric-acid receptor subunit β-3  NAD(P)H dehydrogenase [quinone] 1 Sodium channel protein type 8 subunit α  
Arylamine N-acetyltransferase   γ-Aminobutyric-acid receptor subunit rho-1  NAD-dependent deacetylase sirtuin-5 Sodium channel protein type 9 subunit α  
Ascorbate peroxidase  γ-Butyrobetaine dioxygenase  
NAD-dependent malic enzyme, 
mitochondrial Sodium hydrogen exchanger 1 
Asialoglycoprotein receptor 2  γ-Glutamyl hydrolase  
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 1  
Sodium potassium-transporting ATPase α-1 
chain 
Asparagine synthetase [glutamine-
hydrolyzing]  γ-Glutamyltranspeptidase 
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 10, mitochondrial  Sodium potassium-transporting ATPase γ chain  
Asparaginyl-tRNA synthetase, cytoplasmic  γ-Glutamyltranspeptidase 1 
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 11 Sodium-dependent dopamine transporter 
Aspartate aminotransferase 2 variant  Gap junction alpha-1 protein  
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 12 Sodium-dependent multivitamin transporter 
Aspartate aminotransferase, cytoplasmic Gastrin cholecystokinin type B receptor  
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 13 Sodium-dependent noradrenaline transporter  
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Aspartate aminotransferase, mitochondrial  
GDH 6PGL endoplasmic bifunctional protein 
[Includes: Glucose 1-dehydrogenase  
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 2  Sodium-dependent proline transporter  
Aspartoacylase  GDP-L-fucose synthetase  
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 3 Sodium-dependent serotonin transporter 
Aspartoacylase-2  Geranylgeranyl transferase type-1 subunit β  
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 4  Soluble epoxide hydrolase   
Aspartyl aminopeptidase  Glucagon  
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 4-like 2  Solute carrier family 12 member 1  
Aspartyl asparaginyl beta-hydroxylase  Glucagon receptor 
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 5  Solute carrier family 12 member 2  
Aspartyl-tRNA synthetase, cytoplasmic Glucagon-like peptide 1 receptor 
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 6  Solute carrier family 12 member 3  
ASRGL1 protein  Glucagon-like peptide 2 receptor  
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 7  Solute carrier family 12 member 4  
ATP synthase δ chain, mitochondrial Glucocorticoid receptor 
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 8  Solute carrier family 12 member 5  
ATP-binding cassette subfamily A member 1 Glucokinase Isoform 2 
NADH dehydrogenase [ubiquinone] 1 α 
subcomplex subunit 9, mitochondrial  Solute carrier family 12 member 6  
ATP-binding cassette subfamily G member 1  
Glucosamine-fructose-6-phosphate 
aminotransferase [isomerizing] 2  
NADH dehydrogenase [ubiquinone] 1 β 
subcomplex subunit 1  Solute carrier family 12 member 7  
ATP-binding cassette subfamily G member 2  Glucose-6-phosphate dehydrogenase 
NADH dehydrogenase [ubiquinone] 1 β 
subcomplex subunit 10  Solute carrier family 13 member 1  
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ATP-binding cassette transporter sub-family C 
member 8  Glutamate [NMDA] receptor subunit 3A  
NADH dehydrogenase [ubiquinone] 1 β 
subcomplex subunit 2, mitochondrial  Solute carrier family 13 member 2  
ATP-binding cassette transporter sub-family C 
member 9  Glutamate [NMDA] receptor subunit 3B  
NADH dehydrogenase [ubiquinone] 1 β 
subcomplex subunit 3  Solute carrier family 13 member 3  
ATP-sensitive inward rectifier potassium 
channel 1  Glutamate [NMDA] receptor subunit ε-1 
NADH dehydrogenase [ubiquinone] 1 β 
subcomplex subunit 4  
Solute carrier family 2, facilitated glucose 
transporter member 1  
ATP-sensitive inward rectifier potassium 
channel 11  Glutamate [NMDA] receptor subunit ε-2  
NADH dehydrogenase [ubiquinone] 1 β 
subcomplex subunit 5, mitochondrial  Solute carrier family 22 member 11  
ATP-sensitive inward rectifier potassium 
channel 12  Glutamate [NMDA] receptor subunit ε-3  
NADH dehydrogenase [ubiquinone] 1β 
subcomplex subunit 6  Solute carrier family 23 member 1  
ATP-sensitive inward rectifier potassium 
channel 8  
Glutamate [NMDA] receptor subunit epsilon-
4  
NADH dehydrogenase [ubiquinone] 1 β 
subcomplex subunit 7  
Solute carrier organic anion transporter family 
member 1B1  
ATP-sensitive K+ channel   Glutamate [NMDA] receptor subunit ζ-1  
NADH dehydrogenase [ubiquinone] 1 β 
subcomplex subunit 8, mitochondrial  
Solute carrier organic anion transporter family 
member 2B1 
Atrial natriuretic peptide clearance receptor  Glutamate carboxypeptidase 2  
NADH dehydrogenase [ubiquinone] 1 β 
subcomplex subunit 9  Somatostatin  
Atrial natriuretic peptide receptor A  Glutamate decarboxylase 1  
NADH dehydrogenase [ubiquinone] 1 
subunit C1, mitochondrial  Somatostatin receptor type 1  
Atrial natriuretic peptide receptor B Glutamate decarboxylase 2  
NADH dehydrogenase [ubiquinone] 1 
subunit C2  Somatostatin receptor type 5  
Aurora-2 protein kinase Glutamate dehydrogenase   
NADH dehydrogenase [ubiquinone] 
flavoprotein 1, mitochondrial Sorbitol dehydrogenase  
B2 bradykinin receptor Glutamate dehydrogenase 1, mitochondrial  
NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial  SPARC  
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Bacillolysin  Glutamate dehydrogenase 2, mitochondrial  
NADH dehydrogenase [ubiquinone] 
flavoprotein 3, mitochondrial  Spermidine synthase  
Basement membrane-specific heparan sulfate 
proteoglycan core protein Glutamate receptor 1  
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 2, mitochondrial Spermine oxidase  
Basic fibroblast growth factor receptor 1  Glutamate receptor 2 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 3, mitochondrial  Spermine synthase 
BC269730 Glutamate receptor 3 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 4, mitochondrial  Sphingomyelin phosphodiesterase  
BCAT1 protein  Glutamate receptor 4 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 5  Sphingomyelin phosphodiesterase 3  
B-cell receptor CD22  Glutamate receptor δ-1 subunit  
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 6, mitochondrial  Sphingomyelin phosphodiesterase 4  
BCR/ABL protein   Glutamate receptor δ-2 subunit  
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 7, mitochondrial  Sphingosine-1-phosphate lyase 1  
Β-Platelet-derived growth factor receptor  Glutamate receptor, ionotropic kainate 1  
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 8, mitochondrial  Squalene monooxygenase 
β-1 Adrenergic receptor  Glutamate receptor, ionotropic kainate 2 NADH-cytochrome b5 reductase 3  Src kinase domain 
β-1,3-Glucan synthase  Glutamate receptor, ionotropic kainate 3 
NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial Sterol O-acyltransferase 1  
β-1,4-Galactosyltransferase 1  Glutamate receptor, ionotropic kainate 4 NADH-ubiquinone oxidoreductase chain 1 Sterol O-acyltransferase 2  
β-1,4-Galactosyltransferase 2  Glutamate receptor, ionotropic kainate 5 NADH-ubiquinone oxidoreductase chain 2  
Sterol-4-α-carboxylate 3-dehydrogenase, 
decarboxylating  
β-1,4-Galactosyltransferase 3  
Glutamate--ammonia ligase domain-
containing protein 1  NADH-ubiquinone oxidoreductase chain 3  Steryl-sulfatase  
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β-1,4-Galactosyltransferase 4  Glutamate-cysteine ligase catalytic subunit  NADH-ubiquinone oxidoreductase chain 4  Streptogramin A acetyltransferase  
β-2 Adrenergic receptor Glutamate-cysteine ligase regulatory subunit  NADH-ubiquinone oxidoreductase chain 4L  Stromal cell-derived factor 1  
β-3 Adrenergic receptor Glutamate-gated chloride channel subunit beta NADH-ubiquinone oxidoreductase chain 5  Stromelysin-1  
β-Adrenergic receptor kinase 1  Glutamic acid decarboxylase  NADH-ubiquinone oxidoreductase chain 6  Substance-K receptor  
β-Adrenergic receptor kinase 2  Glutaminase kidney isoform, mitochondrial  NADP-dependent malic enzyme Substance-P receptor  
β-Galactosidase  Glutaminase liver isoform, mitochondrial  
NADP-dependent malic enzyme, 
mitochondrial  
Succinate dehydrogenase [ubiquinone] 
cytochrome b small subunit, mitochondrial  
β-Hydroxysteroid dehydrogenase δ 5 Glutamine synthetase  NADPH azoreductase 
Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial  
Betaine aldehyde dehydrogenase   Glutamine-dependent NAD+ synthetase NADPH-cytochrome P450 reductase  
Succinate dehydrogenase [ubiquinone] iron-
sulfur subunit, mitochondrial  
Betaine-homocysteine S-methyltransferase 1  Glutaminyl-tRNA synthetase  NADPH-linked flavin nitroreductase 
Succinate dehydrogenase cytochrome b560 
subunit, mitochondrial  
Betaine-homocysteine S-methyltransferase 2  Glutamyl aminopeptidase  N-Arachidonyl glycine receptor  Succinate receptor 1  
β-Lactamase  Glutaredoxin-1  Natriuretic peptides B 
Succinate semialdehyde dehydrogenase, 
mitochondrial  
Beta-lactamase CTX-M-9a  Glutaredoxin-2, mitochondrial  
NEDD8-activating enzyme E1 regulatory 
subunit  Succinate-CoA ligase, ADP-forming, β subunit  
Beta-lactamase PSE-2  Glutathione peroxidase 1  Neprilysin  
Succinyl-CoA ligase [ADP-forming] β-chain, 
mitochondrial  
Beta-lactamase SHV-1 precursor  Glutathione peroxidase 2 Neuraminidase 
Succinyl-CoA ligase [GDP-forming] β-chain, 
mitochondrial  
Beta-nerve growth factor  Glutathione peroxidase 3 Neuroendocrine convertase 1  
Succinyl-CoA ligase [GDP-forming] subunit α, 
mitochondrial  
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Beta-Secretase Glutathione peroxidase 4  Neuroendocrine convertase 2  
Succinyl-CoA:3-ketoacid-coenzyme A 
transferase 1, mitochondrial  
Beta-secretase-1 Glutathione peroxidase 6  
Neuronal acetylcholine receptor subunit 
alpha-10  
Succinyl-CoA:3-ketoacid-coenzyme A 
transferase 2, mitochondrial  
Bifunctional aminoacyl-tRNA synthetase 
[Includes: Glutamyl-tRNA synthetase  Glutathione peroxidase 7  
Neuronal acetylcholine receptor subunit 
alpha-2 Sucrase-isomaltase, intestinal  
Bifunctional dihydrofolate reductase-
thymidylate synthase  Glutathione reductase  
Neuronal acetylcholine receptor subunit 
alpha-4 Superoxide dismutase 
Bifunctional methylenetetrahydrofolate 
dehydrogenase cyclohydrolase, mitochondrial  Glutathione reductase, mitochondrial  
Neuronal acetylcholine receptor subunit 
alpha-7  Suppressor of tumorigenicity protein 14  
Bifunctional purine biosynthesis protein 
PURH [Includes: 
Phosphoribosylaminoimidazolecarboxamide 
formyltransferase  Glutathione S-transferase 1, isoform C  
Neuronal acetylcholine receptor subunit 
alpha-9  Syk tyrosine kinase 
Bile acid CoA:amino acid N-acyltransferase  Glutathione S-transferase A1  
Neuronal acetylcholine receptor subunit 
beta-2  Synaptic vesicle glycoprotein 2A  
Bile salt export pump Glutathione S-transferase A2  Neuropeptide S receptor  Synaptic vesicular amine transporter 
Bilin-binding protein  Glutathione S-transferase A3 Neuropilin-1  Synaptosomal-associated protein 25  
Biliverdin Ix Beta Reductase Glutathione S-transferase A4  Neurotensin receptor type 2  Synaptotagmin-2  
Biliverdin reductase A  Glutathione S-transferase A5 Neutral amino acid transporter A  Synaptotagmin-like protein 4  
Biotin--protein ligase  
Glutathione S-transferase class-mu 26 kDa 
isozyme  Neutral amino acid transporter B Syndecan-2  
Blood plasma glutamate carboxypeptidase  
Glutathione S-transferase class-mu 28 kDa 
isozyme  
Neutral and basic amino acid transport 
protein rBAT  System N amino acid transporter 1  
B-lymphocyte antigen CD20 Glutathione S-transferase kappa 1 Neutrophil Collagenase tAntiviral protein DAP-30  
Bone morphogenetic protein 2 (BMP2) Glutathione S-transferase kappa 1  Neutrophil Cytosol Factor 2 tAspartyl-tRNA synthetase, mitochondrial  
Bone Morphogenetic Protein-7 Glutathione S-transferase Mu 1 
NG,NG-dimethylarginine 
dimethylaminohydrolase 1  Taste receptor type 1 member 2  
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Bone-marrow proteoglycan  Glutathione S-transferase Mu 2  
NG,NG-dimethylarginine 
dimethylaminohydrolase 2  Taste receptor type 1 member 3 
B-Raf proto-oncogene serine threonine-
protein kinase  Glutathione S-transferase Mu 3 Nicotinamide N-methyltransferase  T-cell surface antigen CD2 
Brain glycogen phosphorylase variant  Glutathione S-transferase Mu 4 
Nicotinate-nucleotide pyrophosphorylase 
[carboxylating]  T-cell surface glycoprotein CD1a  
Branched-chain-amino-acid aminotransferase, 
cytosolic (BCAT1) Glutathione S-transferase Mu 5  
Nicotinate-nucleotide--
dimethylbenzimidazole 
phosphoribosyltransferase  T-cell surface glycoprotein CD3 epsilon chain  
Branched-chain-amino-acid aminotransferase, 
mitochondrial (BCAT2) Glutathione S-transferase P Nicotinic acetylcholine receptor   tDDC protein  
C-1-tetrahydrofolate synthase, cytoplasmic  Glutathione S-transferase pi  Nicotinic acid receptor 1  Tetracycline repressor protein class H  
C-4 methylsterol oxidase Glutathione S-transferase theta-1  Nicotinic acid receptor 2 Tetranectin  
CAD protein [Includes: Glutamine-dependent 
carbamoyl-phosphate synthase  Glutathione S-transferase theta-2 Nidogen-1  TGF-beta receptor type I 
Calcineurin   Glutathione synthetase  Niemann-Pick C1-like protein 1 Tgf-beta Type II Receptor 
Calcineurin subunit B isoform 1  Glutathione Transferase A1-1 Nitric oxide synthase, inducible Thermonuclease  
Calcineurin subunit B isoform 2  Glutathione transferase omega-1 Nitric-oxide synthase IIB Thiamin pyrophosphokinase 1  
Calcitonin gene-related peptide 1  Glutathione transferase omega-2  Nitric-oxide synthase IIC  Thiamine transporter 2 
Calcitonin receptor  
Glutathione-requiring prostaglandin D 
synthase  Nitric-oxide synthase, brain  Thio oxidoreductase 
Calcium channel, alpha 2 delta subunit 2  Glyceraldehyde-3-phosphate dehydrogenase  Nitric-oxide synthase, endothelial  Thioredoxin domain-containing protein 12  
Calcium channel, voltage-dependent, L type, 
alpha 1B subunit  
Glyceraldehyde-3-phosphate dehydrogenase, 
testis-specific  NMDA receptor   Thioredoxin peroxidase 
Calcium signal-modulating cyclophilin ligand  
Glycerol-3-phosphate dehydrogenase 
[NAD+], cytoplasmic  Noradrenergic re-uptake   Thioredoxin reductase  
Calcium-activated potassium channel subunit 
alpha 1 Glycinamide ribonucleotide formyltransferase  Nuclear factor NF-kappa-B p105 subunit  Thioredoxin reductase, cytoplasmic   
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Calcium-binding mitochondrial carrier protein 
Aralar1  Glycine amidinotransferase, mitochondrial  Nuclear Orphan Receptor Lxr-beta Threonine synthase-like 1  
Calcium-binding mitochondrial carrier protein 
Aralar2  
Glycine cleavage system H protein, 
mitochondrial  Nuclear receptor 0B1  Threonyl-tRNA synthetase, cytoplasmic  
Calcium-transporting ATPase type 2C 
member 1  
Glycine dehydrogenase [decarboxylating], 
mitochondrial Nuclear Vitamin D Receptor Threonyl-tRNA synthetase, mitochondrial  
Calgranulin B Glycine N-acyltransferase  OAT protein  Thrombin 
Calmodulin Glycine N-acyltransferase-like protein 1  Oligopeptide transporter, kidney isoform  Thrombomodulin  
Calnexin  Glycine N-acyltransferase-like protein 2  
Oligopeptide transporter, small intestine 
isoform Thrombospondin-1  
Calreticulin  Glycine N-methyltransferase  
O-phosphoseryl-tRNA(Sec) selenium 
transferase Thromboxane A2 receptor  
cAMP and cAMP-inhibited cGMP 3',5'-cyclic 
phosphodiesterase 10A  Glycine receptor subunit alpha-1  Opioid receptor, sigma 1  Thromboxane A2 synthase  
cAMP response element-binding protein  Glycine receptor subunit alpha-2  Organic anion transporter 3  Thymidine kinase 
CAMPATH-1 antigen Glycine receptor subunit alpha-3  Organic cation carnitine transporter 1 Thymidine phosphorylase  
cAMP-specific 3',5'-cyclic phosphodiesterase 
4A  Glycine receptor subunit beta Organic cation carnitine transporter 2 Thymidylate synthase  
cAMP-specific 3',5'-cyclic phosphodiesterase 
4B  Glycogen phosphorylase, brain form  Ornithine aminotransferase variant  Thymidylate synthase  
cAMP-specific 3',5'-cyclic phosphodiesterase 
4C  Glycogen phosphorylase, liver form Ornithine aminotransferase, mitochondrial  Thymidylate synthase   
cAMP-specific 3',5'-cyclic phosphodiesterase 
4D  Glycogen phosphorylase, muscle form 
Ornithine carbamoyltransferase, 
mitochondrial  Thyroid hormone receptor alpha 
cAMP-specific 3',5'-cyclic phosphodiesterase 
7B  Glycogen synthase kinase-3 beta  Ornithine decarboxylase  Thyroid hormone receptor beta-1  
Canalicular multispecific organic anion 
transporter 1  Glycoprotein IIb/IIIa receptor   Ornithine decarboxylase antizyme  Thyroid hormone receptor beta-2 
Canalicular multispecific organic anion 
transporter 2  Glycosyltransferase Ornithine decarboxylase antizyme 2  Thyroid peroxidase 
Cannabinoid receptor 1 Glycosyltransferase GtfA  Ornithine decarboxylase antizyme 3  Thyrotropin receptor  
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Cannabinoid receptor 2  Glycyl-tRNA synthetase  Ornithine--oxo-acid Aminotransferase Thyroxine-binding globulin 
Carbonic anhydrase 1  GM-CSF Orphan nuclear receptor PXR Tissue factor  
Carbonic anhydrase 12  GMP reductase 1  Osteocalcin  Tissue factor pathway inhibitor 
Carbonic anhydrase 14  GMP reductase 2 Other phosphate group transferase Tissue-type plasminogen activator  
Carbonic anhydrase 2  GMP synthase [glutamine-hydrolyzing]  Other protein kinase family T-lymphocyte activation antigen CD80 
Carbonic anhydrase 4  Gonadotropin alpha Subunit Oxalate oxidase T-lymphocyte activation antigen CD86  
Carbonic anhydrase-III Gonadotropin-releasing hormone receptor  Oxidoreductase  Toll-like receptor 7  
Carboxypeptidase E  
GPI-linked NAD(P)(+)--arginine ADP-
ribosyltransferase 1  Oxidosqualene cyclase Toll-like receptor 9  
Carcinoembryonic antigen-related cell 
adhesion molecule 1  Granulocyte Colony-stimulating Factor Oxygen-insensitive NAD Topoisomerase IV   
Cardiac Muscle Isoforms 
Granulocyte colony-stimulating factor 
receptor  Oxygen-insensitive NADPH nitroreductase  Topoisomerase IV subunit A   
Carnitine acyltransferase 
Granulocyte-macrophage colony-stimulating 
factor receptor alpha chain  Oxytocin receptor  Trace amine-associated receptor 1 
Carnitine O-acetyltransferase  Growth factor receptor-bound protein 2 Oxytocin-neurophysin 1  Transcobalamin-1  
Carnitine O-palmitoyltransferase 2, 
mitochondrial  Growth factor receptor-bound protein 2 SH2 
P protein [Includes: DNA-directed DNA 
polymerase Transcobalamin-2  
Carnitine O-palmitoyltransferase I, liver 
isoform  Growth hormone receptor  p21 gene Transcription attenuation protein mtrB 
Casein Kinase II Growth hormone-releasing hormone receptor P2Y purinoceptor 12  Transcription factor AP-1  
Casein kinase-I gamma-2 Growth-inhibiting protein 18  P2Y purinoceptor 2  Transcriptional regulator ATRX  
Caspase-1  GTPase HRas  p450 2C9 (CYP, CYP450) Transforming growth factor beta-1 
Caspase-3  Guanidinoacetate N-methyltransferase  p450 3A4 (CYP,CYP450) Transforming Protein P21/H-Ras-1 
Caspase-7 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) gamma-2 subunit  PAK-1 protein kinase Transforming protein RhoA  
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Catalase  Haem polymerase   PAK-5 protein kinase 
Transient receptor potential cation channel 
subfamily A member 1  
Catechol O-methyltransferase  Heat shock protein HSP 90-alpha  PAK-6 protein kinase 
Transient receptor potential cation channel 
subfamily M member 8  
Catecholamine uptake   Hematopoietic Prostagladin D Synthase Pancreatic alpha-amylase  
Transient receptor potential cation channel 
subfamily V member 1 
Catenin beta-1  Heme carrier protein 1  Pancreatic triacylglycerol lipase 
Transient receptor potential cation channel 
subfamily V member 3  
Cathepsin B Heme oxygenase 1 Pantothenate kinase 1 Transient tetrodotoxin-resistant Na+ current   
Cathepsin D Heme oxygenase 2  Para-aminobenzoate synthase  Translocator protein  
Cathepsin G Hemoglobin subunit alpha  Para-aminobenzoate synthase component 1 Transmembrane glycoprotein gp41   
Cathepsin L  Hemoglobin subunit beta 
Parathyroid hormone parathyroid hormone-
related peptide receptor Transthyretin  
Cationic amino acid transporter 3 Heparanase  PDE 4b Triacylglycerol lipase, pancreatic   
Cationic amino acid transporter 4  Heparin cofactor 2  PDE 4d 
Trifunctional enzyme subunit alpha, 
mitochondrial  
Cationic trypsin  Heparinase PDK1 protein kinase 
Trifunctional purine biosynthetic protein 
adenosine-3 [Includes: Phosphoribosylamine--
glycine ligase  
C-C chemokine receptor type 5 Heparin-binding growth factor 1  Penicillin-binding protein 1A  
Triggering receptor expressed on myeloid cells 
1  
CD40 ligand  Heparin-binding growth factor 2  Penicillin-binding protein 1B Trimethyllysine dioxygenase, mitochondrial  
CD44 antigen  
Hepatic peroxysomal alanine:glyoxylate 
aminotransferase  Penicillin-binding protein 2  Triosephosphate isomerase  
CD81 Hepatocyte Growth Factor Receptor Penicillin-binding protein 2B  Triosephosphate isomerase, glycosomal  
CDK2/CYCLIN A 
HERV-K_1p13.3 provirus ancestral Env 
polyprotein Penicillin-binding protein 3 TrkA receptor 
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CDNA FLJ23636 fis, clone CAS07176  
High affinity immunoglobulin epsilon 
receptor gamma-subunit Penicillin-binding protein 4  TrkB receptor 
CDNA FLJ46802 fis, clone TRACH3032150, 
moderately similar to Cysteine sulfinic acid 
decarboxylase  
High affinity immunoglobulin epsilon 
receptor subunit alpha  Penicillin-binding protein 5  TrkC receptor 
Cell Division Protein Kinase 2(CDK2) 
High affinity immunoglobulin epsilon 
receptor subunit beta  Penicillin-binding proteins 1A 1B Troponin C, slow skeletal and cardiac muscles 
Cellular retinaldehyde-binding protein 
High affinity immunoglobulin gamma Fc 
receptor I  Peptide methionine sulfoxide reductase  Troponin T 
Cellular retinoic acid-binding protein 1  High affinity nerve growth factor receptor Peptidoglycan synthetase ftsI  Trypsin-1  
Cellular retinoic acid-binding protein 2 
High-affinity cAMP-specific 3',5'-cyclic 
phosphodiesterase 7A  
Peptidyl-glycine alpha-amidating 
monooxygenase  Tryptase   
Cellular Retinoic-Acid-Binding Protein High-affinity cationic amino acid transporter 1  Peptidyl-prolyl cis-trans isomerase A Tryptophan 5-hydroxylase 1  
Ceramide glucosyltransferase  High-affinity choline transporter 1  Peptidyl-prolyl cis-trans isomerase B  Tryptophan 5-hydroxylase 2 
Ceruloplasmin  Histamine H1 receptor  Peptidyl-prolyl cis-trans isomerase C  Tryptophanyl-tRNA synthetase  
cGMP-dependent 3',5'-cyclic 
phosphodiesterase  Histamine H2 receptor Peptidyl-prolyl cis-trans isomerase G  Tryptophanyl-tRNA synthetase, cytoplasmic  
cGMP-inhibited 3',5'-cyclic phosphodiesterase 
A  Histamine H3 receptor  Peptidyl-prolyl cis-trans isomerase H  Tryptophanyl-tRNA synthetase, mitochondrial  
cGMP-specific 3',5'-cyclic phosphodiesterase  Histamine H4 receptor 
Peptidyl-prolyl cis-trans isomerase, 
mitochondrial  Tubulin alpha chain 
CGMP-specific 3',5'-cyclic 
phosphodiesterase   Histamine N-methyltransferase  Periplasmic [Fe] hydrogenase 1 Tubulin beta chain  
Checkpoint kinase 1 Histidine ammonia-lyase Peroxidase 59  Tubulin beta-1 chain  
Chitosanase  Histidine decarboxylase  Peroxidase catalase T  TUMOR NECROSIS FACTOR ALPHA 
Chloramphenicol 3-O phosphotransferase  Histidine triad nucleotide-binding protein 1  Peroxiredoxin-5, mitochondrial  
Tumor Necrosis Factor Receptor Associated 
Protein 2 
Chloramphenicol acetyltransferase  Histidyl-tRNA synthetase, cytoplasmic Peroxisomal bifunctional enzyme  
Tumor necrosis factor receptor superfamily 
member 1B  
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Chloramphenicol acetyltransferase 3  Histocompatibility Peroxisomal carnitine O-octanoyltransferase  
Tumor necrosis factor receptor superfamily 
member 5  
Chloride channel 
Histocompatibility Leukocyte Antigen (Hla)-
Cw4 (Heavy Chain) Peroxisomal multifunctional enzyme type 2  Type I IL-1 receptor 
Chloride channel protein 2  Histone deacetylase   Peroxisomal sarcosine oxidase  Type I TNF receptor 
Chloride channel protein ClC-Ka  Histone deacetylase 1  Peroxisomal trans-2-enoyl-CoA reductase  Type-1 angiotensin II receptor  
Chlorophyll a-b binding protein, chloroplast  Histone deacetylase 2  
Peroxisome proliferator-activated receptor 
alpha (PPAR alpha) Tyrosinase  
Cholecystokinin type A receptor  Histone deacetylase 3  
Peroxisome proliferator-activated receptor 
delta (PPAR delta) Tyrosine 3-monooxygenase  
Choline dehydrogenase, mitochondrial  Histone deacetylase 4 
Peroxisome proliferator-activated receptor 
gamma (PPAR gamma) Tyrosine aminotransferase 
Choline ethanolamine kinase [Includes: 
Choline kinase beta  Histone deacetylase 6  Phenylalanine-4-hydroxylase Tyrosine-protein kinase ABL2  
Choline ethanolaminephosphotransferase  Histone deacetylase 7a Phenylalanyl-tRNA synthetase alpha chain  
Tyrosine-protein phosphatase non-receptor type 
1  
Choline kinase alpha Histone deacetylase 8  Phenylalanyl-tRNA synthetase beta chain  
Tyrosine-protein phosphatase non-receptor type 
4  
Choline O-acetyltransferase Histone deacetylase 9  
Phenylalanyl-tRNA synthetase, 
mitochondrial  Tyrosyl-tRNA synthetase, cytoplasmic  
Choline transporter-like protein 1  Histone lysine methyltransferase Phenylethanolamine N-Methyltransferase Tyrosyl-tRNA synthetase, mitochondrial  
Choline transporter-like protein 2  HIV gp41 protein Phenylethylamine oxidase  
Ubiquinol-cytochrome-c reductase complex 
core protein I, mitochondrial 
Choline transporter-like protein 3  HIV viral infectivity factor 
Phosphatidylcholine:ceramide 
cholinephosphotransferase 2  Ubiquitin thiolesterase-6 
Choline transporter-like protein 4  HIV-1 Integrase 
Phosphatidylinositol 3-kinase regulatory 
subunit alpha  Ubiquitin thiolesterase-7 
Choline-phosphate cytidylyltransferase A  HIV-1 protease  
Phosphatidylinositol-4-phosphate 3-kinase 
C2 domain-containing alpha polypeptide  UDP-glucose 6-dehydrogenase 
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Choline-phosphate cytidylyltransferase B HIV-1 Reverse Transcriptase 
Phosphatidylserine decarboxylase 
proenzyme  UDP-glucuronosyltransferase 2B28  
Cholinesterase  HIV-1 Tat protein   Phosphatidylserine synthase 1  
UDP-N-acetylglucosamine 1-
carboxyvinyltransferase  
C-H-Ras P21 Protein HIV-2 Protease Phosphatidylserine synthase 2  UMP-CMP kinase  
Chromodomain-helicase-DNA-binding 
protein 1  HLA class II histocompatibility antigen, DQ Phosphodiesterase   Uncharacterized protein C20orf38  
Chromosome 14 open reading frame 149  HLA class II histocompatibility antigen, DQ 
Phosphoethanolamine phosphocholine 
phosphatase  Uncharacterized protein YML079W  
Chymase 
HLA class II histocompatibility antigen, 
DRB1-1 beta chain  Phospholipase A2 homolog 2  Uracil phosphoribosyltransferase  
Chymotrypsinogen B 
Holliday junction ATP-dependent DNA 
helicase ruvB  Phospholipase A2 isoform 3  Urease alpha subunit  
Cis-trans isomerase Homocysteine S methyltransferase Phospholipase A2 VRV-PL-VIIIa  Uridine phosphorylase  
c-jun N-terminal kinase (JNK1) HTH-type transcriptional regulator qacR  Phospholipase C  Urokinase 
CLK1 protein kinase Human Class I Histocompatibility Antigen Phospholipase D1  
Urokinase plasminogen activator surface 
receptor  
CLK3 protein kinase Human Fibroblast Collagenase Phospholipase D2  Urokinase-type plasminogen activator  
Coagulation factor IX  Human Leukocyte Antigen Class II Phospholipase D4  Vacuolar ATP synthase catalytic subunit A  
Coagulation factor V  Human Neutrophil Gelatinase 
Phospholipid hydroperoxide glutathione 
peroxidase, mitochondrial  Valyl-tRNA synthetase  
Coagulation factor VII  Human Plasminogen Kringle 4 
Phosphoribosylformylglycinamidine 
synthase  Vascular cell adhesion protein 1  
Coagulation factor VIII  human retinol-binding protein Phosphorylase  Vascular endothelial growth factor A  
Coagulation factor X  Human Rhinovirus 14 Phosphoserine aminotransferase  Vascular endothelial growth factor receptor 1  
Coagulation factor XI  Hyaluronate lyase  Phosphoserine aminotransferase 1  Vascular endothelial growth factor receptor 2  
Coagulation factor XIII A chain Hyaluronic acid receptor Phosphotransferase Vascular endothelial growth factor receptor 3  
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Cob Hyaluronidase PH-20 Photoreceptor  Vasopressin V1a receptor  
Cocaine- and amphetamine-regulated 
transcript protein  Hyaluronidase-1  
Photoreceptor outer segment all-trans retinol 
dehydrogenase  Vasopressin V1b receptor 
Collagen alpha-1(I) chain Hyaluronidase-2  P-hydroxybenzoate hydroxylase  Vasopressin V2 receptor  
Collagen alpha-1(II) chain 
Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial  Phytanoyl-CoA dioxygenase, peroxisomal  VEGF receptor 
Collagen alpha-1(III) chain Hydroxyacylglutathione hydrolase  Pi3K gamma Vesicle-associated membrane protein 1  
Collagen alpha-1(VI) chain Hydroxysteroid Sulfotransferase PIM-1 protein kinase Vesicle-associated membrane protein 2  
Collagen alpha-1(XIII) chain Hydroxysteroid-Dehydrogenase Type 1 Plasma membrane H(+)-ATPase   Vesicular inhibitory amino acid transporter  
Collagen alpha-2(I) chain Hypothetical protein  Plasma retinol-binding protein  Vitamin B12 transporter btuB  
Collagenase Hypothetical protein DKFZp686H15154  Plasma serine protease inhibitor  Vitamin B12-binding protein  
Complement C1q subcomponent subunit A  Hypothetical protein DKFZp686P09201  Plasminogen  Vitamin D3 receptor 
Complement C1q subcomponent subunit B  Hypothetical protein DKFZp761F2423  Plasminogen activator inhibitor 1  Vitamin D-binding protein  
Complement C1q subcomponent subunit C  Hypothetical protein DKFZp761H0716  Plasminogen activator inhibitor 2 Vitamin K epoxide reductase complex subunit 1  
Complement C1r subcomponent  
Hypoxanthine-guanine 
phosphoribosyltransferase Plastid RNA polymerase beta-subunit   
Vitamin K epoxide reductase complex subunit 
1-like protein 1  
Complement C1s subcomponent  Icam-2 Platelet factor 4  Vitamin K-dependent gamma-carboxylase  
Complement C5  ICE Platelet glycoprotein IIIa Vitamin K-dependent protein C  
Complement control protein  Ig kappa chain V-II region 26-10  Platelet glycoprotein IX  Vitamin K-dependent protein S  
Complement decay-accelerating factor  Ig kappa chain V-III region GOL Platelet-derived growth factor receptor   Vitamin K-dependent protein Z  
Corticoliberin IGF binding protein-1 PLK-1 protein kinase Vitronectin  
Corticosteroid 11-beta-dehydrogenase 
isozyme 1  IGSF10 protein  PML RAR alpha  Vng1446h  
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Corticosteroid 11-beta-dehydrogenase 
isozyme 2 IL-3 receptor Poliovirus (Type 1, Mahoney Strain) Voltage gated potassium channel 
Corticosteroid-binding globulin  IL-4 receptor Poly [ADP-ribose] polymerase-1   
Voltage-dependent anion-selective channel 
protein 1  
Corticotropin-lipotropin Immunoglobulin E Polynucleotide kinase  
Voltage-dependent anion-selective channel 
protein 2  
C-reactive protein IMP-1 dehydrogenase Potassium channel subfamily K member 1  
Voltage-dependent anion-selective channel 
protein 3  
Creatine kinase B-type Indoleamine 2,3-dioxygenase Potassium channel subfamily K member 2  
Voltage-dependent calcium channel gamma-1 
subunit  
Creatine kinase M-type  
Inhibitor of nuclear factor kappa-B kinase 
subunit beta  Potassium channel subfamily K member 6  
Voltage-dependent calcium channel subunit 
alpha-2 delta-1 
Creatine kinase, sarcomeric mitochondrial  Inosine-5'-monophosphate dehydrogenase  
Potassium large conductance calcium-
activated channel, subfamily M, alpha 
member 1 
Voltage-dependent L-type calcium channel 
subunit alpha-1C  
Creatine kinase, ubiquitous mitochondrial  Inosine-5'-monophosphate dehydrogenase 1 Potassium transporter  
Voltage-dependent L-type calcium channel 
subunit alpha-1D  
CTP synthase 1  Inosine-5'-monophosphate dehydrogenase 2  
Potassium voltage-gated channel subfamily 
A member 1 
Voltage-dependent L-type calcium channel 
subunit alpha-1F  
Cubilin Inositol monophosphatase  
Potassium voltage-gated channel subfamily 
A member 5   
Voltage-dependent L-type calcium channel 
subunit alpha-1S  
CX3CR1 chemokine Inositol monophosphatase 2  
Potassium voltage-gated channel subfamily 
E member 1 
Voltage-dependent L-type calcium channel 
subunit beta-1  
C-X-C chemokine receptor type 4 Inositol polyphosphate 1-phosphatase  
Potassium voltage-gated channel subfamily 
H member 2  
Voltage-dependent L-type calcium channel 
subunit beta-2  
Cyclin-dependent kinase-2 (Cdk2) Inositol-1(or 4)-monophosphatase 
Potassium voltage-gated channel subfamily 
H member 6  
Voltage-dependent L-type calcium channel 
subunit beta-3  
Cycloinulo-oligosaccharide 
fructanotransferase  Insulin 
Potassium voltage-gated channel subfamily 
H member 7  
Voltage-dependent L-type calcium channel 
subunit beta-4  
Cyclooxygenase   Insulin receptor  
Potassium voltage-gated channel subfamily 
KQT member 1 
Voltage-dependent N-type calcium channel 
subunit alpha-1B  
Cyclophilin Receptor Insulin-degrading enzyme  
Potassium voltage-gated channel subfamily 
KQT member 2 
Voltage-dependent P Q-type calcium channel 
subunit alpha-1A  
Cyclopropane-fatty-acyl-phospholipid 
synthase 1  Insulin-like growth factor 1 receptor  
Potassium-transporting ATPase alpha chain 
1  
Voltage-dependent T-type calcium channel 
subunit alpha-1G  
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CYP2B protein Insulin-like growth factor-binding protein 3  Potassium-transporting ATPase α chain 2  
Voltage-dependent T-type calcium channel 
subunit α-1H  
CYP2C8 Insulin-like growth factor-binding protein 7  Potassium-transporting ATPase subunit β  
Voltage-dependent T-type calcium channel 
subunit α-1I  
CYP2C9 
Integrase - Primate lentivirus group Human 
immunodeficiency virus type 1 (HIV-1) Pregnane X receptor Voltage-gated sodium channel   
CYP2D6 Integrin α-1 
Probable alanyl-tRNA synthetase, 
mitochondrial  von Willebrand factor  
Cystathionine β-synthase  Integrin α-11  Probable arabinosyltransferase A  Xanthine dehydrogenase oxidase  
Cystathionine γ-lyase Integrin α-4  Probable arabinosyltransferase B  Xanthine dehydrogenase/oxidase   
Cystathionine synthase Integrin α-IIb  Probable arabinosyltransferase C  Xylose isomerase  
Cysteine desulfurase, mitochondrial  Integrin α-L  
Probable asparaginyl-tRNA synthetase, 
mitochondrial  Zinc finger protein 123  
Cysteine dioxygenase  Integrin β-1 
Probable cysteinyl-tRNA synthetase, 
mitochondrial  
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